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Abstract
EFSA was asked to deliver a scientiﬁc opinion on free and esteriﬁed 3- and 2-monochloropropane-1,
2-diol (MCPD) and glycidyl esters in food. Esters of 3- and 2-MCPD and glycidol are contaminants of
processed vegetable oils; free MCPDs are formed in some processed foods. The Panel on
Contaminants in the Food Chain (CONTAM Panel) evaluated 7,175 occurrence data. Esters of 3- and
2-MCPD and glycidyl esters were found at the highest levels in palm oil/fat, but most vegetable oil/fats
contain substantial quantities. Mean middle bound (MB) dietary exposure values to total 3-MCPD,
2-MCPD and glycidol, respectively, across surveys and age groups in µg/kg body weight (bw) per day
were 0.2–1.5, 0.1–0.7 and 0.1–0.9; high exposure (P95) values were 0.3–2.6, 0.2–1.2 and 0.2–2.1.
Animal studies show extensive hydrolysis of esteriﬁed 3-MCPD and glycidol following oral
administration; esteriﬁed and free forms were assumed to contribute equally to internal exposures.
Nephrotoxicity was consistently observed in rats treated with 3-MCPD. Data on 2-MCPD toxicity were
insufﬁcient for dose–response assessments. Chronic treatment with glycidol increased the incidence of
tumours in several tissues of rats and mice, likely via a genotoxic mode of action. The Panel selected a
BMDL10 value for 3-MCPD of 0.077 mg/kg bw per day for induction of renal tubular hyperplasia in rats
and derived a tolerable daily intake (TDI) of 0.8 µg/kg bw per day. The mean exposure to 3-MCPD
was above the TDI for ‘Infants’, ‘Toddlers’ and ‘Other children’. For glycidol, the Panel selected a T25
value of 10.2 mg/kg bw per day for neoplastic effects in rats. The margins of exposure (MoEs) were
11,300–102,000 and 4,900–51,000 across surveys and age groups at mean and P95 exposures,
respectively. An exposure scenario for infants receiving formula only resulted in MoEs of 5,500 (mean)
and 2,100 (P95). MoEs of 25,000 or higher were considered of low health concern.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to deliver a scientiﬁc opinion on the risks for human health related to the
presence of 3- and 2-monochloropropanediol (MCPD), and their fatty acid esters, and glycidyl fatty
acid esters (GE) in food.
3-Monochloropropane-1,2-diol (3-MCPD) and 2-monochloropropane-1,3-diol (2-MCPD) are chlorinated
derivatives of glycerol (1,2,3-propanetriol). 3- and 2-MCPD and their fatty acid esters are among
non-volatile chloropropanols, identiﬁed in the late 1970s in the composition of hydrolysed vegetable protein
(HVP) which is used as a savoury ﬂavour-enhancing food ingredient. 3- and 2-MCPD fatty acid esters are
produced in vegetable oils on reﬁning, and they contain the fatty acids common to the parent oils and fats
in a similar ratio.
Glycidol is associated with the formation and decomposition of 3- and 2-MCPD. It forms monoesters
with fatty acids (GE) during the reﬁning of vegetable oils.
Chloropropanols are formed in HVP during the hydrochloric acid-mediated hydrolysis step of the
manufacturing process. In food production, chloropropanols form from the reaction of endogenous or
added chloride with glycerol or acylglycerols, although the precise mechanism has not yet been
elucidated. The major proposed routes of formation of 3- and 2-MCPD fatty acid esters include a direct
nucleophilic attack by chloride ions on the acylglycerol carbon atom attached to an ester or hydroxyl
group; the formation via chlorination of a GE; and formation via a cyclic acyloxonium ion or a cyclic
acyloxonium free radical.
The only identiﬁed source of GE in food is reﬁned vegetable oil where they appear to be formed
during the heating of diacylglycerol (DAG) or monoacylglycerol under the high temperature conditions
of deodorisation.
GE formation is believed to be independent from MCPD fatty acid ester formation, although they
may also be formed by elimination of hydrochloric acid from MCPD monoesters that have a vicinal
chlorohydrin structure. These monoesters are 3-MCPD that is esteriﬁed in the 1- or 2-position and
2-MCPD monoesters.
Processing conditions used in the manufacture of HVP produce free 3- and 2-MCPD. Steps are now
taken routinely to both reduce their formation and to lower their levels, but the problem is not
eliminated. Glycidyl esters are formed from DAG on heating vegetable oils to temperatures in excess of
200°C, for example during the deodorisation stages of reﬁning, and are therefore a particular problem
in palm oil, which can have a high (4–12%) DAG content.
Analytical methods for free 3- and 2-MCPD in foods are well characterised, validated for a suitable
range of foods and ﬁt for purpose. There are no suitable methods for unstable free glycidol. Indirect
methods for ester-bound 3- and 2-MCPD and glycidol in foods are well characterised for the important
range of foods. Three validated American Oil Chemists’ Society (AOCS) methods exist and provide
directly comparable results. The methods for free MCPD do not include MCPD released from esters,
and the methods for ester-bound 3- and 2-MCPD and glycidol do not provide data for the free
compounds. Two methods were therefore applied – one for free MCPD and one for MCPD and glycidol
released from bound forms.
In its exposure assessment, the CONTAM Panel considered a total of 7,175 occurrence data on
3-MCPD, 2-MCPD and glycidol (collated as measures were implemented to reduce the levels of these
compounds in edible fats/oils). Data on glycidol were only available from the ester-bound form. Three
categories of analytical data were considered – one on 3-MCPD (in free form) in soy sauce, HVP and
related products (702 data points); another on 3- and 2-MCPD from esters and glycidol from esters in
oils/fats (4,754 data points); and a third one on 3- and 2-MCPD (free and from esters) and glycidol
(from esters) in food groups other than those mentioned above (1,719 data points). In the third
category, in most cases, the contribution to the total 3- and 2-MCPD from the free form was included,
while the results on glycidol were only from esters. In fats and oils, only the ester-bound forms were
analysed because the contribution of the free forms was considered negligible. More than half of the
data referred to fats and oils, but other food groups where the presence of these substances is
expected were also represented in the data set. Where possible, for food groups not represented in
the data set, the occurrence of 3-, 2-MCPD and glycidol was calculated using a model based on the
available data on fats and oils, taking into account the market share of the different oils in Europe.
This model was also used to estimate the contribution of 3- and 2-MCPD from ester-bound forms in
food groups for which data were available only for the free forms.
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The highest occurrence values were found in the food group ‘Fats and oils’, with ‘Palm oil/fat’
showing a mean middle bound (MB) level of 2,912 µg/kg for 3-MCPD (from esters), 1,565 µg/kg for
2-MCPD (from esters) and 3,955 µg/kg for glycidol (from esters). Lower mean MB levels were
calculated for other oils, ranging between 48 and 608 µg/kg for 3-MCPD (from esters), between 86
and 270 µg/kg for 2-MCPD (from esters) and between 15 and 650 µg/kg for glycidol (from esters).
‘Margarine, normal fat’ had mean MB levels of 668 µg/kg for 3-MCPD (from esters), 236 µg/kg for
2-MCPD (from esters) and 582 µg/kg for glycidol (from esters). Among food groups other than fats
and oils, the highest levels were observed in ‘Potato crisps’ (mean MB levels of 216 µg/kg for total
3-MCPD, 135 µg/kg for total 2-MCPD and 110 µg/kg for glycidol from esters), ‘Hot surface cooked
pastries’ (mean MB levels of 247 µg/kg for total 3-MCPD, 123 µg/kg for total 2-MCPD and 137 µg/kg
for glycidol from esters), ‘Cookies’ (mean MB levels of 200 µg/kg for total 3-MCPD, 103 µg/kg for total
2-MCPD and 134 µg/kg for glycidol from esters) and ‘Short crusts’ (mean MB levels of 154 µg/kg for
total 3-MCPD, 79 µg/kg for total 2-MCPD and 149 µg/kg for glycidol from esters).
The exposure assessment for 3- and 2-MCPD was based upon the level of exposure to the parent
compounds, regardless of their original form (i.e. as free or as ester of fatty acids), and referred to as
3-MCPD and 2-MCPD. Likewise, exposure to glycidol referred to the parent compound, although in this
case, the original forms were exclusively as fatty acid esters.
Chronic dietary exposure to 3- and 2-MCPD and glycidol was assessed as mean and high (95th
percentile, P95) exposure across dietary surveys. The exposure levels showed relatively little difference
between lower bound (LB) and upper bound (UB) estimates, and the risk characterisation was
therefore based on MB estimates of exposure. In all scenarios, the youngest population groups
(‘Infants’, ‘Toddlers’ and ‘Other children’) showed the highest dietary exposure estimates.
The mean exposure to 3-MCPD was 0.5–1.5 µg/kg body weight (bw) per day (MB) across the
dietary surveys for the age groups ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure (P95) to
3-MCPD was 1.1–2.6 µg/kg bw per day (MB) across dietary surveys in these age groups. In
adolescents and adult population groups (adults, elderly, very elderly), the mean exposure to 3-MCPD
ranged from 0.2 to 0.7 µg/kg bw per day (MB) and the high exposure (P95) ranged from 0.3 to
1.3 µg/kg bw per day (MB).
The mean 2-MCPD exposure (MB) across dietary surveys ranged from 0.2 to 0.7 µg/kg bw per day,
for ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure (P95) to 2-MCPD was 0.5–1.2 µg/kg bw
per day (MB) across dietary surveys in these age groups. In adolescents and adult population groups
(adults, elderly, very elderly), the mean exposure to 2-MCPD ranged from 0.1 to 0.3 µg/kg bw per day
(MB) and the high exposure (P95) ranged from 0.2 to 0.6 µg/kg bw per day (MB).
The mean exposure to glycidol was 0.3–0.9 µg/kg bw per day (MB) across the dietary surveys for
the age groups ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure (P95) to glycidol was
0.8–2.1 µg/kg bw per day (MB) across dietary surveys in these age groups. In adolescents and adult
population groups (adults, elderly, very elderly), the mean exposure to glycidol ranged from 0.1 to
0.5 µg/kg bw per day (MB). The high exposure (P95) in ‘Adolescents’ ranged from 0.4 to 1.1 µg/kg bw
per day (MB) and in adults and older population groups ranged from 0.2 to 0.7 µg/kg bw per day (MB).
Exposure scenarios of infants receiving formula only, based on mean consumption and mean
occurrence in the formula, resulted in daily intake of 2.4 µg/kg bw for 3-MCPD, 1.0 µg/kg bw for
2-MCPD and 1.9 µg/kg bw for glycidol. Using P95 occurrence data resulted in daily intake of 3.2 µg/kg
bw for 3-MCPD, 1.6 µg/kg bw for 2-MCPD and 4.9 µg/kg bw for glycidol.
For ‘Infants’, the food groups ‘Infant and follow-on formulae’, ‘Vegetable fats and oils’ and ‘Cookies’
were the major contributors to 3- and 2-MCPD and glycidol exposure. For ‘Toddlers’, the food groups
‘Vegetable fats and oils’, ‘Cookies’ and ‘Pastries and cakes’ were the major contributors to 3- and 2-MCPD
and glycidol exposure. ‘Infant formula’ and follow-on formula’ were also important contributors to 3- and
2-MCPD exposure. For ‘Other children’, the food groups with highest contribution to exposure to 3- and
2-MCPD and glycidol were ‘Pastries and cakes’, ‘Margarine and similar’ and ‘Cookies’. For glycidol, ‘Fried or
roast meat’ was an additional relevant contributor. ‘Vegetable fats and oils’ also contributed to 3- and
2-MCPD, and glycidol exposure. For ‘Adolescents’, ‘Adults’, ‘Elderly’ and ‘Very elderly’, the major sources of
3- and 2-MCPD and glycidol were ‘Margarine and similar’ and ‘Pastries and cakes’. Additionally, ‘Fried or
baked potato products’ were important contributors to 3- and 2-MCPD exposure while ‘Fried or roast
meat’ and in some cases ‘Chocolate spreads and similar’ were important contributors to glycidol
exposure.
3-MCPD and its dipalmitate fatty acid esters appear to be rapidly and efﬁciently absorbed following
ingestion with extensive presystemic de-esteriﬁcation occurring in the gastrointestinal tract of rats.
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Elimination of 3-MCPD from serum was also rapid following dosing with either the parent compound or
its dipalmitate ester. 3-MCPD is extensively metabolised by routes including conjugation to glutathione
and oxidation to b-chlorolactate and oxalic acid, with less than 5% appearing in the urine and faeces
as parent compound. The majority of 3-MCPD is eliminated from serum within a few hours of dosing
with either the parent compound or its dipalmitate ester.
No toxicokinetic data for 2-MCPD were identiﬁed. However, the difference in the structural
localisation of the chorine within the molecule makes it unlikely that 2-MCPD exhibits the same
metabolic pattern as 3-MCPD.
Glycidol and its fatty acid esters are efﬁciently absorbed following ingestion. Signiﬁcant presystemic
hydrolysis of GE occurs, although the de-esteriﬁcation process appears to be more extensive in rats
than in monkeys. Metabolism of the glycidol moiety proceeds rapidly by several enzymatic pathways,
including glutathione conjugation and mercapturate formation. The glycidol moiety is predominantly
excreted in urine as poorly described metabolites.
In short-term studies in rat, 3-MCPD produces severe renal toxicity at single intraperitoneal (i.p.)
doses between 100 and 120 mg/kg bw, which persists for several weeks. Repeated oral doses also
result in renal toxicity, and progressive nephropathy and renal tubule dilation can be seen after a daily
dose as low as 5.2 mg/kg bw. The renal toxicity of 3-MCPD appears to reside with the R isomer.
3-MCPD administered to rats at 30 mg/kg bw per day impaired red blood cell function by
decreasing haemoglobin content and inducing volume fraction changes consistent with normocytic and
normochromic anaemia.
Neurotoxic effects such as hind limb paralysis were reported only at doses over 50 mg/kg bw per
day following short-term exposure in mice.
In long-term studies, doses as low as 2 mg/kg bw per day 3-MCPD caused progressive
nephrotoxicity (characterised by tubular hyperplasia), testicular toxicity (atrophy and arteritis) and
mammary glandular hyperplasia in male rats and nephrotoxicity in female rats. Related to these
effects, benign tumours of the testes (Leydig cell tumours), mammary gland (ﬁbroadenoma) and
kidney (tubular adenoma) developed.
Doses between 5 and 10 mg/kg bw per day 3-MCPD administered to rats can completely impair
male fertility without changing sperm production. This effect has been demonstrated in several species
including primates and is reversible. The no observed adverse effect level (NOAEL) of 3-MCPD on male
fertility is not clear. Single and multiple doses of 3-MCPD administered to pregnant rats decreased the
number of implantations and increased fetal loss but were not teratogenic. The NOAEL for multiple
doses was 10 mg/kg bw per day for maternal toxicity and 30 mg/kg bw per day for fetal toxicity.
Despite some positive genotoxicity tests in vitro, there is no evidence that 3-MCPD is genotoxic
in vivo in any organ tested, including the kidney and testis.
From the available information on 3-MCPD fatty acid esters, it can be concluded that the range of
toxic effects for esteriﬁed 3-MCPD is the same as that seen for the free 3-MCPD, supporting the view
that the esters are cleaved and toxicity is primarily exerted by 3-MPCD.
After equimolar multiple doses of 3-MCPD and 3-MCPD dipalmitate, the biochemical changes
associated with renal toxicity are similar in pattern and magnitude. Both compounds produce an array
of renal histopathology including glomerular lesions and tubular epithelial hyperplasia.
There is limited evidence that some esters of 3-MCPD have male antifertility effects at a similar
molar dose to 3-MCPD, and degenerative changes in the spermatogenic tubules have been recorded
after treatment with 3-MCPD fatty acid esters.
No studies on the in vitro genotoxicity of 3-MCPD fatty acid esters were identiﬁed. From the limited
evidence (one study with different endpoints) available, there is no indication that 3-MCPD fatty acid
esters are genotoxic in vivo.
The CONTAM Panel concluded that the kidney and testis appeared to be the main target organs for
3-MCPD-induced toxicity, the toxic effects being associated with oxidative metabolism of 3-MCPD to
b-chlorolactaldehyde and b-chlorolactic acid. The inhibition of glycolysis by metabolites associated with
the b-chlorolactate pathway was suggested as the possible nephron- and spermo-toxic mechanism of
3-MCPD.
The CONTAM Panel concluded that the Leydig cell and mammary gland tumours observed following
long-term exposure to 3-MCPD were probably not relevant to humans.
The CONTAM Panel selected two long-term exposure studies where rats received 3-MCPD via
drinking water to perform dose–response analysis for effects in the kidney and testis. The results of
both studies were analysed and those showing a monotonic dose–response trend were selected for
benchmark dose (BMD) analysis.
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The CONTAM Panel established a tolerable daily intake (TDI) of 0.8 µg/kg bw per day for 3-MCPD.
This was based on a chronic study in rats in which the lowest BMDL10 of 0.077 mg/kg bw per day for
renal tubular hyperplasia in males was derived and application of an overall uncertainty factor of 100.
Noting the lack of speciﬁc data on 3-MCPD fatty acid esters and their hydrolysis, the CONTAM Panel
conﬁrmed that the toxicity of 3-MCPD fatty acid esters should be considered equivalent (on a molar
basis) to that of the parent compound. Therefore, the CONTAM Panel concluded that the TDI of
0.8 µg/kg bw per day constitutes a group TDI for 3-MCPD and its fatty acid esters (expressed as
MCPD equivalents).
The mean exposure to 3-MCPD was below the established group TDI of 0.8 µg/kg bw per day in
‘Adolescents’, ‘Adults’ and older age classes in all dietary surveys. In ‘Infants’, ‘Toddlers’ and ‘Other
children’, half of the dietary surveys had mean exposure at or above the group TDI, up to a maximum
of about 1.5 µg/kg bw per day in ‘Toddlers’ and ‘Other children’. The high exposure (P95) to 3-MCPD
for ‘Infants’, ‘Toddlers’ and ‘Other children’ was above the group TDI in all dietary surveys, ranging
between a minimum of 1.1 µg/kg bw per day in ‘Other children’ or roughly 1.5 µg/kg bw per day in
‘Infants’ and ‘Toddlers’ up to about 2.5 µg/kg bw per day in all the three age classes. The estimated
exposure to 3-MCPD of infants receiving formula only was 2.4 µg/kg bw per day using mean
occurrence and 3.2 µg/kg bw per day using P95 of occurrence; both values are above the group TDI,
which is exceeded up to fourfold. The high exposure (P95) to 3-MCPD for adolescents was at or above
the group TDI in half of the dietary surveys, with exposure estimates up to 1.4 µg/kg bw per day. For
‘Adults’ and the older age classes, only the maximum P95 of dietary exposure to 3-MCPD was around
the group TDI.
There are limited data on the short-term toxicity of 2-MCPD. Acute median lethal dose (LD50) was
estimated to be between 50 and 60 mg/kg bw in rats. A single i.p. dose of 200 mg/kg bw, although
generally toxic, did not cause signs of renal toxicity. In a 28-day study in rats, daily doses of 16 or
30 mg/kg bw caused severe myopathy and nephrotoxicity. From 8 days of treatment, severe lesions
leading to cell death developed in striated muscle, particularly in cardiac myocytes that resulted in
heart failure and the death of some animals. These effects were not observed at 2 mg/kg bw per day.
No data on long-term studies for 2-MCPD or 2-MCPD fatty acid esters were identiﬁed.
In vitro genotoxicity data on 2-MCPD were too limited to make any conclusion. No mammalian
in vivo genotoxicity studies have been identiﬁed for 2-MCPD and 2-MCPD fatty acid esters.
2-MCPD did not induce kidney toxicity at doses at which 3-MCPD produced renal failure, enlarged
kidneys and long-lasting diuresis. These differences were explained by the fact that metabolism of
2-MCPD to b-chlorolactaldehyde and b-chlorolactate cannot occur, which is believed to play an
important role in nephrotoxicity of 3-MCPD. The underlying mechanisms for renal toxicity and the
destruction of striated muscles, including the heart, are unknown.
Although the exposure data were available, it was not possible to undertake risk characterisation
for 2-MCPD due to the lack of information.
For glycidol, neurotoxicity was observed after 28 days of treatment of rats with 200 mg/kg bw per
day. Glycidol caused renal toxicity in repeated dose studies in rats and mice at doses in the range
150–400 mg/kg bw per day.
Two-year carcinogenicity studies in mice (25 and 50 mg/kg bw per day) and rats (37.5 and 75 mg/kg
bw per day) showed induction of tumours in multiple organs from both sexes. Supporting evidence for
carcinogenicity of glycidol was provided by a short-term study in a transgenic mouse strain.
Male anti-fertility effects have been noted in rats and mice. The lowest observed adverse effect
level (LOAEL) was 25 mg/kg bw per day in the rat, resulting in a 36% reduction in epididymal sperm
count. This may be attributed to conversion of glycidol to 3-MCPD in the stomach. Glycidol was
maternally toxic in mice without producing any major external abnormalities in the fetus. Neurotoxicity
was observed in male pups of rats exposed to a maternal dose of 49 mg glycidol/kg bw per day
during pregnancy and weaning.
Glycidol and its esters, from which the free compound can be derived, possess a reactive epoxide
moiety. There is strong evidence from in vitro data and some evidence from in vivo studies that
glycidol is a genotoxic compound.
The CONTAM Panel only considered toxicity studies in animals with glycidol as no in vivo data were
identiﬁed for glycidyl esters. Dose–response considerations were made for glycidol assuming a
complete hydrolysis of the esters to free glycidol following ingestion. However, the dose–response data
were considered inadequate for BMD modelling. Based on the EFSA Guidance on substances that are
genotoxic and carcinogenic, T25 values were calculated for the incidence of tumours observed in rats
MCPD and glycidyl esters in food
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and mice following long-term exposure to glycidol. A T25 of 10.2 mg/kg bw per day for peritoneal
mesothelioma in male rats was used as the reference point.
In view of the genotoxic and carcinogenic potential of glycidol, a margin of exposure (MoE)
approach was applied. MoE estimates were calculated by dividing the reference point of 10.2 mg/kg
bw per day by the exposure levels. A MoE of 25,000 or higher was considered of low health concern.
For ‘Infants’, ‘Toddlers’ and ‘Other children’, the MoE estimates for the mean exposure ranged from
34,000 to 11,300; the MoE for high (P95) exposure ranged from 12,800 to 4,900. For ‘Adolescents’
and ‘Adults’, ‘Elderly’ and ‘Very elderly’ age groups, the MoE for the mean exposure ranged from
102,000 to 20,400, whereas at high (P95) exposure the range was from 51,000 to 9,300.
The MoE estimates corresponding to the P95 of exposure for ‘Infants’ were particularly low due to
the contribution of glycidyl esters from infant formulae. The scenarios calculated for ‘Infants’ receiving
only formula diet resulted in a MoE of about 5,400 for the mean occurrence and 2,100 for the P95 of
occurrence.
In conclusion, estimated exposure substantially exceeding the group TDI for 3-MCPD is of concern;
this is particularly seen in the younger age groups. Although there is a high uncertainty in the
reference point used as a basis for the calculation of the MoEs for glycidol, the MoEs lower than
25,000 indicate a health concern.
The CONTAM Panel recommended to include all food groups potentially contaminated and foods
where mitigation measures have been enforced in the future monitoring activities for 3-, 2-MCPD and
glycidol. The enantiomeric composition of 3-MCPD and its fatty acid esters present in food should be
studied. Further studies on the rates and degree of de-esteriﬁcation and the metabolic fate for 3- and
2–MCPD fatty acid esters and GE were recommended. For 2-MCPD, the CONTAM Panel recommended
generation of additional data to elucidate the long-term toxicity and the mode and mechanism of
action of the substance. More extensive testing of the dose–response for carcinogenesis from chronic
lifetime oral administration of glycidol and its esters in rats would reduce uncertainty in the risk
assessment.
MCPD and glycidyl esters in food
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
3-Monochloropropane-1,2-diol (3-MCPD) is a food processing contaminant for which a tolerable
daily intake (TDI) of 2 lg/kg bw has been established. A maximum level of 20 lg/kg for hydrolysed
vegetable protein (HVP) and soy sauce has been established for liquid products containing 40% dry
matter, corresponding to a maximum of 50 lg/kg in the dry matter by Commission Regulation (EC)
1881/20061.
Esters of 3-monochloropropane-1,2-diol (3-MCPD) and 2-monochloropropane-1,3-diol (2-MCPD) and
glycidyl esters are important contaminants of processed edible oils used as foods or food ingredients.
The European Food Safety Authority (EFSA) Panel on Contaminants in the Food Chain (CONTAM)
agreed with the estimate of 100% release of 3-MCPD from its esters in humans.2
Glycidyl fatty acid esters (GE) are process contaminants generated during the deodorisation step of
edible oil reﬁning. The toxicological relevance of GE has not yet been fully elucidated. Glycidol itself is
categorised as probably carcinogenic to humans. Latest scientiﬁc studies indicate an (almost) entire
release of glycidol from fatty acid esters within the human digestive tract.
EFSA has published on 20 September 2013 a scientiﬁc report on the analysis of occurrence of
3-MCPD in food in Europe for the years 2009–2011 and preliminary exposure assessment.3
The European Commission would like to request from EFSA a scientiﬁc opinion on the risk for public
health as the consequence of the presence of 3- and 2-MCPD and glycidyl esters in food, with a view
to taking permanent risk management measures.
The opinion should address the possible acute and chronic health effects, including risks for speciﬁc
vulnerable population groups, and address the question whether an acute reference dose (ARfD) is
needed. It should also address the question whether the use of a variability factor would be
appropriate.
In order to enable EFSA to carry out such risk assessment, Member States with the active
involvement of food business operators were requested to monitor the presence of 3- and
2-MCPD and glycidyl esters in food and to submit those data to EFSA and the Commission before
1 October 2014. Monitoring guidelines, deﬁning the data to be submitted and their format, have
been circulated among Member States and food business operators.
Terms of Reference as provided by the European Commission
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002 the Commission asks EFSA
for a scientiﬁc opinion on the risks for human health related to the presence of
3-monochloropropane-1,2-diol (3-MCPD) and 2-monochloropropane1,3-diol (2-MCPD) (3- and 2-MCPD)
and 3- and 2-MCPD fatty acid esters and GE in food.
The scientiﬁc opinion should, inter alia, comprise evaluation of the toxicity of 3- and 2-MCPD,
3- and 2-MCPD fatty acid esters and GE for humans, considering all relevant toxicological
endpoints;
the exposure of the EU population to 3- and 2-MCPD fatty acid esters and GE in addition to the
exposure to 3- and 2-MCPD, including the consumption patterns of speciﬁc (vulnerable) groups of the
population (e.g. high consumers, children, people following a speciﬁc diet, etc.).
1.2. Additional information
1.2.1. Deﬁnitions
This Opinion refers to 3-MCPD and 2-MCPD and their fatty acid esters, and also to fatty acid esters
of glycidol.
1 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5.
2 Statement of the Scientiﬁc Panel on Contaminants in the Food chain (CONTAM) on a request from the European Commission
related to 3-MCPD esters. Available online: http://www.efsa.europa.eu/en/efsajournal/doc/1048.pdf
3 European Food Safety Authority, 2013 Analysis of occurrence of 3-monochloropropane-1,2-diol (3-MCPD) in food in Europe in the
years 2009–2011 and preliminary exposure assessment. EFSA Journal 2013;11(9):3381, 45 pp. doi:10.2903/j.efsa.2013.3381.
Available online: www.efsa.europa.eu/efsajournal
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3-MCPD refers to 3-monochloropropane-1,2-diol [CAS Number 96-24-2].
OH OH
Cl
Its IUPAC name is 3-chloropropane-1,2-diol (3-CPD).
It has also been called a-chlorohydrin and glycerol a-monochlorohydrin.
Its empirical formula is C3H7ClO2 and molecular weight is 110.5.
3-MCPD exists as enantiomers (R)-(-)-3-chloropropane-1,2-diol [CAS Number 57090-45-6] and (S)-(+)-
3-chloropropane-1,2-diol [CAS Number 60827-45-4].
2-MCPD refers to 2-monochloropropane-1,3-diol [CAS Number 497-04-1].
OH
Cl
OH
Its IUPAC name is 2-chloropropane-1,3-diol (2-CPD).
It has also been called beta-chlorohydrin and glycerol b-monochlorohydrin.
Its empirical formula is C3H7ClO2 and molecular weight is 110.5.
Glycidol has the IUPAC name oxiranylmethanol [CAS Number 556-52-5].
OH
O
It has also been called 2,3-epoxy-1-propanol, 3-hydroxypropylene oxide, epoxypropyl alcohol,
hydroxymethyl ethylene oxide, and 2-hydroxymethyl oxiran.
Glycidol has the empirical formula C3H6O2 and molecular weight is 74.08.
Glycidol exists as the optically active isomers (R)-(+)-glycidol [CAS Number 57044-25-4] and (S)-(-)-
glycidol [CAS Number 60456-23-7].
3-MCPD, 2-MCPD and glycidol esters
3-MCPD, 2-MCPD and glycidol can each form esters with the fatty acids commonly present in edible
vegetable oils.
3-MCPD monoester 3-MCPD diester glycidyl ester
R: Fatty acid
Cl
OH
O
R
O
Cl
O
O
O
R
O O
O
R
O
3-MCPD and 2-MCPD can each formmonoesters in which one of the two hydroxyl groups is esteriﬁed. They
can also form diesters where both hydroxyl groups are esteriﬁedwith the same or with different fatty acids.
Glycidol has a single hydroxyl group and so forms only monoesters.
OH H
Cl
H
HOCH2
OH H
Cl
HOCH2
H
HH
( )-3-MCPD ( )-3-MCPDR S
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1.2.2. Background
Chloropropanols are chlorinated derivatives of glycerol (1,2,3-propanetriol), having one or two
chlorine atoms in various conﬁgurations on the glycerol molecule. Their presence in food was
discovered by Velısek et al. (1978) during studies carried out at the Institute of Chemical Technology in
Prague into the composition of acid-HVP used as a savoury ﬂavour-enhancing food ingredient. Several
chloropropanols were identiﬁed in HVP and in subsequent studies on model systems. The major
volatile compounds found were 3-chloropropan-1-ol, 1,3-dichloropropan-2-ol (1,3-DCP), 2,
3-dichloropropan-1-ol (2,3-DCP). Non-volatile chloropropanols found were 3-monochloropropane-1,
2-diol (3-MCPD) and 2-monochloropropane-1,3-diol (2-MCPD) and their fatty acid esters (Velısek et al.,
1979, 1980; Davıdek et al., 1980). Efforts to remove the simple chloropropanols from foodstuffs have
led to a signiﬁcant reduction in contamination; however, the extent and level of contamination of
3- and 2-MCPD fatty acid esters in foods was largely overlooked until Svejkovska et al. (2004) reported
their presence in a range of foods, and the source was later identiﬁed as reﬁned vegetable oil
(Zelinkova et al., 2006).
3- and 2-MCPD fatty acid esters are produced in vegetable oils on reﬁning and they contain the
fatty acids common to the parent oils and fats and in a similar ratio, although some factors such as
volatility and deodorisation conditions can cause small differences. Glycidol is associated with the
formation and decomposition of 3- and 2-MCPD. It forms monoesters with fatty acids (GE) during the
reﬁning of vegetable oils.
The formation, occurrence, analysis and toxicity of 3- and 2-MCPD and their esters including GE has
been reviewed to varying extent in several publications (Hamlet, 2008, 2009; Hamlet and Sadd, 2009;
Larsen, 2009; Bakhiya et al., 2011; Andres et al., 2013; Jala et al., 2015; Teng and Wang, 2015).
1.2.3. Previous assessments
3- MCPD and 3-MCPD fatty acid esters
The European Commission’s Scientiﬁc Committee on Food (SCF) concluded that the increase in
benign tumours observed in the long-term carcinogenicity assay in rats is the result of non-genotoxic
mechanisms (SCF, 1994), either through chronic hormonal imbalance (mammary gland ﬁbromas,
Leydig cell tumours) or sustained cytotoxicity and chronic hyperplasia (renal tumours). This conclusion
was also reached by the UK Committee on Carcinogenicity of Chemicals in Food, Consumer Products
and the Environment (UK COC, 2000). 3-MCPD was classiﬁed by the European SCF in 2001 as a
non-genotoxic, threshold carcinogen (SCF, 2001; JECFA, 2002).
In 2004, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) performed a risk
assessment on the presence of 3-MCPD in food, which results from hydrochloric acid hydrolysis of
vegetable protein and mainly occurred in soy sauce. Renal tubular hyperplasia represented the
critical effect in rats exposed chronically. Data indicating a lack of genotoxicity in vivo led the
Committee to conclude that MCPD induces neoplasia in the rat by a mechanism that does not
involve DNA damage and does require exposure above a threshold dose. A provisional maximum
tolerable daily intake (PMTDI) of 2 lg/kg bw per day was established based on a lowest observed
effect level (LOEL) of 1.1 mg/kg bw per day for renal tubular hyperplasia and a safety factor of 500.
Exposure data available to the Committee, which showed infrequent occurrences of 3-MCPD in the
soy sauce, indicated that the estimated mean intake of 3-MCPD by consumers of soy sauce would be
at or above the PMTDI.
In 2008, the CONTAM Panel released a statement in response to a request from the EC related to
the presence of 3-MCPD fatty acid esters in food. The Panel conﬁrmed the assessment of the
Bundesinstitut f€ur Risikobewertung (BfR) in its 2007 opinion regarding the uncertainties described by
the BfR associated with the toxicity and bioavailability of 3-MCPD from its fatty acid esters and
reafﬁrmed the need for additional toxicokinetic studies.
An opinion on the presence of 3-MCPD and its fatty acid esters in foods was published by the BfR
in 2012 based on its 2007 review of 3-MCPD in food that established a TDI of 2 lg/kg bw per day and
newer ﬁndings related to bioavailability of MCPD from its fatty acid esters and subchronic toxicity
testing of MCPD and its dipalmitate ester in rats. Important data gaps were identiﬁed in the current
exposure assessment arising from incomplete information on the content of MCPD fatty acid esters in
food and the impact of minimisation strategies already implemented by the food industry on the
content of MCPD fatty acid esters in food.
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In 2012, Codex Alimentarius published a code of practice, based on good manufacturing practices,
for the reduction of 3-MCPD during the production of acid-HVP and its products. Several approaches
were recommended to reduce the formation of 3-MCPD during hydrolysis of vegetable protein
products, including careful control of the temperature and heating time for the acid hydrolysis step, its
subsequent neutralisation with alkali, use of sulphuric acid instead of hydrochloric acid, and
substitution by fermentation.
In 2013, the International Agency for Research on Cancer (IARC) noted that there was ‘no
evidence to suggest that 3-MCPD is not genotoxic’. This conclusion was based on the available in vivo
data at that time: micronucleus assay on bone marrow and unscheduled DNA synthesis in the liver
(Robjohns et al., 2003).
None of the authorities have published risk assessments on 2-MCPD.
Glycidol and glycidyl fatty acid esters
Glycidol was classiﬁed by IARC as group 2A, ‘probably carcinogenic to human’ (IARC 2000).
A preliminary assessment of GE in reﬁned vegetable oils was published by the BfR in 2009 based
on the preliminary ﬁndings of mg/kg levels of GE in several common reﬁned vegetable oils,
particularly palm oil. A preliminary estimate of potential dietary intake, especially from margarine and
commercial dairy products for infants, the genotoxic and carcinogenic properties for glycidol, and the
likelihood for hydrolytic metabolism to bioavailable glycidol, led the BfR to conclude that current
levels of exposure of infants and some adults could present a hazard to human health. The BfR
recommended that the levels of GE in vegetable oils should be reduced as far as possible. Important
data gaps were identiﬁed as analytical methodology for accurate quantiﬁcation of glycidol and its
fatty acid esters in edible fats and oils and a determination of the bioavailability of glycidol from its
fatty acid esters.
As a part of a safety assessment of foods containing diacylglycerol (DAG) the Food Safety
Commission of Japan (FSCJ, 2015) conducted a risk assessment of glycidol and GE. From the evidence
available on genotoxicity of glycidol, in particular the glycidol-induced DNA damage and gene
mutation, FSCJ concluded glycidol to be a genotoxic carcinogen. Carcinogenicity tests have shown
increased incidences of tumours attributable to glycidol exposure in rats and mice. FSCJ noted that the
data available for GE show weak genotoxicity compared to glycidol and that the data on
carcinogenicity were limited. A benchmark dose (BMD) approach was applied and margins of exposure
of 17,800 and 10,900 for average and maximum consumers, respectively, were derived. FSCJ
concluded ‘While these data suggest no apparent adverse effects due to the consumption of edible oils
currently available, the genotoxic carcinogenicity of glycidol was not denied. Therefore, glycidyl ester
exposure levels should be kept as low as possible according to the principle of ALARA (as low as
reasonably achievable)’.
1.2.4. Chemistry
1.2.4.1. Physical properties
3-MCPD is a colourless or pale yellow viscous oily liquid at room temperature with a density of
1.32 g/cm3, a melting point of 40°C and a boiling point of 213°C at 760 mmHg. 3-MCPD is
hygroscopic, and is highly soluble in water and in organic solvents of moderate to high polarity
including methanol, ethanol, chloroform and ethyl acetate.
2-MCPD is similarly a colourless or pale yellow oily liquid at room temperature with a hygroscopic
nature. It has a density of 1.3  0.1 g/cm3 and a boiling point of 213°C at 760 mmHg.
Glycidol is a colourless liquid at room temperature, soluble in water and most polar solvents.
Fatty acid esters of 3-MCPD and 2-MCPD and glycidol have similar properties (e.g. polarity and
solubility) to the parent fatty acids, with slightly lower melting points (Hamlet et al., 2011). However,
detailed measurements of these properties are yet to be made.
1.2.4.2. Chemical properties
3-MCPD is a chiral molecule (described in Section 1.2) and exists as a mixture of (R)- and (S)-
enantiomers that are derived from prochiral L-glycerol. They are present in a ratio of 1:1 in acid-HVP.
The biological activity of the enantiomers differs and is discussed in if available. It should be noted
that the majority of investigations described in this report and elsewhere, across a broad variety of
topics from chemistry to toxicity, are for the racemic mixture. 3-MCPD reacts readily with acids,
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alcohols, aldehydes, ammonia, amino compounds, ketones and thiols (Velısek et al., 1991). The
reactions of 2-MCPD with compounds of these classes are likely to be similar.
3-MCPD, 2-MCPD and glycidol can form esters with fatty acids. The reaction usually occurs under the
high temperature conditions of edible oil reﬁning. Thus the fatty acids forming esters are those
commonly encountered in edible vegetable oils. The major esterifying acids depend on the type of oil but
most common oils are lauric acid (dodecanoic acid C12:0), myristic acid (tetradecanoic acid C14:0),
palmitic acid (hexadecanoic acid C16:0), stearic acid (octadecanoic acid C18:0), oleic acid (octadecenoic
acid C18:1), linoleic acid (octadecadienoic acid C18:2) and linolenic acid (octadecatrienoic acid C18:3).
3-MCPD and 2-MCPD can each form monoesters and diesters, and in the case of diesters positional
isomers exist in which the two hydroxyl groups are esteriﬁed with different acids. The esters are formed
in a similar ratio to that of the acids in the parent oil, although some factors such as volatility and
deodorisation conditions can cause small differences.
Fatty acid esters of 3- and 2-MCPD, and GE, are soluble in non-polar solvents and have poor
solubility in water. The full solubility characteristics of individual MCPD fatty acid esters and GE have
not been studied; however, it may be assumed that MCPD monoesters have a higher solubility than
diesters in polar solvents and that increasing the fatty acid chain length in both mono- and diesters
reduces the solubility in polar solvents and increases the solubility in non-polar solvents.
1.2.4.3. Formation mechanisms of 3- and 2-MCPD
Chloropropanols are formed in acid-HVP during the hydrochloric acid-mediated hydrolysis step of
the manufacturing process. Acid-HVP is usually manufactured by treating cereal materials, including
proteinaceous oilseeds, with hydrochloric acid at high temperature and pressure. The hydrochloric acid
reacts with lipids such as triacylglycerols and phospholipids, and with partial acylglycerols
(monoglycerols and DAG) and glycerol formed by acid hydrolysis of triacylglycerols (Collier et al.,
1991). In food production, chloropropanols are formed from the reaction of endogenous or added
chloride with glycerol or acylglycerols, although the precise mechanisms are yet to be fully elucidated.
The mechanism for 3- and 2-MCPD formation involves a cyclic acyloxonium ion intermediate (Collier
et al., 1991; Hamlet et al., 2003, 2004b). Glycerol is protonated by hydrochloric acid at the primary
and secondary hydroxyl groups to form alkyloxonium ions. Water is displaced from the primary
position hydroxyl alkyloxonium cations giving a racemic mixture of both 3-MCPD enantiomers. The
secondary position hydroxyl group alkyloxonium ions dissociate to give water and a carbocation which
reacts with chloride to give 2-MCPD.
The formation of 3-MCPD and 2-MCPD from glycerol and acylglycerols increases with increasing salt
concentration and reaches a maximum with a water content of about 15%, and more is formed from
triacylglycerols than from glycerol alone. In the absence of added water, there is no prior hydrolysis of
the acyl group and 3-MCPD is formed by the direct substitution of the glycerol hydroxyl group by
chloride ion.
1.2.4.4. Formation mechanisms of 3-MCPD and 2-MCPD fatty acid esters
Current knowledge on the factors affecting the formation of 3-MCPD fatty acid esters and GE has
been summarised by Craft et al. (2013). The formation pathways of 3- and 2-MCPD fatty acid esters
have been reviewed (Hamlet, 2009; Hamlet and Sadd, 2009; Hamlet et al., 2011; Zhang et al., 2013;
Jala et al., 2015). The major proposed formation routes have been described in some detail by Zhang
et al. (2013), Hamlet et al. (2011) and by Rahn and Yaylayan (2011).
Under high temperature conditions in the presence of some water, a triacylglycerol is hydrolysed to
give a mixture of DAG isomers (1,2-diacyl- and 1,3-acylglycerol). Further hydrolysis gives a mixture of
monoacylglycerol isomers (1-acylglycerol and 2-acylglycerol). The acylglycerols react through
mechanisms that include formation via an intermediate acyloxonium cation involving a nucleophilic
ring-opening substitution reaction by a chlorine anion, or direct nucleophilic substitution of an ester or
a hydroxyl group by a chlorine anion. Alternatively, a cyclic acyloxonium free radical formed by
elimination of water at high temperature might react with a chlorine radical. MCPD ester formation is
accelerated at high temperatures, but the associated decomposition rates also increase (Svejkovska
et al., 2006; Seefelder et al., 2008).
1.2.4.5. Formation of glycidyl fatty acid esters
The only identiﬁed source of GE in food is reﬁned vegetable oil where they are believed to be
formed during the heating of DAG or monoacylglycerols (partial glycerols) by the elimination of water
or a fatty acid under the high temperature conditions of deodorisation (Hrncirik and Ermacora, 2010;
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Masukawa et al., 2010; Hrncirik and van Duijn, 2011). The greatest amounts are found in oils with a
high DAG content, such as palm oil. The mechanism probably involves an acyloxonium ion or an
intramolecular reaction of DAG (Hamlet et al., 2002; Svejkovska et al., 2006; Hrncirik and Ermacora,
2010; Weißhaar and Perz, 2010; Rahn and Yaylayan, 2011; Craft et al., 2012; Destaillats et al., 2012).
GE formation is believed to be independent from MCPD fatty acid ester formation (Destaillats et al.,
2012), although they may also be formed by elimination of hydrochloric acid from MCPD monoesters
that have a vicinal chlorohydrin structure. These monoesters are 3-MCPD that is esteriﬁed in the 1- or
2-position and 2-MCPD monoesters. The acid composition of GE, and the quantity produced during oil
reﬁning are much dependent on the level of partial acylglycerol precursors and temperature conditions,
as loss through volatilisation accompanies formation, especially for esters of the smaller acids (Craft
et al., 2012).
1.2.4.6. Formation of free and esteriﬁed MCPD and glycidyl esters during food processing
The manufacture of HVP by hydrochloric acid hydrolysis forms signiﬁcant levels of free 3- and
2-MCPD; however, steps have now been incorporated that both reduce their formation and to lower
their levels to below the limits prescribed in some countries by legislation. In the EU a maximum level
of 20 lg/kg 3-MCPD has been set for liquid HVP and soy sauce based on a 40% dry matter content
(Commission Regulation (EC) 1881/20064). Reduction measures include lowering of the hydrolysis
temperature and decomposition of the MCPD by alkaline hydrolysis (Velısek, 2009). Soy sauce
prepared by enzymatic hydrolysis does not contain detectable free or esteriﬁed 3- or 2-MCPD.
3-MCPD is formed in ﬁsh during smoking and curing by salting (Crews et al., 2002). The level of
3-MCPD in ﬁsh (salmon and herring) increases with the smoking time and salt concentration. In long-
term stored samples such as canned ﬁsh 3-MCPD might be released from its esters by lipase activity
(Reece et al., 2005).
In model food heating systems containing water, sodium chloride and glycerol or lipid precursors
3-MCPD production increases with increasing temperature once above 160°C, and with NaCl
concentration up to 10% with acylglycerol precursors but at about 5% NaCl with glycerol. The
optimum water content is 15–20% for 3-MCPD but higher than this for 2-MCPD. Glycerol was the best
precursor of 3-MCPD on a weight basis, and monoacylglycerol was a signiﬁcantly better precursors
than DAG or triacylglycerol.
3-MCPD is formed in cereal (barley) when it is roasted in malt production at temperatures above
170°C. 3-MCPD is extracted from the malt during brewing, but on account of dilution is not detectable
in most beers. Coffee beans have similar concentrations of fat and chloride to barley but unexpectedly
do not form 3-MCPD when heated under similar conditions to malt.
Baked goods are the major source of 3- and 2-MCPD and the formation of these contaminants in
model bakery systems has been studied in some detail in model systems (Hamlet et al., 2003, 2004a,b).
Free glycerol produced by the action of yeast enzymes is the major precursor and the formation reactions
of 3- and 2-MCPD follow zero-order kinetics. The levels of 3-MCPD and 2-MCPD formed increase
exponentially with temperature up to the maximum (about 220°C) used in baking. Low (1% up to 15%)
moisture promotes 3- and 2-MCPD production with levels of 2-MCPD typically 20% of that of 3-MCPD.
The ratio of 3-MCPD to 2-MCPD is related to the water content, on account of either formation or
degradation.
Domestic cooking procedures have been shown to increase the levels of 3-MCPD in a limited
number of foods studied. The effect is particularly observed in the toasting of bread (Crews et al.,
2001; Breitling-Utzmann et al., 2003, 2005; Hamlet and Sadd, 2004). The increase in the level of
3-MCPD content of bread is greater in brown and wholemeal types. It has been shown that domestic
grilling can increase 3-MCPD levels in cheeses, and microwave cooking produces a lesser increase
(Crews et al., 2001). The frying or grilling of meat in the form of beef burgers produces low levels of
3-MCPD, and a signiﬁcant increase in 3-MCPD can occurs on frying batter, depending on the ingredient
composition. Some pre-cooked or cured meats have also been shown to contain low levels of 3-MCPD
(typically < 0.05 lg/kg) prior to cooking under laboratory simulated home cooking, with the highest
levels in salami. The formation of 2-MCPD has not been the subject of similar studies.
3-MCPD has been detected as a product of the combustion of wood (Kuntzer and Weißhaar, 2006).
It was hypothesised that smoke production was associated with the ﬁssion of saccharides to give
compounds such as 3-hydroxyacetone which is known to form 3-MCPD on reaction with hydrochloric
4 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5.
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acid. 3-MCPD can be formed in small amounts from certain carbohydrates (Collier et al., 1991), from
the sweetener sucralose (Rahn and Yaylayan, 2010), and by various routes from epichlorohydrin, used
in the preparation of paper-coating resins that might come into contact with food (Boden et al., 1997).
The formation of 2-MCPD and the epimeric composition of the 3-MCPD formed from the above sources
have not been studied.
Esters of 3- and 2-MCPD are formed during the deodorisation step of edible oil reﬁning either from
partial acylglycerols (Svejkovska et al., 2006; Hrncirik and Ermacora, 2010; Hamlet et al., 2011;
Matth€aus, 2012; Shimizu et al., 2012; Freudenstein et al., 2013) or from triacylglycerol (Destaillats
et al., 2012). Partial acylglycerols form MCPD fatty acid esters more readily than triacylglycerol
(Svejkovska et al., 2006; Matth€aus et al., 2011; Shimizu et al., 2012; Freudenstein et al., 2013). The
quantity of 3- and 2-MCPD fatty acid esters formed in the oil is not clearly correlated with the level of
partial acylglycerols fatty acid ester. The DAG content of oils in fresh fruit pulps such as olive and palm
is usually low (1–3%) but in the oil of fruits of poor quality and in stored and transported oils the
quantity of DAG, particularly 1,3-DAG increases. Where the DAG content exceeds 3–4% there is an
exponential increase in GE formation during deodorisation (Craft et al., 2012). The partial acylglycerol
content of seed oils is generally lower. Partial acylglycerols are also formed from the action of heat and
steam during cooking operations such as frying (Hamlet et al., 2011).
The acylglycerols react with chlorine released from organic compounds present in the oil naturally,
levels of which may be enhanced by uptake of chloride from inorganic fertilisers added to soil (Nagy
et al., 2011). The chlorine is released under high temperatures, particularly during deodorisation,
forming MCPD fatty acid esters and other compounds from reactants that might compete for the
available chlorine (Matth€aus et al., 2011, 2012; Shimizu et al., 2012, 2013a,b; Freudenstein et al., 2013).
The quantity of available chlorine is the limiting factor of MCPD fatty acid ester formation in edible
oil reﬁning. The chlorine source comprises a number of organic and inorganic compounds that have
not been characterised. Those of higher polarity form the major chloride source through either their
greater abundance or higher reactivity (Ermacora and Hrncirik, 2014).
Glycidyl esters are formed mainly from DAG on heating vegetable oils to temperatures in excess of
200°C (Masukawa et al., 2010; Hrncirik and van Duijn, 2011; Destaillats et al., 2012; Craft et al., 2012)
for example during the deodorisation stages of chemical or physical reﬁning, and are therefore a
particular problem in palm oil, which can have a high (4–12%) DAG content. The formation rate and
level is related to the availability of precursors, the deodorisation time and temperature (Weißhaar and
Perz, 2010; Hrncirik and van Duijn, 2011; Craft et al., 2012), and is independent of the formation of
MCPD fatty acid esters. GE can also be formed by the dehydration of monoacylglycerol, but as levels
of monoacylglycerol are naturally low and reduced further during deodorisation they are not signiﬁcant
contributors to GE contamination (Craft et al., 2012). The formation mechanism from DAG is likely to
proceed via an acyloxonium ion or an intramolecular SN2 reaction (Hamlet et al., 2002; Weißhaar and
Perz, 2010; Rahn and Yaylayan, 2011; Destaillats et al., 2012).
There is no evidence of signiﬁcant change in the levels of MCPD fatty acid esters or GE during the
cooking of non-cereal foods (cheeses, salami, cooking oils and potato products). No MCPD fatty acid
esters were seen to be formed or lost under conditions that simulated biscuit baking, but in dough
containing a commercial lipase, free 3- and 2-MCPD isomers were readily released from isotopically
labelled added 3-MCPD fatty acid esters.
1.2.5. Methods of analysis
1.2.5.1. Free 3- and 2-MCPD
Methods for the analysis of free 3- and 2-MCPD were targeted initially at the ﬁrst identiﬁed food
source of 3-MCPD, acid-HVP and then at foods found to be frequently contaminated (soy sauce,
processed meats and ﬁsh, and baked cereals). More recently, the analytical methods for free 3- and
2-MCPD have been included in indirect methods for the measurement of ester-bound MCPD.
Descriptions of the methods have been included in various review publications, notably by Wenzl et al.
(2007, 2015), Hamlet (2008), Hamlet and Sadd (2009) and Teng and Wang (2015).
Methods are based on the use of gas chromatography with mass spectrometric detection (GC-MS).
Derivatisation is required prior to the determination of free 3- and 2-MCPD to improve volatility and the
mass spectrometric response.
The ﬁrst method used for the routine determination of 3-MCPD in acid-HVP was that applied to
acid-HVP by Van Bergen et al. (1992). Acid-HVP, which was originally produced as a liquid of high salt
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content, was ﬁrst absorbed on to a solid phase extraction (SPE) column. Volatile and less polar
chloropropanols such as 1,3-dichloropropanol (1,3-DCP) were eluted with a mixture of hexane and
diethyl ether, and 3-MCPD was eluted separately with diethyl ether. The extracts were combined and
derivatised with heptaﬂuorobutyrylimidazole (HFBI) and resulting heptaﬂuorobutyrate (HFB) ethers
determined by GC with electron capture detection (GC-ECD).
More sensitive methods were developed from the van Bergen procedure. HVP powders (which
replaced earlier liquid products) were dissolved in sodium chloride solution to replicate the liquid
HVP. The diethyl ether extract was concentrated to low volume and the 3-MCPD derivatised to the
di-(HFB) prior to GC-MS. Deuterated internal standards were also introduced. Food samples were
also analysed in this way (after removal of fat) by Hamlet (1998) who used GC with tandem mass
spectrometric determination (GC-MS/MS), and by Brereton et al. (2001) who used GC-MS in selected
ion monitoring (SIM) mode. The latter method was validated by collaborative trial and was accepted
as ofﬁcial methods by the Association of Ofﬁcial Analytical Chemists (AOAC) and by the European
Committee for Standardization (CEN, 2004) and has found widespread use (Nyman et al., 2003;
Leon et al., 2008).
Ethyl acetate has frequently been used as an alternative extraction solvent to diethyl ether
(Wittmann, 1991; Spyres, 1993; Hamlet, 1998; Chung et al., 2002) and it has been reported to give
higher recoveries of 3-MCPD from cereal products such as ﬂour and bread (Hamlet, 1998; Retho and
Blanchard, 2005).
Alternative derivatisation reagents have been applied including N,O-bis(trimethylsilyl)
triﬂuoroacetamide (BSTFA) (Kissa, 1992; Cao et al., 2009; Racamonde et al., 2011), and
heptaﬂuorobutyric anhydride (HFBA) (Chung et al., 2002; Abu-El-Haj et al., 2007).
The most popular current method for determining 3-MCPD is to use a combined extraction and
derivatisation procedure by adding an organic solution of phenylboronic acid (PBA), which binds across
hydroxyl groups that are in close proximity to form dioxaborolanes (Rodman and Ross, 1986;
Pesselman and Feit, 1988). In the PBA procedure an aqueous extract of foodstuff is shaken with a
solution of PBA in acetone made basic with pyridine, sodium chloride is added to promote partition
and the derivative formed is extracted into hexane. A high concentration of PBA is required for
quantitative reaction and the reagent causes some damage to the GC column, but the use of a low
temperature injection (< 180°C) can reduce the transfer of reagent to the column (Breitling-Utzmann
et al., 2005). The method has been applied widely with minor variations (Ushijima et al., 1995;
Breitling-Utzmann et al., 2003; Divinova et al., 2004).
The PBA method as described by Plantinga et al. (1991) has been validated and accepted as the
German ofﬁcial methods for 3-MCPD in food (LMBG, 1995). Solvent extraction for removal of fat from
some foods prior to implementation of the PBA method has been reported by Divinova et al. (2004).
Alternative derivatisation methods based on bonding across the MCPD hydroxyl groups have been
based on the formation of the dioxolane derivative by reaction with acetone or cyclohexanone
(Meierhans et al., 1998; Dayrit and Ni~nonuevo, 2004; Retho and Blanchard, 2005; Becalski et al.,
2013) (Figures 1 and 2).
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Figure 1: Derivatives formed from reaction of 3-monochloropropane-1,2-diol (3-MCPD) with acetone,
phenylboronic acid (PBA) and heptaﬂuorobutyrylimidazole (HFBI)
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These methods all have advantages and disadvantages. HFBI derivatises many co-extracted
compounds and gives relatively clean chromatograms and better GC column life. The mass spectra of
HFB derivatives have relatively low intensity in electron impact (EI) mode but peak identity can be
conﬁrmed by the ratio of particular masses. MCPD isomers have a low molecular weight, and the
addition of the relatively bulky HFB groups reduces the effect of background mass spectral noise from
co-extracted compounds. Unfortunately, the reagent is very sensitive to moisture and relatively
unstable, making it difﬁcult to handle. HFBA is less expensive than HFBI and easier to handle, but its
efﬁciency has been questioned and catalysis with triethylamine has been recommended (Xu et al.,
2006). The trimethylsilyl derivatives of 3- and 2-MCPD have ions of such low intensity in EI mode that
limits of detection are unsatisfactory (Wenzl et al., 2007). The EI mass spectra of HFB derivatives of
3- and 2-MCPD do not show the molecular ion at m/z 502. The ions normally used for quantitative
determination of 3-MCPD di-HFB are at m/z 453 [M-CH2Cl]+, 289 [M-C3F7CO2]+, 275
[M-C3F7CO2CH2]+ and 253 [M-C3F7CO2HCl]+. The di-HFB derivative of 2-MCPD has a similar mass
spectrum but lacks the ions at m/z 453 and m/z 275. The characteristic ions in NCI modes are m/z
502 (molecular ion), 482 [M-HF] and 446 [M-HF-HCl].
2-MCPD can readily be determined by using reagents (HFBI, HFBA, BSTFA) that derivatise the –OH
groups individually. Although boronate reagents can act across pairs of –OH groups that are not on
adjacent carbon atoms, their quantitative reaction with 2-MCPD has not been assured, and the
dioxolane forming reagents do not react with 2-MCPD.
Quantiﬁcation of 3-MCPD is always achieved by use of a calibration graph and isotope dilution with
d5-labelled 3-MCPD. Quantiﬁcation of 2-MCPD has been approximated by comparison with the 3-MCPD
calibration graph (Meierhans et al., 1998; Chung et al., 2002) but reference standards are now
available.
GC-MS/MS has been used less routinely for 3-MCPD detection, Hamlet (1998) used an ion trap
instrument in multiple reaction monitoring (MRM) mode, and Kuballa and Ruge (2004) showed that
sensitivity was improved by using a triple quadrupole instrument operated in the selected reaction
monitoring mode.
There is only a single report of the separation of the (R)- and (S)- isomers of 3-MCPD, this was
achieved by GC with ﬂame ionisation and GC-MS of the PBA derivatives on a stationary phase of
c-cyclodextrin after pentylation of the 2,6-hydroxyl groups and triﬂuoroacetylation of the 3-position
hydroxyl groups (Reece, 2005).
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Figure 2: Flow chart showing solid phase extraction/heptaﬂuorobutyrylimidazole (HFBI) and boronate
methods
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Method validation
Reference standards of both 3-MCPD and 2-MCPD are commercially available, along with their
deuterated analogues. Reference materials containing 3-MCPD are commercially available only for soy
sauce. The HFBI method has been validated for 3-MCPD in acid-HVP, stocks and soups, soy sauce,
salami, ﬁsh, cheese, cereals and bread by an international collaborative trial (Brereton et al., 2001).
The PBA method has been validated in-house for 3- and 2-MCPD using samples of biscuits, potato
crisps, cereals, bread, meat and ﬁsh (Wenzl et al., 2015) and found to have good agreement with
results obtained with HFBI. Limits of quantiﬁcation (LOQs) are typically 15 and 10 lg/kg for the free
forms of 3-MCPD and 2-MCPD, respectively.
1.2.5.2. Esters of 3- and 2-MCPD and of glycidol
The determination of fatty acid esters of 3- and -2-MCPD is complicated by their great variety and
structural diversity. Ester bonds can be formed at either or both of the free hydroxyl positions of MCPD
with any of the fatty acids naturally present in the sample. Taking into account the number of possible
positional isomers of MCPD the formation of about 100 different ester compounds is possible. For GE
the number is much reduced on account of the single hydroxyl group and lack of positional isomers.
However, in practice, because of the relative abundance of the fatty acids only a core of six or seven
esters (lauric, myristic, palmitic, stearic, oleic, linoleic and linolenic acids) needs to be considered in
food analysis (Dubois et al., 2011).
Wenzl et al. (2015) have provided a comprehensive overview of the development and testing of
methods for both free and ester-bound 3- and 2-MCPD.
Two approaches are used for the determination of the fatty acid esters of 3-MCPD, 2-MCPD and
glycidol; these are direct methods that quantify the targeted intact esters, and indirect methods that
quantify the chloropropanol or glycidol (as MCPD) released from the ester bond.
For the analysis of the large numbers of food samples required to obtain data for exposure
estimates the indirect methods have predominated.
Direct analysis of 3- and 2-MCPD fatty acid esters
Direct analysis of 3-MCPD fatty acid esters by GC has not proceeded beyond initial investigation
(Reece 2005) but several LC-MS approaches have evolved. In the direct methods based on LC-MS a
sample of oil or of lipid extracted from a foodstuff with solvents such as mixtures of hexane with
t-butylmethyl ether, acetone or diethyl ether is diluted and injected into the LC column either with or
without prior clean-up or fractionation. SPE clean-up typically involves the use of a dual cartridge
system using ﬁrst a C18 SPE cartridge with acetonitrile elution, followed by a silica SPE cartridge
(MacMahon et al., 2013a).
3- and 2-monoesters and diesters of MCPD can be separated from each other under the protocols
of direct methods provided that esters of the same molecular mass and product ion spectra do not
coelute from the LC column.
Indirect analysis
For the indirect determination of ester-bound 3- and -2-MCPD oil samples are transmethylated after
dissolving in solvent. For food samples the fat or oil fraction is ﬁrst isolated by solvent extraction and
the residue discarded.
Separation of monoester from diesters prior to analysis by indirect methods has been achieved
using silica, diol or amino-phase SPE cartridges, with diol and amino phases being most effective
(Dubois et al. 2011; Hamlet et al., 2014).
The indirect determination of ester-bound 3- and 2-MCPD in oils involves the cleavage of the ester
bonds by transmethylation (methanolysis) and the measurement of the released 3- and 2-MCPD by
one of the methods described above for free MCPD. The MCPD can be released by the use of lipase
enzymes (Hamlet and Sadd, 2004; Chung and Chan, 2012; Chung et al., 2013), but the use of acid
(Divinova et al., 2004; Zelinkova et al. 2006) or alkali (Weißhaar, 2008, K€usters et al., 2010) is much
more common. GE are cleaved in the same reaction. In an alternative procedure described below
esteriﬁed glycidol is brominated prior to cleavage of the monobromopropanediol (3-MBPD) produced
(Figures 3 and 4).
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For the extraction of 3- and 2-MCPD fatty acid esters (with or without GE) from food samples for
indirect determination a variety of solvents have been used. They generally need to be more polar
than simple alkanes such as hexane for complete recovery, particularly for 3-MCPD monoesters. The
solvents commonly used are t-butyl methyl ether or mixtures of t-butylmethyl ether with hexane or
petroleum ether, or mixtures of hexane with diethyl ether (Hamlet and Asuncion, 2011; Wenzl et al.,
2015). The inclusion of acetone is particularly useful for the extraction of MCPD fatty acid esters from
dry infant formula.
The BfR compared extraction methods for MCPD fatty acid esters in infant formula, sweet spread
and chocolate cream, each containing vegetable fats, plant-based onion lard, and mayonnaise (BfR
2013; Fry et al. 2013). For a collaborative trial an extraction step based on accelerated solvent
extraction (ASE, also known as pressurised liquid extraction, PLE) with a solvent mixture of
petroleum ether/iso-hexane/acetone (2/2/1 v/v) using two extraction cycles at a temperature of
125°C was used. The ASE method had very good repeatability within the laboratories and
reproducibility between the laboratories for all of the matrices. It was compared with Soxhlet
extraction, which was less reproducible, possibly on account of variations in the procedures used,
and with several cold solvent extraction methods, which had poorer recovery. The accuracy and
precision were better for hot extraction methods than for cold ones, and they varied with type of
food product analysed.
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Problems with and pitfalls of the methods
Early applications and trials of the methods for 3-MCPD based on acid and alkali transesteriﬁcation
revealed that there were both discrepancies between the methods and irregular results for the
application of the same (acid or alkali) approach to oils analysis.
If acid methanolysis is carried out without due care, 3- and 2-MCPD can be formed from the
reaction of chloride with various precursors, of which glycidol is the major compound identiﬁed
(Weißhaar 2008, Weißhaar and Perz, 2010 Haines et al., 2011). This unwanted formation reaction has
been mitigated by pre-treatment with acid to destroy glycidol, and to a lesser extent by washing the
lipid extract with water to remove chloride (Hamlet and Asuncion, 2011; Chung et al., 2013).
Alkaline methanolysis suffers from the instability of 3- and 2-MCPD under basic conditions and the
temperature and time of the reaction must be very carefully controlled. Data produced before the
introduction of these controls in 2013 must be considered suspect.
The current situation – AOCS methods
Early standardisation of methods based on alkali methanolysis was carried out by the German
Society for Fat Science (DGF), the methods underwent frequent revision and comparison with other
procedures (Fiebig, 2011).
Well-characterised procedures for the determination of MCPD fatty acid esters and GE in edible
oils have now been presented (Karasek et al., 2013) by the EU Joint Research Centre (JRC) and
have been adopted by the American Oil Chemists’ Society (AOCS). The methods can determine fatty
acid esters of 3- and 2-MCPD and glycidol. The methods have been validated in trials involving 20
participants from eight countries (AOCS 2013). These three methods (AOCS Cd 29a-13, Cd 29b-13
and Cd 29c-13), which are described below, are today considered to be the most reliable in giving a
true result.
AOCS Method Cd 29a-13 determines fatty acid esters of 3- and 2-MCPD and glycidol based on the
procedure of Ermacora and Hrncirik (2013). The sample is incubated with sodium bromide in acid
solution to convert GE to 3-MBPD monoesters. The reaction is stopped by the addition of dilute alkali
and the oil phase containing the esters is extracted with n-heptane. The residue, containing 3-MBPD
esters, together with 3- and 2-MCPD fatty acid esters present in the original sample, is subjected
to sulphuric acid methanolysis at 40°C for 16 h, after which the released free 3-MBPD, 2-MCPD
and 3-MCPD are determined by the PBA method. For quantiﬁcation deuterated internal standards
(d5-3-MCPD dipalmitate and d5-glycidyl palmitate) are added to the oil sample.
AOCS Method Cd 29b-13 determines glycidol together with the total 2-MCPD and 3-MCPD present
in both bound and free forms. The method is based on alkaline-catalysed hydrolysis prior to the
conversion of released glycidol to MBPD as published by Kuhlmann (2011). Parallel analyses of two
aliquots of the same sample are carried out. One aliquot (A) is spiked with an isotopically labelled GE
and a second aliquot (B) is spiked with isotopic labelled 3- and 2-MCPD fatty acid esters as
standards. Free MCPD and free glycidol are released from both assays by hydrolysis with dilute
sodium hydroxide in methanol at low temperature. The reaction is stopped by the addition of sodium
bromide in dilute phosphoric acid whereby free glycidol is converted into 3-MBPD with a trace amount
of 2-MBPD which are determined after PBA derivatisation. GE is quantiﬁed against the isotopically
labelled GE in aliquot (A) and bound 3- and 2-MCPD against the labelled MCPD fatty acid esters in
aliquot (B).
AOCS Method Cd 29c-13 determines the sum of bound 3-MCPD and bound glycidol. In a ﬁrst
assay, free 3-MCPD and free glycidol are released by dilute sodium hydroxide or sodium methoxide
in methanol, and the reaction is stopped by the addition of an acidic chloride salt solution. Glycidol
reacts with the chloride to form additional 3-MCPD and a small amount of 2-MCPD. The released
3- and 2-MCPD are determined as their PBA derivatives as before. In a second assay, the base-
catalysed transesteriﬁcation is followed as above but the reaction is stopped by the addition of
acid under chloride-free conditions in which the free glycidol does not generate additional 3-MCPD.
The two assays allow the calculation of the sum of bound MCPD and GE and a second
determination of bound glycidol, the latter assuming that glycidol is the only precursor of 3-MCPD
present.
Application of both direct and indirect methods to the determination of the esters in food products
other than oil has been limited, and restricted mainly to indirect methods applied to small surveys
(Svejkovska et al., 2004; Zelinkova et al., 2009; Chung and Chan, 2012; Becalski et al., 2013).
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Validation
In addition to validation for oils and fats carried out for the AOCS methods, method
performance data for the determination of MCPD fatty acid esters and glycidyl esters in processed
foods has been reported by K€usters et al. (2010, 2011). A BfR proﬁciency test of methods for
MCPD fatty acid esters in infant formulae, mayonnaise, and spreads (Fry et al., 2013) showed that
about 75% of results for 3-MCPD fatty acid esters and 78% for 2-MCPD fatty acid esters were
satisfactory (z-score < 2).
The indirect methods applied to foods typically have LOQs of about 15 lg/kg MCPD released from
esters on a fat basis for both 3- and 2-MCPD. The LOQ for glycidol released from esters on a fat basis
is about 30 lg/kg. Only limited data are available for other parameters such as precision, Wenzl et al.
(2015) reporting values of 5–15% for oil spiked at about 50 lg/kg with 3- and 2-MCPD fatty acid
esters and GE and similar values for potato crisps.
A comprehensive range of chemical standards of individual 3- and 2-MCPD fatty acid esters and GE
is now commercially available, including isotopically labelled forms. Certiﬁed reference materials are
however not yet available.
Summary
Analytical methods for free 3- and 2-MCPD in foods are well characterised, validated for a
suitable range of foods and ﬁt for purpose. There are no suitable methods for the unstable free
glycidol.
Indirect methods for ester-bound 3- and 2-MCPD and glycidol in foods are well characterised for
the important range of foods. The critical stage of the methods is the ﬁssion of the MCPD from the
ester in the oil extract. This has been validated for all three AOCS-adopted methods, which should
provide directly comparable results.
The methods for free MCPD do not include MCPD released from esters, and the methods for ester-
bound 3- and 2-MCPD and glycidol do not provide data for the free compounds. Thus the two
approaches were applied independently to obtain the exposure data.
1.2.6. Legislation
In this scientiﬁc opinion, where reference is made to European legislation (Regulations, Directives,
Decisions), the reference should be understood as relating to the most current amendment, unless
otherwise stated.
In order to protect public health, Article 2 of the Council Regulation (EEC) No 315/935 stipulates
that, where necessary, maximum tolerances for speciﬁc contaminants shall be established. Thus, a
number of maximum levels for contaminants, natural plant toxicants as well as the process
contaminant 3-MCPD are currently laid down in Commission Regulation (EC) No 1881/20066. According
to the ANNEX, Section 4 of this Regulation, the maximum levels for 3-MCPD in HVP and soy sauce are
each 20 lg/kg. The maximum level is given for the liquid product containing 40% dry matter,
corresponding to a maximum level of 50 lg/kg in the dry matter. The level needs to be adjusted
proportionally according to the dry matter content of the products. In contrast to 3-MCPD, no
maximum levels are laid down for 2-MCPD, 2-MCPD fatty acid esters, 3-MCPD-esters, glycidol and its
esters.
In order to gain more occurrence data on the presence of MCPD fatty acid esters and GE in
food, and to enable a more accurate exposure assessment, the EU Commission enacted
Recommendation 2014/661/EU7 on the monitoring of the presence of 2 and 3-MCPD, 3- and
2-MCPD fatty acid esters and GE in food. The Recommendation inter alia speciﬁes details on the
type of food to be analysed, sampling procedures and analytical methods, including requirements for
LOQs.
5 Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–5.
6 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
7 Commission Recommendation 2014/661/EU of 10 September 2014 on the monitoring of the presence of 2 and
3-monochloropropane-1,2-diol (2 and 3-MCPD), 3- and 2-MCPD fatty acid esters and glycidyl fatty acid esters in food. OJ L
271, 12.9.2014, p. 93–95.
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2. Data and methodologies
2.1. Data
2.1.1. Occurrence data
In September 2013, EFSA published a scientiﬁc report analysing the occurrence data on 3-MCPD
(both in free and ester-bound form) in food in Europe based on results on samples collected by EU
Member States’ authorities in the years 2009–2011 and submitted to the EFSA chemical occurrence
database (EFSA, 2013). The report highlighted uncertainties affecting the occurrence data, in
particular in relation to the analytical methods applied for bound forms (no validated method for
3-MCPD from esters was available at that time) and to the coverage of the relevant food categories
(the available data did not cover many food categories potentially contaminated with 3-MCPD). In
August 2013, three analytical methods for ester-bound MCPDs and glycidol were validated by the
AOCS in a collaborative study involving 20 laboratories from eight countries. The three new methods
for the analysis of 3- and 2-MCPD from esters and glycidol from esters are those described in
Section 1.2.5 (AOCS Cd 29a-13, Cd 29b-13 and Cd 29c-13).
In order to address the requirement of Commission Recommendation 2014/661/EU (see
Section 1.2.6) and reduce the uncertainties identiﬁed in the above mentioned EFSA report, EFSA
activated two new data collection initiatives on 3- and 2-MCPD and glycidol; the collection was
restricted (when originating from esters) to results obtained with methods corresponding or strictly
related to the three new methods. Data produced with one of these methods before the AOCS
validation were also considered acceptable for the data collection.
The ﬁrst initiative was a Service Level Agreement (SLA) with the JRC of the European Commission,
Institute for Reference Materials and Measurements (JRC-IRMM) (SLA/EFSA-JRC/DCM/2013/01) for the
development and in-house validation of analytical methods for the analysis of 3-, 2-MCPD (both free
and from esters) and glycidol from esters in various food matrices (Wenzl et al., 2015). It was
requested that the method for the analyses from esters be derived from one of the three validated
methods. The project included the performance of an ad hoc survey on speciﬁc food groups to test
the analytical methods and provide a minimum database on levels of 3- and 2-MCPD and glycidol in
the food groups indicated in Table 1. The analyses of 3- and 2-MCPD covered both, those originally
present in food in free form and those from esters of fatty acids. The analyses of glycidol were for
glycidol derived from esters only.
The second initiative was to publish (in October 2014) an open call for data for MCPDs (free
and from esters) and glycidol from esters with a deadline of December 2014.8 The call for data
was addressed to all potential data providers, including food business operators and academia.
The speciﬁc requirements for the analysis of the ester-bound forms were substantially aligned
with those of Recommendation 2014/661/EU and with those of the SLA with the JRC. Several
food groups were indicated as highest priority for the data collection, as summarised in
Table 2.
Table 1: Food groups addressed by the survey included in the JRC Project
Food group
Bread and rolls
Fine bakery wares
Smoked ﬁsh products
Smoked meat products
Fried or roast meat (all possible types, including grilled and griddled)
Chips, crisps, fries and dough-based analogues (both, potato- or cereal-based)
Margarine
Infant and follow-on formulae
JRC: Joint Research Centre.
8 Available on the EFSA website at the address http://www.efsa.europa.eu/en/data/call/141111.htm (consulted on 11/05/2015)
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By the end of April 2015, EFSA collected different sets of data submitted for the purpose of the
present assessment of the occurrence of 3- and 2-MCPD and glycidol.
• A total of 2,535 results on the concentration of 3- and 2-MCPD both free and from esters and
of glycidol from esters in 507 food samples were produced in the framework of the SLA with
the JRC. For all the samples, both the MCPD forms (i.e. free and from esters) were measured
separately. The total occurrence levels for both 2- and 3-MCPD were then calculated during the
data analysis as the sum for each sample of the results obtained for the free and the ester-
bound form. The data cover the food groups listed in Table 1;
• A total of 210 results on the concentration of 3- and 2-MCPD and glycidol from esters in
70 samples of infant formulae were submitted by the BfR of Germany; these data only covered
the three contaminants present in ester-bound form; they did not include the potential
presence of 3- and 2-MCPD in free form; therefore, the occurrence levels calculated from these
data may be underestimated;
• A total of 4,503 results on 3- and 2-MCPD- and glycidol from esters from vegetable fats and
oils were submitted by the Association of the EU Vegetable Oil & Proteinmeal Industry
(FEDIOL); these data only refer to 3-, 2-MCPD and glycidol present in ester-bound form and
did not cover the potential presence of 3- and 2-MCPD in free form; this might imply
underestimation of the total occurrence levels; however, the presence of 2- and 3-MCPD in
free form in fat and oils is expected to be negligible respect to the ester-bound form (Zelinkova
et al., 2006);
Table 2: Food groups indicated as highest priority for the data collection in the call for data
published by EFSA in October 2014
Food group
Bread and similar products
Leavened bread and similar
Unleavened or ﬂat bread and similar
Crackers and breadsticks
Crisp bread
Rusk
Fine bakery wares
Biscuits
Cakes
Yeast-leavened pastry
Shortcrust (pies-tarts)
Puff pastry
Smoked ﬁsh products
Canned/jarred smoked ﬁsh in oil
Smoked ﬁsh
Smoked meat products
Charcuterie meat products (when smoked, particularly hot smoked)
Fried or roast meat (all possible types, including grilled and griddled)
Chips, crisps, fries and dough-based analogues (both, potato- or cereal-based)
Chips/crisps
Puffs/curls-type extruded snack
Fries (ﬁnger chips)
Infant and follow-on formulae
Infant formulae
Follow-on formulae
Traditional margarine
Vegetable fats and oils, edible
Animal fats and oils (processed fat from animal tissue)
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• A total of 420 results on 3- and 2-MCPD- and glycidol from esters in margarines and similar
products were submitted by the European Margarine Association (IMACE); as in the case of
the data on fats and oils, these data did not cover the potential presence of 3- and 2-MCPD
in free form, but this is expected not to be relevant in comparison with the ester-bound
form.
At the beginning of September 2015, two additional data sets were submitted and included in the
assessment:
• A group of results on the concentration of 3- and 2-MCPD from esters and glycidol from esters
in 35 samples including ‘olive oil’ (9 samples), and fried or baked ﬁsh (26 samples), were
submitted by the JRC; these data did not include the potential presence of 3- and 2-MCPD in
free form; while the lack of data on 3- and 2-MCPD in free form is expected not to be relevant
for estimating the occurrence in olive oil, underestimation of the occurrence in the fried or
baked ﬁsh samples is possible;
• A total of 344 results on concentration of 3-MCPD from esters (138 results), 2-MCPD from
esters (68 results) and glycidol from esters (138 results) in sunﬂower seed oil samples were
submitted by the Lebensmittelchemisches Institut des Bundesverbandes der Deutschen
S€ußwarenindustrie (K€oln); these data do not include the potential presence of 3- and 2-MCPD
in free form; however, the presence of 3- and 2-MCPD in free form in fat and oils is expected
to be negligible with respect to the ester-bound form.
In order to also include the food groups addressed by Commission Regulation (EC) No 1881/2006,
analytical results on 3-MCPD in free form in soy sauce, HVP and related food products such as
condiments and soup preparations were retrieved from the EFSA chemical occurrence database.
Overall, 708 data were obtained by selecting results submitted by the national competent authorities of
the EU Member States on the mentioned food groups in the last 5 years (sampling year from 2009 to
now) in the framework of the annual data collection on chemical contaminants. The data were retrieved
on 6 April 2015. These data only refer to 3-MCPD in free form and do not include the potential presence
of 3- and 2-MCPD and glycidol from esters, therefore the occurrence levels calculated from these data
may be underestimated. Data on 3-MCPD in free form in food groups already covered by the previously
mentioned data collection initiatives (which included the contribution from both, free and ester-bound
forms) were not retrieved from the database, because they would have increased the uncertainty in the
assessment. For the same reason, data on 3- and 2-MCPD from esters not submitted to the above
mentioned call for data and not generated with the analytical methods deﬁned in the call were not
considered in this assessment. Data submitted after beginning of September 2015 could not be
considered in the assessment.
2.1.2. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at the individual level. It
was ﬁrst built in 2010 (EFSA, 2011b; Huybrechts et al., 2011; Merten et al., 2011) and then updated in
20159. Details on how the Comprehensive Database is used are published in the Guidance of EFSA
(EFSA, 2011a).
The database used to estimate dietary exposure in the present opinion included the 17 surveys
from 2014 and surveys conducted between 2005 and 2012, with two exceptions (DIPP 2001–2009,
Finland; VELS 2001–2002, Germany - see Table B.2, Appendix B). The database contains data from 41
surveys in 23 different European countries for a total of 78,990 participants (Appendix D). Data from
six surveys were available for ‘Infants’ (< 12 months old), 11 for ‘Toddlers’ (≥ 12 months to
< 36 months old), from 19 surveys for ‘Other children’ (≥ 36 months to < 10 years old), from 19
surveys for ‘Adolescents’ (≥ 10 years to < 18 years old), from 21 surveys for ‘Adults’ (≥ 18 years to
< 65 years old), from 15 surveys for the ‘Elderly’ (≥ 65 years to < 75 years old) and from 13 surveys
for the ‘Very elderly’ (≥ 75 years old).
In the surveys above, consumption data were collected using single or repeated 24- or 48-h dietary
recalls or dietary records covering from 3 to 7 days per subject. Owing to the differences in the
methods used for data collection, direct country-to-country comparisons must be taken with caution.
9 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database (consulted on 01/02/2016)
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2.2. Methodologies
2.2.1. Management of occurrence data
2.2.1.1. Data cleaning
The reported concentration values were checked in order to identify duplicate data (based on the
sample code) and possible errors in the unit of measurement. The check of the unit of measurement
was performed by comparing the order of magnitude of the values provided for the analytical results,
the limit of detection (LOD) and the LOQ across the database. One result was identiﬁed where LOD
and LOQ were reported wrongly (by a factor of 1,000) and this was corrected.
2.2.1.2. Sampling method and sampling strategy
All data were from analysis of individual samples. With respect to the sampling strategy,10 almost
all of the samples were from objective or selective sampling. A total of six results on free 3-MCPD were
reported as from suspect sampling and were removed from the data set.
2.2.1.3. Left-censored results
Left-censored results are analytical results reported either as < LOD or < LOQ. The limit (LOD or
LOQ) applied for each speciﬁc result is the left-censoring limit. Depending on the scope of the analysis
(free form, ester-bound form), the analytical method and the left-censored limits may vary. For the
analysis of free 3-MCPD in food, left-censored limits have been established in some foods (the LOQ
must be ≤ 10 lg/kg on dry matter basis (LOD ≤ 5 lg/kg) for HVP and soy sauce) as deﬁned in
Commission Regulation (EC) No 333/2007. The left-censored limits for the analytical results on HVP
and soy sauce were at or below the prescribed limits. For the analysis of 3-MCPD-, 2-MCPD- and
glycidol from esters, the limit indicated in the call for data was 100 lg/kg (referred to fat). No
exclusion criterion was applied based on left-censored limits.
2.2.1.4. Management of left-censored results
Left-censored results were treated by the substitution method (EFSA, 2010b). This approach, based
on the consideration that the true value for left-censored results may actually be any value between 0
and the left-censored limit, compares the two extreme scenarios. The lower bound (LB) scenario
assumes that the substance is absent; thus, to left-censored results a value of 0 is input. The upper
bound (UB) scenario assumes that the substance is present at the level of the limit; thus, to results
reported as < LOD or < LOQ the value of the respective left-censored limit is assigned. Additionally, as
a point estimate between the two extremes, the middle bound (MB) scenario is calculated by assigning
a value of LOD/2 or LOQ/2 to the left-censored results.
2.2.1.5. Food classiﬁcation
The analytical results were classiﬁed according to the FoodEx1 food classiﬁcation system. FoodEx1
is a provisional food classiﬁcation system developed by the EFSA’s Dietary and Chemical Monitoring
Unit in 2009 with the objective to link occurrence and food consumption data at a detailed level to
assess exposure to hazardous substances. It contains about 1,800 food descriptors (food codes) which
can be grouped according to the needs of a speciﬁc analysis (EFSA, 2011b). For the purpose of the
present assessment, based on the FoodEx1 codes and additional information present in the chemical
occurrence database, the classiﬁcation of the analytical results was revised and some ad hoc food
groups were created to allow a more detailed analysis of the results.
The ad hoc food group ‘Vegetable fats and oils’ was created, aggregating the FoodEx1 groups
A.01.001362 ‘Vegetable fat’ and A.01.001367 ‘Vegetable oil’. An ad hoc group ‘Special fats’ was also
created to collect particular fat compositions used as ingredients in food processing. Within the
FoodEx1 group A.01.001632 ‘Seasoning or extracts’ the ad hoc group ‘Other seasoning products’ was
10 Objective sampling is based on the selection of a random sample from a population on which the data are reported; Selective
sampling is based on the selection of a random sample from a subpopulation (or more frequently from subpopulations) of a
population on which the data are reported. The subpopulations are often determined on a risk basis; Convenient sampling is
based on the selection of a sample for which units are selected only on the basis of feasibility or ease of data collection;
Suspect sampling is based on samples taken repeatedly from the same site as a consequence of evidence or suspicion of
(illegal) contamination. Suspect samples are usually taken as a follow-up of demonstrated non-compliance with legislation.
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created, to aggregate seasoning or extracts other than stock cubes. Within the FoodEx1 group
A.01.001649 ‘Condiments’, the ad hoc group ‘Other condiment sauces’ was created to aggregate
condiments other than soy sauce and similar.
Some ad hoc groups were created to classify occurrence data referred to speciﬁc food categories for
which only FoodEx1 groups at less detailed level were available. Within the food group A.01.000876 ‘Fish
and other seafood’ the ad hoc group ‘Fish meat (smoked)’ was created, as subgroup of the FoodEx1
group A.01.000877 ‘Fish meat’ containing only smoked ﬁsh meat. Within the food group A.01.000727
‘Meat and meat products (including edible offal)’ the ad hoc group ‘Preserved meat (smoked)’ was
created, as subgroup of the FoodEx1 group A.01.000795 ‘Preserved meat’ containing only smoked
products. Within the FoodEx1 group A.01.001757 ‘Protein and amino acids supplements’ the ad hoc group
‘Hydrolysed vegetable proteins’ was created. Within the FoodEx1 group A.01.001789 ‘Composite food’ the
ad hoc group ‘Dry preparations for soups (to be reconstituted)’ was created, a subgroup of the FoodEx1
group A.01.001856 ‘Ready-to-eat soups’ including only dry products to be reconstituted. An overview of
the food groups used to evaluate occurrence in this report is provided in Table B.1 in Appendix B.
2.2.1.6. Substances
All analytical results were expressed as free moiety (3-MCPD, 2-MCPD or glycidol) from one of the
forms listed in Recommendation 2014/661/EU. They are available in the PARAMCODE catalogue of the
standard sample description (SSD), the EFSA standard for collecting data (EFSA, 2010a); the reported
substance codes are summarised in Table 3.
For the analyses of the JRC data set where both forms (free and from ester) of 3- and 2-MCPD
were determined, LB, MB and UB values for 3-MCPD or 2-MCPD were calculated as their respective
sums; the calculated sum was used for the assessment of occurrence.
2.2.1.7. Expression of reported analytical results
The analytical results were expressed on different bases: whole weight (w.w.), 40% dry matter, dry
matter or fat weight.
• In the case of analytical results reported on 40% dry matter, the values were transformed into
whole weight dividing by 40 and multiplying by the dry matter of the sample expressed as a
percentage (i.e. 100% of moisture);
• In the case of analytical results reported on dry matter, the values were transformed into
whole weight dividing by 100 and multiplying by the dry matter of the sample expressed as a
percentage (i.e. 100% of moisture).
• In the case of analytical results reported on fat weight, the values were transformed into
whole weight dividing by 100 and multiplying by the fat content of the sample expressed as a
percentage.
Among the data submitted for the present assessment, a total of 205 results on free 3-MCPD were
reported as 40% dry matter or dry matter; a total of 210 results on infant formulae were reported as
fat weight; all the remaining results were reported as whole weight.
2.2.1.8. Recovery rates
Commission Regulation (EC) No 333/2007 deﬁnes methods of analysis to be applied to 3-MCPD in
soy sauce and HVP as needing to have recovery rates in the range of 75–110%. No prescription is on
Table 3: Substance codes reported in the data set for MCPDs and glycidol
PARAMCODE Description
RF-00000377-ORG 3-MCPD free
RF-00000380-ORG 3-MCPD esters [expressed as 3-MCPD moiety]
RF-00000378-ORG 3-MCPD total [expressed as 3-MCPD moiety]
RF-00002832-PAR 2-MCPD free
RF-00002833-PAR 2-MCPD esters [expressed as 2-MCPD moiety]
RF-00002834-PAR 2-MCPD total [expressed as sum of 2-MCPD free and 2-MCPD esters
expressed as 2-MCPD moiety]
RF-00001344-PAR Glycidyl esters [expressed as glycidol moiety]
The codes refer to the PARAMCODE catalogue of the EFSA standard sample description.
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place for other food categories. Recovery rates were only reported for 639 results. Although recovery
rates were not reported for a majority of analytical results, no data were excluded based on this
criterion since the analytical methods for both free and bound forms include the use of isotope-labelled
internal standards which correct automatically for recovery losses.
2.2.2. Statistical analysis
All analyses were run using the SAS® Statistical Software (SAS software, 1999). Frequency tables
per sampling year, sampling country and food group were produced to describe the 3-MCPD, 2-MCPD
and glycidol data collection. Descriptive summary statistics of concentration levels per food group were
calculated. The Guidance on the use of the Comprehensive Food Consumption Database indicates that
the 95th percentile estimates obtained with less than 60 observations may not be statistically robust
(EFSA, 2011c) and therefore they should be considered with caution.
2.2.3. Methodology used for hazard identiﬁcation and characterisation
2.2.3.1. Methodology literature search
Strategy for literature search
For the present evaluation the CONTAM Panel considered literature made publicly available until 10
February 2015. A comprehensive search for literature was conducted for peer-reviewed original
research pertaining to the occurrence of 3-monochloropropane-1,2-diol (3-MCPD) and 2-
monochloropropane-1,3-diol (2-MCPD) fatty acid esters and glycidyl fatty esters in food and its adverse
health effects on humans, experimental animals and in vitro systems. The search strategy was
designed to identify scientiﬁc literature dealing with chemical analysis, chemistry, occurrence,
exposure, toxicity, mode of action, toxicokinetics and epidemiology of 3- and 2-MCPD fatty acid esters
and glycidyl fatty esters.
Additionally, research or reports on chloropropanols in food were considered. Articles with other
meanings of the acronym MCPD and articles on other esters were excluded. The literature search was
not restricted to publications in English language; however, literature in other languages was only
considered if an English abstract was available. The ﬁrst literature search was performed in September
2014 and has since been updated in November 2014, December 2014, February 2015 and January
2016. Web of Science11 and PubMed12 were identiﬁed as databases appropriate for retrieving literature
for the present evaluation. The references resulting from the literature search were imported and
saved using a software package (EndNote13), which allows effective management of references and
citations. Additionally, reviews, relevant scientiﬁc evaluations by national or international bodies were
considered for the current risk assessment, i.e. previous evaluations of SCF (1994, 2001), FAO/WHO
(2002), FSA (2008, 2009, 2010) and BfR (2007, 2009, 2012). Two scientiﬁc opinions by the BfR (2007,
2012), available only in the original language, were translated into English by the Translation
Centre for the Bodies of the European Union.
Appraisal of studies
Information retrieved has been reviewed by the CONTAM Working Group on MCPD and GE in food
and used for the present assessment using expert judgement. Any limitations of the information used
are clearly documented in this opinion.
Methodology applied for risk assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO/IPCS (2009), which include hazard identiﬁcation and characterisation,
exposure assessment and risk characterisation. In addition to the principles described by WHO/IPCS
(2009), the principles in the EFSA guidances on risk assessment (EFSA SC, 2012a) and the applicability
of a margin of exposure (MoE) approach to safety assessment of impurities which are both genotoxic
11 Web of Science (WoS), formally ISI Web of Knowledge, Thomson Reuters. Available online: http://thomsonreuters.com/
thomson-reuters-web-of-science/
12 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available online: http://www.ncbi.nlm.nih.gov/pubmed/
13 EndNote X5, Thomson Reuters. Available online: http://endnote.com/
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and carcinogenic (EFSA SC, 2012b) have been applied for the present assessment. In brief, the EFSA
guidance covers the procedures currently used within EFSA for the assessment of dietary exposure to
different chemical substances and the uncertainties arising from such assessments (EFSA, 2006). For
details on the speciﬁc EFSA guidances applied, see Appendix A.
3. Assessment
3.1. Occurrence of 3- and 2-MCPD and glycidol in food
The available occurrence data (see Section 2.1.1) were divided in three groups and considered
separately:
• 3-MCPD (in free form) in soy sauce, HVP and related products;
• 3- and 2-MCPD from esters and glycidol from esters in oils/fats;
• 3- and 2-MCPD (free and from esters) and glycidol (from esters) in food groups other than
those mentioned above. In most cases, the contribution to the total 3- and 2-MCPD from the
free form was included, while the results on glycidol were only from esters.
3.1.1. Occurrence of free 3-MCPD in soy sauce, HVP and related products
The number of analytical results on free 3-MCPD in soy sauce, HVP and related products are
summarised per sampling year in Table 4 and per sampling country in Table 5.
Table 4: Distribution of results on free 3-MCPD in soy sauce, HVP and related products per
sampling year
Sampling year N(a) %
2009 78 11
2010 150 21
2011 185 26
2012 217 31
2013 72 10
Total 702 100
3-MCPD: 3-monochloropropane-1,2-diol; HVP: hydrolysed vegetable protein.
(a): N = number of analytical results reported.
Table 5: Distribution of results on free 3-MCPD in soy sauce, HVP and related products per
sampling country
Sampling country N(a) %
Belgium 91 13
Czech Republic 112 16
Denmark 17 2
Finland 137 20
France 18 3
Germany 114 16
Greece 15 2
Ireland 19 3
Lithuania 4 < 1
Luxembourg 25 4
Malta 15 2
Poland 85 12
Spain 50 7
Total 702 100
3-MCPD: 3-monochloropropane-1,2-diol; HVP: hydrolysed vegetable protein.
(a): N = number of analytical results reported.
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All the data referred to individual samples and no aggregated data were present in the data set.
More than 80% of the results reported the analytical method and in all cases this was based on GC-MS
techniques.
The sampling strategy was reported as ‘Objective sampling’ in 58% of the results, and ‘Selective
sampling’ in 35% of the results and in the remaining cases it was not reported. The two reported
strategies (objective and selective sampling) are substantially equivalent in this case, considering that
the food categories included in the assessment were selected based on the potential presence of
3-MCPD in free form.
Most of the data were expressed on whole weight, while some of them were reported on 40% dry
matter (21% of the results) or on dry matter (8% of the results); in the last two cases, the occurrence
value was recalculated as whole weight.
The data set included several left-censored results (i.e. reported as < LOD or < LOQ). The left
censoring value ranged from 1 to 28 lg/kg with a median of 10 lg/kg. The number and percentage of
left-censored results is shown in Table 6. For the evaluation of occurrence, the left-censored results
were considered following the approach explained in Section 2.2.2.
The mean, median and 95th percentile of concentrations (lg/kg) of free 3-MCPD in food groups
related to the Comprehensive Food Consumption groups (including some ad hoc ones) in the data set
on free 3-MCPD are presented in Table 7. The values are reported as MB followed by the range LB–UB;
when the values are coincident, the range is not reported.
Table 6: Number of results and number and percentage of left-censored values in the free-3-MCPD
data set, by level 1 food categories
Food group N(a) LC(b) %LC(b)
Composite food 26 13 50
Herbs, spices and condiments 660 525 80
Protein and amino acid supplements 16 11 69
Total 702 549 78
3-MCPD: 3-monochloropropane-1,2-diol.
(a): N = Number of results.
(b): LC = Number of left-censored results; %LC = percentage of left-censored results in each food group.
Table 7: Mean, median and 95th percentile of concentrations (lg/kg) of free 3-MCPD by food
groups related to the Comprehensive Food Consumption groups (including some ad hoc
ones). The data set on free 3-MCPD covers soy sauce, HVP and related products. The
values are reported as MB followed by the range LB–UB; when the values are coincident,
the range is not reported
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e) MB
(LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Herbs, spices and condiments 660 80 (1–30) 7.1 (3.8–10) 5 (0–9.3) 23 (23–24)
Herb and spice mixtures 46 43 (5–10) 23 (19–27) 12 (8.3–24) –
Seasoning or extracts 97 65 (3–10) 11 (9.3–14) 5 (0–10) 54
Stock cubes (bouillon cube) 69 62 (3–10) 10 (8.5–13) 5 (0–10) 43
Other seasoning products* 28 71 (7–10) 14 (11–17) 5 (0–10) –
Condiment 497 86 (1–30) 4.7 (1.3–8.2) 3.92 (0–6.6) 10 (8–20)
Soy sauce 469 85 (1–30) 4.5 (1.1–7.9) 3.75 (0–6.2) 10 (7.6–18)
Other condiment sauces* 28 93 (5–22) 8.8 (4.2–13) 5 (0–10) –
Dressing 5 40 10 8.8 (7–10) – –
Savoury sauces 15 93 (5–10) 5.4 (1.3–9.4) 5 (0–10) –
Protein and amino acid
supplements
16 69 (10–13) 25 (22–28) 5 (0–10) –
Hydrolysed vegetable
proteins*
16 69 (10–13) 25 (22–28) 5 (0–10) –
MCPD and glycidyl esters in food
www.efsa.europa.eu/efsajournal 30 EFSA Journal 2016;14(5):4426
The food groups having higher mean values are ‘Hydrolysed vegetable proteins’ with levels MB (LB–UB)
of 25 (22–28) lg/kg and ‘Herb and spice mixtures’ with 23 (19–27) lg/kg.
As anticipated in Section 2.1.1, food groups such as seasonings, condiments, savoury sauces and dry
preparations for soups may contain fats and oils and the presence of 3-MCPD in the form of fatty acid
esters is possible. As this potential presence was not covered by the available data, the occurrence in
these food groups summarised in Table 7 may underestimate the total 3-MCPD occurrence.
3.1.2. Occurrence of 3- and 2-MCPD from esters and glycidol from esters in fats
and oils
Data on the levels of 3- and 2-MCPD from esters and glycidol from esters in reﬁned fats and oils were
available from sampling year 2010. All of them were generated with one of the methods mentioned
previously in this section; those generated before August 2013 applied the same methods but before the
AOCS validation. The original set of data on oils and fats was qualitatively examined to investigate
whether all of them should be used in this assessment. To this end, the yearly average per type of oil was
reported in a graph for 3-MCPD, 2-MCPD and glycidol. The graphs are shown in Figure 5.
The qualitative evaluation of the data shows a decrease in the average levels of 3-MCPD and glycidol
from esters in the years between 2010 and 2012 for palm oil. The same observation is not applicable to
other oils. Based on this ﬁnding it was decided to limit the data analysis in fats and oils to the years
2012–2015 and exclude the previous data, as it did not reﬂect the present situation.
The number of analytical results on 3- and 2-MCPD from esters and glycidol from esters in fats and
oils used the present assessment are summarised per sampling year in Table 8.
Table 9 shows the distribution of the results per sampling country. Many of the results in this data set
were classiﬁed as sampled in the European Union and do not allow tracing the actual country of sampling.
All the samples were analysed individually and no aggregated results were included in the data set.
Industry sampling (samples collected during industrial processing) accounted for 63% of the results.
All the results were obtained with GC-MS based methods of Ermacora and Hrncirık (2013)
(corresponding to AOCS cd 29a-13), Kuhlmann (2011) (corresponding to AOCS cd 29b-13), DGF C-VI
18 (10) (corresponding to AOCS cd 29c-13) and JRC (proposed, 2014) (based on AOCS cd 29a-13).
The sampling strategy was reported as ‘Objective sampling’ in 93% of the results, and ‘Selective
sampling’ in 6% of the results and in the remaining cases it was not reported; no ‘Suspect sampling’ was
reported. It can therefore be assumed that the sampling inside each food group was random. Selective
and objective sampling are substantially equivalent in this case, considering that the food categories
included in the assessment were selected based on the known possible presence of these substances.
All results were reported as whole weight. The data set included variable proportions of left-
censored results (i.e. reported as < LOD or < LOQ), depending on the food group. The left censoring
value ranged from 13 to 172 lg/kg with a median at 100 lg/kg. The number and percentage of left-
censored results is shown in Table 10. For the evaluation of occurrence, the left-censored results were
considered following the approach explained in Section 2.2.2.
The mean, median and 95th percentile of concentrations (lg/kg) of 3- and 2-MCPD and glycidol (all
from esters) by food groups related to the Comprehensive Food Consumption groups (including some ad
hoc ones) in the data set on oils/fats are presented in Tables 11, 12 and 13. The values are reported as
MB followed by the range LB–UB; when the values are coincident, the range is not reported.
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e) MB
(LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Composite food 26 50 10 10 (8.7–12) 5.2 (2.7–9.7) –
Dry preparations for soups
(to be reconstituted)*
26 50 10 10 (8.7–12) 5.2 (2.7–9.7) –
3-MCPD: 3-monochloropropane-1,2-diol; HVP: hydrolysed vegetable protein; LOQ: limit of quantiﬁcation; MB: middle bound;
LB: lower bound; UB: upper bound.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC% = percentage of left-censored results; the values are rounded to the nearest integer.
(e): Mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported).
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Table 8: Distribution of results on 3- and 2-MCPD from esters and glycidol from esters in fats and
oils per sampling year
Sampling
year
Substance analysed
3-MCPD
(from esters)(a)
2-MCPD
(from esters)(a)
Glycidol
(from esters)(a)
N(b) %
2012 499 – 482 981 21
2013 664 – 648 1,312 27
2014 808 425 754 1,987 42
2015 179 116 179 474 10
Total 2,150 541 2,063 4,754 100
3-MCPD: 3-monochloropropane-1,2-diol; 2-monochloropropane-1,3-diol.
(a): Number of analytical results reported per substance analysed.
(b): Total number of reported analytical results.
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Figure 5: Graphs showing the evolution across the years 2010–2015 of the average level (lg/kg) of
3- and 2-monochloropropanediol (MCPD) from esters and glycidol from esters (all
expressed as free moiety) in different types of oils and fats
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For 3-MCPD, the food groups having higher mean values were ‘palm oil/fat’ with levels MB (LB–UB)
of 2,912 lg/kg (LB and UB were equal), ‘margarine, normal fat’ with 668 (667–669) lg/kg, ‘palm
kernel oil’ with 624 lg/kg and ‘coconut oil/fat’ with 608 lg/kg. ‘Special fats’ also had a relatively high
level (867 lg/kg) but their practical use in foodstuffs could not be established.
Table 9: Distribution of results on 3- and 2-MCPD and glycidol (all from esters) in fats and oils per
sampling country
Sampling country N(a) %
Belgium 48 1
Croatia 3 < 1
Denmark 3 < 1
Germany 292 6
Netherlands 18 < 1
Unspeciﬁed country of the European Union 4,357 92
Total 4,754 100
3-MCPD: 3-monochloropropane-1,2-diol; 2-MCPD: 2-monochloropropane-1,3-diol.
(a): N = number of analytical results reported.
Table 10: Number of results and number and percentage of left-censored values by level 1 and 2
food categories in the 3- and 2-MCPD from esters and glycidol from esters data set on
fats and oils
Food group N(a) LC(b) %LC(b)
Animal and vegetable fats and oils 4,754 584 12
Margarine and similar products 510 36 7
Special fats 113 7 6
Vegetable fats and oils 4,131 541 13
3-MCPD: 3-monochloropropane-1,2-diol; 2-MCPD: 2-monochloropropane-1,3-diol.
(a): N = Number of results.
(b): LC = Number of left-censored results; %LC = percentage of left-censored results in each food group.
Table 11: Mean, median and 95th percentile of concentrations (lg/kg) of 3-MCPD (from esters) in
food groups related to the Comprehensive Food Consumption groups (including some
ad hoc ones) in the data set on fats and oils
Food groups(a)
levels 1–3(b)
N(c)
%
LC(d)
LOQ
(min-max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Animal and vegetable
fats and oils
2,150 5 (13–150) 1,034 (1,032–1,037) 490 3,900
Margarine and similar
products
170 2 (16–150) 408 (406–409) 244 (240–246) 1,150
Margarine, normal fat 73 – (16–150) 668 (667–669) 430 1,640
Margarine, low fat 82 4 (22–100) 218 (215–220) 180 (177–180) 430
Fat emulsions 15 – (50–100) 181 150 –
Special Fats* 41 – (100–150) 867 750 –
Vegetable fats and
oils*
1,939 5 (13–150) 1,093 (1,090–1,095) 510 4,020
Maize oil 38 3 (100–150) 503 (502–505) 430 –
Olive oil 9 11 13 48 (48–49) 32 –
Palm kernel oil 97 – (100–150) 624 590 1,410
Peanut oil 8 – (13–150) 229 235 –
Rapeseed oil 294 16 (100–150) 232 (224–239) 180 630
Soya bean oil 191 4 (100–150) 394 (392–396) 330 914
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For 2-MCPD, the food groups having higher mean values were ‘palm oil/fat’ with levels MB (LB–UB)
of 1,565 (1,563–1,566) lg/kg, ‘palm kernel oil’ with 270 (249–291) lg/kg, ‘margarine, normal fat’ with
236 (224–248) lg/kg and ‘sunﬂower seed oil’ with 218 (207–229) lg/kg. ‘Special fats’ also had a
relatively high level (544 lg/kg) but their practical use in foodstuffs could not be established.
Food groups(a)
levels 1–3(b)
N(c)
%
LC(d)
LOQ
(min-max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Sunﬂower seed oil 596 7 (90–150) 521 (517–524) 410 1,510
Walnut oil 1 – 13 236 – –
Coconut oil/fat* 204 – (100–150) 608 590 1,050
Palm oil/fat* 501 < 1 (100–150) 2,912 2,920 5,210
3-MCPD: 3-monochloropropane-1,2-diol; LOQ: limit of quantiﬁcation; MB: middle bound; LB: lower bound; UB: upper bound.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC % = percentage of left-censored results; the values are rounded to the nearest integer.
(e): Mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
Table 12: Mean, median and 95th percentile of concentrations (lg/kg) of 2-MCPD (from esters) in
food groups related to the Comprehensive Food Consumption groups (including some
ad hoc ones) in the data set fats and oils
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min-max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Animal and vegetable
fats and oils
541 20 (15–150) 341 (330–352) 160 1,510
Margarine and similar
products
170 14 (18–150) 159 (152–166) 100 (100–107) 498 (494–500)
Margarine, normal fat 73 22 (18–150) 236 (224–248) 180 550
Margarine, low fat 82 7 (25–100) 104 (101–107) 80 230
Fat emulsions 15 7 (50–100) 80 (77–84) 70 –
Special Fats* 31 – (100–150) 544 460 –
Vegetable fats and oils* 340 25 (15–150) 414 (400–427) 184 1,830
Maize oil 6 – (100–150) 233 170 –
Olive oil 9 22 (15–15) 86 (85–88) 27 –
Palm kernel oil 25 28 (100–150) 270 (249–291) 180 –
Peanut oil 4 25 15 102 (90–115) – –
Rapeseed oil 48 56 (100–150) 109 (78–140) 75 (0–100) –
Soya bean oil 12 17 100 167 (159–175) 130 –
Sunﬂower seed oil 153 22 (90–150) 218 (207–229) 200 530
Walnut oil 1 – 15 127 – –
Coconut oil/fat* 27 37 (100–150) 169 (143–194) 150 –
Palm oil/fat* 55 4 (100–150) 1,565 (1,563–1,566) 1,510 –
2-MCPD: 2-monochloropropane-1,3-diol; LOQ: limit of quantiﬁcation; MB: middle bound; LB: lower bound; UB: upper bound.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC% = percentage of left-censored results; the values are rounded to the nearest integer.
(e): Mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
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For glycidol, the food groups having higher mean values were ‘palm oil/fat’ with levels MB (LB–UB)
of 3,955 (3,954–3,955) lg/kg, ‘Maize oil’ with 650 (647–654) lg/kg, ‘margarine, normal fat’ with
582 (580–584) lg/kg, ‘coconut oil/fat’ with 476 (472–479) lg/kg and ‘palm kernel oil’ with 421
(415–428) lg/kg. ‘Special fats’ also have a considerable level (386 (373–399) lg/kg) but their practical
use in foodstuffs could not be established.
As highlighted in Section 2.1.1, the occurrence data in this data set were limited to the ester-bound
form and the potential presence of 3- and 2-MCPD in free form (however expected to be practically
negligible) was not considered.
3.1.3. Occurrence of total 3- and 2-MCPD and glycidol from esters in food other
than oils/fats, soy sauce, HVP and related products
In this data set, the free and ester-bound form of 3- and 2-MCPD were separately reported for all
samples except 70 infant formula samples and 26 ‘Fried or baked ﬁsh’ samples where only the
contribution from esters was reported. The total occurrence of 3- and 2-MCPD in infant formulae and
fried or baked ﬁsh may thus be underestimated, while for the other food groups the contribution of
both free and ester-bound forms was considered.
The number of analytical results on total 3- and 2-MCPD and glycidol from esters in food groups
other than those mentioned in Sections 3.1.1 and 3.1.2 are summarised per sampling year in Table 14.
The majority of the analyses were performed in 2014.
Table 13: Mean, median and 95th percentile of concentrations (lg/kg) of glycidol (from esters) in
food groups related to the Comprehensive Food Consumption groups (including some
ad hoc ones) in the data set on fats and oils
Food groups(a)
levels 1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e) MB
(LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Animal and vegetable
fats and oils
2,063 18 (31–172) 1,176 (1,167–1,184) 261 6,070
Margarine and similar
products
170 6 (38–172) 361 (358–364) 175 (175–176) 1,280
Margarine, normal fat 73 3 (38–150) 582 (580–584) 270 1,946
Margarine, low fat 82 0 (50–172) 209 (204–213) 140 (140–142) 500
Fat emulsions 15 – (50–100) 114 100 –
Special Fats* 41 17 (100–150) 386 (373–399) 360 –
Vegetable fats and
oils*
1,852 19 (31–150) 1,268 (1,259–1,277) 280 6,260
Maize oil 36 6 (100–150) 650 (647–654) 475 –
Olive oil 9 100 31 15 (0–31) 15 (0–31) –
Palm kernel oil 95 13 (100–150) 421 (415–428) 320 1,120
Peanut oil 8 50 (31–150) 148 (133–162) 110 (85–135) –
Rapeseed oil 290 49 (100–150) 166 (144–188) 100 (100–110) 560
Soya bean oil 189 30 (100–150) 171 (157–186) 120 (120–140) 560
Sunﬂower seed oil 542 20 (90–150) 269 (259–279) 200 680
Walnut oil 1 – 31 247 – –
Coconut oil/fat* 184 8 (100–150) 476 (472–479) 426 1,065
Palm oil/fat* 498 1 (100–150) 3,955 (3,954–3,955) 3,610 9,700
LOQ: limit of quantiﬁcation; MB: middle bound; LB: lower bound; UB: upper bound.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC% = percentage of left-censored results; the values are rounded to the nearest integer.
(e): Mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
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Table 15 shows the distribution of the results per sampling country. The data in this data set were
produced in ad hoc studies. For products where a large variability across Europe was not expected the
samples were taken near the laboratories performing the study (Belgium and Germany) while for products
where a larger variability across Europe was expected, sampling was extended to different European areas.
All the samples were analysed as individual samples and no aggregated sample was present in the
data set.
The sampling strategy was reported as ‘Objective sampling’ in 83% of the results, and ‘Convenient
sampling’ in 12% of the results (infant formulae) while in the remaining cases it was not reported; no
‘Suspect sampling’ was reported. The selection of the infant formula samples based on the ease of
data collection (convenient sampling) introduces an uncertainty that might be partially mitigated by a
relative concentration on few producers (with respect to other food groups) of the market of infant
formulae.
Table 14: Distribution of results on total 3- and 2-MCPD and glycidol from esters in food other than
oils/fats, soy sauce, HVP and related products per sampling year
Sampling
year
Substance analysed
3-MCPD
(expressed as
3-MCPD moiety)(a)
2-MCPD
(expressed as
2-MCPD moiety)(a)
Glycidyl esters
(expressed as
glycidol moiety)(a)
N(b) %
2012 2 2 2 6 < 1
2013 68 68 68 204 12
2014 478 478 478 1,434 83
2015 25 25 25 75 4
Total 573 573 573 1,719 100
3-MCPD: 3-monochloropropane-1,2-diol; 2-MCPD: 2-monochloropropane-1,3-diol.
(a): Number of analytical results reported per substance analysed.
(b): Total number of reported analytical results.
Table 15: Distribution of results on total 3- and 2-MCPD and glycidol from esters in food other than
oils/fats, soy sauce, HVP and related products per sampling country
Sampling country N(a) %
Austria 57 3
Belgium 561 33
Bulgaria 12 < 1
Croatia 3 < 1
Czech Republic 9 < 1
Denmark 24 1
France 30 1
Germany 519 32
Greece 9 < 1
Hungary 15 < 1
Italy 135 8
Latvia 57 3
Netherlands 183 11
Poland 6 < 1
Portugal 6 < 1
Slovakia 3 < 1
Spain 12 < 1
Unknown 78 5
Total 1,719 100
3-MCPD: 3-monochloropropane-1,2-diol; 2-MCPD: 2-monochloropropane-1,3-diol.
(a): N = number of analytical results reported.
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All the results were reported on whole weight, with the exception of 210 data on infant formulae
reported on fat basis. In this case, the occurrence was converted to whole weight using the fat
content declared for the samples.
The data set included various left-censored results (i.e. reported as < LOD or < LOQ). The left
censoring value ranged from < 0.1 to 56 lg/kg with a median of 9 lg/kg. The number and percentage
of left-censored results is shown in Table 16. For the evaluation of occurrence, the left-censored
results were considered following the approach explained in Section 2.2.2.
The mean, median and 95th percentile of concentrations (lg/kg) of 3- and 2-MCPD and glycidol
in food groups related to the Comprehensive Food Consumption groups (including some ad hoc ones)
in the data set on food other than oils/fats, soy sauce, HVP and related products are presented in
Tables 17, 18 and 19. The values are reported as MB followed by the range LB–UB; when the values
are coincident, the range is not reported.
Table 16: Number of results and number and percentage of left-censored values by level 1 food
categories in the data set on total 3- and 2-MCPD and glycidol from esters in food other
than oils/fats, soy sauce, HVP and related products
Food group N(a) LC(b) %LC(b)
Cereal-based products and similar 687 310 45
Fried, baked or roast meat or ﬁsh products 225 71 32
Infant formulae (powder) 210 56 27
Smoked meat or ﬁsh products 387 284 73
Snacks and potato products 210 22 10
3-MCPD: 3-monochloropropane-1,2-diol; 2-MCPD: 2-monochloropropane-1,3-diol; HVP: hydrolysed vegetable protein.
(a): N = Number of results.
(b): LC = Number of left-censored results; %LC = percentage of left-censored results in each food group.
Table 17: Mean, median and 95th percentile of concentrations (lg/kg) of total 3-MCPD in food
groups related to the Comprehensive Food Consumption groups (including some ad hoc
ones) in the data set on food other than oils/fats, soy sauce, HVP and related products
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Infant formulae (powder) 70 1 200 108 (108–109) 105 147
Infant formula, milk-based,
powder(f)
70 1 200 108 (108–109) 105 147
Cereal-based products
and similar*
229 35 14 83 (77–90) 16 (11–20) 405 (398–412)
Bread and bread rolls 75 55 14 29 (23–36) 7.1 (0–14) 125 (118–132)
Wheat bread and rolls 21 48 14 31 (24–37) 11 (4–18) –
Rye bread and rolls 12 83 14 8.5 (1.9–14) 7.1 (0–14) –
Mixed wheat and rye bread
and rolls
20 75 14 11 (5.2–17) 7.1 (0–14) –
Multigrain bread and rolls 12 50 14 19 (13–25) 8.1 (1–14) –
Unleavened bread,
crispbread, rusk
10 – 14 101 (95–108) 59 (52–66) –
Breakfast cereals 66 45 14 26 (19–33) 8.7 (1–17) 75 (68–82)
Cereal ﬂakes 27 48 14 12 (6.1–19) 8 (1–15) –
Muesli 8 38 14 95 (88–102) 8.5 (1.5–15) –
Cereal bars 10 30 14 21 (14–29) 12 (5.5–19) –
Popped cereals 11 18 14 29 (23–35) 20 (13–27) –
Porridge 10 90 14 8.8 (0.6–17) 8.4 (0–16) –
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Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Fine bakery wares 88 11 14 172 (167–178) 104 (97–110) 518 (511–525)
Cookies 36 11 14 200 (194–206) 128 (123–135) –
Fatty cake products* 13 8 14 138 (132–145) 66 (59–73) –
Hot surface cooked
pastries*
9 – 14 247 (242–253) 257 –
Puff pastry* 7 29 14 106 (100–112) 20 (19–25) –
Shortcrusts* 7 – 14 154 (148–160) 116 (109–123) –
Yeast leavened pastries* 16 19 14 133 (127–138) 59 (52–66) –
Fried, baked or roast
meat or ﬁsh products*
75 15 (0.03–14) 30 (26–34) 17 (12–22) 119
Fried or baked ﬁsh*(f) 28 – (0.03–14) 42 (42–43) 22 –
Fried or roast meat* 47 23 14 23 (17–29) 16 (10–22) –
Smoked meat or ﬁsh
products*
129 47 14 21 (15–28) 9.1 (1–17) 57 (54–61)
Smoked ﬁsh* 60 43 14 18 (12–24) 9 (1.5–17) 59 (55–65)
Smoked meat products* 69 51 14 24 (17–30) 9.4 (0–18) 49 (45–56)
Snacks and potato
products*
70 4 14 130 (123–137) 63 (56–70) 502 (495–509)
Miscellaneous snack
products*
8 13 14 119 (112–126) 100 (93–107) –
Potato products* 62 3 14 132 (125–138) 61 (54–68) 502 (495–509)
French fries 8 13 14 57 (51–63) 37 (30–44) –
Potato croquettes 10 – 14 30 (23–37) 23 (16–30) –
Potato crisps 32 – 14 216 (210–223) 158 (151–165) –
Oven baked potato
products (include also
home-made products like
pan fried potato
pieces or Roesti)*
12 8 14 40 (33–47) 31 (24–38) –
3-MCPD: 3-monochloropropane-1,2-diol; HVP: hydrolysed vegetable protein; LOQ: limit of quantiﬁcation; MB: middle bound;
LB: lower bound; UB: upper bound; P95: 95th percentile.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC % = percentage of left-censored results; the values are rounded to the nearest integer.
(e): mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
(f): ‘Infant formula, milk-based, powder’ and 26 samples of ‘Fried or baked ﬁsh’ do not include the contribution from free 3-MCPD
Table 18: Mean, median and 95th percentile of concentration (lg/kg) of total 2-MCPD in food
groups related to the Comprehensive Food Consumption groups (including some ad hoc
ones) in the data set on food other than oils/fats, soy sauce, HVP and related products
Food groups(a) levels
1–3(b)
N(c)
%
LC (d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Infant formulae (powder) 70 53 200 44 (31–58) 28 (0–55) 73
Infant formula, milk-
based, powder(f)
70 53 200 44 (31–58) 28 (0–55) 73
Cereal-based products
and similar*
229 48 9 42 (38–47) 6.5 (1–12) 219 (215–224)
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Food groups(a) levels
1–3(b)
N(c)
%
LC (d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Bread and bread rolls 75 68 9 14 (9.8–19) 4.7 (0–9.3) 59 (55–64)
Wheat bread and rolls 21 57 9 15 (10–19) 4.7 (0–9.3) –
Rye bread and rolls 12 100 9 4.6 (0–9.3) 4.7 (0–9.3) –
Mixed wheat and rye
bread and rolls
20 85 9 6.1 (1.5–10) 4.7 (0–9.3) –
Multigrain bread and rolls 12 67 9 7.3 (2.7–11) 4.7 (0–9.3) –
Unleavened bread,
crispbread, rusk
10 20 9 49 (44–54) 29 (24–33) –
Breakfast cereals 66 65 9 15 (10–20) 5.6 (0–11) 82 (78–87)
Cereal ﬂakes 27 81 9 8.7 (3.8–13) 4.8 (0–9.6) –
Muesli 8 63 9 50 (46–55) 5.6 (0–11) –
Cereal bars 10 30 9 12 (7.3–16) 6.50 (2–11) –
Popped cereals 11 27 9 17 (12––22) 8.50 (4–13) –
Porridge 10 100 9 5.9 (0–11) 5.70 (0–11) –
Fine bakery wares 88 18 9 87 (82–92) 48 (43–52) 268 (264–273)
Cookies 36 11 9 103 (98–107) 66 (61–70) –
Fatty cake products* 13 8 9 71 (66–75) 30 (29–32) –
Hot surface cooked
pastries*
9 22 9 123 (118–128) 126 (122–131) –
Puff pastry* 7 57 9 47 (42–53) 6.8 (0–13) –
Shortcrusts* 7 14 9 79 (75–84) 62 (58–67) –
Yeast leavened pastries* 16 25 9 65 (60–70) 31 (26–35) –
Fried, baked or roast
meat or ﬁsh products*
75 57 (0.07–9) 10 (7–14) 6.5 (0–11) 46 (42–51)
Fried or baked ﬁsh*(f) 28 46 (0.07–9) 14 (13–15) 3 (2–3.5) –
Fried or roast meat* 47 64 9 8.38 (3–13) 6.7 (0–13) –
Smoked meat or ﬁsh
products*
129 98 9 6.2 (0.5–11) 5.5 (0–11) 7.60 (0–15)
Smoked ﬁsh* 60 98 9 6.1 (0.8–11) 5.2 (0–10) 7.10 (0–14)
Smoked meat products* 69 99 9 6.2 (0.2–12) 6.1 (0–12) 7.70 (0–15)
Snacks and potato
products*
70 9 9 79 (75–84) 32 (28–37) 285 (281–290)
Miscellaneous snack
products*
8 13 9 67 (62–71) 55 (50–59) –
Potato products* 62 8 9 81 (76–85) 31 (26–35) 285 (281–290)
French fries 8 25 9 23 (19–28) 13 (8.5–17) –
Potato croquettes 10 – 9 17 (12–21) 17 (12–21) –
Potato crisps 32 – 9 135 (131–140) 67 (63–72) –
Oven baked potato products
(include also home-made
products like pan fried
potato pieces or Roesti)*
12 25 9 28 (23–32) 16 (12–21) –
2-MCPD: 2-monochloropropane-1,3-diol; HVP: hydrolysed vegetable protein; LOQ: limit of quantiﬁcation; MB: middle bound;
LB: lower bound; UB: upper bound; P95: 95th percentile.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC % = percentage of left-censored results; the values are rounded to the nearest integer.
(e): mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
(f): ‘Infant formula, milk-based, powder’ and 26 samples of ‘Fried or baked ﬁsh’ do not include the contribution from free 2-MCPD.
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Table 19: Mean, median and 95th percentile of concentrations (lg/kg) of glycidol (from esters) in
food groups related to the Comprehensive Food Consumption groups (including some ad
hoc ones) in the data set on food other than oils/fats, soy sauce, HVP and related
products
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Infant formulae (powder) 70 26 200 87 (80–94) 68 220
Infant formula, milk-based,
powder
70 26 200 87 (80–94) 68 220
Cereal-based products
and similar*
229 52 (0.03–15) 51 (50–51) 3 (0–4.8) 318
Bread and bread rolls 75 76 (0.1–8.9) 8 (7.8–8.3) 0.3 (0–0.6) 62
Wheat bread and rolls 21 67 (0.1–8.9) 12 (11–12) 0.3 (0–0.6) –
Rye bread and rolls 12 92 (0.3–0.6) 0.4 (0.08–0.6) 0.3 (0–0.6) –
Mixed wheat and rye bread
and rolls
20 90 (0.1–0.6) 0.8 (0.8–1) 0.3 (0–0.6) –
Multigrain bread and rolls 12 92 (0.2–4.6) 4.1 (3.8–4.3) 0.3 (0–0.6) –
Unleavened bread,
crispbread, rusk
10 30 (0.3–7.4) 28 (27–28) 11 –
Breakfast cereals 66 67 (0.03–14) 17 (16–18) 2 (0–2.9) 64
Cereal ﬂakes 27 67 (0.03–7.3) 6.3 (5.5–7.1) 1 (0–1.2) –
Muesli 8 75 (0.1–4.9) 84 (83–85) 1.8 (0–3.5) –
Cereal bars 10 60 (0.1–8.1) 12 (11–12) 2.1 (0–3.1) –
Popped cereals 11 36 (0.6–7.8) 15 (14–16) 3.9 (3–7.2) –
Porridge 10 100 (1.8–14) 3 (0–6) 2.5 (0–5) –
Fine bakery wares 88 20 (0.1–15) 112 (112–113) 39 585
Cookies 36 8 (0.3–15) 134 (134–135) 67 –
Fatty cake products* 13 15 (0.1–7.2) 102 (102–103) 16 –
Hot surface cooked
pastries*
9 44 (0.3–8.1) 137 (136–138) 56 –
Puff pastry* 7 57 (3.8–9.5) 21 (19–23) 4.8 (0–9.5) –
Shortcrusts* 7 14 (0.2–8.1) 149 (148–149) 58 –
Yeast leavened
pastries*
16 25 (0.6–9.4) 81 (81–82) 13 –
Fried, baked or roast
meat or ﬁsh products*
75 23 (0.08–13) 38 (38–39) 19 144
Fried or baked ﬁsh* 28 – (0.08–13) 30 12 –
Fried or roast meat* 47 36 (0.3–11) 43 (42–44) 22 –
Smoked meat or ﬁsh
products*
129 74 (0.2–17) 17 (15–19) 3.4 (0–6.4) 18
Smoked ﬁsh* 60 57 (0.2–17) 5.8 (4.7–6.8) 3 (0–4.8) 18
Smoked meat products* 69 90 (0.2–17) 27 (24–30) 3.5 (0–7) 13 (13–17)
Snacks and potato
products*
70 19 (0.01–17) 58 (58–59) 19 249
Miscellaneous snack
products*
8 63 (4.7–17) 15 (12–17) 6 (0–12) –
Potato products* 62 13 (0.01–10) 64 22 249
French fries 8 25 (1.9–4.5) 41 (40–41) 14 –
Potato croquettes 10 30 (0.2–7.4) 5 (4.8–5.2) 6 –
Potato crisps 32 – (2–10) 110 44 –
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For 3-MCPD, the food groups showing higher mean values were ‘Hot surface cooked pastries’ with
levels MB (LB–UB) of 247 (242–253) lg/kg, ‘Potato crisps’ with 216 (210–223) lg/kg, ‘Cookies’ with
200 (194–206) lg/kg and ‘Shortcrusts’ with 154 (148–160) lg/kg.
For 2-MCPD, the food groups showing higher mean values were ‘Potato crisps’ with levels MB
(LB–UB) of 135 (131–140) lg/kg, ‘Hot surface cooked pastries’ with 123 (118–128) lg/kg, ‘Cookies’
with 103 (98–107) lg/kg and ‘Shortcrusts’ with 79 (75–84) lg/kg.
For glycidol, the food groups showing higher mean values were ‘Shortcrusts’ with 149 (148–149)
lg/kg, ‘Hot surface cooked pastries’ with 137 (136–138) lg/kg, ‘Cookies’ with 134 (134–135) lg/kg and
‘Potato crisps’ with 110 (LB and UB coincident) lg/kg.
3.1.4. Correlation of total 3-MCPD and 2-MCPD levels in food
The possible correlation between total 3-MCPD and total 2-MCPD levels was analysed in the data
on food submitted in the framework of the JRC survey. The data on the samples where both 3-MCPD
and 2-MCPD were quantiﬁed were used. A linear least squares ﬁtting of ﬁrst order was performed
using 2-MCPD level as dependent variable and 3-MCPD level as independent variable.
The ﬁtting is shown in Figure 6.
The straight line of best ﬁt has a slope of 0.53 and an R2 value of 0.88. Among the food data, the
food group with the best correlation is ‘Cereal-based products and similar’ with a slope of 0.5 and an
R2 value of 0.98. The model suggests therefore an expected level of 2-MCPD at about (or slightly
higher than) half of the 3-MCPD level.
Food groups(a) levels
1–3(b)
N(c)
%
LC(d)
LOQ
(min–max)
(lg/kg)
Mean(e)
MB (LB–UB)
(lg/kg)
Median(e)
MB (LB–UB)
(lg/kg)
P95(e) MB
(LB–UB)
(lg/kg)
Oven baked potato products
(include also home-made
products like pan fried potato
pieces or Roesti)*
12 25 (0.01–4.4) 6.4 4.5 –
HVP: hydrolysed vegetable protein; LOQ: limit of quantiﬁcation; MB: middle bound; LB: lower bound; UB: upper bound;
P95: 95th percentile.
(a): Some ad hoc groups created for the purpose of this assessment are present together with FoodEx1 groups; ad hoc groups
are ﬂagged with an asterisk * after the name.
(b): The names are provided in indented form to show the hierarchical relationship of the food groups.
(c): N = number of analytical results reported.
(d): LC % = percentage of left-censored results; the values are rounded to the nearest integer.
(e): Mean = arithmetic mean; median = 50th percentile (when the number of data points is less than 11, the median is not
reported); P95 = 95th percentile (when the number of data points is less than 60, the value of P95 is not reported). The
values are reported as MB followed by the range LB–UB; when the values are coincident, the range is not reported.
Figure 6: Linear ﬁrst-order ﬁtting (least squares method) of total 3-monochloropropane-1,2-diol
(3-MCPD) level versus total 2-monochloropropane-1,3-diol (2-MCPD) level in the different
samples of the Joint Research Centre data set on food
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3.2. Exposure assessment of 3-, 2-MCPD and glycidol in humans
The exposure to 3- and 2-MCPD was based upon the level of exposure to the parent compounds
regardless of their original form (i.e. as free or as ester of fatty acids), and referred to as 3-MCPD and
2-MCPD. Likewise, exposure to glycidol refers to the parent compound, but in this case the original
form was exclusively as fatty acid esters.
3.2.1. Occurrence data used for exposure assessment
The assessment of dietary exposure to MCPDs, and glycidol from esters required the combination
of occurrence values for all relevant food groups with food consumption data from the EFSA
Comprehensive Food Consumption Database (as described in Section 2.1.2).
The Foodex1 groups used to estimate exposure are those listed in Table B.3. For many of those
food groups occurrence data were available as described in Sections 3.1.1, 3.1.2 and 3.1.3.
Occurrence data were not available for some relevant food groups, but could be calculated from
models based on estimates of the amount of oil in the products:
• Vegetable oils not included in the data set;
• Mayonnaise, emulsion sauces and salad dressings;
• Chocolate spreads and similar spreadable products.
For the ﬁrst two food groups an occurrence value was calculated based on the occurrence data
measured in vegetable oils using models making assumptions on the type and proportion of oils in the
food. For mayonnaise, emulsiﬁed sauces and salad dressings, the occurrence of 3-MCPD in free form
was also taken into account.
The occurrence value for an ‘average edible vegetable oil’ was calculated considering the market
share expressed as a percentage for the oils included in the data set (from the data on edible oil
consumption in the EU in 2011 made available by FEDIOL as summarised in Table 20), and the mean
occurrence values calculated for these oils. Palm oil, coconut oil and palm kernel oil were excluded
from the model representing the ‘average edible vegetable oil’, because they often have different uses
than the other oils. Olive oil was also excluded because it is not often used in the products modelled.
The occurrence values calculated for the ‘average edible vegetable oil’ were used to attribute an
occurrence value to edible oils not included in the occurrence data set and also to calculate the
occurrence values for products such as mayonnaise, emulsion sauces and salad dressings. The
calculation is described in Table B.3 in Appendix B.
No data were available on the occurrence of MCPDs and glycidol from esters in chocolate spreads and
similar spreadable products. To identify a model, the ingredient labels of the products of this type were
consulted in the Global New Products Database (GNPD) published by Mintel;14 the fat content and fat
Table 20: Data on edible oil consumption in the EU in 2011 (data provided by FEDIOL); the
amount in 1,000 tons and the corresponding percentage are reported
Oil source
EU27 oil consumption
2011 (3 1,000 tons)
%
Sunﬂower oil 2,963 23
Palm oil 2,751 22
Rapeseed oil 2,665 21
Olive oil 2,045 16
Soybean oil 1,150 9
Coconut oil 415 3
Palm kernel oil 398 3
Maize germ oil 196 2
Peanut oil 88 1
Total 12,671
EU: European Union; FEDIOL: Association of the EU Vegetable Oil & Proteinmeal Industry.
14 Product launches in European countries in August-September 2015, accessed at: http://www.mintel.com/global-new-products-
database
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type in the products varied, and many products declared the presence of palm oil alone or in combination
with other vegetable oils. Choosing the most often featured brand and several similar products produced
under distribution labels, variability in fat content between 29% and 31% was observed. In many cases,
hazelnuts was declared on the label as ingredient at about 13%; therefore, a contribution of roughly 8%
fat from the hazelnuts was subtracted; consequently, a proportion of vegetable oil of 22% was estimated.
The model assumed the use of only palm oil; this may represent a worst-case scenario.
No model was possible for some additional food groups not covered by the available data and where
3- and 2-MCPD and glycidol were potentially present but sufﬁcient information on the fat source or on the
proportion of fat in the food was not available. These included for example chocolate and related
products, ice cream, meat specialties (such as terrine or pate), meat and dairy imitations and ﬁsh oil. The
absence of these food groups may lead to underestimation to some extent of the dietary exposure.
Table B.3 in Appendix B describes the occurrence values used for calculating exposure and for the
groups where a model was applied it also brieﬂy describes the calculation applied.
In ﬁsh and ﬁsh products the Foodex1 code does not record the treatment, therefore the occurrence
value for ‘Fried or baked ﬁsh’ was applied, because the occurrence levels in this group were either
higher (more conservative choice) or similar to those in ‘Smoked ﬁsh’. It is assumed here that ﬁsh
were either fried or smoked which leads to overestimation of occurrence. No occurrence data were
available for potential combination of the two treatments. In the case of meat and meat products, the
occurrence values in ‘Fried or roast meat’ were used for unprocessed meat food groups, while the
occurrence values for ‘Smoked meat products’ were used for sausages and similar charcuterie
products. These assumptions are conservative and might overestimate the exposure.
3.2.2. Mean and high chronic dietary exposure to 3- and 2-MCPD and glycidol
For calculating the chronic dietary exposure to 3- and 2-MCPD or glycidol, food consumption and
body weight data at the individual level were accessed from the Comprehensive Food Consumption
Database. The occurrence data described in the previous section and consumption data were linked at
FoodEx1 level. In addition, different but related food commodities were grouped in food categories to
better explain their contribution to the total dietary exposure to these substances. For each country,
exposure estimates were calculated per dietary survey and age class. Chronic exposure estimates were
calculated for 41 different dietary surveys carried out in 22 different European countries. Not all
countries provided consumption information for all age groups, and in some cases the same country
provided more than one consumption survey; the dietary surveys available for the different age classes
are reported in Table B.2 in Appendix B. The mean and the high (95th percentile) chronic dietary
exposures (in lg/kg bw per day) were calculated by combining the mean occurrence values as shown
in Table B.3 in Appendix B with the average daily consumption for each food at individual level and
choosing the mean and P95 of exposure for each age class in each dietary survey.
The chronic dietary exposure was calculated separately for 3-MCPD, 2-MCPD and glycidol. The
tables present the minimum, median and maximum exposure across surveys for each age class. As
the occurrence values were calculated as LB, MB and UB scenarios, the exposure corresponding to the
three occurrence values is presented in the form MB (LB–UB). Considering the relatively narrow range
between exposure estimates based on LB and UB occurrence, the Panel decided to focus on the
exposure estimates corresponding to MB occurrence. The full range of estimated exposure based on
LB, MB and UB occurrence data is shown in Tables 21–26.
3.2.2.1. 3-MCPD
The mean and P95 of chronic dietary exposure to 3-MCPD across dietary surveys from different
European countries for the different age classes are summarised in Tables 21 and 22, respectively.
The median across dietary surveys of mean chronic exposure to 3-MCPD was below 1 lg/kg bw per day
(MB) in all age classes, with ‘Infants’, ‘Toddlers’ and ‘Other children’ in the range 0.7–0.9 lg/kg bw per day
(MB). The minimum across dietary surveys of the mean exposure in the same age classes was 0.5–0.6 lg/kg
bw per day (MB). The maximum of mean exposure across dietary surveys in the age classes ‘Toddlers’ and
‘Other children’ reached a value of 1.4–1.5 lg/kg bw per day (MB). In adolescents and adult population groups
(adults, elderly, very elderly) themean exposure to 3-MCPD ranged from 0.2 to 0.7 lg/kg bw per day (MB).
Considering the P95 of exposure (high exposure), the median across dietary surveys for ‘Infants’,
‘Toddlers’ and ‘Other children’ was in the range 1.4–1.7 lg/kg bw per day (MB). The minimum across
dietary surveys in the same age classes was in the range 1.1–1.5 lg/kg bw per day (MB) and the
maximum was in the range 2.4–2.6 lg/kg bw per day (MB).
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For ‘Adolescents’ and adult population groups (adults, elderly, very elderly), the median across
dietary surveys of P95 of exposure (high exposure) was ≤ 0.9 lg/kg bw per day (MB) with a minimum
in the survey with lowest exposure of 0.3 lg/kg bw per day (MB) and a maximum in the survey with
highest exposure of 1.3 lg/kg bw per day (MB).
3.2.2.2. 2-MCPD
The mean and P95 of chronic dietary exposure to 2-MCPD for the different age classes are
summarised in Tables 23 and 24, respectively.
The median across dietary surveys of mean chronic exposure to 2-MCPD was below 0.5 lg/kg bw per
day (MB) in all age classes, with ‘Infants’, ‘Toddlers’ and ‘Other children’ in the range 0.3–0.4 lg/kg bw
per day (MB). The minimum of mean exposure across dietary surveys in these age classes was
0.2–0.3 lg/kg bw per day (MB). The maximum of mean exposure across dietary surveys was similar to
the median in ‘Infants’, while in ‘Toddlers’ and ‘Other children’ reached a value of 0.6–0.7 lg/kg bw per
day (MB).
In adolescents and adult population groups (adults, elderly, very elderly) the mean exposure to
2-MCPD ranged from 0.1 to 0.3 lg/kg bw per day (MB).
Considering the P95 of exposure (high exposure), the median across dietary surveys for
‘Infants’, ‘Toddlers’ and ‘Other children’ was in the range 0.7 – 0.8 lg/kg bw per day (MB); the
minimum across dietary surveys in the same age classes was in the range 0.5 – 0.7 lg/kg bw
per day (MB). The maximum for the same age classes was in the range 1.0 – 1.2 lg/kg bw per
day (MB).
Table 22: The minimum, median and maximum values for the P95 chronic exposure to 3-MCPD
(lg/kg bw per day) across dietary surveys from different countries. The exposure
estimates corresponding to MB (LB–UB) occurrence scenarios are reported
Age class(a)
Min MB (LB–UB)(b)
(lg/kg bw per day)
Median MB (LB–UB)(b)
(lg/kg bw per day)
Max MB (LB–UB)(b)
(lg/kg bw per day)
Infants 1.5 (1.5–1.6) 1.7 (1.7–1.8) 2.5 (2.5–2.6)
Toddlers 1.4 (1.4–1.5) 1.7 (1.6–1.9) 2.4 (2.3–2.6)
Other children 1.1 (1.1–1.2) 1.4 (1.4–1.6) 2.6 (2.5–2.7)
Adolescents 0.5 (0.5–0.6) 0.9 (0.8–0.9) 1.3 (1.3–1.4)
Adults 0.4 (0.4–0.5) 0.7 (0.6–0.7) 0.9 (0.8–0.9)
Elderly 0.4 (0.3–0.4) 0.6 (0.6–0.7) 0.8 (0.8–0.9)
Very elderly 0.3 (0.3–0.4) 0.7 (0.6–0.7) 0.9 (0.8–0.9)
P95: 95th percentile; 3-MCPD: 3-monochloropropane-1,2-diol; bw: body weight; LB: lower-bound; MB: middle bound;
UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b) and therefore they should not be considered in the risk characterisation. Those estimates were not
included in this table.
Table 21: The minimum, median and maximum values for the mean chronic exposure to 3-MCPD
(lg/kg bw per day) across dietary surveys from different countries
Age class(a)
Min MB (LB–UB)
(lg/kg bw per day)
Median MB (LB–UB)
(lg/kg bw per day)
Max MB (LB–UB)
(lg/kg bw per day)
Infants 0.5 0.9 (0.8–0.9) 1.0 (0.9–1.0)
Toddlers 0.6 (0.5–0.6) 0.8 (0.8–0.9) 1.4 (1.3–1.5)
Other children 0.5 (0.5–0.6) 0.7 (0.7–0.8) 1.5 (1.4–1.6)
Adolescents 0.2 (0.2–0.3) 0.4 (0.4–0.5) 0.7 (0.6–0.7)
Adults 0.2 0.3 0.4 (0.4–0.5)
Elderly 0.2 0.3 (0.3–0.4) 0.4
Very elderly 0.2 0.3 0.5 (0.4–0.5)
3-MCPD: 3-monochloropropane-1,2-diol; bw: body weight; LB: lower-bound; MB: middle bound; UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
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In adolescents and adult population groups (adults, elderly, very elderly) the high exposure (P95)
ranged from 0.2 to 0.6 lg/kg bw per day (MB) across dietary surveys.
3.2.2.3. Glycidol from esters
The mean and P95 of chronic dietary exposure to glycidol for the different age classes are
summarised in Tables 25 and 26, respectively.
Table 24: The minimum, median and maximum values for the P95 chronic exposure to 2-MCPD
(lg/kg bw per day) across dietary surveys from different countries
Age class(a)
Min MB (LB–UB)(b)
(lg/kg bw per day)
Median MB (LB–UB)(b)
(lg/kg bw per day)
Max MB (LB–UB)(b)
(lg/kg bw per day)
Infants 0.7 (0.5–0.8) 0.8 (0.6–1) 1.0 (0.8–1.4)
Toddlers 0.6 (0.5–0.7) 0.8 (0.7–0.9) 1.1 (1–1.2)
Other children 0.5 (0.4–0.5) 0.7 (0.6–0.8) 1.2 (1.1–1.3)
Adolescents 0.3 (0.2–0.3) 0.4 (0.4–0.5) 0.6 (0.6–0.7)
Adults 0.2 (0.2–0.3) 0.3 (0.3–0.4) 0.4 (0.3–0.4)
Elderly 0.2 0.3 (0.2–0.3) 0.4 (0.3–0.4)
Very elderly 0.2 0.3 0.4 (0.3–0.4)
P95: 95th percentile; 2-MCPD: 2-monochloropropane-1,3-diol; bw: body weight; LB: lower-bound; MB: middle bound;
UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b) and therefore they should not be considered in the risk characterisation. Those estimates were not
included in this table.
Table 23: The minimum, median and maximum values for the mean chronic exposure to 2-MCPD
(lg/kg bw per day) across dietary surveys from different countries
Age class(a)
Min MB (LB–UB)
(lg/kg bw per day)
Median MB (LB–UB)
(lg/kg bw per day)
Max MB (LB–UB)
(lg/kg bw per day)
Infants 0.2 (0.2–0.3) 0.4 (0.3–0.5) 0.4 (0.3–0.5)
Toddlers 0.3 (0.2–0.3) 0.4 (0.3–0.4) 0.6 (0.6–0.7)
Other children 0.3 (0.2–0.3) 0.3 (0.3–0.4) 0.7 (0.6–0.7)
Adolescents 0.1 0.2 0.3
Adults 0.1 0.1 (0.1–0.2) 0.2
Elderly 0.1 0.1 (0.1–0.2) 0.2 (0.1–0.2)
Very elderly 0.1 0.1 (0.1–0.2) 0.2
2-MCPD: 2-monochloropropane-1,3-diol; bw: body weight; LB: lower-bound; MB: middle bound; UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
Table 25: The minimum, median and maximum values for the mean chronic exposure to glycidol
from esters (lg/kg bw per day) across dietary surveys
Age class(a)
Min MB (LB–UB)
(lg/kg bw per day)
Median MB (LB–UB)
(lg/kg bw per day)
Max MB (LB–UB)
(lg/kg bw per day)
Infants 0.4 (0.3–0.4) 0.7 0.8 (0.7–0.8)
Toddlers 0.4 (0.4–0.5) 0.6 0.9
Other children 0.3 0.6 (0.5–0.6) 0.9 (0.9–1)
Adolescents 0.2 0.3 0.5
Adults 0.2 (0.1–0.2) 0.2 0.3
Elderly 0.1 0.2 (0.2–0.3) 0.3
Very elderly 0.1 0.2 (0.2–0.3) 0.3
bw: body weight; LB: lower-bound; MB: middle bound; UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
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The median across dietary surveys of mean chronic exposure to glycidol was at 0.7 lg/kg bw per
day (MB) in ‘Infants’, and at 0.6 lg/kg bw per day (MB) in ‘Toddlers’ and ‘Other children’; for
‘Adolescents’ and older age classes it was in the range 0.2–0.3 lg/kg bw per day (MB). The range of
mean exposure to glycidol across the dietary surveys for the age groups ‘Infants’, ‘Toddlers’ and ‘Other
children’ was 0.3–0.9 lg/kg bw per day (MB). In ‘Adolescents’ and adult population groups (‘Adults’,
‘Elderly’, ‘Very elderly’) the mean exposure to glycidol ranged from 0.1 to 0.5 lg/kg bw per day (MB).
Considering the P95 of exposure (high exposure), the median across dietary surveys was 1.4 lg/kg
bw per day (MB) for ‘Infants’, and 1.1 lg/kg bw per day (MB) for ‘Toddlers’ and ‘Other children’. The
minimum across dietary surveys in the same age classes was only slightly lower, with ‘Infants’ at
1.2 lg/kg bw per day (MB) and ‘Toddlers’ and ‘Other children’ in the range 0.8–1 lg/kg bw per day
(MB). The maximum for the same age classes reached values in the range 1.7–2.1 lg/kg bw per day
(MB); for ‘Adolescents’ the maximum exposure in this scenario (high exposure) was 1.1 lg/kg bw per
day (MB). For ‘Adults’ and older age classes, the median across dietary surveys of P95 of exposure
(high exposure) was 0.5 lg/kg bw per day (MB) with maximum in the surveys with highest exposure
in the range 0.6–0.7 lg/kg bw per day (MB). The range of P95 of exposure (high exposure) to glycidol
across the dietary surveys for the age groups ‘Infants’, ‘Toddlers’ and ‘Other children’ was 0.8–2.1
lg/kg bw per day (MB). The high exposure (P95) in ‘Adolescents’ ranged from 0.4 to 1.1 lg/kg bw per
day (MB) and in adults and older population groups ranged from 0.2 to 0.7 lg/kg bw per day (MB).
3.2.3. Contributions of different food groups to 3- and 2-MCPD and glycidol
exposure
The contribution of the different food groups to the MB mean exposure to 3- and 2-MCPD and
glycidol by population groups is summarised in Tables B.5, B.6 and B.7 in Appendix B. The tables
cover different ranges of % contribution to the MB mean exposure (< 1%, 1–5%, 5–10%, 10–20%,
20–30%, 30–40%, 40–60%, > 60%) presenting for each age class and each food group the number
of dietary surveys where the % contribution of the speciﬁc food group falls into a speciﬁc range. Food
groups where a higher number of surveys are listed on the right-hand columns of the tables are those
more contributing to the overall mean exposure of the respective age class. In the large majority of
the cases, while the % contribution of a particular food group is high in one or more national dietary
survey, it may be low or even very low in others. The considerations on these tables represent
therefore a warning of potential higher contribution to the exposure in speciﬁc areas or age classes.
3.2.3.1. 3-MCPD
The food group with higher contribution to the mean MB chronic dietary exposure to 3-MCPD in
‘Infants’ was ‘infant and follow-on formulae’ (around or more than 50% contribution), followed by
‘vegetable fats and oils’ and ‘cookies’. As stated previously, these data must be considered with
caution, because the age class of ‘Infants’ is not homogeneous and the diet is diversiﬁed only after
weaning.
Table 26: The minimum, median and maximum values for the P95 chronic exposure to glycidol
from esters (lg/kg bw per day) across dietary surveys
Age class(a)
Min MB (LB–UB)(b)
(lg/kg bw per day)
Median MB (LB–UB)(b)
(lg/kg bw per day)
Max MB (LB–UB)(b)
(lg/kg bw per day)
Infants 1.2 (1.2–1.3) 1.4 (1.3–1.5) 2.1 (2.1–2.2)
Toddlers 1 1.1 (1.1–1.2) 2.0 (2.0–2.1)
Other children 0.8 1.1 1.7
Adolescents 0.4 0.6 (0.6–0.7) 1.1
Adults 0.3 0.5 0.7 (0.6–0.7)
Elderly 0.3 (0.2–0.3) 0.5 0.6
Very elderly 0.2 0.5 0.7 (0.7–0.8)
P95: 95th percentile; bw: body weight; LB: lower-bound; MB: middle bound; UB: upper-bound.
(a): Details on the dietary surveys in the different age classes are in Table B.2 in Appendix B. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b) and therefore they should not be considered in the risk characterisation. Those estimates were not
included in this table.
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The most relevant contributors to the mean MB chronic dietary exposure to 3-MCPD in ‘Toddlers’
were ‘vegetable fats and oils’, ‘cookies’, ‘pastries and cakes’ and ‘infant and follow-on formulae’. In the
class ‘Other children’, the foods having higher contribution were ‘pastries and cakes’, ‘margarine and
similar’, ‘vegetable fats and oils’ and ‘cookies’.
In the age class ‘Adolescents’, ‘margarine and similar’, ‘fried or baked potato products’ and ‘pastries
and cakes’ were important contributors to the mean MB chronic dietary exposure to 3-MCPD, followed
by ‘bread and bread rolls’, ‘fried or roast meat’ and other food groups in lower proportion. In ‘Adults’,
relevant contributors to the mean MB chronic dietary exposure to 3-MCPD were ‘margarine and similar’
and ‘pastries and cakes’ and ‘vegetable fats and oils’; however, ‘bread and bread rolls’ and ‘fried or
roast meat’ were also important contributors in many surveys, though at a lower degree.
‘Margarine and similar’, ‘pastries and cakes’, ‘vegetable fats and oils’ and ‘bread and bread rolls’
were the major contributors to the mean MB chronic dietary exposure to 3-MCPD in the classes
‘Elderly’ and ‘Very elderly’.
3.2.3.2. 2-MCPD
The food groups with the higher contribution to the mean MB chronic dietary exposure to 2-MCPD
in ‘Infants’ were ‘infant and follow-on formulae’ (around or more than 50% contribution), together
with ‘vegetable fats and oils’ and ‘cookies’. These data must be considered with caution, because the
age class of ‘Infants’ is not homogeneous and the diet is diversiﬁed only after weaning. Regarding the
consumption of vegetable fats, they also include the fats considered in the disaggregation of
composite food.
The most relevant contributors to the mean MB chronic dietary exposure to 2-MCPD in ‘Toddlers’
were ‘vegetable fats and oils’, ‘cookies’, ‘pastries and cakes’ and in some surveys ‘infant and follow-on
formulae’. In the class ‘Other children’, the foods having higher contribution in some surveys were
‘pastries and cakes’, ‘margarine and similar’, ‘vegetable fats and oils’ and ‘cookies’.
‘Margarine and similar’, ‘fried or baked potato products’, ‘cookies’ and ‘pastries and cakes’ were
important contributors to the mean MB chronic dietary exposure to 2-MCPD in ‘Adolescents’, but
different other food groups contribute in somewhat lower proportions. ‘Adults’ showed a relevant
contribution from ‘margarine and similar’, ‘vegetable fats and oils’ and ‘pastries and cakes’; at
lower level, ‘bread and bread rolls’ and ‘fried or roast meat’ were relevant contributors in many
surveys.
‘Margarine and similar’, ‘pastries and cakes’, ‘vegetable fats and oils’ and ‘bread and bread rolls’
were the major contributors to the mean MB chronic dietary exposure to 2-MCPD in the classes
‘Elderly’ and ‘Very elderly’.
3.2.3.3. Glycidol from esters
The food group with higher contribution to the mean MB chronic dietary exposure to glycidol in
‘Infants’ was ‘infant and follow-on formulae’ (around or more than 50% contribution), followed by
‘vegetable fats and oils’ and ‘cookies’. As stated previously, these data must be considered with
caution, because the age class of ‘Infants’ is not homogeneous and the diet is diversiﬁed only after
weaning.
The most relevant contributors to the mean MB chronic dietary exposure to glycidol in ‘Toddlers’
were ‘vegetable fats and oils’, ‘cookies’, ‘fried or roast meat’ and ‘pastries and cakes’. Only one survey
with very high contribution (40–60%) was observed for ‘margarine and similar’. In the class ‘Other
children’, the foods having higher contribution were ‘margarine and similar’, ‘pastries and cakes’, ‘fried
or roast meat’, ‘cookies’ and in some surveys ‘chocolate spread and similar’.
In the age class ‘Adolescents’, ‘margarine and similar’, ‘fried or roast meat’, ‘pastries and cakes’ and
in some surveys ‘chocolate spreads and similar’ were the major contributor to the exposure to glycidol.
Important contributors to the mean MB chronic dietary exposure of ‘Adults’ to glycidol were
‘margarine and similar’, ‘fried or roast meat’ and ‘pastries and cakes’; in some surveys, ‘vegetable fats
and oils’ were also relevant contributors. The pattern of contributors to the mean MB chronic dietary
exposure to glycidol of ‘Elderly’ and ‘Very elderly’ was similar.
3.2.4. Dietary exposure to 3- and 2-MCPD and glycidol for infants receiving
formula only
In the previous sections, exposure estimates were presented for 3-, 2-MCPD and glycidol including
the age class ‘Infants’. Actually, this class contains individuals before and after weaning and are
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therefore not homogeneous in terms of diet. For this reason, a speciﬁc scenario was calculated for
exposure from infant formula, assuming exclusive formula feeding and this was compared with the
exposure calculated from the consumption surveys. To calculate occurrence values, the mean
occurrence values in infant formulae were used. The occurrence data for infant formula were reported
as powdered dry product; therefore, the value was converted to ready-to-use liquid formula with a
dilution factor of 7.7.
In addition to the average scenario, a worst-case scenario was also calculated to take into
account brand loyalty or bulk single-lot purchases in case of highly contaminated brands or
production lots. To this end, the P95 values of occurrence in powdered infant formula were used.
The correction to ready-to-eat liquid infant formulae was performed as in the previous scenario using
a dilution factor of 7.7.
As consumption ﬁgures, an average consumption per kg body weight was calculated based on the
dosage suggested on the label of seven different infant formulae randomly chosen between products
featured in the GNPD database of new products published by Mintel. As body weight, the mean
between males and females for the classes 1–2 months, 2–3 months and 3–4 months from the WHO
growth standards15 was used. The calculated average consumption of infant formula (diluted, ready to
eat) over the period from 1 to 4 months is 170 g per kg bw per day.
3.2.4.1. 3-MCPD
The mean occurrence of 3-MCPD in infant formula (powder) was 108 (108–109) lg/kg (MB
(LB–UB)). The calculated value for the diluted formula was 14.03 (14.03–14.16) lg/kg. The P95 of
occurrence of 3-MCPD in infant formulae (powder) was 147 lg/kg (MB = LB = UB). The calculated
value for the diluted formula was 19.1 lg/kg. The resultant exposure scenarios for infants receiving
formula only are presented in Table 27.
In the scenarios for 3-MCPD, no difference was observed between LB, MB and UB exposure
estimates. The dietary exposure to 3-MCPD corresponding to mean occurrence is 2.4 lg/kg bw per
day while the dietary exposure corresponding the P95 of occurrence is 3.24 lg/kg bw per day.
3.2.4.2. 2-MCPD
The mean occurrence of 2-MCPD in infant formulae (powder) was 44 (31–58) lg/kg (MB (LB–UB)).
The calculated value for the diluted formula was 5.71 (4.03–7.53) lg/kg. The P95 of occurrence of
2-MCPD in infant formulae (powder) was 73 lg/kg (MB = LB = UB). The calculated value for the
diluted formula was 9.48 lg/kg. The resultant exposure scenarios for infants receiving formula only
are presented in Table 28.
In the scenario based on mean occurrence, the dietary exposure to 2-MCPD based on LB
occurrence data is 0.7 lg/kg bw per day. It can be observed that in this case the difference between
LB and UB approach is large and the dietary exposure based on the UB approach (1.3 lg/kg bw per
day) is almost the double of the one estimated in the LB approach.
In the scenario based on the P95 of occurrence, the dietary exposure is 1.6 lg/kg bw per day.
Table 27: Scenarios(a) for exposure to 3-MCPD of infants receiving formula only
Consumer
Exposure estimate
(lg/kg bw per day)
Infants consuming 170 g/kg bw per day of liquid formula at the
mean occurrence values
2.4
Infants consuming 170 g/kg bw per day of liquid formula at the
P95 occurrence values
3.2
3-MCPD: 3-monochloropropane-1,2-diol; P95: 95th percentile; LB: lower bound; MB: middle bound; UB: upper bound; bw: body
weight.
(a): The scenarios use the mean and P95 occurrence values calculated for infant formulae. The exposure estimates
corresponding to LB, MB and UB occurrence scenarios are coincident
15 Available online: http://www.who.int/childgrowth/standards/weight_for_age/en/ (accessed on 28 September 2015)
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3.2.4.3. Glycidol
The mean occurrence of glycidol in infant formula (powder) was 87 (80–94) lg/kg (MB (LB–UB)).
The calculated value for the diluted formula was 11.3 (10.39–12.21) lg/kg. The P95 of occurrence of
glycidol in infant formulae (powder) was 220 lg/kg (MB = LB = UB). The calculated value for the
diluted formula was 28.57 lg/kg. The resultant exposure scenarios for infants receiving formula only
are presented in Table 29.
In the scenarios for exposure to glycidol of infants based on mean occurrence, the difference
between the estimates in the LB and UB approaches is limited. The dietary exposure to glycidol using
LB occurrence data is 1.8 lg/kg bw per day while the exposure estimated using UB occurrence data is
2.1 lg/kg bw per day.
In the scenario based on the P95 of occurrence, the dietary exposure is 4.9 lg/kg bw per day.
3.3. Hazard identiﬁcation and characterisation
3.3.1. Toxicokinetics
3.3.1.1. 3-MCPD and 3-MCPD fatty acid esters
Abraham et al. (2013) evaluated the toxicokinetics of 3-MCPD (10 mg/kg bw) in comparison with
an equimolar dose of 3-MCPD di-palmitate (53 mg/kg bw) using GC-MS measurements on both free
MCPD and the ester in plasma from male Wistar rats (8–9 weeks of age) after gavage administration.
Absorption of 3-MCPD was rapid with the maximal concentration (4,850 ng/mL) observed near the
ﬁrst sampling time (0.37 h). The appearance of 3-MCPD in plasma after gavage of the diester was
slower with the maximal concentration (949 ng/mL) observed at 3.0 h. Absorption rate constants
derived from ﬁtting the data to a one-compartment model were reported as 7.0 and 0.36 L/h for
3-MCPD and its diester, respectively with half-lives of 0.10 and 1.9 h, respectively. Elimination rate
constants were similarly derived from the data, and were reported as 0.31 and 0.69 L/h for 3-MCPD
Table 28: Scenarios(a) for exposure to 2-MCPD of infants receiving formula only
Consumer
Exposure based on
LB occurrence
(lg/kg bw per day)
Exposure based on
MB occurrence
(lg/kg bw per day)
Exposure based on
UB occurrence
(lg/kg bw per day)
Infants consuming 170 g/kg bw
per day of liquid formula at the
mean occurrence values
0.7 1 1.3
Infants consuming 170 g/kg bw
per day of liquid formula at the
P95 occurrence values
1.6 1.6 1.6
2-MCPD: 2-monochloropropane-1,3-diol; P95: 95th percentile; LB: lower bound; MB: middle bound; UB: upper bound; bw: body
weight.
(a): The scenarios use the mean and P95 occurrence values calculated for infant formulae. The exposure estimates
corresponding to LB, MB and UB) occurrence scenarios are reported
Table 29: Scenarios(a) for exposure to glycidol of infants exclusively formula-fed
Consumer
Exposure based on
LB occurrence
(lg/kg bw per day)
Exposure based on
MB occurrence
(lg/kg bw per day)
Exposure based on
UB occurrence
(lg/kg bw per day)
Infants consuming 170 g/kg bw
per day of liquid formula at the
mean occurrence values
1.8 1.9 2.1
Infants consuming 170 g/kg bw
per day of liquid formula at the
P95 occurrence values
4.9 4.9 4.9
P95: 95th percentile; LB: lower bound; MB: middle bound; UB: upper bound; bw: body weight.
(a): The scenarios use the mean and P95 occurrence values calculated for infant formulae. The exposure estimates
corresponding to MB (LB–UB) occurrence scenarios are reported
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and its diester, respectively. The respective elimination half-times were calculated by the CONTAM
Panel to be 1 and 2.2 h. The area under the curve (AUC) values for plasma 3-MCPD were 9.03 and
7.76 microg 9 h/mL for the parent compound and its diester, respectively. The diester was quantiﬁed
in luminal contents of small and large intestinal segments from 1.5 to 24 h and apparent transit of the
diester from small to large intestine was observed; however, by 24 h, only 0.015–0.05% of the diester
remained in the two intestinal segments. Concentrations of 3-MCPD were measured in liver, kidney,
and adipose tissue and were similar to plasma levels in liver and kidney, but consistently lower in
adipose tissue after dosing with either 3-MCPD or its diester. After administration of the diester, the
parent compound itself was not observed in plasma, liver, kidney or adipose tissue at any time point
(LOQ < 50 ng/g). It was reported that excretion of 3-MCPD into urine was approximately 2% of the
administered dose for either compound and that 0.5–1.4% of the dose was observed in faeces. The
similar AUCs for plasma 3-MCPD for the two compounds (86% for the diester compared with 3-MCPD)
were interpreted as reﬂecting essentially complete hydrolysis of the diester during transit through the
gastrointestinal (GI) tract resulting in similar bioavailability; however, a ﬁvefold lower maximal
concentration (Cmax) was observed for the diester and was interpreted as resulting from delayed
hydrolysis during transit that could affect toxicity endpoints related to maximal concentration levels.
Gavage administration of either 3-MCPD or three of its fatty acid esters produced no detectable
glycidol in either the serum or gastric, duodenal and caecal contents of male F344 rats 30 min after
dosing (Onami et al., 2015).
In conclusion, 3-MCPD and its dipalmitate fatty acid esters appear to be rapidly and efﬁciently
absorbed following ingestion with extensive presystemic de-esteriﬁcation occurring in the GI tract
of rats. Elimination of 3-MCPD from serum was also rapid following dosing with either the parent
compound or its diester. While the serum AUC values were similar for a single gavage dose of
3-MCPD and its di-palmitate diester (80%), the Cmax value for the diester was only 20% of that
for the parent compound. The lower Cmax and longer elimination half-life of free MCPD in blood
in the case of the diester is consistent with a delayed hydrolysis during transit through the GI
tract. Conjugation with glutathione is one well-characterised metabolic pathway but its extent is
limited. The formation of other 3-MCPD metabolites is poorly characterised. Urinary excretion of
3-MCPD and its metabolites appears to be predominant, as faecal excretion is quite limited, but
is not completely characterised (see section on metabolism; Jones, 1975; Jones et al., 1978).
Conversion of 3-MCPD, administered in either free or esteriﬁed forms, into glycidol was not
observed in vivo.
2-MCPD and 2-MCPD fatty acid esters
No data were identiﬁed.
Glycidol and glycidyl fatty acid esters
The disposition of 14C-labelled glycidol was evaluated in male F344 rats approximately 11 weeks of
age (Nomeir et al., 1995). The single doses administered were the same as used in the National
Toxicology Program (NTP) chronic bioassay for carcinogenicity, 37.5 and 50 mg/kg bw, by the oral
(gavage) and intravenous (i.v.) routes. Urinary excretion of total radioactivity was predominant
(40–48%), followed by exhaled CO2 (27–32%), faeces (5–12%), and at 72 h tissues contained 7–8%.
The urinary metabolite excretion proﬁle, which was similar between oral and i.v. routes, showed one
major unidentiﬁed metabolite at 14–21% of the total radioactivity and four lesser unidentiﬁed
metabolites, comprising 2–8% of the total radioactivity. Based on total radioactivity recovered after
gavage (91%) and i.v. (91%) dosing at 50 mg/kg bw, glycidol was quantitatively absorbed from the GI
tract. There was retention of radioactivity in tissues (9–12% at 24 h and 7–8% at 72 h) with the
skeletal muscle, skin, blood cells and liver containing the highest amounts (1–4% of dose each at
24 h), which could result from either covalent binding of glycidol or incorporation of radiolabel into
macromolecules through entry into normal intermediary metabolism.
Wakabayashi et al. (2012) evaluated the plasma pharmacokinetics of glycidol using GC-MS after
oral and i.v. administration to Sprague-Dawley rats (n = 189) and cynomolgus monkeys (n = 3). The
principal dose used (75 mg/kg bw) was chosen to match the high dose from the NTP
carcinogenicity bioassay (NTP, 1990). Absorption of glycidol after gavage was rapid with Tmax
observed at 0.25 h in rats and 0.83 h in monkeys. Absolute (systemic) bioavailability of glycidol was
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69% in rats and 34% in monkeys, based on the ratio of glycidol AUC for oral relative to the AUC
for i.v. Elimination was rapid with i.v. half-times reported to be 0.37 and 0.41 h for rats and
monkeys, respectively, and oral half-times of 1.3 and 1.5 h, respectively. Some pharmacokinetic data
(Cmax and AUC) were also reported for oral dosing at 1.64 and 4.92 mg/kg bw in rats and for
monkeys at 4.92 mg/kg bw.
Wakabayashi et al. (2012) also evaluated the plasma toxicokinetics for a single dose of glycidyl
di-linoleate (341 mg/kg bw, which was equimolar to the dose of glycidol, using gavage administration)
to Sprague-Dawley rats and cynomolgus monkeys. While the parent ester was observed in plasma
from dosed rats, it was undetectable in monkeys; however, the pharmacokinetics of the glycidol
derived from ester hydrolysis was measured in plasma in both species. The time to maximal plasma
glycidol concentration was slower after glycidyl di-linoleate gavage than seen for glycidol (0.5 vs
0.25 h in rats and 1.8 vs 0.83 h in monkeys) and achieved lower glycidol concentrations (Cmax values
of 26 vs 34 lg/mL in rats and 1.5 vs 8.6 lg/mL in monkeys). However, while the glycidol AUC
achieved after glycidyl di-linoleate gavage to rats exceeded that from glycidol itself by 28% (41.6 vs
32.4 lg/mL 9 hour), the glycidol AUC was 45% lower in monkeys given glycidyl linoleate (9.1 vs
16.4 lg/mL 9 hour). These observations were interpreted as representing important species
differences in ester hydrolysis and bioavailability based on physiology (e.g. lingual vs gastric lipases,
stomach pH effects) or epoxide metabolism (epoxide hydrolase or glutathione S-transferase), although
no speciﬁc mechanism was proposed.
Appel et al. (2013) reported the relative bioavailability of glycidol after administration of equimolar
doses of glycidol (50 mg/kg bw) or glycidyl di-palmitate (209 mg/kg bw) to male Wistar rats by
gavage. In one experiment, the relative amounts of dihydroxypropyl-valine adducts derived from the
reaction of glycidol with the N-terminal residue of haemoglobin were measured using GC-MS. Similar
maximal levels of dihydroxypropyl-valine adducts were observed in blood collected 24–48 h after
dosing, although the maximal adduct level achieved after glycidol dosing was achieved earlier than for
the ester (approximately 4 vs 24 h). The excretion of the glycidol metabolite derived from initial
glutathione conjugation, dihydroxypropyl-mercapturate (DHPMA), was also measured in these rats
using LC/MS/MS. Similar total excretion of the mercapturate was observed over a 48-h period for the
two groups of dosed rats (14% of the administered glycidol dose vs 13.7% of the glycidyl di-palmitate
dose). These similar apparent blood AUC values for glycidol, derived from either formation of a
haemoglobin adduct or the similar urinary excretion for an important glycidol metabolite, after
ingestion of either glycidol or its di-palmitate ester were interpreted as resulting from quantitative ester
hydrolysis during transit through the GI tract in rats. In a second experiment, the disposition of [14C]-
glycidyl-[3H] di-palmitate was evaluated over a 7-day period. Excretion of the 14C label occurred
primarily through the urine (41%) whereas excretion of the 3H label occurred primarily through the
faeces (51%). It was also reported that 9% of the 14C label and 23% of the 3H label were associated
with the tissues, although it was not determined whether this was due to covalent binding or
metabolic incorporation.
Gavage administration of either glycidol or two of its fatty acid esters produced concentrations of
3-MCPD in serum of male F344 rats that exceeded those of glycidol at 30 min after dosing (Onami
et al., 2015). Formation of 3-MCPD after gavage of two glycidyl mono-esters was observed in
duodenal and caecal contents of male F344 rats, but at levels near the LOQ and inconsistently among
the replicate animals.
In conclusion, glycidol and its fatty acid esters are efﬁciently absorbed following ingestion.
Substantial presystemic hydrolysis of GE occurs, although the de-esteriﬁcation process appears to be
more extensive in rats than in monkeys based on different measures of glycidol internal exposure;
however, the physiological basis for this observation is uncertain. Metabolism of the glycidol moiety
proceeds by several enzymatic pathways, including glutathione conjugation and mercapturate
formation. The glycidol moiety is predominantly excreted in urine as poorly described metabolites, with
smaller amounts exhaled through the breath as CO2, and smaller amounts excreted through the
faeces. In addition, the glycidol moiety can bind covalently to cellular macromolecules (e.g. DNA and
haemoglobin) by virtue of the electrophilic nature of the epoxide ring. Binding of the glycidol moiety to
DNA may result in genotoxicity and mutations (see Section 3.3.5.; Mode of Action Carcinogenicity,
Section 3.3.2. Genotoxicity). Alternatively, the carbon atoms in the glycidol moiety can also become
incorporated into cellular macromolecules via normal intermediary metabolism after conversion to
precursor molecules, including glycerol and CO2. Extensive conversion of glycidol and its monoesters
into 3-MCPD has been observed in vivo.
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3.3.2. Metabolism
3-MCPD
The metabolic pathways of 3-MCPD (as well as of glycidol) are depicted in Figure 7. Two
biotransformation routes have been postulated for 3-MCPD metabolism. One leads to conjugation with
glutathione and the formation of mercapturic acids (DHPMA), and the other terminates in oxalic acid
(Figure 7).
The ability of the microbial enzyme halohydrin dehalogenase to dehalogenate haloalcohols to
produce glycidol has been demonstrated by Van den Wijngaard et al. (1989) using microbial strains
isolated from freshwater sediments. The authors supposed that microbes containing enzymes capable
of catalysing the dehalogenation reactions can utilise 3-MCPD as an exclusive carbon source (microbial
cultures that grow on halogenated organic compounds). Whether other bacterial strains, including
those present in the human gut microbiome, are able to convert 3-MCPD into glycidol is unknown;
however, conversion of orally administered 3-MCPD or it esters into glycidol was not observed in rats
(Onami et al., 2015).
Based on data from in vivo studies in rats with radiolabelled 3-MCPD (Jones et al., 1978), the
oxidation to b-chlorolactaldehyde with further conversion to b-chlorolactic acid and oxalic acid was
considered to be the main metabolic route of 3-MCPD in mammals (Lynch et al., 1998).
About 30% of a single dose of [14C]-labelled 3-MCPD (100 mg/kg bw) administered
intraperitoneally was exhaled as CO2 and 8.5% was eliminated as unchanged 3-MCPD in the urine
within 24 h post-dosing of male rats (Jones, 1975). After a single intraperitoneal (i.p.) injection of
[36Cl]-labelled 3-MCPD to rats (100 mg/kg bw), 23% of the total urinary radioactivity recovered was
b-chlorolactate (Jones et al., 1978). Tissue distribution studies revealed no tissue-speciﬁc retention of
radioactivity in rats treated with [36Cl]-3-MCPD.
3-MCPD can undergo conjugation with glutathione, yielding S-(2,3-dihydroxypropyl)cysteine and the
corresponding mercapturic acid (DHPMA) (Jones, 1975). Data from a recent biomonitoring study in
rats (Barocelli et al., 2011) indicate that the conjugation with glutathione may play a more important
role than was considered before. After a single oral application of 1.8 mg/kg bw 3-MCPD (the lowest
Figure 7: Overview of the metabolic pathways of 3-monochloropropane-1,2-diol (3-MCPD) and
glycidol. EH: epoxide hydrolase; ADH: alcohol dehydrogenase; ALDH: aldehyde
dehydrogenase; DHPMA: N-acetyl-S-(2,3-dihydroxypropyl)cysteine or 2,3-dihydroxypropyl
mercapturic acid. (adapted from Appel et al., 2013)
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dose in this study), about 10.5% and 27.5% of the dose was found as mercapturic acid in urine of
female and male rats, respectively. At the middle (7.37 mg/kg bw) and high (29.5 mg/kg bw) 3-MCPD
doses, urinary mercapturic acid excretion amounted to 5.4% and 7.3% of the dose in female rats, and
11.5% and 12.5% of the dose in male rats, respectively. Thus, at least in rats, the urinary excretion of
3-MCPD mercapturate shows dose-dependence (higher rates at lower doses) as well as gender
differences (higher proportion of the dose found in urine from male rats). Furthermore, only trace
amounts of b-chlorolactate (less than 1% of the administrated dose) were recovered in urine of
3-MCPD-treated animals in a study of Barocelli et al. (2011), which contradicts earlier ﬁndings of Jones
et al. (1978).
3-MCPD fatty acid esters
Based on studies described above, it can be assumed that 3-MCPD-esters are effectively hydrolysed
in the gut after ingestion, liberating 3-MCPD. It has been shown in vitro that pancreatic lipase accepts
3-MCPD fatty acid esters as substrates and that ester hydrolysis takes place within minutes (Seefelder
et al., 2008). In two in vivo studies, it was shown that after oral administration of 3-MCPD-1,
2-dipalmitate to rats, the bioavailability of 3-MCPD originating from the diester was 70% based on the
measurement of 3-MCPD metabolites in urine (Barocelli et al., 2011) and 86% based on the
determination of 3-MCPD in blood (Abraham et al., 2013), respectively.
In vitro experiments have shown that fatty acid esters of 3-MCPD and of 2-MCPD are hydrolysed by
a model of small intestinal juice containing pancreatic lipase. In these experiments, 2-MCPD fatty acid
esters were more efﬁciently cleaved than their 3-MCPD counterparts (Schilter et al., 2011). In studies
with the Caco-2 cell line as a model for the human intestinal cell wall, fatty acid esters of 3-MCPD as
well as 2-MCPD were efﬁciently hydrolysed by Caco-2 cells within hours, although there was no
pancreatic lipase present in the experimental set-up (Burke et al., 2011, 2015). The authors suggested
that the membrane-bound lipolytic activity of the Caco-2 cells could be responsible for the observed
de-esteriﬁcation of MCPD-esters. It was concluded that under in vivo conditions the activity of
pancreatic lipase in the gut lumen as well as lipolytic activities in the membranes of intestinal
enterocytes will contribute to the hydrolysis of 2-MCPD and 3-MCPD fatty acid esters in the gut (Burke
et al., 2015).
2-MCPD and 2-MCPD fatty acid esters
No data were identiﬁed; however, the difference in the structural localisation of the chlorine within
the molecule makes it unlikely that the metabolic patterns of 2- and 3-MCPD overlap.
Glycidol
Toxicokinetics of glycidol was studied in male Fischer 344 rats following oral or i.v. administration of
[14C]-labelled compound at single doses of 37.5 and 75 mg/kg bw (Nomeir et al., 1995).
Approximately 87–92% of orally administered glycidol was absorbed from the GI tract. About 40–48%
of radioactivity was excreted in the urine, 5–12% in faeces and 26–32% was exhaled as CO2. At both
doses, 7–8% of the dose remained in tissues 72 h following administration. The highest concentrations
of radioactivity were observed in blood cells, thyroid, liver, kidney and spleen (Nomeir et al., 1995).
The extensive distribution and persistence of glycidol in the tissues was attributive to the property of
the epoxide group of glycidol to react with cellular nucleophiles. High performance liquid
chromatography (HPLC) analysis of the urine revealed extensive metabolism: 15 different metabolites
were detected. There was one major (14–21% of the dose) and four lesser metabolites (each
representing 2–8%); the others were minor, each representing 1% or less of the dose. The structure
of these metabolites was not clariﬁed (Nomeir et al., 1995).
Glycidol can be conjugated with glutathione or hydrolysed to form glycerol (Figure 4). The
formation of glycerol from glycidol, catalysed by epoxide hydrolases, was conﬁrmed in vitro by
incubation with rat liver and pulmonary microsomes (Jones and O’Brien, 1980; Patel et al., 1980).
Urinary excretion of S-(2,3-dihydroxypropyl)cysteine and N-acetyl-S-(2,3-dihydroxypropyl)cysteine
(2,3-dihydroxypropyl mercapturic acid, DHPMA) in rats and mice after i.p. application of glycidol was
ﬁrst demonstrated by Jones (1975). In the recent study of Appel et al. (2013), about 14% of orally
administrated glycidol dose (50 mg/kg bw) was recovered as DHPMA in the urine of rats within 48 h
after dosing. A single dose by gavage of 500 lL/kg (560 mg/kg) bw glycidol to male rats led to
signiﬁcant decreases in hepatic glutathione content between 30 min and 12 h after treatment
(Montaldo et al., 1984).
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S-(2,3-Dihydroxypropyl)glutathione, DHPMA, as well as b-chlorolactic acid were reported as major
metabolites isolated from rat urine after i.p. administration of glycidol (NTP, 1990). Oral glycidol doses
of 100 mg/kg bw were given to male rats 48, 54 and 72 h after i.p. injection of [36Cl]saline (Jones and
O’Brien, 1980). The only radioactively labelled metabolite found in the urine 80 h after glycidol
administration was b-chlorolactic acid. It was suggested that in the presence of acid in the lumen of
the stomach, glycidol could be partially converted to 3-MCPD, which is then further metabolised and
excreted in urine as b-chlorolactic acid (Jones and O’Brien, 1980). However, Nomeir et al. (1995)
found that only a small amount of urinary radioactivity was co-eluted with authentic b-chlorolactic acid
following oral or i.v. glycidol administration (37.5 or 75 mg/kg bw), suggesting that the conversion of
glycidol to 3-MCPD is quantitatively insigniﬁcant at the doses studied (0.02% of pooled radioactivity).
However, Onami et al. (2015) showed that signiﬁcant amounts of glycidol were converted into 3-MCPD
in serum from male F344 rats dosed orally at a dose of 510 lmol/kg bw (37.7 mg/kg bw) using a
GC-MS-based method with potentially better sensitivity.
Glycidyl fatty acid esters
In the study on relative bioavailability of glycidol from glycidyl esters (Appel et al., 2013), similar
amounts, about 14% of the dose was recovered as DHPMA the urine of rats 48 h after oral
administration of 50 mg/kg bw glycidol or equimolar amount of glycidyl palmitate.
3.3.3. Toxicity in experimental animals
3.3.3.1. 3-MCPD
The acute toxic effects of 3-MCPD treatment in the 24 h following dosing has not been extensively
studied possibly because the systemic effects such as death, renal toxicity and male infertility develop
primarily in the week following the initiation of treatment. The toxicokinetics of 3-MCPD, described
elsewhere, show that 3-MCPD is efﬁciently absorbed, metabolised and these substances are excreted
within a few hours (Section 3.3.1). Therefore, it is likely that cellular toxicity is produced within the ﬁrst
few hours after administration but requires several days to be expressed pathophysiologically.
Single dose
The acute median lethal dose (LD50) of a single dose of 3-MCPD administered by gavage to adult
male rats was reported as 150 mg/kg bw (cited in Ericsson and Baker 1970). No change in general
health of adult male rats was noted after 7 weeks treatment with 5.0 mg per day, approximately
14 mg/kg bw per day or 5.0 mg per rat per day (Ericsson and Baker, 1970). The LD50 for 3-MCPD in
ICR mice has been reported to be 190.7 mg/kg (Qian et al., 2007).
Repeated dose
In a 90-day study, 3-MCPD dissolved in corn oil was administered by daily gavage to groups
(n = 10) of adult male and female Wistar rats at doses of 1.8, 7.37 or 429.5 mg/kg bw per day
(Barocelli et al., 2011). Substantial mortality occurred as early as 8 days treatment with the highest
dose, 429.5 mg/kg, of 3-MCPD. General morbidity was noted in the animals receiving the lower doses
of 3-MCPD especially in the ﬁrst 10 days of treatment. BMD analysis by the authors of female rat
mortality after 3-MCPD gave a BMD10 and BMDL10 of 7.4 and 2.3 mg/kg per day, respectively. In F344
rats MCPD was lethal (40 mg/kg approx. LD50) when administered for 5 days a week to female but
not male rats (Onami et al., 2014a,b).
No clinical symptoms were observed short term or later in a 104-week study in which Fischer 344
rats were administered 3-MCPD in drinking water at concentrations of 20, 100 or 500 mg/L
(Sunahara et al., 1993; described in long-term toxicity below). This was estimated to produce mean
daily intakes of 1.1, 5.2 and 28.3 mg/kg bw per day in males and 1.4, 7.0 and 35.3 mg/kg bw per
day in females. However, pathological examination revealed systemic toxicity resulting from this
sustained treatment.
Renal and hepatic toxicity
Toxicity has been reported only to be observed with the R isomer of 3-MCPD (Porter and Jones,
1982; Morris and Williams, 1980; Jones and Cooper, 1999; Barocelli et al., 2011). 3-MCPD at a single
i.p. dose of 120 mg/kg administered to male rats causes kidney failure and death usually in the week
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following administration. A lower i.p. dose (100 mg/kg bw) produces diuresis accompanied by high
urinary protein and glucose; these effects persist for about 7–15 days. No effect was seen with a
single dose of 80 mg/kg bw, or multiple doses of 10 mg/kg bw for 5 days. Renal injury, tubule focal
necrosis, regeneration and dilatation were documented 75 days after treatment of male rats with a
single sub cutaneous dose of 75 mg/kg bw 3-MCPD (Kluwe et al., 1983).
Renal and hepatic effects have been documented in Sprague-Dawley rats given 3-MCPD at doses of
30 or 60 mg/kg bw per day by gavage for 5 days a week for 4 weeks (Marchesini and Stadler, 1983).
On the second day of treatment with 60 mg/kg bw per day the serum concentrations of alanine
aminotransferase, creatinine, urea, and glucose were increased and these remained elevated until the
end of the study and increased levels were often seen in the 30 mg/kg bw per day-treated rats.
Kidney and liver weight were increased and the renal histopathology showed progressive nephropathy
and renal tubule dilatation. Similar changes were seen when 3-MCPD was administered via the
drinking water for 90 days at estimated daily intakes of between 9 and 46 mg/kg bw per day
(Marchesini et al., 1989). It is notable that renal toxicity is a common observation in the chronic
carcinogenicity studies described here below.
In the carcinogenicity study reported by Sunahara et al. (1993) in which Fischer 344 rats were
exposed to 3-MCPD in drinking water for 104 weeks, chronic progressive nephropathy
accompanied by hypertrophy of the kidney was reported at terminal necropsy in the dose groups
receiving 100 or 500 mg/kg which was more pronounced in male rats (dose range 5.2–35.3 mg/kg
bw per day).
At the end of a 90-day repeated dose study of 3-MCPD in Wistar rats (1.84, 7.37, or 29.5 mg/kg
bw per day), the combined weights of the kidney and adrenal gland were increased in both sexes.
(Barocelli et al., 2011). The weight increases were dose dependent such that they were about 70%
higher after the highest daily dose of 3-MCPD (29.5 mg/kg bw per day). As the adrenal gland is
relatively small, it can be assumed that this change in combined weights was primarily due to renal
changes. 3-MCPD also increased water consumption in male and female rats but only towards the
end of the 90-day study. In spite of no signiﬁcant changes being observed in the volume of urine
output, after 3-MCPD (29.5 mg/kg bw per day) administration, the urine was acidiﬁed and the
concentrations of several substances were changed, notably the proteins Nag, B2M, albumin and
a-GST. The large variation in the clinical biochemistry measurements did not allow rigorous statistical
analysis of these results. Serum urea was not changed but serum creatinine concentrations were
reduced.
The study reported an extensive array of degenerative changes in the renal tubules after 90 days
treatment across the range of doses for 3-MCPD and in both sexes (Barocelli et al., 2011). When
examined quantitatively these pathological effects were restricted to the highest dose of 3-MCPD
(29.5 mg/kg bw per day). Histopathology scores were slightly lower in the female compared to male rats.
At the end of a 91-day study in F344 rats, kidney weight was increased by 3-MCPD (Onami et al.,
2014b). These weight changes reﬂect a similar but not such a deﬁnitive pattern as seen for the
increases in liver weight. A fall in serum creatinine concentration was observed. Severe tubular
necrosis was conﬁrmed in the rats which died after 3-MCPD treatment. In rats surviving 91 days of
3-MCPD treatment, the only histopathological changes seen were in the epididymis.
Haematology
Decreased levels of haemoglobin and erythrocyte volume fraction have been reported after
treatment of rats with 3-MCPD at 30 mg/kg per day for 5 days per week for 4 weeks (Marchesini and
Stadler, 1983). In female rats, the erythrocyte count was also reduced by the highest dose (60 mg/kg
per day). In another study, anaemia was reported at 30 and 90 days treatment of female rats with
3-MCPD administered in drinking water (Marchesini et al., 1986). The estimated intake was 31 or
46 mg/kg per day. There was no histopathological evidence of impaired haemopoiesis.
Severe haematological toxicity was seen in 50% of a group of rhesus monkeys (n = 6) given an
oral dose of 3-MCPD for 6 weeks. The dose, 30 mg/kg per day, was administered primarily in drinking
water (as 3-MCPD absorbed in a sugar cube was unpalatable). Two of the affected group died towards
the end of treatment displaying symptoms of severe bone marrow depression. The lack of toxicity in
the three with apparently normal haematological parameters was unexplained (Kirton et al., 1970). No
toxicity was noted in an unpublished study (Kirton; cited in Kirton et al., 1970) in which rhesus
monkeys were given oral doses of 25 mg/kg bw per day 3-MCPD for 8 weeks.
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Neurotoxicity
Exposure of CD-1 mice to 3-MCPD by daily gavage at doses of 50 or 100 mg/kg resulted in hind-
limb paralysis within a few days (50 mg/kg bw per day: 4.4  0.2 days; 100 mg/kg per day:
2.6  0.2 days, mean  SEM, n = 8; Ford and Waites, 1982). In a study by Kim et al. (2004) there
was no observable neurobehavioural toxicity in male and female Sprague-Dawley rats after
administration of 3-MCPD (each group n = 10; 10, 20 or 30 mg/kg bw, control groups received either
saline or acrylamide).
Long-term toxicity and carcinogenicity
In a long-term toxicity study Jeong et al. (2010) investigated the carcinogenicity of 3-MCPD in
B6C3F1 mice by administration in drinking water over a period of 104 weeks. Three groups, each
comprising 50 male and 50 female mice received 3-MCPD at levels of 30, 100 or 300 mg/L up to day
100, and 200 mg/L onwards (4.2, 14.3 and 33.0 mg/kg bw per day for males; 3.7, 12.2, and 31.0 mg/kg
bw per day for females). At least 80% of males and 72% of females in each group survived over
104 weeks. Body weights and body weight gain were decreased in males and females receiving drinking
water with 300/200 mg/L. Water and food consumptions of both sexes at 300/200 mg/L were lowered.
An emaciated appearance or adoption of a crouching position was observed in animals of both sexes
exposed to 300/200 mg/L per day. There were no consistent, dose-dependent differences in
haematology and serum biochemistry. Histopathological examination did not reveal any neoplastic or
non-neoplastic ﬁndings attributable to treatment with 3-MCPD.
Sunahara et al. (1993) treated four groups of 50 male and 50 female F344 rats (between 5 and
6 weeks old) over a period of 104 weeks with 0, 20, 100 or 500 mg/L 3-MCPD added to the drinking
water (Table 30). The calculated mean daily intakes are given in the report as 0, 1.1, 5.2 or 28.3
mg/kg bw for males and 0, 1.4, 7.0 or 35.3 mg/kg bw for females. The water which the control
animals received was found not to be ‘free’ of 3-MCPD but to contain 2.7 mg/L. The analysed mean
values for the other groups were 26.5, 105.9 and 502.8 mg/L. Although the daily dose of 3-MCPD in
the ‘controls’ was not determined, on the basis of the average daily volume consumed in the 20 mg/L
group (41.5 mL/kg bw in males, 52.8 mL/kg bw in females) the CONTAM Panel calculated the intake in
controls as 0.11 mg/kg bw per day in males and 0.14 mg/kg bw per day in females.
At the highest dose, body weight gain was reduced to below 70% of the control, while no increase
in mortality was observed, i.e. none of the tumour incidences was associated with early death. At
necropsy, the incidences of tubular adenoma were increased at the two highest dose levels in both
sexes (Table 31). These were reported to be benign tumours, while no malignant kidney tumours were
observed. All adenomas were microscopic and most were classiﬁed as early adenoma, i.e. being
borderline between hyperplasia and adenoma.
Furthermore, signiﬁcant increases in the incidences of hyperplasia and adenoma of the Leydig cells
were found.
In males, mammary gland hyperplasia and ﬁbroadenoma were more abundant at the two highest
dose levels. No signiﬁcant increases in malignant mammary tumours were found.
Cho et al. (2008a) treated groups of 50 male and 50 female Sprague-Dawley rats over 2 years with
3-MCPD in drinking water containing 0, 25, 100 or 400 mg/L. These resulted in average daily intakes
of 0, 2.0, 8.3, or 29.5 mg/kg bw for males and 0, 2.7, 10.3 or 37.0 mg/kg bw for females. The body
weights and water consumptions of the male and female rats given water with 400 mg/L 3-MCPD
were signiﬁcantly lower than those of the controls. The incidences of renal tubule adenomas or
carcinomas and Leydig cell tumours showed dose-related positive trends in male rats and were
signiﬁcantly increased in male rats having received drinking water containing 400 mg/L 3-MCPD. The
incidence of renal tubule adenomas showed a positive trend in female rats, which was signiﬁcant in
the highest dose group.
Non-neoplastic changes such as seminiferous tubular atrophy and arteritis or periarteritis were also
found in all other dose groups. The incidence of renal tubule adenomas showed a positive trend in
female rats, which was signiﬁcant in the highest dose group. Renal tubule neoplasms were
accompanied by signiﬁcant increases in the incidences of renal tubule hyperplasia and chronic
progressive nephropathy. In males, this effect was seen in all dose groups, while females appeared to
be less sensitive, i.e. no signiﬁcant nephropathy was observed in the lowest dose group.
In mice treated with a similar range of doses, no non-neoplastic or neoplastic histopathological
changes were observed (Cho et al., 2008b).
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Table 31: Chronic non-neoplastic, preneoplastic and neoplastic lesions in a 2-year carcinogenicity
with 3-MCPD in Sprague-Dawley rats (Cho et al., 2008a, modiﬁed)
Organ/lesion
Dosage (mg/L drinking water)
0 25 100 400
Males
Testes
Number examined 50 50 50 50
Atrophy 6 16 13(a) 34(a)
Arteritis/periarteritis 3 15(a) 9(a) 11(a)
Leydig cell tumours 1 1 4 14(a)
Pituitary gland, pars distalis
Number examined 50 50 50 50
Adenoma 25 26 24 13(a)
Table 30: Chronic non-neoplastic, preneoplastic and neoplastic lesions in a 2-year carcinogenicity
with 3-MCPD in Fischer 344 rats (Sunahara et al., 1993, modiﬁed)
Organ/lesion
Dosage (mg/L drinking water)
‘0’(a) 25 100 400
Males
Testes
Number examined 50 50 50 50
Leydig cell hyperplasia 39 27(b) 4(d) 0(d)
Leydig cell adenoma 38 43 50 47(b)
Leydig cell carcinoma 0 0 0 3
Kidney
Number examined 50 50 50 50
Chronic nephropathy 36 40 45(b) 49(d)
Tubular hyperplasia 3 6 15(c) 34(c)
Tubular adenoma 0 0 1 5
Preputial glands(d) 5 13 16 11
1 2 6 5
0 0 1 2
Mammary gland
Number examined 45 48 47 49
Glandular hyperplasia 2 6 24(d) 42(d)
Fibroadenoma 0 0 2 10(c)
Adenoma 0 0 1 1
Adenocarcinoma 0 0 1 1
Females
Kidney
Number examined 50 50 50 50
Nephropathy 24 23 42(d) 48
Tubular hyperplasia 2 4 20(d) 31(d)
Tubular adenoma 0 1 0 9(c)
3-MCPD: 3-monochloropropane-1,2-diol.
(a): The untreated animals, in the ‘0’ dose group were estimated to receive 2.7 mg/L in drinking water.
(b,c,d): Statistically signiﬁcantly different from controls at bp < 0.05, cp < 0.01, dp < 0.001.
(e): Preputial glands were not examined in all animals; no statistical analysis was carried out.
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Reproductive toxicity
The antifertility effects of 3-MCPD in male animals are well established, initially having been
considered as a non-hormonal human male contraceptive (Jones, 1983). Development was curtailed
on appearance of adverse haematology in monkeys (Kirton et al., 1970). However, 3-MCPD was
subsequently marketed as an indirectly acting rodenticide, Epibloc, in the USA (Ericsson, 1982). The
mechanism of action of the male antifertility effects are twofold, and should not be confused when
considering the testicular actions of 3-MCPD and its potential hazard. They can be considered as a low
dose and high dose effects (Jones, 1983). Doses which have been reported to not affect the fertility of
the male rat range from 0.5 mg/kg bw per day (Ericsson and Baker, 1970) to 5 mg/kg bw per day
(Jones and Jackson, 1976).
Low-dose antifertility
After 2 or 3 days of dosing daily by oral gavage with 5–10 mg/kg bw, male rats were not able to
impregnate untreated female rats in spite of normal mating, normal spermatogenesis and normal
ejaculation. Infertility is reversible (Jones, 1983). Although the timing indicated an effect on the
epididymis, evidence accumulated to show inhibition of sperm glyceraldehyde-3-phosphate
dehydrogenase reducing the availability of ATP which completely inhibits motility and the ability to
fertilise the ovum. This action occurs exclusively in the caput epididymis which also exhibits impaired
sodium and water reabsorption into the systemic circulation from the intraluminal ﬂuid containing the
sperm.
High-dose antifertility
These effects develop 7–14 days after the administration of single or multiple does of 3-MCPD
above 90 mg/kg (Jones, 1983) and have been likened to the ligation of the ductulii efferentes which
cause accumulation of ﬂuid in the epididymis and subsequently the testis resulting in back pressure
necrosis and ablation, the spermatogenic epithelium. This effect in itself will result in infertility but in
contrast to the reversibility of the low dose it is permanent.
The male antifertility effects and mechanisms of 3-MCPD have been studied in hamsters, gerbils,
dogs, sheep, pigs and monkeys but was not observed the mouse or quail (cited in Jones, 1983). The
common embryological origin of the kidney and epididymis could suggest a speciﬁc impairment of a
mechanism involved in ﬂuid transport shared by both tissues.
The male antifertility activity of 3-MCPD has been demonstrated in rhesus monkeys receiving 30 mg/kg
per day orally for 6 weeks. During treatment pregnancies were reduced from 50% to 4% of matings.
Sperm motility, morphology and production were apparently normal in the majority of monkeys.
Organ/lesion
Dosage (mg/L drinking water)
0 25 100 400
Kidney
Number examined 50 50 50 50
Nephropathy 15 27(a) 39(a) 41(a)
Tubular hyperplasia 1 11(a) 21(a) 36(a)
Tubular adenoma 0 0 1 4
Tubular carcinoma 0 0 0 5(a)
Tubular adenoma or carcinoma 0 0 1 7(a)
Females
Kidney
Number examined 50 50 50 50
Nephropathy 6 8 23(a) 42(a)
Tubular hyperplasia 1 0 1 10(a)
Tubular adenoma 0 0 1 6(a)
Tubular carcinoma 1 0 1 3
Tubular adenoma or carcinoma 1 0 2 9(a)
3-MCPD: 3-monochloropropane-1,2-diol.
(a): Statistically signiﬁcantly different from controls at p ≤ 0.05.
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However, the study was compromised due to severe hematologic abnormalities in 50% of the monkeys
resulting in some deaths (Kirton et al., 1970).
Testis histopathology is frequent in rats treated with 3-MCPD. For instance, relatively high daily
doses of 3-MCPD (29.5 mg/kg) for 90 days in rats produced complete ablation of the spermatogenic
epithelium in 90% of the animals accompanied by inﬂammatory changes in the head of the
epididymis. A 3-MCPD dose–response analysis of the testicular histopathology gave a BMD10 of
8.4 mg/kg bw per day and a BMDL10 of 6.0 mg/kg bw per day (Barocelli et al., 2011).
3-MCPD inhibited the oestrous cycle of female rats when administered by subcutaneous injection at
3-MCPD (10 mg) every alternate day for 30 days (dose of approximately 60 mg/kg bw) (Lohika and
Arya, 1979). The weights of the uterus and ovary were reduced and histology suggested ovulation was
absent.
Developmental toxicity
3-MCPD has been administered by gavage as single doses (62.5, 75 or 90 mg/kg bw to female
Wistar rats on days 1 or 6 or 14 days of pregnancy (Rahmaniah, 1999). The two highest doses (75
and 90 mg/kg) decreased implantation and increased fetal loss at all three dosing time points in
pregnancy. A similar study in Sprague-Dawley rats used doses of 10, 30 and 90 mg/kg per day. The
pregnant rats received daily treatment with 3-MCPD from gestational days 6 to 19. Developmental
toxicity was only observed in the presence of maternal toxicity and a NOAEL was suggested to be
10 mg/kg per day for the pregnant rats and 30 mg/kg per day for embryo-fetal development.
Teratogenic effects were not observed (Lee et al., 2009). In a study aimed at investigating whether
testicular organogenesis was affected by 3-MCPD, pregnant Sprague-Dawley rats were given daily oral
doses of either 5, 10 or 25 mg/kg on days 10.5, 15 and 17.5 of gestation and the pups autopsied on
day 18. Interestingly, although the authors demonstrated that 3-MCPD and its metabolite were present
in the foetus at levels similar to those observed in the mother, no testicular toxicity was seen. Maternal
toxicity was recorded at 10 and 25 mg/kg bw per day; however, fetal weight, deaths and resorptions
were similar to control values. (El Ramy et al., 2006).
Jones and Jackson (1976) studied the effects of 3-MCPD treatment of male rats upon their
subsequent offspring after mating treated males with untreated females. Male Wistar rats were
administered oral doses at 5, 10 or 20 mg/kg per day for 5 days and then mated with untreated
females 3, 10, 17 or 21 days after the ﬁrst treatment. In rats in which fertility was maintained there
was no effect on the incidence of non-viable fetal implantations conﬁrming a previous observation in
the mouse (Epstein et al., 1972).
Genotoxicity
3-MCPD
In vitro
Bacteria
3-MCPD was positive in reverse mutations assays in S. typhimurium TA100 and TA1535 (base pair
substitution strains) in the absence of an exogenous metabolic activation system. Both positive and
negative results have been obtained in TA98 and negative results have been observed in TA1537 and
TA1538 as well as in Escherichia coli WP2, TM930, TM1080. In the presence of an exogenous
metabolic system, it was positive in TA100 and TA1535, but was negative in TA97, TA98, TA1537 and
TA1538 as well as in E. coli strains (Stolzenberg and Hine, 1979, Stolzenberg and Hine, 1980;
Silhankova et al., 1982; Zeiger et al., 1988, Ohkubo et al., 1995; All cited in FAO/WHO, 2002 and
IARC, 2012).
Yeast
In a forward mutation assay in Schizosaccharomyces pombe 3-MCPD was positive in the absence of
metabolic activation and negative in the presence of metabolic activation (Rossi et al., 1983).
Mammalian cells
The results of in vitro genotoxicity assays in mammalian cells, including a gene mutation test in
mouse lymphoma cell tk locus (2–9 mg/mL, positive in the presence of metabolic activation,
negative without metabolic activation), a gene mutation test in V79 cell hprt locus (0.033–7.7 mg/mL)
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and a sister chromatid exchange test in V79 cells (0.7–2.8 mg/mL with and without metabolic
activation) were reported to be generally positive. However, in V79 cells a weak mutagenic effect was
observed only at cytotoxic concentrations (5.5 mg/mL) (unpublished reports by Henderson et al.,
1987; G€orlitz, 1991; May, 1991 cited in JECFA WHO Food Additives series 48 and in Bakhiya et al.,
2011). 3-MCPD was negative in a DNA synthesis inhibition assay in HeLa cells both with and without
metabolic activation (Painter and Howard, 1982). In the absence of metabolic activation, it was
positive in a transformation assay in mouse ﬁbroblast M2 clone (Piasecki et al., 1990; cited in FAO/
WHO, 2002 and IARC, 2012). In an alkaline Comet assay in Chinese hamster ovary (CHO) cells)
exposed for 3 h to 0.5, 1.0, 2.5 and 5.0 mg/mL 3-MCPD, a statistically signiﬁcant increase in DNA
damage was observed with the two highest concentrations, in the presence of minimal toxicity (El
Ramy et al., 2007).
In vivo
Micronucleus tests
Robjohns et al. (2003) investigated 3-MCPD for induction of structural and/or numerical
chromosomal aberrations in a standard micronucleus (MN) assay in bone marrow erythrocytes. Based
on a preliminary dose range ﬁnding study, the following doses were administered by gavage: 0, 15, 30
and 60 mg/kg bw. Groups of six outbred Crl:HanWist BR (Glx:BRL) BR rats were dosed once daily for
two consecutive days. Bone marrow was sampled 24 h after the last administered dose. Water was
used as vehicle and negative control. Administration of 3-MCPD at the highest dose produced signs of
toxicity (piloerection). In 3-MCPD-treated animals, there was a dose-related decrease in the
polychromatic to normochromatic erythrocyte ratio (PCE/NCE) indicating toxicity to the target cells.
There was no statistically signiﬁcant increase in the group mean frequencies of micronucleated PCE
compared to the control group frequencies of micronucleated PCE which fell within the laboratory
historical negative control range for all test groups. The positive control, cyclophosphamide, induced a
signiﬁcant increase in micronucleated PCE. Under the test conditions performed, 3-MCPD was negative
in this MN test.
In a study by Onami et al. (2014a) the potential of 3-MCPD to induce micronuclei in bone
marrow was tested in male F344 gpt delta rats carrying a transporter transgene lambda EG10. The
rats were dosed by intragastric administration for 4 weeks, ﬁve times a week. The rats were
randomly allocated to six groups with ﬁve animals in the positive control group, six rats in the
negative control group (olive oil) and test group. Only one dose was given to the test group:
40 mg/kg bw 3-MCPD. The 40 mg/kg bw dose of 3-MCPD corresponds to 26% of LD50. The dose of
3-MCPD was selected on basis of a previous carcinogenicity study in Sprague-Dawley rats (Cho
et al., 2008a). Olive oil was used as vehicle for the test substances. No positive control was used in
this experiment. The animals were killed on day 29, 24 h after administration of the last dose and
bone marrow tissues were taken for the (MN) assay. No increase in the frequency of micronucleated
reticulocytes was observed in the 3-MCPD treated compared with the control group. The percentage
of reticulocytes among total erythrocytes (measure of chemical-induced bone marrow toxicity) did
not differ between the treated and control groups. However, while levels were not measured in the
target organ, the pharmacokinetics (described in Section 3.3.1) suggest that 3-MCPD would reach
the bone marrow.
Negative results were also reported in MN tests in mouse (40–120 mg/kg bw) or rat (2 days, 15, 30 or
60 mg/kg bw per day) bone marrow (Jaccaud and Aeschbacher, 1989; Marshall, 2000).
Comet assays
In a study by El Ramy et al. (2007), 3-MCPD was tested for its potential to induce DNA damage in
an alkaline single cell gel electrophoresis (Comet) assay in Sprague-Dawley and Fischer 344 rats. In
one study 3-MCPD was administered by gavage once daily to male Sprague-Dawley rats for 2 days at
doses of 25 or 60 mg/kg bw. DNA damage was assessed in blood leucocytes, bone marrow, liver,
kidney and testis 3 h after the second administration. Water (solvent) was used as negative control
and methyl methanesulfonate (MMS) was used as positive control. Five rats were dosed per group. At
high dose, the body weight gain of rats was slightly impaired. No microscopic abnormalities have been
observed in testis and kidneys of treated rats. Dose-related increases in the incidence of hepatocellular
mitotic ﬁgures were observed in the livers of treated rats. 3-MCPD did not induce DNA lesions in the
various organs at any tested dose. The validity of the test was demonstrated by the statistically
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signiﬁcant increases in both olive tail moment (OTM) and percentage of DNA in the tail in cells isolated
from organs and tissues (except the bone marrow) of rats treated with MMS.
In the second study, 3-MCPD was administered by gavage once daily to male F344 rats for 2 days
at a dose of 60 mg/kg bw. DNA damage was assessed in leucocytes and testis 3 h after the second
administration. Four rats were dosed per group. The same positive and negative controls were used as
in the ﬁrst study. The body weight gain of treated rats was slightly impaired. 3-MCPD did not induce
DNA lesions neither in leucocytes, nor in testis. Statistically signiﬁcant increases in DNA damage were
observed after MMS treatment.
Gene mutation assays
Onami et al. (2014a) tested also the potential of 3-MCPD to induce Pig-a mutations in male F344
gpt delta rats carrying a transporter transgene lambda EG10. The same treatment protocol as
described above for the MN test was applied. Peripheral blood samples from the tail vein were
collected from each animal at day 0 and 15. At day 29, within 24 h after ﬁnal administration, blood
samples were collected from the abdominal aorta for Pig-a mutation assays. The frequency of Pig-a
mutant red blood cells did not differ among groups at any time point.
This study has some limitations because it is documented that in RBC the mutant phenotype at day
29 is only modest and that additional time is required to reach the maximum value in RBCs (Dertinger
et al., 2010). On the contrary, mutation responses occur earlier in reticulocytes (RET). However, there
was no tendency of accumulation of mutations in RBC after 29 days.
In the study by Onami et al. (2014a), described above, genomic DNA was extracted from the
kidney and testis and investigated for gene mutations in the gpt or Spi gene. No increase was
observed in mutation frequencies compared to control and olive oil treated animals in either gene in
the treated group. Mutation frequencies were according to the authors within negative control values
described earlier by the authors (Hibi et al., 2011). It was claimed by the authors that for the
mutations frequencies of DEN-treated liver performed as positive controls were signiﬁcantly elevated.
Only one dose was used in this study, and not a minimum of three, appropriately-spaced dose levels
as recommended in OECD Test Guideline 488. In addition, there was only 1 day between the end of
the administration period and the sampling time, compared to 3 days normally used in TGR gene
mutation assays. For slowly proliferating tissues, like kidney, a later sampling time following the
cessation of administration may be more appropriate.
Unscheduled DNA synthesis assay
Robjohns et al. (2003) investigated the induction of DNA repair in an unscheduled DNA synthesis
(UDS) assay in rat liver (Table 32). Rats (Crl:HanWist (Glx:BBL) BR) were given a single
administration by oral gavage of 0 (water) 40 or 100 mg 3-MCPD/kg bw. The selected doses were
based on a preliminary range ﬁnding study in which 100 mg/kg bw was close to the maximum
tolerated dosage. Two studies were performed. In the ﬁrst study, animals (4/group) were sampled
2–4 h after administration using DMN as positive control. In the second study rats were sampled
12–14 h after administration using 2-AAF as positive control. In the 3-MCPD treated groups, the net
nuclear grain count was well below zero at all doses and sampling time and no more than 0.3% of
the cells were seen in repair at any dose of 3-MCPD. The positive controls were clearly active.
Therefore, under the test conditions used, 3-MCPD did not induce DNA damage that is detectable by
this test.
A negative result was also reported in an UDS assay in male Han Wistar rats exposed to 40 or
100 mg 3-MCPD/kg bw (Fellows, 2000).
Dominant lethal mutation assays
3-MCPD was also negative in dominant lethal mutations assays in rats exposed by gavage (5 days, 5,
10 or 20 mg/kg bw per day) and mice exposed by i.p. (125 mg/kg bw) or by gavage (5 days, 5, 10 or
20 mg/kg bw per day) to 3-MCPD (Epstein et al., 1972; Jones et al., 1969 and Jones and Jackson, 1976).
Somatic mutation in Drosophila
3-MCPD was negative in a mutation/recombination assay wing spot test in D. melanogaster (Frei
and W€urgler, 1997).
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Summary of toxicity
The LD50 after a single oral dose of 3-MCPD has been reported as 150 mg/kg bw per day in rats
and 191 mg/kg in mice. Death occurs several days after dosing. In a subchronic study in rats, a BMD
for 10% mortality was calculated as 7.4 mg/kg bw per day. In a six-week study, The LD50 in rhesus
monkeys was slightly above 30 mg/kg bw per day as two out of six animals died at this dose.
3-MCPD produces severe renal toxicity which persists for several weeks after single i.p. doses
between 100 and 120 mg/kg bw per day. Multiple daily oral doses also result in renal toxicity and
more subtle toxicity such as progressive nephropathy and renal tubule dilation can be seen after a
daily dose as low as 5.2 mg/kg bw. Barocelli et al. (2011) calculated a BMD10 for a combined renal
histopathology score of less than 1.84 mg/kg bw per day.
3-MCPD administered to rats at 30 mg/kg bw per day impairs red blood cell function by decreasing
haemoglobin content and inducing volume fraction changes consistent with normocytic and
normochromic anaemia. Severe bone marrow suppression was reported in 50% of male rhesus
monkeys receiving 30 mg/kg bw per day.
After long-term exposure at doses as low as 2.0 mg/kg bw per day. 3-MCPD caused progressive
nephrotoxicity (characterised by nephropathy and tubular hyperplasia) testicular toxicity (atrophy and
arteritis) and mammary glandular hyperplasia in male rats and nephrotoxicity in female rats. Related to
these effects, benign tumours of the testes (Leydig cells tumours), mammary gland (ﬁbroadenoma)
and kidney (tubular adenoma) were found to develop. In one study a signiﬁcant increase in malignant
kidney tumours was observed in male rats.
There are extensive data documenting the male antifertility activity of 3-MCPD. Doses of around
5 mg/kg bw day 3-MCPD administered to the rat can completely impair male fertility without changing
sperm production. This effect has been demonstrated in several species and is reversible. The NOAEL of
3-MCPD on male fertility is not clear. Higher doses of 3-MCPD approximately 90 mg/kg bw per day
permanently impair fertility most likely by blocking the passage of sperm from the testis, which may explain
the testicular pathology seen in some studies. The BMD10 for testicular pathology of unknown relationship
to fertility has been calculated as 8.4 mg/kg bw per day in a 90-day study (Barocelli et al., 2011).
Single and multiple doses of 3-MCPD administered to the pregnant rat decreased the numbers of
implantation sites and increased fetal loss but were not teratogenic. The NOAEL for multiple dose was
10 mg/kg bw per day for maternal toxicity and 30 mg/kg bw per day for fetal toxicity. Pregnancies
achieved by male rats receiving doses which partially maintained fertility were apparently normal and
there was no increase in intra-uterine fetal abnormalities.
3-MCPD induces gene mutations in some strains of bacteria and DNA strand breaks and gene
mutations in mammalian cells in vitro. It was not genotoxic in Drosophila melanogaster. The genotoxic
potential of 3-MCPD has been investigated in vivo in mammalians considering various endpoints: gene
mutations, chromosomal aberrations, DNA strand breakage and induction of DNA repair (UDS). Several
organs were analysed: peripheral blood, bone marrow, liver and also the target organs for cancer:
kidney and testis. Although some of the in vivo studies have limitations, the genotoxic potential
observed in some in vitro tests could not be reproduced in vivo. Overall, the CONTAM Panel considered
that there is no evidence indicating that 3-MCPD is genotoxic in vivo.
3.3.3.2. 3-MCPD fatty acid esters
Single dose
In an acute study in mice, Liu et al. (2012) gave single oral doses (1,000–5,000 mg/kg bw) of
the mono- and dipalmitate esters of 3-MCPD dissolved in blended edible oil to mixed groups of adult
male and female Swiss mice and examined the responses up to 14 days later. Some mice died
within 48 h of dosing and the median LD50 of the monopalmitate was 2,676 mg/kg bw. The
3-MCPD dipalmitate was less toxic and the LD50 could only be estimated to be greater than
5,000 mg/kg bw. Body weight in the mice which subsequently died fell up to 50% in the 5 days
after dosing of both esters. In surviving mice, body weight gain recovered suggesting these toxic
changes were transient.
Li et al. (2013) assessed the acute toxicity of 3-MCPD dipalmitate in male and female Wistar rats.
Rats were exposed via a single gavage administration (soybean oil as vehicle) to 100–3,160 mg/kg bw
3-MCPD dipalmitate (two rats/sex per group) and subject to a 14-days observation period. No signs of
toxicity were recorded at 100 and 316 mg/kg bw. Acute locomotor toxicity was noted at doses
1,000 mg/kg and greater. All rats exposed to the top dose died within 36 h. An LD50 of 1,780 mg/kg
bw was calculated.
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Repeated dose
In a 90-day study 3-MCPD dipalmitate dissolved in corn oil was administered by daily gavage to adult
male and female Wistar rats using equimolar doses over the range 9.78–156.7 mg/kg for
3-MCPD dipalmitate, equivalent to 1.84–29.5 mg/kg per day for 3-MCPD. (Barocelli et al., 2011). In
contrast to treatment with the 3-MCPD general good health was retained in 3-MCPD dipalmitate-treated
rats although the discomfort score was elevated after the highest dose, 156.7 mg/kg. Analysis of female
rat mortality after 3-MCPD exposure gave a BMD10 and BMDL10 of 7.4 and 2.3 mg/kg per day,
respectively. Death was not observed after 90 days treatment with 156.7 mg/kg 3-MCPD dipalmitate.
No mortality was observed in a 90-day study in which male and female Wistar rats were exposed to
12.3 and 267 mg/kg bw per day 3-MCPD dipalmitate diluted in soybean oil. Reduced body weights
were observed in the high dose group after 90 days of treatment (Li et al., 2013).
Another investigation administered either 3-MCPD mono- or dipalmitate or 3-MCPD dioleate in olive
oil to adult F344 male and female rats for 5 days a week for 13 weeks. (Onami et al., 2014a,b). Doses
were equimolar, again reﬂecting the intention of several authors to ensure the mass of the 3-MCPD
given was comparable between the different esters. These doses were, 14–220 mg/kg, MCPD
dipalmitate; 8–130 mg/kg 3-MCPD monopalmitate; 15-240 3-MCPD dioleate. 3-MCPD 40 mg/kg was
used as a reference dose. In F344 female rats 3-MCPD was lethal after 1–4 weeks of treatment
(40 mg/kg approximate LD50). Deaths in the other treatment groups including the esters were low,
sporadic and not dose related. There was no loss of body weight or weight gain.
Tee et al. (2001) indicated in an abstract that in Sprague-Dawley rats the esters 1-palmitoyl,
1-steroyl, 2-oleoyl or 1-palmitoyl-2-oleoyl 3-MCPD at doses between 50 and 400 mg/kg per day for
14 days were not toxic.
Renal and hepatic toxicity
At the end of a 90-day repeated dose study of 3-MCPD dipalmitate in Wistar rats the combined
weight of the kidney and adrenal gland was increased in both sexes (Barocelli et al., 2011). The
weight increases, probably reﬂecting changes in the kidney, were dose dependent such that they were
about 70% higher after the highest dose of both MCPD dipalmitate (156.7 mg/kg) and 3-MCPD
(29.5 mg/kg).
The highest doses of both 3-MCPD and its ester increased water consumption in male and female
rats but only towards the end of the 90-day study. The lower doses of both 3-MCPD and its ester did
not change water consumption throughout the 13 week study. In spite of no signiﬁcant changes being
observed in urine output, after both the highest does of 3-MCPD dipalmitate (156.7 mg/kg) and
3-MCPD (29.5 mg/kg) the urine was acidiﬁed and the concentrations of several substances were
changed, notably the proteins Nag, B2M, albumin and a-GST. Serum creatinine concentrations were
reduced by both compounds.
The study by Barocelli et al. (2011) reported an extensive array of degenerative changes in the renal
tubules after 90 days treatment across the range of doses for both 3-MCPD dipalmitate and 3-MCPD and
in both sexes. These included primary effects, such as glomerular lesions and tubular epithelial
hyperplasia and secondary changes such as cellular inﬁltration in interstitial spaces and ﬁbrosis. When
examined quantitatively these pathological effects were restricted to the highest dose of both 3-MCPD
and its ester. The overall scores at the highest dose of 3-MCPD and its ester were not different in the male
rats. Histopathology scores were slightly lower in the female rats and the 3-MCPD dipalmitate score was
slightly less severe than the 3-MCPD score. Both primary and secondary histopathological data were
combined into a total renal score which was used for BMD modelling. In male rats the BMD10 and BMDL10
for 3-MCPD dipalmitate for the total renal histopathology scores were 41.1 and 17.4 mg/kg, respectively,
compared to the BMD10 and BMDL10 for 3-MCPD as 5.6 and 2.5 mg/kg bw per day. In female rats the
BMD10 and BMDL10 for 3-MCPD dipalmitate for renal histopathology were 7.9 and 3.6 mg/kg,
respectively. The renal toxicity of 3-MCPD was high even at the lowest dose studied, 1.84 mg/kg bw per day,
BMD modelling was not reliable and the authors estimated BMD10 and BMDL10 for MCPD were both
between 0.1 and 1.84 mg/kg bw per day. It should be noted that primary and secondary data were
combined for use in the BMD modelling, as these data are not independent from each other some bias
may have been introduced into the estimates of the BMD and BMDL.
Another rat 90-day repeated dose study of 3-MCPD dipalmitate did not reveal any change in renal
weight after 12.3 mg/kg bw per day; however, kidney weight increased by 46% after 267 mg/kg bw
per day (Li et al., 2013). Serum urea and creatinine showed signiﬁcant increases 90 days after the
start of treatment conﬁrming only the observation in serum for creatinine by Barocelli et al. (2011).
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Liver weights and hepatic biomarkers were unchanged. Tubular cell degeneration, hyaline castes and
inﬂammatory inﬁltration were noted after 90 days in the 3-MCPD dipalmitate 267 mg/kg treated group
supporting the histopathology reported by other studies.
Proﬁling of endogenous metabolites in urine from rats treated with 3-MCPD dipalmitate has been
achieved by principal component analysis and partial least squares discriminant analysis (PLS-DA)
which when displayed in a score plot, showed in complete separation of the endogenous metabolite
proﬁles between controls, 12.3 and 267 mg/kg bw per day MCPD dipalmitate after 90 days treatment.
After 63 days treatment only the 267 mg/kg bw daily dose was different from control indicating
progressive development of renal toxicity during prolonged treatment with 3-MCPD dipalmitate (Li
et al., 2013).
At the end of a 90-day study in F344 rats absolute and relative kidney weights were increased by
3-MCPD (dosed at 40 mg/kg bw per day) and by mid and high doses of 3-MCPD dipalmitate (55 and
220 mg/kg bw per day), MCPD monopalmitate (32 and 130 mg/kg bw per day) or 3-MCPD dioleate (60
and 240 mg/kg bw per day). No changes in kidney weight were observed in rats treated with the lowest
tested doses of the three esters (14, 8 and 15 mg/kg bw per day for 3-MCPD dipalmitate,
monopalmitate and dioleate, respectively) (Onami et al., 2014b). The kidney weight increases for the
highest doses of the esters were comparable to 3-MCPD alone. These weight changes reﬂect a similar but
not so a deﬁnitive pattern for increases in liver weight as the only signiﬁcant changes were seen after the
highest dose of 3-MCPD dipalmitate (220 mg/kg bw per day), 3-MCPD monopalmitate (130 mg/kg bw
per day) or 3-MCPD dioleate (240 mg/kg bw per day). Serum urea was decreased in 3-MCPD
monopalmitate-treated female rats only. Falls in serum creatinine were more frequently observed the
exception being the low dose 3-MCPD monopalmitate in males, and low dose 3-MCPD monopalmitate and
3-MCPD dioleate in females. Severe tubular necrosis was conﬁrmed in the rats which died after 3-MCPD
treatment. In rats surviving 13 weeks of 3-MCPD treatment and in others receiving 3-MCPD fatty acid
esters no histopathological changes (including renal) were seen except in the epididymis.
In contrast to the rat studies of 3-MCPD fatty acid esters there were no changes in the relative
kidney weights after treatment of Swiss mice with a single dose of 3-MCPD monopalmitate or
dipalmitate (Liu et al., 2012). Mice receiving 3-MCPD monopalmitate (up to 4,162 mg/kg) which
subsequently died displayed high serum urea and creatinine concentrations indicative of acute renal
failure. In contrast both serum urea and creatinine concentrations in mice which survived 14 days after
treatment were lower than control at all doses of the monopalmitate examined. No changes were
reported after treatment with 3-MCPD dipalmitate.
In the mouse renal tubules focal degeneration, cell necrosis and protein casts were consistently
observed after treatment with 3-MCPD monopalmitate (2,014 mg/kg and above) but were not reported
in the kidneys of the 3-MCPD dipalmitate treated mice (up to 4,162 mg/kg) that survived treatment.
Haematology
Males and females Wistar rats treated with 3-MCPD dipalmitate for 90 days showed mild
dose-dependent changes consistent with normocytic and normochromic anaemia (Barocelli et al.,
2011). At the highest dose of both 3-MCPD (29.5 mg/kg) and 3-MCPD dipalmitate (156.7 mg/kg) there
were small reductions of red blood cell number, haemoglobin concentration and haematocrit. There
seems to be a discrepancy between haemoglobin concentration and haematocrit, the latter being
relatively unchanged. Increased serum bilirubin was an indirect indicator that anaemia has mainly a
haemolytic origin. White blood cells were raised in male rats and platelets in both sexes. In one study
90 days treatment with 3-MCPD dipalmitate, both 12.3 and 267 mg/kg, increased the weight of the
spleen (Li et al., 2013). The BMDL10 and BMD10 for 5% loss of RBC (5% loss) for 3-MCPD and
3-MCPD dipalmitate was 2.6, 4.5, 90.4, 187.0 mg/kg, respectively, in female rats and 3.5, 7.2, 24.8,
53.5 mg/kg in male rats (Barocelli et al., 2011).
Haematological changes consistent with anaemia were also seen in the 13 week F344 male and
female rat study (Onami et al., 2014b). Serum haemoglobin fell after the highest dose of all ester
groups (3-MCPD dipalmitate 220 mg/kg, 3-MCPD monopalmitate 130 mg/kg and 3-MCPD dioleate
240 mg/kg) with the exception of 3-MCPD dioleate in male rats. There was some indication of a dose–
response relationship. These changes were sometimes accompanied by changes in haematocrit and
red blood cell count but variation between groups was high making precise conclusions difﬁcult.
No haematological changes were reported in 3-MCPD fatty acid ester treated mice (Liu et al., 2012).
Long-term toxicity and carcinogenicity
No long-term toxicity or carcinogenicity studies with 3-MCPD fatty acid esters were identiﬁed.
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Reproductive toxicity
Robust fertility studies have not been conducted with the esters of 3-MCPD but there is evidence
for reproductive toxicity. In a brief paper some mono-esters of 3-MCPD have been reported to possess
male antifertility activity when administered to rats at doses between 15 and 100 mg/kg bw per day
for 8 days. The esters were less potent than 3-MCPD itself, which was active at 3 mg/kg bw per day
(Ericsson and Youngdale, 1970). 3-MCPD dipalmitate when administered orally to male rats at a dose
of 100 mg/kg bw (0.17 mmol/kg bw) showed comparable molar potency to 3-MCPD 10 mg/kg bw
(0.09 mmol/kg bw) in the inhibition of male fertility (Rooney and Jackson, 1980).
At the end of 90 days treatment of Wistar rats with 3-MCPD dipalmitate at doses up to 156.7 mg/kg
bw per day the weights of both male and female gonads were not different from controls (Barocelli et al.,
2011). However, degenerative changes in testes from rats receiving daily treatment MCPD dipalmitate for
at equimolar doses to a testis toxic dose of 3-MCPD were present but inconsistent. No pathology was
reported for the ovary although sexual cycles were not examined.
F344 Rats treated for 13 weeks with 3-MCPD dipalmitate (at 14, 55 or 220 mg/kg bw per day),
monopalmitate (at 8, 32 or 130 mg/kg bw per day) or dioleate (15, 60 or 240 mg/kg bw per day) did not
show any effects on testis weight or treatment-related testicular histology including the spermatogenic
tubules and Leydig cells. However, dose-related apoptotic cell death was observed in the head of the
epididymis and achieved statistical signiﬁcance at the highest tested doses, equimolar to 3-MCPD 40 mg/kg
bw per day, for the three 3-MCPD fatty acid esters (Onami et al., 2014b). In contrast, another study
using Wistar rats reported that testis weight was increased after 90 days treatment with 267 mg/kg
3-MCPD dipalmitate but this was not reﬂected by changes in histopathology. (Li et al., 2013).
In mice, testis and ovarian relative weights were not changed 14 days after treatment with single
doses of the 3-MCPD mono- and dipalmitic esters (Lui et al., 2012). There were some histopathological
changes in testicular sections but these were subtle and may not have fully developed 14 days after
dosing due to the length of time the spermatogenic epithelium takes to turnover. However, the
changes may have indicated impairment in the production of round spermatids.
Developmental toxicity
No developmental studies with 3-MCPD fatty acid esters were identiﬁed.
Genotoxicity
In vivo
Micronucleus tests
In a study by Onami et al. (2014a) the potential of equimolar concentrations of 3-MCPD (see
above) and three 3-MCPD fatty acid esters: palmitate diester, palmitate monoester and oleate diester
to induce micronuclei in bone marrow was tested in male F344 gpt delta rats carrying a transporter
transgene lambda EG10. The rats were dosed by intragastric administration for 4 weeks, ﬁve times a
week. The rats were randomly allocated to six groups with ﬁve animals in the positive control group,
six rats in the negative control group (olive oil) and test groups. Only one dose was given to each test
group: 3-MCPD dipalmitate (220 mg/kg bw), 3-MCPD monopalmitate (130 mg/kg bw) and
3-MCPD dioleate (240 mg/kg bw). Olive oil was used as vehicle for the test substances. No positive
control was used in this experiment. The animals were killed on day 29, 24 h after administration of
the last dosing and bone marrow tissues were taken for the MN assay. No increase in the frequency of
micronucleated reticulocytes was observed in the 3-MCPD fatty acid ester treated groups compared
with the control group. The percentage reticulocytes among total erythrocytes (measure of chemical-
induced bone marrow toxicity) did not differ between the treated and control groups.
Gene mutation assays
Onami et al. (2014a) tested also the potential of equimolar concentrations of 3-MCPD (see above) and
three 3-MCPD fatty acid esters (palmitate diester, palmitate monoester and oleate diester) to induce Pig-a
mutations in male F344 gpt delta rats carrying a transporter transgene lambda EG10 (Table 33). The
same treatment protocol as described above for the MN test was applied. Peripheral blood samples from
the tail vein were collected from each animal at day 0 and 15. At day 29, within 24 h after ﬁnal
administration, blood samples were collected from the abdominal aorta for Pig-a mutation assays. The
frequency of Pig-a mutant red blood cells did not differ among groups at any time point.
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In the study by Onami et al. (2014a), described above, genomic DNA was extracted from the
kidney and testis and investigated for gene mutations in the gpt or Spi gene. No increase was
observed in mutation frequencies compared to control and olive oil treated animals in either gene in
any of the treated groups. Mutation frequencies were according to the authors within negative control
values described earlier by the authors (Hibi et al., 2011).
Summary
It can be concluded that the range of toxic effects for esteriﬁed 3-MCPD are the same as those
seen for the free 3-MCPD, supporting the view that the esters are cleaved and toxicity primarily
exerted by 3-MPCD.
Acute LD50 of 2,676 mg/kg bw was calculated for 3-MCPD monopalmitate in mice. Acute LD50 of
> 5,000 mg/kg bw and 1,780 mg/kg bw were determined for 3-MCPD dipalmitate in mice and rats,
respectively. Considering 3-MCPD equivalents, 3-MCPD dipalmitate and palmitate showed lower acute
toxicity than free 3-MCPD. This reduction of toxicity was also noted following repeated exposure to a
variety of esters, monopalmitate, and steroyl diester, oleate diester and oleate-palmitate diester.
There are no data for single doses of 3-MCPD fatty acid esters. Multiple doses in rats of 3-MCPD
dipalmitate were not as toxic as equimolar doses of free 3-MCPD for some endpoints but not for
others. For instance, in one multiple administration study, a dose of 3-MCPD equivalent to the LD50
when given as the equimolar dipalmitate was not lethal. This reduction of toxicity was also noted after
a variety of esters, monopalmitate, and steroyl diester, oleate diester and oleate-palmitate diester. In
mice, 3-MCPD has an oral LD50 after a single dose of 191 mg/kg bw per day but when administered as
the mono palmitate it is increased to 2,676 mg/kg bw per day and the LD50 of the dipalmitate could
only be estimated to be greater than 5,000 mg/kg bw per day.
After equimolar multiple doses of 3-MCPD and 3-MCPD dipalmitate the biochemical changes
associated with renal toxicity are similar in pattern and magnitude. Both compounds produce an
extensive array of renal histopathology including glomerular lesions and tubular epithelial hyperplasia.
An estimated BMD10 for a combined histopathological score in the rat was 41.1 mg/kg bw per day for
3-MCPD dipalmitate compared to 5.6 mg/kg bw per day for the free 3-MCPD. Similar patterns of
toxicity are seen after the other 3-MCPD fatty acid esters were tested but dose comparisons between
the different MCPD fatty acid esters are difﬁcult to make.
Haematological changes consistent with anaemia of haemolytic origin have been seen in rats after
treatment with 3-MCPD or one of several 3-MCPD fatty acid esters. The BMD10 for 5% red blood cell
loss in male rats was 4.5 mg/kg bw per day for 3-MCPD compared to 187 mg/kg bw per day for 3-
MCPD dipalmitate.
No long-term toxicity or carcinogenicity studies with 3-MCPD fatty acid esters were identiﬁed.
There is limited evidence that 3-MCPD esters possess male antifertility activity. For example 3-MCPD
dipalmitate when administered orally to male rats at 0.17 mmol/kg bw showed comparable potency to
3-MCPD at 0.09 mmol/kg bw in the inhibition of pregnancy in untreated females.
Degenerative changes in testes from rats receiving prolonged daily treatment MCPD esters such as
mono- and dipalmitate or the dioleate at equimolar doses to testis toxic doses of 3-MCPD have been
reported but the changes are generally inconsistent. However, increases in testis weight in the absence
of testicular histopathology was noted after 90 days treatment with 267 mg/kg 3-MCPD. Apoptotic cell
death was observed in the head of the epididymis which appeared dose-related after the 3-MCPD fatty
acid esters and was comparable to 3-MCPD 40 mg/kg bw per day. No pathology was reported for the
ovaries from treated female rats.
In mice, testis and ovarian weights were not changed 14 days after treatment with single doses of the
3-MCPD mono- and dipalmitic esters although there were some histopathological changes in the testis.
There are no data describing the developmental toxicity of the esters of 3-MCPD.
The genotoxic potential of some 3-MCPD fatty acid esters has been investigated in one in vivo
study (a MN test and in gene mutation assays). From the limited evidence available there is no
indication that 3-MCPD fatty acid esters are genotoxic in vivo.
3.3.3.3. 2-MCPD
Single dose
2-MCPD can be lethal within 24 h when given by gavage to adult male Sprague-Dawley rats.
Marchesini and Huggett (1992) used the ‘up and down’ protocol to estimate the LD50 to be between
50 and 60 mg/kg bw (n = 10). Death was accompanied by a brief series of convulsions.
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Repeated dose
Only limited data are available on 2-MCPD toxicity. In contrast to 3-MCPD, a single i.p. injection of
200 mg/kg bw 2-MCPD did not cause diuresis in male Sprague-Dawley rats (Jones and Fakhouri, 1979).
It should be noted that the corresponding LD50 dose for 3-MCPD was given as 90 mg/kg bw, which
produced enlarged kidneys and severe renal failure, and the LD50 for 2-MCPD was approximately
200 mg/kg bw, which produced no evidence for kidney damage (Jones and Fakhouri, 1979).
The toxicity of 2-MCPD has been described in a repeated dose 28-day oral protocol in young adult
male and female Sprague-Dawley rats (Perrin et al., 1994). 2-MCPD was dissolved in distilled water
and administered by gavage at daily doses of 2, 16 or 30 mg/kg bw per day to groups (n = 10–15) of
4–5 week old male and female rats. There were a few deaths in the high dose group and their timings
ranged from 8 to 23 days of treatment. Death was attributed to cardiac failure.
Dose-dependent lesions in striated muscle such as cytoplasmic vacuolisation and lysis of myocytes
were recorded in the 16 and 30 mg/kg bw per day at the 8 day and terminal (29 day) study points.
These pathological changes were present throughout the body but were most extensive and severe in
the myocardium. Over-contraction of the heart was also noted at autopsy. Serum biochemistry was
altered and the changes mainly reﬂected acute muscle damage. For example ASAT, ALAT, LDH and CK
were elevated which was accompanied by raised serum phosphorus and potassium. There was some
functional cardiac adaptation in the less severely affected rats after 29 days of treatment.
Renal damage in the form of increased kidney weight and cytoplasmic vacuolisation in the proximal
convoluted tubules was also dose dependent occurring in the 16 and 30 mg/kg bw per day treated
rats. The renal tubule changes were more prominent in the male rats. The renal pathology was
accompanied by a water diuresis which was unexpected given the severity of the cardiac failure.
The effects of 2-MCPD were restricted to the 16 mg/kg per bw and the 30 mg/kg bw per day
treated rats. No adverse effects were documented at the 2 mg/kg bw per day dose group which was
recorded as the NOAEL.
No long-term toxicity or carcinogenicity studies with 2-MCPD were identiﬁed.
Genotoxicity
Bacteria
Very few genotoxicity studies on 2-MCPD have been identiﬁed, with most of those identiﬁed being
unpublished study reports. 2-MCPD was mutagenic in a bacterial test system (metabolic system not
stated) (Jones and Gant, unpublished data cited by Schilter et al., 2011).
Mammalian cells
In V79 cells 2-MCPD did not induce gene mutations at the hprt locus when tested up to extreme
high concentrations (50 mM) either with or without metabolic activation (Morgenthaler, 1993,
unpublished report).
Drosophila
In an in vivo ‘wing spot test’ in Drosophila melanogaster no genotoxic effect was observed (Frei
and W€urgler, 1997).
No mammalian in vivo genotoxicity studies have been identiﬁed for 2-MCPD.
Summary of toxicity
2-MCPD
There are limited data on the short-term toxicity of 2-MCPD. A single i.p. dose of 200 mg/kg bw per
day although potentially lethal did not cause signs of renal toxicity. However, multiple doses of 16 or
30 mg/kg bw per day in a 28-day oral protocol caused severe lesions leading to cell death in striated
muscle, particularly in cardiac myocytes, resulting in heart failure and the death of some animals as
from treatment day 8. Renal effects consisting in increased diuresis, increased kidney weight and
histopathological changes in proximal renal tubules were observed at the highest dose tested (30 mg/kg
bw per day). An oral NOAEL was reported by the authors of the study as 2 mg 2-MCPD/kg bw per day.
No long-term toxicity or carcinogenicity studies with 2-MCPD were identiﬁed.
3.3.3.4. 2-MCPD fatty acid esters
There are no relevant data for the esters of 2-MCPD.
MCPD and glycidyl esters in food
www.efsa.europa.eu/efsajournal 70 EFSA Journal 2016;14(5):4426
3.3.3.5. Glycidol
Single dose
No relevant data were identiﬁed.
Repeated dose
A relatively fast onset of the effects of daily doses of glycidol were seen when administered in
water by gavage to groups (n = 5) of F344/N rats and B6C3F1 mice of each sex for 16 days. (NTP,
1990). Glycidol doses for rats ranged from 37.5 to 600 mg/kg bw per day. All rats that received
600 mg/kg bw per day died between days 3 and 13. All mice that received 600 mg/kg bw per day and
40% that received 300 mg/kg bw per day, died by day 4 of the studies. Glycidol-related
histopathologic lesions included demyelination of brain neurones in both male and female mice that
received 150 or 300 mg/kg bw per day, and renal tubular cell degeneration in male mice that received
300 mg/kg bw per day. No renal toxicity was reported in rats after 16 days of daily treatment.
However, 13 weeks after administration to groups of rats (n = 10) at doses of 25 to 400 mg/kg bw
per day, renal tubular cell degeneration was seen in rats receiving 400 mg/kg bw per day. Doses for
groups of mice (also given for 13 weeks, n = 10) ranged from 19 to 300 mg/kg bw per day. Renal
tubular degeneration was only seen in male mice receiving 300 mg/kg bw per day. The brains of
female mice that received daily doses of 300 mg/kg bw glycidol for 16 days or 91 days displayed focal
demyelination in the medulla and thalamus. These histopathologic lesions were only present in the
brains of male mice that received either 150 or 300 mg/kg bw per day. Cerebellar necrosis was seen in
rats of both sexes after treatment with 400 mg/kg bw per day for 91 days.
In a 28-day study neurotoxicity developed in 5-week-old Sprague-Dawley rats which were given
glycidol by gavage at 0, 30 or 200 mg/kg bw per day (Akane et al., 2014b). Neurotoxicity was only
observed at highest dose in which rats showed progressively increasing abnormalities of the gait along
with essentially the same lesions of central and peripheral nervous systems as those also observed in
pregnant rats (Akane et al., 2013). The authors suggested that glycidol disrupts processes involving
late-stage neurite extension in the subgranular zone of the dental gyrus.
It was found that 28-day exposure to glycidol to young adult rats by gavage at 200 mg/kg bw per
day caused down regulation of genes related to the function of axon and synaptic transmission (Akane
et al., 2014c). Observed loss of Arc+, Fos+ or Jun+ neurons in the dentate granule cell layer, cingulate
cortex and cerebellar vermis at the end of 28-day glycidol exposure was suggested to signify
suppressed neuronal plasticity (Akane et al., 2014a,c).
Long-term toxicity and carcinogenicity
The carcinogenicity of glycidol was evaluated by the US NTP, based on 14 day dose-range ﬁnding
(n = 5 animals/sex), 13 week subchronic (n = 10), and 2 year chronic exposures (n = 50) via gavage
for ﬁve times a week in adult (PND 53) F344 rats and B6C3F1 mice of both sexes (NTP, 1990). Dosing
was started when the animals had reached the age of 53 days. Doses selected for the 16 day study
ranged from 37.5 to 600 mg/kg bw per day, for the 13-week study 25–400 mg/kg bw in rats and
19–300 mg/kg bw in mice, and for the 2-year study 37.5 and 75 mg/kg bw per day in rats and 25 and
50 mg/kg bw per day in mice. Survival rates until the end of the 2-year study for rats were poor with
100% mortality in both glycidol-dosed groups of males and 96–100% mortality in glycidol-dosed
females vs 68 and 44% mortality in the respective control groups. Mortality in mice was 46–50% in
glycidol-dosed males (34% in controls) and 46–66% in glycidol-dosed females (42% in controls).
Clear evidence for carcinogenicity of glycidol was reported based on signiﬁcantly increased
incidences of a number of tumours in both sexes of both rodent species from chronic exposures. As
shown in Table 34, signiﬁcantly increased tumour incidences were observed in male F344 rats for:
peri-testicular mesotheliomas; mammary gland ﬁbroadenomas; brain gliomas; thyroid gland follicular
cell adenomas and carcinomas; forestomach papillomas and carcinomas; intestinal adenomatous
polyps and carcinomas; skin adenomas and adenocarcinomas of the sebaceous gland and basal cell
tumours; and Zymbal gland carcinomas. Signiﬁcantly increased tumour incidences were observed in
female F344 rats for: mammary gland ﬁbroadenomas and adenocarcinomas; thyroid gland follicular
cell adenomas and carcinomas; brain gliomas; forestomach papillomas and carcinomas; oral mucosa
papillomas or carcinomas; clitoral gland adenomas, adenocarcinomas or carcinomas; and leukaemia.
Signiﬁcantly increased tumour incidences were observed in male mice for: Harderian gland
adenomas or adenocarcinomas; forestomach squamous cell papillomas and carcinomas; skin
squamous cell papillomas or carcinomas; liver adenoma or carcinomas; and lung alveolar/bronchiolar
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adenomas or carcinomas. Signiﬁcantly increased tumour incidences were observed in female mice for:
Harderian gland adenomas or adenocarcinomas; mammary gland adenomas, ﬁbroadenomas or
adenocarcinomas; uterus carcinomas or adenocarcinomas; subcutaneous tissue sarcomas or
ﬁbrosarcomas; and skin squamous cell papillomas or carcinomas.
As shown in Table 35, signiﬁcantly increased tumour incidences were observed in male B6C3F1
mice for: Harderian gland adenomas or adenocarcinomas; forestomach squamous cell papillomas and
carcinomas; skin squamous cell papillomas or carcinomas; liver adenoma or carcinomas; and lung
alveolar/bronchiolar adenomas or carcinomas. Signiﬁcantly increased tumour incidences were observed
in female B6C3F1 mice for: Harderian gland adenomas or adenocarcinomas; mammary gland
adenomas, ﬁbroadenomas or adenocarcinomas; uterus carcinomas or adenocarcinomas; subcutaneous
tissue sarcomas or ﬁbrosarcomas; and skin squamous cell papillomas or carcinomas.
The International Agency for Research on Cancer (IARC) evaluated the carcinogenicity of glycidol in
2000 and determined that it is probably carcinogenic to humans (Group 2A) (IARC, 2000). The IARC
had previously reported that the carcinogenicity of glycidyl oleate and glycidyl stearate were not
classiﬁable (Group 3, 1987 suppl 7) (IARC 1987).
The NTP evaluated the carcinogenicity of glycidol using a transgenic mouse model haploinsufﬁcient for
the p16Ink4a and p19Arf tumour suppressor genes (NIH publication 08-5962, 2007) based on results
from the 1990 conventional 2 year bioassays in mice and despite a negative ﬁnding in a related transgenic
haploinsufﬁcient model, the p53  mouse (Tennant et al., 1999). Male and female p16Ink4a/p19Arf mice
received glycidol at doses of 25, 50, 100, or 200 mg/kg bw in deionised water by gavage at ﬁve times
per week for 40 weeks. The study found ‘clear evidence’ for carcinogenicity of glycidol in males based
Table 34: Neoplasms associated with the 2-year gavage administration of glycidol to F344 rats [incidences (%)]
Site
Males Females
Vehicle
37.5 mg/kg
bw per day
75 mg/kg
bw per day
Vehicle
37.5 mg/kg
bw per day
75 mg/kg
bw per day
Tunica vaginalis/
peritoneum
mesothelioma
3/49 (6) 34/50 (68) 39/47 (83)
Mammary gland
Fibroadenoma
Adenocarcinoma
3/45 (7) 8/39 (21) 7/17 (41) 14/49 (29)
1/50 (2)
32/46 (70)
11/48 (23)
29/44 (66)
16/48 (33)
Brain
Glioma
0/46 (0) 5/50 (10) 6/30 (20) 0/49 4/46 (9) 4/46 (9)
Oral mucosa
Papilloma or carcinoma
1/46 (2) 2/50 (4) 6/32 (19) 0/47 (0) 4/38 (11) 11/30 (37)
Intestine
Adenomatous polyp or
adenocarcinoma
0/47 (0) 1/50 (2) 4/37 (11)
Skin
Sebaceous gland
adenoma, basal cell
tumour, or sebaceous
gland adenocarcinoma
0/45 (0) 5/41 (12) 4/18 (22)
Zymbal gland
Carcinoma
1/49 (2) 3/50 (6) 6/48 (13)
Clitoral gland
Adenoma,
adenocarcinoma, or
carcinoma
5/49 (10) 9/47 (19) 12/45 (27)
Thyroid gland
Follicular cell adenoma
or carcinoma
1/46 (2) 4/42 (10) 6/19 (32) 0/49 (0) 1/38 (3) 3/35 (9)
Haematopoeitic system
Leukaemia
13/49 (27) 14/44 (32) 20/41 (49)
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on signiﬁcantly increased incidences of histiocytic sarcomas and alveolar/bronchiolar adenomas and
‘some evidence’ in females based on the occurrence of alveolar/bronchiolar adenomas.
Reproductive toxicity
Glycidol when administered orally to male rats at 100 or 200 mg/kg bw per day for 5 days or
100 mg/kg bw per day for 14 days produced infertility which was similar to the low dose effect of
3-MCPD (Cooper et al., 1974). The authors suggested that this effect may be related to in vivo
conversion in the stomach of glycidol to 3-MCPD. The appearance of 3-MCPD in the serum of rats after
oral administration of glycidol has recently been conﬁrmed (Onami et al., 2015). Low doses of glycidol
equivalent in molar terms to 5 mg 3-MCPD/kg bw per day and given by i.p. injection reduce sperm
motility although fertility was maintained (Brown-Woodman et al., 1979).
Glycidol in water given by gavage to groups of F344/N rats and B6C3F1 mice of each sex was
studied by the US national toxicology program (NTP, 1990). The glycidol used was 94% pure and
contained 0.4% 3-MCPD. In rats that received 300 mg/kg per day after 16 days there was oedema
and degeneration of the epididymal stroma and atrophy of the testis. Granulomatous inﬂammation of
the epididymis occurred. However, these effects were not reported in mice. A13-week study used
doses for rats ranging from 25 to 400 mg/kg per day, while doses for mice ranged from 19 to 300 mg/kg
bw per day. Sperm count and sperm motility were reduced in rats. The rat lowest observable adverse
effect level (LOAEL) was 25 mg/kg bw per day for epididymal sperm count which was reduced by 36%.
Testicular atrophy and or degeneration occurred in rats that received 200 or 400 mg/kg bw per day.
Table 35: Neoplasms associated with the 2-year gavage administration of glycidol to B6C3F1 mice [incidences (%)]
Site
Males Females
Vehicle
25 mg/kg
bw per day
50 mg/kg
bw per day
Vehicle
25 mg/kg
bw per day
50 mg/kg
bw per day
Harderian gland
Adenoma or
adenocarcinoma
8/46 (17) 12/41 (29) 22/44 (50) 4/46 (9) 11/43 (26) 17/43 (40)
Mammary gland
Adenoma,
ﬁbroadenoma, or
Adenocarcinoma
2/50 (4) 6/50 (12) 15/50 (30)
Forestomach
Squamous cell
papilloma or
carcinoma
1/50 (2) 2/50 (4) 10/50 (20)
Uterus
Carcinoma or
adenocarcinoma
0/50 (0) 3/50 (6) 3/50 (6)
Subcutaneous
tissue
Sarcoma or
ﬁbrosarcoma
0/50 (0) 3/50 (6) 9/50 (18)
Skin
Squamous cell
papilloma or
carcinoma
0/50 (0) 0/50 m (0) 4/50 (8) 0/50 (0) 0/50 (0) 2/50 (4)
Liver
Adenoma or
carcinoma
24/50 (48) 31/50 (62) 35/50 (70)
Lung
Alveolar/
bronchiolar
adenoma or
carcinoma
13/50 (26) 11/50 (22) 21/50 (42)
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In all mice that received glycidol the sperm count and sperm motility were reduced and accompanied by
testicular atrophy. The mouse LOAEL was 75 mg/kg bw per day when the sperm count was 44% of
controls.
Developmental toxicity
No evidence of teratogenicity was demonstrated in a study in which pregnant CD-1 mice received
100, 150, or 200 mg/kg glycidol by gavage during days 6–15 of gestation. The doses were maternally
toxic (Marks et al., 1982). However, when glycidol was injected into the amniotic sac of pregnant
Sprague-Dawley rats on day 13 of gestation there was embryo lethality and induced malformations in
a signiﬁcant number of fetuses (Slott and Hales, 1985). The relevance of this exposure approach is not
clear.
Developmental neurotoxicity of rats to glycidol was further investigated by exposing pregnant
Sprague-Dawley rats via the drinking water to 0, 100, 300, or 1,000 mg glycidol/L from day 6
following appearance of vaginal plug until weaning on postnatal day (PND) 21 (Akane et al., 2013).
These concentrations resulted in maternal doses of 0, 18.5, 48.8, and 108.8 mg glycidol/kg bw per
day. The highest dose of glycidol severely affected gait causing inability to support the body and
spreading of extremities in some animals. These effects where accompanied by axonopathy in both
central and peripheral nervous systems (Akane et al., 2013). There was a dose-dependent reduction in
body weight of male pups of dams exposed to 48.8 and 108.8 mg glycidol/kg bw per day (in females
signiﬁcant only in the high-dose group), but the body weight recovered in pups of dams exposed to
48.8 mg/kg bw per day after the end of the lactation period. The highest dose caused a reversible loss
of immature granule cells in the subgranular zone of the dental gyrus in offspring. The results
suggested abnormalities of late-stage neurogenesis particularly of the hippocampal dentate gyrus
(Akane et al., 2013). Doses of 48.8 and 108.8 mg/kg bw/day given to the dams resulted in an
increase in NeuN- and reelin-positive cells and mature neurons in the dentate hilus of male pups.
These results are indicative of an aberration in the distribution of interneuron subpopulations in the
hilus. No effects were observed in dams or offspring at the lowest dose of 18.5 mg/kg bw per day.
Genotoxicity
In vitro
Glycidol can alkylate DNA directly and form adducts with puriﬁed DNA on incubation in vitro (Segal
et al., 1990). This can result in the induction of genotoxic effects by glycidol.
Bacteria
Glycidol has a mutagenic effect in in vitro test systems with prokaryotes both with and without the
addition of metabolic activation system (Wade et al., 1979; Thompson et al. 1981; NTP, 1990).
Glycidol was tested for its ability to induce gene mutations in bacteria (NTP, 1990). The test
substance, dissolved in water, was tested up to 10,000 lg/plate in a pre-incubation assay in the
following Salmonella Typhimurium strains: TA100, TA1535, TA97 and TA98. Glycidol was a potent
inducer of gene mutations especially in the base pair substitution strains TA100 and TA1535 both with
and without S9-mix from rats and hamsters. It was less potent in the frameshift strain TA97. Weak or
equivocal results were obtained in TA98.
Glycidol and glycidol linoleate were tested in a bacteria reverse mutation test in S. typhimurium
TA98, TA100, TA1535, TA1537 and E. coli WP2uvrA (Ikeda et al., 2012). The test was performed with
and without metabolic activation. Glycidol was dissolved in water and glycidol linoleate in dimethyl
sulphoxide (DMSO). For glycidol no precipitation and no bacterial toxicity was observed in any strain
up to 5,000 lg/plate. Glycidol was a very potent mutagen in the base pair substation strains (TA100,
TA1535) and to a lesser extent to E. coli WP2uvrA, but only weakly mutagenic/non mutagenic in the
frameshift mutation strains TA98 and TA 1537, respectively, both with and without metabolic
activation. For glycidol linoleate precipitation was observed at concentrations > 2,500 lg/plate without
metabolic activation and at 5,000 lg/plate with metabolic activation. Toxicity was observed in all
Salmonella strains especially with metabolic activation. No toxicity was observed in the E. coli strain,
regardless of metabolic activation. Glycidol linoleate induced a concentration-dependent increase in
revertants in TA100 and TA1535 both with and without S9-mix and in WP2uvrA only with metabolic
activation, but it was less potent than glycidol. Glycidol linoleate did not induce mutagenicity in TA98
and TA1537. The test was performed according to OECD TG 471. It was concluded by the study
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authors that the genotoxic response of glycidol linoleate was due to release of glycidol, and not to
genotoxicity of glycidol linoleate itself.
Mammalian cells
Glycidol and glycidol linoleate were tested for the induction of chromosomal aberrations in Chinese
hamster lung cells (CHL/IU) (Ikeda et al., 2012). The test was performed according to OECD TG 473.
Both short-term treatment (with and without S9-mix) and long-term treatment (24 and 48 h without
S9-mix) were performed. Glycidol was dissolved in saline and glycidol linoleate in DMSO. Glycidol was a
very potent inducer of structural chromosomal aberrations without metabolic activation after short-term
treatment and after 24 h continuous treatment, but to a much lesser extent after short-term treatment
with metabolic activation and after 48 h treatment without S9-mix. No numerical chromosomal
aberrations were observed at any concentration or time point analysed. Glycidol linoleate did not induce
structural or numerical chromosomal aberrations either with or without metabolic activation at any time
point analysed. Glycidol linoleate was less toxic to mammalian cells than glycidol.
Glycidol was tested in CHO cells for induction of primary DNA damage in the comet assay. The cells
were exposed for 3 h to 0, 5, 10, 20 and 30 lg glycidol/mL. A positive and concentration-related response
was obtained, with statistical signiﬁcance at the two highest concentrations (El Ramy et al., 2007).
In mouse lymphoma L5178Y/TK cells glycidol was a potent inducer of mutations at low
concentration levels. A clear and concentration related response was observed in the concentration
range 5–40 ng/mL without S9-mix. It was not tested with S9-mix (NTP, 1990).
Glycidol induced Sister Chromatid Exchange (SCE) in CHO cells. Strong positive results were
obtained without S9 in the following concentrations range: 1.11 to 15 lg/mL, at all concentrations
tested. The substance was less potent with S9-mix but tested positive in the following concentration
range: 11.1 to 150 lg/mL at all concentrations tested.
In various mammalian cells, glycidol has induced a wide spectrum of genotoxic effects in vitro
(genetic mutations, chromosomal aberrations, sister chromatid exchanges, unscheduled DNA
synthesis), in most cases both with and without the addition of a metabolic activation system (IARC,
2000; MAK, 2000).
In vivo
In an NTP study (NTP, 1990) the potential of glycidol to induce MN in the bone marrow of B6C3F1
mice was investigated. Glycidol was dissolved in phosphate buffered saline. Based on a preliminary
dose range ﬁnding study the following concentrations: 0, 37.5, 75 and 150 mg/kg bw were
administered by i.p. injection twice at 24 h intervals. The animals were killed 24 h after the last dose.
Two trials were performed. In the ﬁrst experiment a clear, dose-related and statistically signiﬁcant
response was observed (p < 0.001), in the second experiment a less clear but also statistically
signiﬁcant response was observed (0.01 < p < 0.05). Based on these results it is concluded that
glycidol can induce micronucleus in vivo under the test conditions performed in this study.
Glycidol and glycidol linoleate were investigated for the induction of MN in the bone marrow of ICR
mice (Ikeda et al., 2012). The test was performed according to OECD TG 474. Glycidol was dissolved
in water and glycidol linoleate in olive oil. The test substance was administered by gavage in two
doses separated by 24 h. Based on a preliminary dose range ﬁnding study the dose levels for glycidol
were 50, 100 and 200 mg/kg bw and for glycidol linoleate 250, 500 and 1,000 mg/kg bw. For glycidol
linoleate the frequency of micronucleated polychromatic erythrocytes was not different from the
vehicle control in any of the test groups. For glycidol the number of micronucleated polychromatic
erythrocytes was signiﬁcantly increased in the mid-dose group compared to the control group (0.17
compared to 0.06). The frequencies were 0.07 and 0.11 at the low and high dose, respectively. Due to
the lack of dose-response relationship it was concluded that glycidol did not induce MN under the test
conditions performed. No toxicity was observed on the bone marrow measured as the PCE/NCE ratio.
Some publications on the induction of chromosomal aberrations in rodents in vivo report different
results: positive results in Thompson and Gibson (1984), quoted in MAK (2000); negative results in
Thompson and Hiles (1981), quoted in IARC (2000).
In a feeding study with Drosophila melanogaster, glycidol (1,230 mg/L feed) caused sex-linked
recessive lethal mutations and reciprocal translocations in germ cells (NTP, 1990).
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Summary
In both male and female mice that received daily doses of Glycidol in the range 150 – 300 mg/kg
bw per day for 16 days, histopathologic CNS lesions developed including demyelination of neurones in
the medulla and thalamus, and renal tubular cell degeneration was also observed. A higher dose
400 mg/kg bw per day was also associated with neuronal cell death. No renal toxicity was reported in
rats after 16 days of daily treatment up to a lethal dose of 600 mg/kg bw per day but renal tubular
degeneration was seen even at 400 mg/kg bw per day after 13 weeks of treatment. Neurotoxicity was
observed after 28 days daily treatment of rats with 200 mg/kg bw per day which showed progressive
abnormalities of the gait along with lesions of central and peripheral nervous systems. Exposure of
young adult rats to glycidol downregulates genes related to the function of axon and synaptic
transmission in the dentate granule cell layer, cingulate cortex and cerebellar vermis.
Clear evidence for carcinogenicity of glycidol has been reported by the US NTP based on increased
incidences of tumours in both sexes of mice and rats chronically exposed to Glycidol for up to 2 years.
Tumour in rats, exposed to 25–50 mg/kg bw per day, included peri-testicular mesotheliomas;
mammary gland ﬁbroadenomas; brain gliomas; thyroid gland follicular cell adenomas and carcinomas;
forestomach papillomas and carcinomas; intestinal adenomatous polyps and carcinomas; skin
adenomas and adenocarcinomas of the sebaceous gland and basal cell tumours; and leukaemia.
The NTP also evaluated the carcinogenicity of glycidol using a transgenic mouse model
haploinsufﬁcient for tumour suppressor genes Male and female p16Ink4a/p19Arf mice received glycidol
doses up to 200 mg/kg bw, ﬁve times per week for 40 weeks (NTP, 2007). The study found ‘clear
evidence’ for carcinogenicity of glycidol in males based on increased incidences of histiocytic sarcomas
and alveolar/bronchiolar adenomas and ‘some evidence’ in females based on the occurrence of
alveolar/bronchiolar adenomas.
The International Agency for Research on Cancer determined that Glycidol is probably carcinogenic
to humans (Group 2A) and that the carcinogenicity of glycidyl oleate and glycidyl stearate were not
classiﬁable.
When administered to male rats glycidol produces infertility which is similar to that observed with
low doses of 3-MCPD. The authors suggested that this effect may be related to in vivo conversion in
the stomach of glycidol to 3-MCPD. Glycidol, when administered to rats at doses that do not impair
fertility, reduced sperm motility. In rats receiving more prolonged treatment with 300 mg/kg per day
epididymal inﬂammation oedema and degeneration as well as atrophy of the testis develops. Sperm
counts and sperm motility were reduced in rats. The rat lowest observable adverse effect level
(LOAEL) was 25 mg/kg bw per day for epididymal sperm count which was reduced by 36%. Testicular
atrophy and/or degeneration occurred in rats that received 200 or 400 mg/kg bw per day. Similar
effects were seen in mice. The mouse LOAEL was 75 mg/kg bw per day when the sperm count was
44% of controls.
No evidence of teratogenicity was seen in a study in which pregnant mice received up to 100, 150,
or 200 mg/kg bw glycidol during days 6–15 of gestation. The doses were maternally toxic which in
some animals severely affected gait which was accompanied by axonopathy of central and peripheral
neurones. In rat pups exposed throughout pregnancy and weaning to a maternal dose of up to
108.8 mg glycidol/kg bw per day during pregnancy and weaning body weight was reduced and
abnormalities of neurogenesis observed in the brain from 48.8 mg glycidol/kg bw per day.
Glycidol is a strong inducer of gene mutations in bacteria, both with and without metabolic
activation; it mainly induces base pair substitution mutations. In mammalian cells it also induces gene
mutations without S9-mix (it was not tested with S9-mix).
Glycidol is a potent direct acting clastogen in mammalian cells in vitro; it is less potent when S9-mix
is added, indicating a metabolic detoxiﬁcation by rat liver S9 mix.
There are few in vivo studies on glycidol. Only chromosomal aberrations have been investigated
with diverging results. A clear positive result was obtained in mice after i.p. injection. However, in a
more recent oral study in mice negative results were obtained for both glycidol and glycidol linoleate.
The reason for this discrepancy could be that two different exposure routes were used in the two
studies. Glycidol is a highly reactive molecule, and a direct acting mutagen and clastogen. In in vitro
studies it appears to be deactivated, at least to some degree, by liver enzymes. This may explain the
negative result after oral exposure, where lower concentrations may have reached the bone marrow
than after i.p. injection.
Based on consistent evidence of genotoxicity in vitro and some indication that it can be genotoxic
in vivo the overall conclusion is that there is strong evidence that glycidol is a genotoxic compound.
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The glycidol ester (glycidyl linoeate) that has been tested in vitro was found to be less potent than
glycidol. The authors hypothesise that this is due to the incomplete release of glycidol.
3.3.3.6. Glycidyl fatty acid esters
Single dose
No relevant data were identiﬁed.
Repeated dose
In 1958, Walpole evaluated the carcinogenicity of several glycidyl esters, including stearate. Daily
subcutaneous injections of pure glycidyl stearate to rats (550 mg total dose/100 g bw for 41 days) in
peanut oil produced sarcomata at the site of injection after 454–608 days; however, the author
questioned the reliability of the tumour induction model based on vehicle effects and recommended
further study using other methods.
No further relevant information on toxicity of glycidyl esters were identiﬁed.
3.3.4. Observations in humans
3.3.4.1. 3-MCPD, 2-MCPD, Glycidol and their fatty acid esters
No data were identiﬁed.
3.3.5. Biomarkers of exposure/effects
3.3.5.1. Biomarkers of exposure
3-MCPD
Urinary metabolites
Urinary 3-MCPD-metabolites, including MCPD-mercapturate (2,3-dihydroxypropyl mercapturic acid,
DHPMA) and b-chlorolactic acid, are discussed as potential biomarkers of exposure for MCPD fatty acid
esters. Both urinary metabolites (DHPMA and b-chlorolactic acid) are stable compounds and can be
quantiﬁed with high sensitivity (Eckert et al., 2010; Barocelli et al., 2011).
Urinary metabolites of 3-MCPD were investigated as potential biomarkers of 3-MCPD exposure/
availability in the 90-day repeated dose study in rats with oral application of 3-MCPD diester
(dipalmitate) or equimolar doses of 3-MCPD (Barocelli et al., 2011; study considered in section ‘Toxicity
in experimental animals’). Relevant amounts of 3-MCPD mercapturate (DHPMA) as well as free
3-MCPD, but only traces of b-chlorolactic acid and no glucuronidated metabolites, were detected in the
collected (24 h) urine of the test animals. Gender and dose-dependent metabolite excretion were
observed. Furthermore, 3-MCPD diester exposure was associated with urinary excretion rates of both
3-MCPD and 3-MCPD mercapturate were about 20% lower as compared to the same urinary
biomarkers observed after exposure to equimolar doses of 3-MCPD (Barocelli et al., 2011). The
disadvantage of mercapturate (DHPMA) as biomarker is its speciﬁcity: this metabolite may be derived
not only from 3-MCPD but also from glycidol (Jones, 1975; see toxicokinetics, metabolism and
uncertainty sections). Moreover, the relatively high background levels of DHPMA and a strong
correlation with urinary creatinine reported in humans indicate a possible endogenous origin of DHPMA
(Eckert et al., 2011, discussed in the next section).
Protein/DNA adducts
There is no evidence that 3-MCPD or its metabolites could covalently bind to proteins or DNA.
2-MCPD
No data were identiﬁed.
Glycidyl esters
Biomarkers of exposure for glycidyl esters/glycidol include its urinary metabolites
(2,3-dihydroxypropyl mercapturic acid, DHPMA) and its adducts with haemoglobin (Hb). However,
2,3-dihydroxypropyl mercapturic acid is not a speciﬁc biomarker of glycidyl ester exposure, as it was
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also conﬁrmed to be a urinary metabolite of 3-MCPD (as mentioned in the previous section).
Furthermore, 2,3-dihydroxypropyl mercapturic acid has been shown to be the urinary excretion
product of several industrial chemicals (epichlorohydrin and several halogenated propanes or
propanols, Gingell et al., 1985; James et al., 1981; Jones et al., 1974; Weber et al., 1995) which
however do not normally occur environmentally. Eckert et al. (2011) reported comparatively high
background levels of 2,3-dihydroxypropylmercapturic acid in urine of smokers (median levels of
206 lg/g creatinine) and non-smokers (median levels of 217 lg/g creatinine) whose origin is
still unknown. Because the determined 2,3-dihydroxypropylmercapturic acid levels revealed a
very strong correlation with urinary creatinine, the authors supposed a possible endogenous origin of
2,3-dihydroxypropyl mercapturic acid background levels. Which compound may serve as an
endogenous precursor for 2,3-dihydroxypropyl mercapturic acid background levels has not yet been
clariﬁed (Eckert et al., 2011).
Protein/DNA adducts
Due to its electrophilic epoxide structure, glycidol has alkylating properties. It was shown to form
the haemoglobin adduct N-(2,3-dihydroxypropyl)valine (diHOPrVal) which could be quantiﬁed by GCMS
after detachment of the N-terminal valines in haemoglobin via the N-alkyl Erdman method (Hindsø
Landin et al., 1996, 1997). Because of the long lifespan of erythrocytes (120 days) these adducts
accumulate in the human body, making them a very sensitive parameter for human biomonitoring over
this time period. Haemoglobin adducts level in blood enable the estimation of internal exposure as well
as biochemical effects and seems to be better estimates for cancer risk than measuring the genotoxic
substances or their metabolites in human body ﬂuids (Angerer et al., 2007).
The formation of N-(2,3-dihydroxypropyl)valine as an adduct to haemoglobin after in vitro
incubation of haemolysate with glycidol was ﬁrst shown by Hindsø Landin et al. (1996). The same
authors found background levels of diHOPrVal (1–2 pmol/g Hb) in blood of persons without known
exposure and suggested that this background levels could originate from glycidol or related compounds
found in heat-processed foods (Hindsø Landin et al., 1997). Indeed, increased levels of diHOPrVal were
found in Sprague-Dawley rats fed heat-processed (fried) diet (Hindsø Landin et al., 2000).
Appel et al. (2013) monitored the levels of diHOPrVal adducts in blood of rats administered
equimolar doses of glycidyl palmitate or glycidol to address the question of relative bioavailability of
glycidol from glycidol esters in vivo. The extent of N-(2,3-dihydroxypropyl)valine adduct formation was
comparable in groups treated with glycidol or glycidyl palmitater, suggesting a similar bioavailability of
glycidol in both groups. This conclusion was also supported by the similar quantities of urinary
excreted 2,3-dihydroxypropylmercapturic acid (Appel et al., 2013).
Previous biomonitoring studies have shown that humans are continuously exposed to exogenous
(and possibly also endogenous) sources of glycidol or glycidol-like compounds forming N-(2,3-
dihydroxypropyl)valine adducts in blood (Hindsø Landin et al., 1997). Honda et al. (2012) investigated
levels of N-(2,3-dihydroxypropyl)valine adducts in blood of donors who consumed over a 4-month
period a DAG-rich oil, previously reported to contain signiﬁcantly higher levels of GE than regular
cooking oils. While background adducts were measurable in all donors, no signiﬁcant difference was
observed between the DAG oil consumers and non-consumers (Honda et al., 2012).
Recently the same group (Honda et al., 2014) investigated the kinetics of N-(2,3-dihydroxypropyl)
valine formation and its elimination in vitro and in vivo. A linear correlation between glycidol and
N-(2,3-dihydroxypropyl)valine levels at 24 h after oral administration of glycidol (0–75 mg/kg bw) was
observed in rats, indicating that glycidol was rapidly absorbed and bound to haemoglobin in a dose-
dependent manner. Furthermore, a linear decrease in N-(2,3-dihydroxypropyl)valine levels over the
following 40 days was observed, which was also similar to the normal turnover of rat erythrocytes
(60 day half-life), suggesting that the N-(2,3-dihydroxypropyl)valine adduct is chemically stable (Honda
et al., 2014). Further, in vitro kinetic measurements for the reaction of glycidol with N-terminal valine
in rat and human haemoglobin showed a comparable binding kinetics between the species. The
authors concluded that N-(2,3-dihydroxypropyl)valine is a useful biomarker for quantiﬁcation of glycidol
exposure and for risk evaluation (Honda et al., 2014).
3.3.5.2. Biomarkers of effect
3-MCPD
Metabolomic studies of 3-MCPD dipalmitate were carried out based on a 90-day repeated dose study
in male Wistar rats with oral application of 3-MCPD dipalmitate (0, 12.3 and 267 mg/kg bw per day).
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UPLC–MS (ultra-performance liquid chromatography–mass spectrometry) analysis of the urine samples
revealed the differences in metabolic proﬁles between control and treated rats, which were clearly
distinguished by partial least squares-discriminant analysis (PLS-DA, a measure of component change)
of the chromatographic data. Five endogenous metabolites used as biomarkers which had earlier and
signiﬁcant variations have been identiﬁed – xanthurenic acid, phenylacetylglycine, taurine, indoxyl
sulfate and nonanedioic acid. Of these markers, xanthurenic acid and phenylacetylglycine levels were
signiﬁcantly increased and taurine level was signiﬁcantly decreased on the 28th day while nonanedioic
acid and indoxyl sulfate levels were signiﬁcantly increased on the 35th day of treatment. Authors
suggest these metabolites as candidates for the early and sensitive biomarkers in evaluating the effect
of 3-MCPD dipalmitate exposure (Li et al., 2013).
3.3.6. Mode of action
3-MCPD
The kidney and testis were found to be the main target organs for 3-MCPD-induced toxicity in
animal studies. Both speciﬁc toxic effects (renal and testicular toxicity) were associated with oxidative
metabolism of 3-MCPD to b-chlorolactaldehyde and b-chlorolactic acid (Lynch et al., 1998). The
analogous embryological origins of the kidney and the testis – epididymis complex suggest that both
nephropathy and epididymal sperm granuloma formation in the rat could arise by the same (or similar)
mechanism (Jones, 1983).
Mode of action for nephrotoxicity
The inhibition of glycolysis by metabolites associated with the b-chlorolactate pathway was suggested
as possible nephrotoxic mechanism of 3-MCPD. b-Chlorolactaldehyde, produced from 3-MCPD via alcohol
dehydrogenase, has been shown to inhibit glyceraldehyde-3-phosphate dehydrogenase and
triosephosphate isomerase, both enzymes involved in glycolysis (Jones and Porter, 1995). The
impairment of the glycolytic pathway and energy production was supposed to contribute to the kidney
damage. Additionally, the accumulation of oxalic acid (the degradation product of b-chlorolactic acid) in
the kidney was also thought to contribute to the kidney toxicity of 3-MCPD (Jones et al., 1981).
In a recent metabolomics study in rats exposed to 3-MPCD (30 mg/kg bw per day for 40 days)
urine galactosylglycerol was identiﬁed as a possible early biomarker for the effects of 3-MCPD
exposure. The authors suggested that 3-MCPD disrupts the homeostasis of lysosomal b-galactosidase
in kidney and epididymis, leading to decreased hydrolysis of galactosylglycerol to galactose and
glycerol and elevation of galactosylglycerol in the urine (Li et al., 2010).
To study the molecular mechanisms of 3-MCPD fatty acid ester toxicity, a comparative proteomic
analysis was performed based on a 28-day oral toxicity study in male Wistar rats which were treated
with equimolar doses of 3-MCPD (10 mg/kg bw) or 3-MCPD dipalmitate (53 mg/kg bw) and a lower
dose of 3-MCPD dipalmitate (13.3 mg/kg bw). The snap-frozen kidney samples were analysed by
two-dimensional gel electrophoresis-mass spectrometry, and the Ingenuity Pathway Analysis was used
for data evaluation. Both 3-MCPD and 3-MCPD dipalmitate treatments caused an increased expression
of alcohol dehydrogenase in the rat kidney – the enzyme which was previously postulated to be
involved in the metabolic pathway of 3-MCPD to b-chlorolactaldehyde. Moreover, several glycolytic
enzymes (e. g. triosephosphate isomerise, which has been previously been shown to be inhibited by
b-chlorolactaldehyde) were downregulated in the kidney of 3-MCPD and 3-MCPD dipalmitate treated
animals. Among others, isoforms of protein DJ-1 (also known as Parkinson protein 7) and glutathione
S-transferase P (GSTP) were strongly upregulated, indicating responses to oxidative stress and
perturbations of multiple cellular pathways. Patterns of protein deregulation pointed to metabolic shifts
in glucose, amino acid and fatty acid metabolism, which may generally affect energy metabolism.
Further network analysis revealed that in all treatment groups several proteins controlling cell survival
and cell death were deregulated. The results of this study indicate similar toxicity mechanisms (mode
of action) for 3-MCPD and its esters (3-MCPD dipalmitate) and conﬁrmed the previously hypothesised
(Jones et al., 1981) mechanisms of 3-MCPD-induced nephrotoxicity (Sawada et al., 2013).
Mode of action for male fertility inhibition
3-MCPD was shown to inhibit male fertility in several reproductive toxicity studies (Jones, 1983).
When given to rats, 3-MCPD decreased sperm motility and impaired male fertility; alterations in sperm
morphology and epididymal lesions were found. 3-MCPD also reduced fertility in males of several other
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mammalian species including primates. Although the exact molecular mechanisms are unknown, the
inhibition of sperm motility was suggested to be partly due to the inhibition of spermatozoa glycolysis
enzymes by the 3-MPCD metabolites (Jones, 1983).
The activity of all glycolytic enzymes in the epididymal and testicular tissue of rats was reduced
following daily subcutaneous injections of 6.5 mg/kg bw 3-MCPD for 9 days (Kaur and Guraya, 1981a).
The inhibition of glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase and triosephosphate
isomerase by the 3-MCPD metabolite b-chlorolactaldehyde, was suggested as possible mechanism
(Jones and Porter, 1995; Lynch et al., 1998).
Signiﬁcantly decreased levels of RNA and protein were observed in the testis and epididymis of
rats that received 6.5 mg/kg bw 3-MCPD per day for 9 days. These changes were paralleled by
increases in the concentrations of proteinase and ribonuclease, whereas the DNA content was
unchanged (Kaur and Guraya, 1981b). The spermatotoxic effect of 3-MCPD were also suggested to
be mediated by reduction of H+-ATPase expression and subsequent alteration of the pH level in the
cauda epididymis, leading to a disruption of sperm maturation and acquisition of motility (Kwack
et al., 2004). 3-MCPD inhibited progesterone production in R2C rat Leydig cells in a time- and dose-
dependent inhibitory manner. Disruption of progesterone production induced by 3-MCPD was
considered to be potentially related to the inhibition of the cAMP signal transduction cascade (Sun
et al., 2013).
A comparative proteomic analysis, performed based on a 28-day oral toxicity study in male Wistar
rats treated with equimolar doses of 3-MCPD or 3-MCPD dipalmitate (described above in ‘Mode of
action of nephrotoxicity’) revealed a deregulation of several proteins controlling lipid metabolism,
reproductive system disease and cancer in all treatment groups. Also in testis, one isoform of protein
DJ-1 was among the most upregulated proteins in all treatment groups, suggesting a pivotal role of
protein DJ-1 in 3-MCPD-mediated toxicity. Network analysis veriﬁed close relationships between
molecular effects induced by 3-MCPD and its dipalmitate ester. Altogether, the results indicate similar
mode of action for 3-MCPD and its esters (3-MCPD dipalmitate) (Sawada et al., 2015).
Mode of action for neurotoxicity
3-MCPD is considered to cause toxicity in several tissues and spermatozoa through inhibition of
GAPDH and therefore glycolysis with energy depletion as result (Ford and Waites, 1982; Kwack et al.,
2004; Skamarauskas et al., 2007). This mechanism may be involved also in neurons because
cytotoxicity of 3-MCPD in primary mouse neocortical cells was associated with a drop in cellular ATP,
and both decrease in ATP and cell death were ameliorated by addition of pyruvate to the culture
medium (Sheline and Choi, 1998). However, in brains of both rats and mice, toxicity of 3-MPCD is
selective towards glial cells with loss of neurons occurring subsequently to death of astrocytes
(Cavanagh and Nolan, 1993). In brain slices from rats injected i.p. (up to 160 mg/kg bw) there was
only a modest (46%) reduction in GAPDH activity and no drop in pyruvate or lactate concentrations,
indicating limited effect on energy metabolism. Furthermore, brain lesions following 3-MCPD treatment
do not fully map onto areas of glucose utilisation (rats) or cerebral blood ﬂow (mice) with the inferior
colliculi identiﬁed as a particularly susceptible region in rats, suggesting additional effects on other
pathways (Cavanagh et al., 1993). A possible alternative mechanism was identiﬁed in brains of rat
where an i.p. injection caused regionally selective decrease of glutathione reductase and glutathione in
the inferior colliculi (Skamarauskas et al., 2007).
Kim (2008) studied the effects of 3-MCPD on the expression of neuronal nitric oxide synthase
(nNOS) and inducible nitric oxide synthase (iNOS) in male Sprague-Dawley rats by oral
administration on a daily basis for 13 weeks (each group n = 5; 10 or 30 mg/kg bw, control groups
received saline). The authors concluded that the observed effects in the nNOS and iNOS expression
were mediated, at least in part, by disturbances of the nitric oxide signalling pathway and that the
caudal area may be more vulnerable to 3-MCPD than the rostral area of the neocortex and striatum.
It can be speculated that the observed reduction in expression of nNOS and iNOS could be a
compensation for the decrease of glutathione reductase and glutathione observed by others
(Skamarauskas et al., 2007) and, therefore, a reduced capacity to sequester reactive oxygen and
nitrogen species.
Mode of action for carcinogenicity
The ﬁnding of Leydig cell tumours was discussed from a mechanistic point of view by Lynch et al.
(1998). The authors claim that this tumour type has a relatively high spontaneous incidence in F344
rats (Bar, 1992; Gilliland and Key, 1995) resulting in an almost 100% incidence in aging male F344
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rats. This ﬁnding was related to a high density of luteinizing hormone (LH) receptors in F344 Leydig
cells (Prentice and Meikler, 1995). Furthermore, rat Leydig cells bear receptors for the luteinizing
hormone releasing hormone (LHRH) which are not found in human or murine Leydig cells (Clayton and
Huhtaniemi, 1982; Wang et al., 1983). Testicular damage resulting in a loss of testosterone
production, perturbation of metabolic activation of testosterone and/or of androgen receptor binding
can all result in an increased level of LH. In rats LH is a potent activator of Leydig cell proliferation
which can eventually lead to Leydig cell tumours (Prentice and Meikler, 1995). 3-MCPD affects
testicular lipid (Gill and Guraya, 1993) and carbohydrate metabolism in rats and leads to a decline in
testosterone production (Paz et al., 1985), followed by an increase in luteinizing hormone (LH), follicle
stimulating hormone (FSH) and prolactin release (Morris and Jackson, 1978). Thus, it appears that
3-MCPD can induce a compensatory pituitary response which causes Leydig cell tumours.
The human relevance of the rat ﬁndings was also questionable since Leydig cell tumours are rare in
humans and drugs which increase LH levels in human and rodents are known to induce Leydig cell
proliferation and Leydig cell tumours in rats but not in humans (Roberts et al., 1989; B€ar, 1992; Crisp
et al., 1998).
The ﬁnding of an enhanced incidence of mammary tumours in male rats is a rare event, it is not
reported for most carcinogens (Boorman et al., 1990b). In F344 rats bearing Leydig cell tumours,
mammary tumour rates were signiﬁcantly increased. It has been shown that hormones such as
estrogens, progesterone and prolactin which are produced by Leydig cell tumours (Jacobs and Huseby,
1968; Turek and Desjardins, 1979; Amador et al., 1985; Reddy and Rao, 1987; Chatani et al., 1990;
Konishi et al., 1991) act as strong proliferative stimuli in the mammary gland (Neumann, 1991). Thus,
it has been surmised that the ﬁnding of mammary gland tumours in male rats is due to testicular
damage, formation of Leydig cell tumours and an abnormal release of proliferative hormones which act
on the mammary gland (Lynch et al.,1998).
Leydig cell tumours of the testis are rare in both humans and laboratory animals. However, in certain
strains of rat their incidence increases with age so that in animals at the end of chronic toxicological
studies over 1–2 years their prevalence is signiﬁcant reaching 70% in some studies. (Prentice and
Meikler, 1995, Cook, Klinefelter, Hardisty, Sharpe, Foster 1999). This observation has been well
documented in Fischer F355 rats. Leydig cell adenomas are more frequently observed than Leydig cell
carcinomas. The testicular steroid secretion is changed in tumour bearing animals such that serum
testosterone concentrations are reduced while oestradiol concentrations are raised. (Cook, Murray,
Frame, Hurt 1992, Turek, Desjardins, 1979). It is likely that most Leydig cell tumours arise because of a
hormonal disturbance especially involving elevated secretion of pituitary prolactin. The consensus is that
the Leydig cell tumours are rat strain-speciﬁc and may not be relevant to man. In particular, occurrence
of Leydig cell hyperplasia in test species after lifetime exposure to a chemical does not constitute a
cause for concern in a risk assessment for carcinogenic potential for humans (Clegg et al., 1997).
In the present study 3-MCPD was associated with Leydig cell tumours as well as an increased
incidence of mammary gland hyperplasia in male rats. Mammary gland hyperplasia was not
documented in any other studies of 3-MCPD in male animals. The mammary gland in male rodents
does not develop if testicular steroidogenesis is normal. However, exogenous oestrogen is capable of
promoting extensive growth and proliferation of the breast tissue in male animals (Lucas et al., 2008).
It is likely that in the present 3-MCPD study that male rat mammary hyperplasia is a consequence of
the pathologically elevated oestrogen secretion arising from the testis with the Leydig cell adenomas.
The ﬁnding of benign kidney tumours in rats is strongly associated with a progressive tubular
damage and subsequent nephropathy in those animals; kidney tumours can arise on the grounds of a
prolonged nephropathy with local regenerative tissue responses as has been described for the rat
(Montgomery and Seely, 1990; Hard, 1998; Alden and Frith, 1991). Considering the absence of in vivo
genotoxicity of 3-MCPD and the close link with and sequential occurrence of nephropathy and kidney
tumour formation in rats, a non-genotoxic mode of action at nephrotoxic doses appears likely.
2-MCPD
In a rat study 2-MCPD failed to produce kidney damage or diuresis at a dose of 200 mg/kg bw,
whereas its isomer 3-MCPD produced renal failure, enlarged kidneys, and long lasting diuresis after
single dose of 75 mg/kg bw (Jones and Fakhouri, 1979). These differences were explained by the fact
that metabolism of 2-MCPD to b-chlorolactaldehyde and b-chlorolactate cannot occur, which is believed
to play an important role in nephrotoxicity of 3-MCPD (Lynch et al., 1998).
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The subchronic toxicity of 2-MCPD (see Section 3.3.2.) has been described in a repeated dose
28-day oral protocol in young adult male and female Sprague-Dawley rats (Perrin et al., 1994). The
authors suggest that the adverse effects observed are due to oxidative stress.
The underlying mechanisms for renal toxicity and the destruction of striated muscles, including the
heart, are unknown.
Glycidol
Glycidol reacts readily with cellular glutathione and conjugation with glutathione seems to be the
major detoxiﬁcation route of glycidol) as shown in vivo (NTP, 1990; refer to section ‘Metabolism’). In
rat, a signiﬁcant decrease in hepatic glutathione content (glutathione depletion) was observed
following exposure to glycidol by gavage (single dose, 168 mg/kg bw) (Montaldo et al., 1984; cited by
IARC, 2000).
Onami et al. (2015) detected higher levels of 3-MCPD than glycidol in serum after dosing rats with
glycidol, suggesting that some of the toxicity of glycidol may be due to its partial conversion to
3-MCPD in vivo.
Glycidol and its esters, from which the free compound can be derived, possess a reactive epoxide
moiety, which is likely to be responsible for the genotoxic activity of the compound without a
requirement for metabolic activation (IARC, 2000). (see the respective section ‘Genotoxicity’ under
3.3.2.5.). Glycidol induces tumours in numerous organs in both sexes of F344 rats and B6C3F1 mice.
Furthermore, the tumours produced by glycidol in rats and mice (e.g. peri-testicular mesothelioma,
mammary gland, brain, thyroid in rats; Harderian gland, lung, mammary gland in mice) are similar to
those produced by other low molecular weight epoxide (or epoxide-forming) carcinogens, including
ethylene oxide, glycidamide, and acrylamide (Melnick, 2002; EFSA, 2015).
3.4. Identiﬁcation of critical effect and dose–response assessment
3-MCPD
In long-term studies, 3-MCPD causes progressive nephrotoxicity (characterised by tubular
hyperplasia, adenoma and carcinoma), testicular toxicity (atrophy and arteritis), mammary glandular
hyperplasia in male rats and nephrotoxicity in female rats. Related to these effects, benign tumours of
the testes (Leydig cells tumours), mammary gland (ﬁbroadenoma) and kidney (tubular adenoma) were
found to develop.
Leydig cell tumours are a rat strain speciﬁc consequence of testis toxicity and probably not relevant
to man (see Section 3.3.5 Mode of action). The Leydig cell tumours observed in the two above
mentioned studies were therefore not considered further. The CONTAM Panel concluded that it is likely
that in the study on 3-MCPD by Sunahara et al. (1993) the male rat mammary hyperplasia is a
consequence of the pathologically elevated oestrogen secretion arising from the testis with the Leydig
cell adenomas. Consequently it was seen as inappropriate to use mammary gland tumours in the study
by Sunahara et al. (1993) for human risk assessment.
The CONTAM Panel applied the BMD analysis to the results obtained in two long-term exposure
studies where rats received 3-MCPD via drinking water. In the ﬁrst study (Sunahara et al., 1993;
described in Section 3.3.2.), Fisher 344 rats were exposed to nominal concentrations of 0, 2, 50 or
100 mg/L. However, in order to derive the dose levels, the CONTAM Panel corrected the nominal
concentrations considering the background concentration of 2.7 mg 3-MCPD/L reported in drinking
water used as vehicle. The corrected doses, applying the same dose-speciﬁc conversion factors applied
by the authors of the study resulted in the following estimated average daily doses (for nominal
concentrations of 0, 2, 50 or 100 mg/L, respectively):
Males: 0.15, 1.3, 5.5 or 29 mg/kg bw per day
Females: 0.19, 1.6, 7.4 or 36 mg/kg bw per day
Cho et al. (2008a) exposed Sprague-Dawley rats to concentrations of 0, 25, 100 or 400 mg/L,
converted by the authors to average daily doses of 0, 2.0, 8.3 or 29.5 mg/kg bw per day, and 0, 2.7,
10.3 or 37.0 mg/kg bw per day for male and female rats, respectively.
In both studies kidney and testes resulted as the key target organs for 3-MCPD. Pre-neoplastic
and neoplastic effects on male mammary glands were also observed in the Sunahara et al. (1993)
study.
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The results related to kidney and testis toxicity of both studies were initially screened by visual
analysis for the presence of monotonic dose–response trends; the presence of a dose-response trend
in the subset of results selected in the screening phase was subsequently conﬁrmed by applying the
Cochran-Armitage trend test (Haseman, 1984). The effects showing a monotonic dose-response trend
were selected for BMD analysis. The full details of the BMD analyses are reported in Appendix C and D
for the Sunahara et al. (1993) and Cho et al. (2008a) studies, respectively.
In the analysis of the Sunahara et al. (1993) study results, a lowest BMDL10 of 0.10 mg/kg bw per
day was calculated for the increased incidence of nephropathy in male rats (see Appendix C). In the
Cho et al. (2008a) study, a lowest BMDL10 of 0.077 mg/kg bw per day resulted from the analysis of
the incidence of tubular hyperplasia in male rats (see Appendix D).
3-MCPD fatty acid esters
In a subchronic gavage study with 3-MCPD vs 3-MCPD dipalmitate (Barocelli et al., 2011), it was
found that certain toxic endpoints were more sensitive towards the parent compound than towards the
diester (red blood cell loss, mortality), whereas others (kidney, testis, protein urea) exhibited similar
sensitivities on a molar basis. Furthermore, a toxicokinetic comparison of 3-MCPD and its dipalmitate
ester showed similar oral bioavailability, based on AUCs. Taken together, these ﬁndings led the
CONTAM Panel to conclude that the toxicity of 3-MCPD fatty acid esters should be considered
equivalent (on a molar basis) to that of the parent compound and no dose-response modelling for the
3-MCPD fatty acid esters was needed.
Glycidol
Glycidol is genotoxic and carcinogenic and carcinogenicity was seen as the critical effect of glycidol.
The results of the 2 year NTP (1990) study on glycidol were considered for the dose–response
assessment. In this study, rats and mice were exposed by gavage to 0, 37.5 or 75 mg glycidol/kg bw
per day, and to 0, 25 or 50 mg/kg bw per day, respectively. Both in rats and mice glycidol dose
dependently increased the incidence of tumours in different tissues.
As only two dose levels were administered in the study, the CONTAM Panel did not consider the
data suitable for BMD modelling. As such, the EFSA Guidance (2009) was followed and a T25
approach (25% increase in incidence of a speciﬁc tumour above background incidence in the lifespan
of the species) was used. The CONTAM Panel noted that the lowest T25 was 14.2 mg/kg bw per day
for the incidence of peritoneal mesothelioma in male rats (Appendix F).
As the animals in these studies were dosed on 5 out of 7 days per week, the Contam
Panel considered that with dosing 7 days per week the tumour incidence would have been greater.
The T25 was therefore adjusted by multiplying by 5/7 (0.71) to compensate for the lower cumulative
administered dose (Benford et al., 2010), giving an estimated T25 of 10.2 mg/kg bw per day for
peritoneal mesothelioma. Table 36 gives the T25 values adjusted for dosing duration for the various
tumour incidences in rats and mice.
Table 36: T25 values for tumour incidences (calculated from 2 year NTP study on glycidol, 1990) in
rats and mice. The T25 values are adjusted for dosing duration
T25 mg/kg bw per day
Male rats
Peritoneal mesothelioma 10.2
Female rats
Mammary gland ﬁbroadenoma 11.7
Male mice
Harderian gland adenoma 22.6
Female mice
Harderian gland adenoma 24.1
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3.4.1. Derivation of health-based guidance values
3-MCPD and 3-MCPD fatty acid esters
The CONTAM Panel considered that the intact 3-MCPD fatty acid esters are not responsible for the
relevant adverse effects, which are due to the release of free 3-MCPD upon ingestion. There is only
one long-term study with a 3-MCPD fatty acid ester (dipalmitate) in rodents. In this subchronic gavage
study with 3-MCPD vs 3-MCPD dipalmitate (Barocelli et al., 2011), it was found that certain toxic
endpoints were more sensitive towards the parent compound than towards the diester (red blood cell
loss, mortality), whereas others (kidney, testis, protein urea) exhibited similar sensitivities on a molar
basis (Table 37 and Appendix E). Furthermore, a toxicokinetic comparison of 3-MCPD and its
dipalmitate ester showed similar oral bioavailability, based on AUCs. Taken together, these ﬁndings led
the CONTAM Panel to conclude that the toxicity of 3-MCPD fatty acid esters should be considered
equivalent (on a molar basis) to that of the parent compound.
Non-neoplastic and neoplastic effects
The CONTAM Panel evaluated the risks of non-neoplastic and neoplastic effects. These were
combined since the analysis of mode of action of 3-MCPD in rats revealed that it acts as a nephrotoxic
agent but lacks convincing evidence for a genotoxic mode of action in vivo. Thus, renal hyperplasia
was identiﬁed as the most sensitive non-neoplastic effect that might also lead to cancer by a
non-genotoxic mode of action. Sustained hyperplasia, is recognised as such a mode of action
(Wilkinson and Killeen, 1996). A BMDL10 value of 0.077 mg/kg bw per day derived from the 3-MCPD-
induced renal tubular hyperplasia in male rats was selected as the reference point. This lesion is
considered as both the most sensitive and highly indicative since renal toxicity has been observed in
rats of both sexes in several independent studies.
For the protection of human health from neoplastic and adverse non-neoplastic effects of 3-MCPD,
the CONTAM Panel applied an overall uncertainty factor of 100 to the selected reference point (77 lg/kg
bw per day) to account for intraspecies and interspecies differences and derived a rounded group TDI of
0.8 lg/kg bw per day. The CONTAM Panel concluded that the TDI of 0.8 lg/kg bw per day constitutes a
group TDI for 3-MCPD and its fatty acid esters (expressed as MCPD equivalents).
2-MCPD and 2-MCPD fatty acid esters
The data on 2-MCPD toxicity are limited to a single study, a 24 h dose ranging protocol informing a
28-day repeated dose study. Cardiac and renal toxicity were observed. In the absence of a long-term
study from which the toxicological proﬁle and the mode of action could be ﬁrmly established, the
CONTAM Panel concluded that the available data were insufﬁcient to derive a HBGV for 2-MCPD and
2-MCPD fatty acid esters.
Glycidol and glycidyl esters
The CONTAM Panel only considered toxicity studies in animals with glycidol since no relevant in vivo
data were identiﬁed for glycidyl esters. The dose-response considerations were made for glycidol
based on the likely complete release of the parent compound after ingestion.
Table 37: BMDL10 and BMD10 (lmol/kg bw per day) calculated for various non-carcinogenic
toxicological endpoints (adapted from Barocelli et al., 2011)
3-MCPD lmol/kg bw per
day
3-MCPD dipalmitate
lmol/kg bw per day
BMDL10 BMD10 BMDL10 BMD10
Kidney female (degenerative tubule changes) 6.1 13.3
Kidney male (degenerative tubule changes) 22.6 50.7 29.4 69.4
Testis 54.3 76.0 74.8 108.7
Proteinuria male 24.4 57.9 31.6 79.4
RBC 5% loss male 31.7 65.1 41.9 90.3
RBC 5% loss female 23.5 40.7 152.6 315.7
Mortality female 20.8 66.9 < 270 < 270
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There is evidence that the mode of action of glycidol as a carcinogen is mainly due to its
electrophilic properties which enable the compound to bind covalently to DNA and cause genotoxic
effects. The CONTAM Panel considered the dose-response data inadequate for BMD modelling. In
agreement with the EFSA Guidance with respect to substances that are genotoxic and carcinogenic,
T25 values were calculated for the incidence of tumours observed in rats and mice following long-term
exposure to glycidol. The lowest T25 of 10 mg/kg bw per day for peritoneal mesothelioma in male rats
was used as the reference point (EFSA, 2005).
3.5. Risk characterisation
3-MCPD and 3-MCPD fatty acid esters
The exposure to 3-MCPD including 3-MCPD from fatty acid esters (described in Section 3.2.4,
Tables 21 and 22) showed little difference between LB and UB estimates, and the risk characterisation
is therefore based on MB estimates of exposure.
In ‘Infants’, ‘Toddlers’ and ‘Other children’ the median across dietary surveys of the mean MB
exposure was 0.7 to 0.9 lg/kg bw and the maximum MB ranged up to 1.5 lg/kg bw, indicating that in
more than half of the dietary surveys for these age groups the exposure was at or above the group
TDI of 0.8 lg/kg bw. The mean exposure to 3-MCPD including 3-MCPD from fatty acid esters
(described in Section 3.2.4, Table 21) was below the group TDI in ‘Adolescents’, ‘Adults’ and older
population groups.
The median across dietary surveys of MB high exposure estimate (P95) for ‘Infants’, ‘Toddlers’
‘Other children’ ranged from 1.4 to 1.7 lg/kg bw per day (shown in Table 22). All these levels were
above the TDI. For ‘Adolescents’, the median across dietary surveys was 0.9, ranging from 0.5 to
1.3 lg/kg bw per day. This indicates that in more than half of the dietary surveys 5% of the
‘Adolescents’ had an exposure to 3-MCPD above the TDI. For ‘Adults’, ‘Elderly’ and ‘Very elderly’ the
high exposure estimate across all dietary surveys ranges from 0.3 to 0.9 lg/kg bw. These values are
below or only slightly above the group TDI.
The estimated exposure to 3-MCPD of infants receiving formula only (described in Table 27) was
2.4 lg/kg bw per day using mean occurrence level and 3.2 lg/kg bw per day using P95 of
occurrence; both values are above the group TDI, which is exceeded up to fourfold.
Estimated exposure substantially exceeding the group TDI is of concern, this is particularly seen in
the younger age groups.
2-MCPD and 2-MCPD fatty acid esters
The exposure data in Tables 23 and 24 indicate that 2-MCPD exposure is highest in the younger
age groups (‘Infants’, ‘Toddlers’ and ‘Other children’). Although the exposure data are available, the
CONTAM Panel considered that the toxicological information on 2-MCPD and 2-MCPD fatty acid esters
is insufﬁcient for risk characterisation.
Glycidol and glycidyl esters
The CONTAM Panel concluded that it is not appropriate to establish a TDI for glycidol since it has
genotoxic and carcinogenic potential. Therefore the MoE approach was chosen to characterise the risk.
The CONTAM Panel followed the EFSA Guidance on risk assessment approach for substances that are
genotoxic and carcinogenic (EFSA, 2005) stating that where the data are unsuitable for deriving a
BMD, the T25, representing the dose corresponding to a 25% incidence of tumours, may be used. As
such the reference point (T25) derived for glycidol (in Section 3.4.1) was 10.2 mg/kg bw per day.
From this, MoE estimates are calculated by dividing the reference point T25 (converted to the same
unit as the exposure i.e. lg/kg bw per day) by the exposure levels.
According to the aforementioned EFSA Guidance (EFSA, 2005) ‘an MoE of an order of magnitude of
10,000 or higher would not be considered of low health concern under circumstances where there
were greater uncertainties, for example if the MoE was calculated using a T25, or if the reference
point were based on a poor animal database’. The T25 approach is inherently less conservative than
BMDL10 modelling, in that the former considers a level of tumour incidence of 25% and the latter
10%. When the reference point is based upon T25 data it is considered that the MoE should be 2.5
times higher than an MoE based upon BMDL10 data, i.e. 25,000 (Dybing et al., 2008). Based on this
consideration, the CONTAM Panel concluded that an MoE of 25,000 or larger would be of low health
concern.
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The MoEs derived from the exposure estimates across dietary surveys for the mean and high
exposure (P95) to glycidol from esters across different population groups (Tables 25 and 26) are
shown in Table 38. Considering the low range between exposure estimates based on LB and UB
occurrence, the Panel considered the MOEs corresponding to MB occurrence. The complete table of
MoEs across dietary surveys, based on LB, MB and UB occurrence data is shown in the
Appendix (Table B.8).
For all age groups the MoE estimates revealed that the 95th percentile of exposure was below
25,000 in at least half of the dietary surveys; moreover, the MoEs for the age classes of ‘Infants’,
‘Toddlers’ and ‘Other children’ were below 25,000 in all dietary surveys. For ‘Infants’, ‘Toddlers and
‘Other childrens’ also the MoEs for the mean exposure were below 25,000 in more than half of the
dietary surveys.
In the case of ‘Infants’, a scenario was calculated for infants receiving only formula (Table 29),
giving a MoE of 5,400 for the mean exposure based on MB occurrence and of 2,100 for the P95 of
occurrence (Table 39). Although the period of exclusive formula consumption is relatively short
(compared to lifetime exposure), it is during a critical developmental phase assumed to be particularly
sensitive to carcinogens that are genotoxic (see e.g. US EPA, 2005a,b).
Table 38: Margins of exposure (MOEs) calculated for glycidol; the table presents the MoEs for
exposure across dietary surveys based on middle bound occurrence for both, mean and
P95 of exposure
MoE range across dietary surveys (using middle bound occurrence)(a)
Min Median Max
Mean exposure
Infants 25,500 14,600 12,800
Toddlers 25,500 17,000 11,300
Other children 34,000 17,000 11,300
Adolescents 51,000 34,000 20,400
Adults 51,000 51,000 34,000
Elderly 102,000 51,000 34,000
Very elderly 102,000 51,000 34,000
P95 of exposure
Infants 8,500 7,800 4,900
Toddlers 10,200 9,300 5,100
Other children 12,800 9,300 6,000
Adolescents 25,500 17,000 9,300
Adults 34,000 20,400 17,000
Elderly 51,000 20,400 17,000
Very elderly 51,000 20,400 14,600
bw: body weight; min: minimum across dietary surveys using middle-bound occurrence; median: median across dietary surveys
using middle-bound occurrence; max: maximum across dietary surveys using middle-bound occurrence.
(a): The minimum, median and maximum exposures are shown.
Table 39: Margins of exposure (MoEs) calculated for glycidol exposure in the scenarios on infants
receiving only formula
MoE based on exposure
scenario MB (LB–UB)(a)
Infants (receiving only formula) – scenario
based on mean occurrence
5,400 (5,700–4,900)
Infants (receiving only formula) – scenario
based on P95 of occurrence
2,100
(a): The table presents the values corresponding to LB, MB and UB occurrence levels in the form MB (LB–UB). When LB and UB
values were coincident, only one value was reported. The T25 of 10.2 mg/kg bw per day for peritoneal mesothelioma was
used as point of departure
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Although there is a high uncertainty in the reference point used as a basis for the calculation of the
MoEs for glycidol, the MoEs lower than 25,000 indicate a health concern.
3.6. Uncertainty analysis
The evaluation of the inherent uncertainties in the assessment of dietary exposure to 3- and
2-MCPD and glycidol has been performed following the guidance of the Opinion of the Scientiﬁc
Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, 2006; EFSA, 2009b). In
addition, the report on ‘Characterising and Communicating Uncertainty in Exposure Assessment’ has
been considered (WHO/IPCS, 2008). According to the guidance provided by the EFSA opinion (2006),
the following sources of uncertainties have been considered: assessment objectives, exposure
scenario, exposure model, and model input (parameters).
3.6.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.6.2. Exposure scenario/Exposure model
A total of 7,175 occurrence values were available to estimate dietary exposure to 3- and 2-MCPD
and glycidol, of which 702 were on free 3-MCPD in soy sauce, HVP and related products, 4,754 were
on 3- and 2-MCPD or glycidol from esters in fats and oils and 1,719 were on 3- and 2-MCPD or glycidol
from esters in other food. The data on fats and oils were mostly submitted by associations of food
business operators while those on food other than fats and oils were produced in speciﬁc studies with
a limited number of samples.
The food surveys used to provide the occurrence data were mostly targeted at particular food
groups that were expected to potentially contain free MCPD or MCPD and glycidol fatty acid esters.
Although most of the data were randomly sampled inside the respective food group and none of
them were data from targeted samples, the representativeness of the entire EU market is not clearly
known and might be weak in the case of food groups with small numbers of samples. The levels of
free glycidol in the food samples analysed are unknown; this may lead to underestimation of
exposure.
The data set on free 3-MCPD in soy sauce, HVP and related products does not include the potential
contribution of 3-MCPD released from the esteriﬁed form; this may lead to underestimation of 3-MCPD
occurrence in these food groups. The data set on fats and oils does not include the potential
contribution from 3- and 2-MCPD in free form; however, the proportion of 3- and 2-MCPD in free form
in fats and oils is expected to be minimal with respect to the esteriﬁed forms, therefore the potential
underestimation of exposure would also be minimal.
The occurrence data on infant formulae and those on 26 out of 28 samples of ‘fried or baked ﬁsh’
do not include the potential contribution from free 3- and 2-MCPD; this may lead to underestimation of
the occurrence of 3- and 2-MCPD in these food groups.
The use of occurrence data on fried or baked ﬁsh to calculate the exposure related to the
consumption of all ﬁsh may overestimate the exposure contribution of this food group. Similarly,
overestimation of the exposure contribution is possible for meat (where occurrence values for fried or
roast meat were used) and charcuterie products (where occurrence values for smoked meat were
used). Data were missing for different food groups where some detectable content of 3- and 2-MCPD
and glycidol would be expected. In some cases (e.g. oil-based sauces and condiments) the information
available allowed an exposure to be modelled based on the occurrence in fats and oils; in other cases
(e.g. ice cream or chocolate) it was not possible to model the exposure; only the food groups where
an occurrence value was available or could be modelled were included in the exposure scenarios.
Using available data to model the occurrence in food groups where measured data were not available
is a source of uncertainty.
While occurrence data from a relatively recent period were used, current industry action to mitigate
the formation of 3- and 2-MCPD fatty acid esters and glycidol fatty acid esters during oil reﬁning might
have led to a recent reduction in their levels in certain oils, leading to an overestimate of the exposure.
Consumption data for ‘Infants’ were available only from a limited number of dietary surveys; the
model used for infants receiving only formula was based on assumptions. In both cases, over- or
underestimation of exposure is possible.
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3.6.3. Other uncertainties
The experimental data for the toxicology and toxicokinetics of 3- and 2-monochloropropanediol
(MCPD), and their fatty acid esters, and GE in food has been generated in experimental animals and
its relevance to humans remains uncertain.
The optical isomers of 3-MCPD differ in their toxicity. In the occurrence data provided there is no
information on the isomeric composition of the free 3-MCPD or the 3-MCPD fatty acid esters.
Absorption rates and rates of hydrolysis of 3- and 2-MCPD fatty acid esters and glycidol fatty acid
esters might vary with different fatty acids or between 3- and 2-MCPD mono- and diesters. There is a
lack on toxicity data on 2-MCPD. The mode and mechanism of action of 2-MCPD is unknown.
Based on lower bioavailability of glycidol in monkeys, relative to rats, following controlled oral dosing
with either glycidol or an esteriﬁed form, the rate and extent of hydrolysis of esteriﬁed forms of MCPD and
glycidol by humans could be less than quantitative, as conservatively assumed in this Opinion.
Conversion of glycidol to 3-MCPD in vivo has been observed; however, the extent of conversion is
unknown.
The data set used to derive a point of departure for glycidol carcinogenicity was deemed unsuitable for
BMDL10 modelling (control and two glycidol doses only). The T25 approach implemented as an alternative
does not include an estimate of variability, which introduces an uncertainty because differences in sensitivity
between individuals were not considered. Also, the T25 was extrapolated from the lowest dose (37.5 mg/kg
body weight), which resulted in a 62% tumour incidence. Thus, it can only be stated with reasonable
certainty that the dose resulting in a mean tumour incidence of 25% is < 37.5 mg/kg body weight, a dose
fourfold greater than the calculated point of departure of 10 mg/kg body weight.
In addition, the rats in this study were dosed with glycidol on 5 out of the 7 days per week. To
reﬂect this the resulting T25 (14.2 mg/kg body weight) was multiplied by 5/7, giving a point of
departure of 10.2 mg/kg body weight. It is uncertain if this calculation reﬂects the toxicokinetics of
dosing 7 days per week.
The possible contribution to toxicities associated with 3-MCPD and its esters from co-exposure to
glycidyl esters in the diet, based on in vivo conversion of glycidol to 3-MCPD, cannot be quantiﬁed at
this time.
3.6.4. Summary of uncertainties
In Table 40, a summary of the uncertainty evaluation for 3- and 2-MCPD and glycidol is presented
which highlights the main sources of uncertainty and indicates an estimate of whether the respective
source of uncertainty might have led to an over- or underestimation of the exposure or the resulting risk.
Table 40: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of the dietary exposure to 3- and 2-MCPD and glycidol
Sources of uncertainty Direction(a)
Data from few sources and from a limited number of samples +/
For some food groups not represented in the analytical data set occurrence data were
imputed using a model
+/
Missing occurrence data on some food groups 
Data on only one form (free or ester-bound) of 3- or 2-MCPD in samples that may
contain both forms

Unknown levels of free glycidol in food 
Use of occurrence data from a speciﬁc food group for a broader food group +/
Consumption data from few dietary surveys +/
Extent of hydrolysis of esteriﬁed forms of MCPD and glycidol in human GI tract +
Extrapolation from animal data for human risk assessment +/
Conversion of glycidol to 3-MCPD may occur +/
Lack of long-term toxicity data on 2-MCPD 
T25 approach has intrinsic uncertainties +/
Adjusting data to reﬂect dosing regime (5/7) +/
(a): +: uncertainty with potential to cause over-estimation of exposure/risk; : uncertainty with potential to cause under-
estimation of exposure/risk.
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Overall, the CONTAM Panel concluded that the impact of the uncertainties on the risk assessment is
high. The exposure assessment most likely underestimates the exposure.
4. Conclusions
4.1. Background
• 3-monochloropropane-1,2-diol (MCPD)- and 2-monochloropropane-1,3-diol (2-MCPD) and their
esters and glycidyl esters are food contaminants found at highest levels in reﬁned vegetable oils.
• 3- and 2-MCPD esters and glycidol esters are hydrolysed to their respective free forms in the
GASTROINTESTINAL (GI) tract.
4.2. Formation
• 3- and 2-MCPD and their esters are formed during the hydrochloric acid hydrolysis of cereal
materials, by reaction of the acid with lipids. They are also formed during high temperature
food processing operations such as the baking of low-moisture cereal based foods.
• Glycidyl esters, along with 3- and 2-MCPD esters are formed during the deodorisation step of
edible oil reﬁning, from the reaction of chloride present naturally in the oil.
• Glycidyl esters and 3- and 2-MCPD esters are mainly formed from the reaction of diacylglycerol (DAG)
with chloride.
4.3. Analysis
• Free 3- and 2-MCPD are determined by validated methods based on extraction, derivatisation,
and gas chromatography-mass spectrometry.
• 3- and 2-MCPD and glycidol bound as fatty acid esters are determined by the methods used
for the free compounds after chemical cleavage of the ester bonds. The methods have been
validated for oils and food samples.
4.4. Occurrence data
• Three categories of analytical data were considered, one on 3-MCPD (in free form) in soy
sauce, hydrolysed vegetable protein (HVP) and related products; another on 3- and 2-MCPD
from esters and glycidol from esters in oils/fats; and a third one on 3- and 2-MCPD (free and
from esters) and glycidol (from esters) in food groups other than those mentioned above. In
the third category, in most cases the contribution to the total 3- and 2-MCPD from the free
form was included, while the results on glycidol were only from esters.
• Occurrence was estimated using 7,175 analytical results, more than half of which were derived
from oils and fats.
• Palm oils and fats had the highest mean middle bound (MB) levels of 3-MCPD bound as esters
(2,912 lg/kg), 2-MCPD bound as esters (1,565 lg/kg) and glycidol bound as esters (3,955 lg/kg).
• Levels in other oils had lower mean MB levels, ranging from 48 to 608 lg/kg for 3-MCPD from
esters, from 86 to 270 lg/kg for 2-MCPD from esters and from 15 to 650 lg/kg for glycidol
from esters. Levels of ester-bound 3- and 2-MCPD and glycidol in margarines and related fats
were in a similar range.
• In other food groups the highest mean MB levels were in ‘Potato crisps’, ‘Hot surface cooked
pastries’, ‘Shortcrusts’ and ‘Cookies’. In these products total 3-MCPD ranged from 154 to
247 lg/kg, total 2-MCPD ranged from 79 to 135 lg/kg, whereas glycidol from esters ranged
from 110 to 149 lg/kg.
4.5. Chronic exposure assessment
• The exposure to 3- and 2-MCPD was based upon the level of exposure to the parent
compounds regardless of their original form (i.e. as free or as ester of fatty acids), and
referred to as 3-MCPD and 2-MCPD. Likewise, exposure to glycidol refers to the parent
compound, but in this case the original form was exclusively as fatty acid esters.
• The mean exposure to 3-MCPD was 0.5 to 1.5 lg/kg bw per day (MB) across the dietary
surveys for the age groups ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure (P95) to
3-MCPD was 1.1 to 2.6 lg/kg bw per day (MB) across dietary surveys in these age groups.
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• In adolescents and adult population groups (adults, elderly, very elderly) the mean exposure to
3-MCPD ranged from 0.2 to 0.7 lg/kg bw per day (MB) and the high exposure (P95) ranged
from 0.3 to 1.3 lg/kg bw per day (MB).
• The mean 2-MCPD exposure across dietary surveys ranged from 0.2 to 0.7 lg/kg bw per day
(MB), for ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure (P95) to 2-MCPD was
0.5 to 1.2 lg/kg bw per day (MB) across dietary surveys in these age groups.
• In adolescents and adult population groups (adults, elderly, very elderly) the mean exposure to
2-MCPD ranged from 0.1 to 0.3 lg/kg bw per day (MB) and the high exposure (P95) ranged
from 0.2 to 0.6 lg/kg bw per day (MB).
• The mean exposure to glycidol was 0.3 to 0.9 lg/kg bw per day (MB) across the dietary
surveys for the age groups ‘Infants’, ‘Toddlers’ and ‘Other children’. The high exposure
(P95) to glycidol was 0.8 to 2.1 lg/kg bw per day (MB) across dietary surveys in these age
groups.
• In adolescents and adult population groups (adults, elderly, very elderly) the mean exposure to
glycidol ranged from 0.1 to 0.5 lg/kg bw per day (MB). The high exposure (P95) in
‘Adolescents’ ranged from 0.4 to 1.1 lg/kg bw per day (MB) and in adults and older population
groups ranged from 0.2 to 0.7 lg/kg bw per day (MB).
• Scenarios of exposure in infants receiving formula only, based on mean consumption and mean
occurrence in the formula, resulted in daily intake of 2.4 lg/kg bw for 3-MCPD, 1.0 lg/kg bw
for 2-MCPD and 1.9 lg/kg bw for glycidol. Using P95 occurrence data resulted in daily intake
of 3.2 lg/kg bw for 3-MCPD, 1.6 lg/kg bw for 2-MCPD and 4.9 lg/kg bw for glycidol.
• For ‘Infants’ the food groups ‘Infant and follow-on formulae’, ‘Vegetable fats and oils’ and
‘Cookies’ were the major contributors to 3- and 2-MCPD and glycidol exposure.
• For ‘Toddlers’ the food groups ‘Vegetable fats and oils’, ‘Cookies’ and ‘Pastries and cakes’ were
the major contributors to 3- and 2-MCPD and glycidol exposure. ‘Infant formula’ and follow-on
formula’ were also important contributors to 3- and 2-MCPD exposure.
• For ‘Other children’ the food groups with highest contribution to exposure to 3- and 2-MCPD
and glycidol were ‘Pastries and cakes’, ‘Margarine and similar’ and ‘Cookies’. For glycidol, an
additional relevant contributor was ‘Fried or roast meat’. ‘Vegetable fats and oils’ also
contributed to 3- and 2-MCPD, and glycidol exposure.
• For ‘Adolescents’, ‘Adults’, ‘Elderly’ and ‘Very elderly’ the major sources of 3- and 2-MCPD and
glycidol were ‘Margarine and similar’ and ‘Pastries and cakes’. Additionally, ‘Fried or baked
potato products’ were important contributors to 3- and 2-MCPD exposure while ‘Fried or roast
meat’ and in some cases ‘Chocolate spreads and similar’ were important contributors to
glycidol exposure.
4.6. Hazard identiﬁcation and characterisation
4.6.1. Toxicokinetics
• There is no available information on toxicokinetics in humans, the information below is from
studies in experimental animals.
3-MCPD and 3-MCPD fatty acid esters
• 3-MCPD and its dipalmitate fatty acid esters are rapidly and efﬁciently absorbed into the
systemic circulation following ingestion, with extensive pre-systemic de-esteriﬁcation occurring
in the GI tract.
• 3-MCPD is extensively metabolised with less than 5% appearing in the urine and faeces as the
parent compound. The majority of 3-MCPD is eliminated from serum within a few hours of
dosing with either the parent compound or its dipalmitate ester.
• The formation of 3-MCPD metabolites and their role in toxicity is not completely characterised.
Metabolism includes conjugation with glutathione with subsequent formation of
2,3-dihydroxypropyl mercapturic acid and oxidation to b-chlorolactaldehyde and oxalic acid.
Conjugation with glutathione is one well-characterised metabolic pathway but its extent is
limited.
• Urinary excretion of 3-MCPD and its metabolites appears to predominate.
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2-MCPD and 2-MCPD fatty acid esters
• No toxicokinetic data were identiﬁed. However the difference in the structural localisation of
the chorine within the molecule makes it unlikely that 2-MCPD exhibits the same metabolic
pattern as 3-MCPD.
Glycidol and glycidyl fatty acid esters
• Glycidol and its fatty acid esters are efﬁciently absorbed following ingestion. Gastro-intestinal
hydrolysis of glycidyl fatty acid esters (GE) occurs and appears to be more extensive in rats
than in monkeys.
• Metabolic pathways include glutathione conjugation and mercapturate formation, epoxide
hydrolysis to glycerol, and conversion to 3-MCPD.
• In addition, the glycidol moiety can bind covalently to cellular nucleophiles (e.g. DNA and
haemoglobin) by virtue of the electrophilic nature of the epoxide ring.
4.6.2. Toxicity in experimental animals
3-MCPD and 3-MCPD fatty acid esters
• 3-MCPD produced severe renal toxicity in rats at single i.p. doses between 100 and 120 mg/kg
bw, which persists for several weeks.
• Repeated oral doses also result in renal toxicity and progressive nephropathy and renal tubule
dilation can be seen after daily dose as low as 5.2 mg/kg bw in rats.
• 3-MCPD administered to rats at 30 mg/kg bw per day impaired red blood cell function by
decreasing haemoglobin content and inducing volume fraction changes consistent with
normocytic and normochromic anaemia.
• Neurotoxic effects such as hind limb paralysis were reported only at doses over 50 mg/kg bw
per day following short-term exposure in mice.
• In long-term studies at doses as low as 2 mg/kg bw per day 3-MCPD caused progressive
nephrotoxicity (characterised by tubular hyperplasia) testicular toxicity (atrophy and arteritis)
and mammary glandular hyperplasia in male rats and nephrotoxicity in female rats.
• Related to these effects, benign tumours of the testes (Leydig cells tumours), mammary gland
(ﬁbroadenoma) and kidney (tubular adenoma) developed.
• The renal toxicity of 3-MCPD appears to reside with the R isomer.
• Doses between 5 and 10 mg/kg bw day 3-MCPD administered to the rat can completely impair
male fertility without changing sperm production. This effect has been demonstrated in several
species including primates and is reversible. The no observed adverse effect level (NOAEL) of
3-MCPD on male fertility is not clear.
• Single and multiple doses of 3-MCPD administered to the pregnant rat decreased the number of
implantations and increased fetal loss but were not teratogenic. The NOAEL for multiple doses
was 10 mg/kg bw per day for maternal toxicity and 30 mg/kg bw per day for fetal toxicity.
• Despite some positive genotoxicity tests in vitro, there is no evidence that 3-MCPD is genotoxic
in vivo in any organ tested, including kidney, and testis.
• From the available information on 3-MCPD fatty acid esters, it can be concluded that the toxic
effects for esteriﬁed 3-MCPD are the same as those seen for the free 3-MCPD, supporting the
view that the esters are cleaved and toxicity primarily exerted by 3-MPCD.
• After equimolar multiple doses of 3-MCPD and 3-MCPD dipalmitate the biochemical changes
associated with renal toxicity are similar in pattern and magnitude. Both compounds produce
an array of renal histopathology including glomerular lesions and tubular epithelial
hyperplasia.
• There is limited evidence that some esters of 3-MCPD have male antifertility effects at a similar
molar dose to 3-MCPD and degenerative changes in the spermatogenic tubules have been
recorded after treatment with 3-MCPD fatty acid esters.
• No studies on the in vitro genotoxicity of 3-MCPD fatty acid esters were identiﬁed. From the
limited evidence (one study with different endpoints) available there is no indication that
3-MCPD fatty acid esters are genotoxic in vivo.
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2-MCPD and 2-MCPD fatty acid esters
• In a 28-day study in rats, daily doses of 16 or 30 mg/kg bw per day caused severe myopathy
and nephrotoxicity. From 8 days of treatment severe lesions leading to cell death developed in
striated muscle particularly in cardiac myocytes that resulted in heart failure and the death of
some animals. These effects were not observed at 2 mg/kg bw per day.
• No data on long-term studies for 2-MCPD or 2-MCPD fatty acid esters were identiﬁed.
• In vitro genotoxicity data on 2-MCPD are too limited to make any conclusion. No
mammalian in vivo genotoxicity studies have been identiﬁed for 2-MCPD and 2-MCPD fatty
acid esters.
Glycidol
• Neurotoxicity was observed after 28 days of treatment of rats with 200 mg glycidol/kg bw per
day.
• Glycidol caused renal toxicity in repeated dose studies in rats and mice at doses in the range
150–400 mg/kg bw per day.
• Two-year carcinogenicity studies in mice (25 and 50 mg/kg bw/day) and rats (37.5 and 75 mg/kg
bw per day) showed induction of tumours in multiple organs from both sexes. Supporting
evidence for carcinogenicity of glycidol was provided by a short-term study in a transgenic mouse
strain.
• Male anti-fertility effects have been noted in rats and mice. The lowest LOAEL was 25 mg/kg
bw day in the rat, resulting in 36% reduction in epididymal sperm count. This may be
attributed to conversion of glycidol to 3-MCPD in the stomach.
• Glycidol was maternally toxic in mice without producing any major external abnormalities in
the fetus. Neurotoxicity was observed in male pups of rats exposed to a maternal dose of
49 mg glycidol/kg bw per day during pregnancy and weaning.
• There is strong evidence from in vitro data and some evidence from in vivo studies that
glycidol is a genotoxic compound.
Observations in humans
• No relevant toxicity data were identiﬁed.
4.6.3. Biomarkers of exposure
• In animals urinary 3-MCPD-metabolites, including MCPD-mercaptenurate (2,3-dihydroxypropyl
mercapturic acid, DHPMA) and b-chlorolactic acid, have been identiﬁed as potential biomarkers
of exposure for MCPD fatty acid esters.
4.6.4 Mode of action
3-MCPD and 3-MCPD fatty acid esters
• Toxic effects to kidneys and testis were associated with oxidative metabolism of 3-MCPD to
b-chlorolactaldehyde and b-chlorolactic acid.
• The inhibition of glycolysis by metabolites associated with the b-chlorolactate pathway was
suggested as possible nephrotoxic mechanism of 3-MCPD and can explain the reduction in
sperm motility.
• In rats regionally selective decrease of glutathione reductase activity and glutathione content were
identiﬁed as a possible alternative mechanism for neurotoxicity. In brains of both rats and mice,
toxicity of 3-MPCD affects glial cells with loss of neurons occurring subsequent to death of astrocytes.
• Mammary tumours in male rats were a consequence of the development of Leydig cell
tumours. Leydig cell tumours were considered rat strain speciﬁc and not relevant to humans.
• Benign kidney tumours in rats is associated with tubular hyperplasia, a non-genotoxic mode of
action is likely.
2-MCPD and 2-MCPD fatty acid esters
• The underlying mechanisms for renal toxicity and the destruction of striated muscles, including
the heart are unknown.
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Glycidol and glycidyl fatty acid esters
• Glycidol is a strong electrophilic agent which reacts readily with cellular nucleophiles.
• Detection of higher levels of 3-MCPD than glycidol in serum after dosing rats with glycidol,
suggests that some of the toxicity of glycidol may be due to its partial conversion to 3-MCPD
in vivo.
• Signiﬁcant hepatic glutathione depletion was observed following exposure to glycidol.
4.6.5. Hazard characterisation
3-MCPD and 3-MCPD fatty acid esters
• The critical effect of 3-MCPD was kidney toxicity. The CONTAM Panel applied BMD analysis to
the results obtained in kidney in two long-term exposure studies where rats received 3-MCPD
via drinking water.
• For 3-MCPD, a tolerable daily intake (TDI) of 0.8 lg/kg bw per day was established. This was
based on a chronic study in rats in which the lowest BMDL10 of 0.077 mg/kg bw per day for
renal tubular hyperplasia in males was derived and application of an overall uncertainty factor
of 100.
• Noting the lack of speciﬁc data on 3-MCPD fatty acid esters and their hydrolysis, the CONTAM
Panel conﬁrmed that the toxicity of 3-MCPD fatty acid esters should be considered equivalent
(on a molar basis) to that of the parent compound. Therefore the CONTAM Panel concluded
that the TDI of 0.8 lg/kg bw per day constitutes a group TDI for 3-MCPD and its fatty acid
esters (expressed as MCPD equivalents).
2-MCPD and 2-MCPD fatty acid esters
• No health-based guidance value could be established for 2-MCPD due to insufﬁcient
toxicological information, i.e. no data on metabolism and long-term toxicity, little information
on mode of action and equivocal in vitro genotoxicity ﬁndings.
Glycidol and glycidyl fatty acid esters
• The CONTAM Panel only considered toxicity studies in animals with glycidol as no
in vivo data was identiﬁed for glycidyl esters. Dose-response considerations were made
for glycidol, assuming a complete hydrolysis of the esters to free glycidol following
ingestion.
• The CONTAM Panel considered the dose-response data inadequate for benchmark dose (BMD)
modelling.
• Based upon the EFSA Guidance on substances that are genotoxic and carcinogenic, T25 values
were calculated for the incidence of tumours observed in rats and mice following long-term
exposure to glycidol. The T25 of 10.2 mg/kg bw per day for peritoneal mesothelioma in male
rats was used as the reference point.
4.7. Risk characterisation
3-MCPD and 3-MCPD fatty acid esters
• The mean exposure to 3-MCPD was below the group TDI of 0.8 lg/kg bw per day in
‘Adolescents’, ‘Adults’ and older age classes in all dietary surveys. In ‘Infants’, ‘Toddlers’ and
‘Other children’ half of the dietary surveys had mean exposure at or above the group TDI, up
to a maximum of about 1.5 lg/kg bw per day in ‘Toddlers’ and ‘Other children’.
• The high exposure (P95) for ‘Infants’, ‘Toddlers’ and ‘Other children’ was above the group TDI
in all dietary surveys, ranging between a minimum of 1.1 lg/kg bw per day in ‘Other children’
or roughly 1.5 lg/kg bw per day in ‘Infants’ and ‘Toddlers’ up to about 2.5 lg/kg bw per day
in all the three age classes.
• The high exposure (P95) for adolescents was at or above the group TDI in half of the dietary
surveys, with exposure estimates up to 1.4 lg/kg bw per day. For ‘Adults’ and the older age
classes, only the maximum P95 of dietary exposure to 3-MCPD was around the group TDI.
• The estimated exposure to 3-MCPD of infants receiving only formula was 2.4 lg/kg bw per day
using mean occurrence and 3.2 lg/kg bw per day using P95 of occurrence; both values are
above the group TDI, which is exceeded up to fourfold.
MCPD and glycidyl esters in food
www.efsa.europa.eu/efsajournal 93 EFSA Journal 2016;14(5):4426
2-MCPD and 2-MCPD fatty acid esters
• No TDI could be established so although the exposure data were available, it was not possible
to undertake risk characterisation.
Glycidol and glycidyl fatty acid esters
• In view of the genotoxic and carcinogenic potential of glycidol, a margin of exposure (MoE)
approach was applied. MoEs were calculated by dividing the reference point of 10.2 mg/kg bw
per day by the exposure levels. A MoE of 25,000 or higher was considered of low health
concern.
• For ‘Infants’, ‘Toddlers’ and ‘Other children’ the MoE estimates for the mean exposure ranged
from 34,000 to 11,300; the MoE for high (P95) exposure ranged from 12,800 to 4,900.
• For ‘Adolescents’ and ‘Adults’, ‘Elderly’ and ‘Very elderly’ age groups the MoE for the mean
exposure ranged from 102,000 to 20,400, whereas at high (P95) exposure the range was from
51,000 to 9,300.
• Scenarios of exposure in infants receiving formula only resulted in a MoE of about 5,500 for
the mean occurrence and 2,100 for the P95 of occurrence.
5. Recommendations
• For future data collection activities, the inclusion of samples from all food groups potentially
contaminated by 3-, 2-MCPD and glycidol is recommended, including foods where mitigation
measures have been enforced. For each food analysed, the levels deriving from both forms,
free and ester bound, should be measured, when applicable.
• Analysis of the enantiomeric composition of 3-MCPD and its fatty acid esters is recommended
for foods containing high levels of these compounds.
• Further studies are recommended on the rates and degree of release of the free compounds
from 3- and 2-MCPD fatty acid mono- and diesters, and on the rates and degree of release of
the free 3- and 2-MCPD and glycidol from esters of different fatty acids. Such studies should
include studies to clarify the metabolic fate of the compounds.
• The mode and mechanism of action of 2-MCPD needs to be investigated.
• Long-term toxicity testing of 2-MCPD is required to provide a basis for quantitative risk assessment.
• More extensive testing of the dose-response for carcinogenesis from chronic lifetime oral
administration of glycidol and its esters in rats (2-year carcinogenicity study utilising
appropriate doses) would reduce uncertainty in the risk assessment.
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Abbreviations
2-AAF 2-acetylaminoﬂuorene
1,3-DCP 1,3-dichloropropan-2-ol
2,3-DCP 2,3-dichloropropan-1-ol
2-MCPD 2-monochloropropane-1,3-diol
3-MCPD 3-monochloropropane-1,2-diol
ADH alcohol dehydrogenase
AOAC Association of Ofﬁcial Analytical Chemists
AOCS American Oil Chemists’ Society
APCI atmospheric pressure chemical ionisation
ARfD acute reference dose
ASE accelerated solvent extraction
AUC area under the curve
ALARA as low as reasonably achievable
BfR German Federal Institute for Risk Assessment
BIOCONTAM Biological Hazard and Contaminants Unit
BMD benchmark dose
BMDL benchmark dose (lower conﬁdence limit)
BSTFA N,O-bis(trimethylsily)triﬂuoroacetamine
bw body weight
cAMP cyclic adenosine monophosphate
CDO oleate diester
CDP palmitate diester
CEN European Committee for Standardization
CMP palmitate monoester
COC UK Committee on Carcinogenicity of Chemicals in Food, Consumer Products and
the Environment
CONTAM Panel EFSA Panel on the Contaminants in the Food Chain
CPA cyclophilin A
DGF German Society for Fat Science
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DHPMA N-acetyl-S-(2,3-dihydroxypropyl)cysteine or 2,3-dihydroxypropyl mercapturic acid
diHOPrVal N-(2,3-dihydroxy-propyl)valine
DIPP Type I Diabetes Prediction and Prevention (DIPP) Study, Finland
DMN dimethylnitrosamine
EC European Commission
EH epoxide hydrolase
EI electron impact
EU European Union
FAO/WHO Food and Agriculture Organisation of the United Nations/World Health Organization
FEDIOL Association of the EU Vegetable Oil and Proteinmeal Industry
FoodEx1 EFSA food classiﬁcation and description system, version 1
FSA UK Food Standards Agency
FSH Follicle stimulating hormone
GC gas chromatography
GC-ECD gas chromatography with electron capture detection
GC-MS gas chromatography-mass spectrometry
GC-MS/MS gas chromatography-tandem mass spectrometry
GE glycidyl fatty acid esters
GI gastrointestinal tract
GL Guideline
GST glutathione S-transferase
Hb haemoglobin
HCl hydrochloric acid
HDC highly damaged cells
HFB heptaﬂuorobutyrate
HFBA heptaﬂuorobutyric anhydride
HFBI heptaﬂuorobutyrylimidazole
HPLC high performance liquid chromatography
HPV hydrolysed vegetable protein
IARC International Agency for Research on Cancer
IMACE European Margarine Association
iNOS inducible nitric oxide synthase
IOM Institute of Medicine of the US National Academies of Science
i.p. intraperitoneal injection
i.v. intravenous injection
JECFA Joint FAO/WHO Expert Committee on Food Additives
JRC Joint Research Centre of the European Commission
JRC-IRMM Joint Research Centre of the European Commission and Institute for Reference
Materials and Measurements
LB lower bound
LC liquid chromatography
LC-MS liquid chromatography-mass spectrometry
LC-MS/MS liquid chromatography-tandem mass spectromery
LD50 median lethal dose
LH luteinizing hormone
LHRH luteinizing hormone releasing hormone
LMBG German Food and Feed Code
LOD limit of detection
LOEL lowest observed effect level
LOQ limit of quantiﬁcation
LVI large volume injection
MB middle bound
MBPD monobromopropanediol
MCPD monochloropropanediol
MF mutation frequencies
MMS methyl methanesulfonate
MN micronucleus
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MOE margin of exposure
MRM multiple reaction monitoring
NaCl sodium chloride
NCI negative chemical ionisation
NITR Korean National Institute of Toxicological Research
nNOS neuronal nitric oxide synthase
NOAEL no observed adverse effect level
NTP US National Toxicology Program
OECD Organisation for Economic Co-operation and Development
PBA pheylboronic acid
PCE polychromatic erythrocytes
PCE/NCE polychromatic erythrocytes to normochromatic erythrocytes
PLE pressurised liquid extraction
PMTDI provisional maximum tolerable daily intake
RBC red blood cells
RET retiulocytes
SAS SAS statistical software
SCE sister chromatide exchange
SCF EU Scientiﬁc Committee for Food
SIM selected ion monitoring
SLA service level agreement
SN2 Second-order Nucleophilic Substitution
SPE solid phase extraction
SSD standard sampling description
TDI tolerable daily intake
UB upper bound
UDS unscheduled DNA synthesis
UPLC-MS ultra-performance liquid chromatography-mass spectrometry
WHO World Health Organization
WHO/IPCS World Health Organization/International Programme on Chemical Safety
w.w. whole weight
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Appendix A – EFSA guidance documents applied for the assessment
• EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a
request from EFSA related to uncertainties in Dietary Exposure Assessment. EFSA Journal
2006;4(1):438, 54 pp. doi:10.2903/j.efsa.2007.438
• EFSA (European Food Safety Authority), 2009. Guidance of the Scientiﬁc Committee on
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Appendix B – Support tables for the occurrence and exposure sections
Table B.1: Structure of food groups (N = 68) used to organise the analytical results in the present
report. Where the groups correspond to FoodEx1 groups, the corresponding code is
provided. Groups created for the purpose of this report are ﬂagged as ‘ad-hoc’
Code(a) Food group Name(b) Note
A.01.001580 Herbs, spices and condiments
A.01.001625 Herb and spice mixtures
A.01.001632 Seasoning or extracts
A.01.001640 Stock cubes (bouillon cube)
Ad-hoc grp Other seasoning products Seasoning or extracts other than stock cubes
A.01.001649 Condiment
A.01.001660 Soy sauce
Ad-hoc grp Other condiment sauces Sauces included in the condiment group, other
than soy sauce
A.01.001665 Dressing The group includes mayonnaise and similar sauces
used as dressing
A.01.001684 Savoury sauces
A.01.001757 Protein and amino acids supplements
Ad-hoc grp Hydrolysed vegetable proteins Subgroup of the FoodEx1 group A.01.001757
Protein and amino acids supplements including only
hydrolysed vegetable proteins
A.01.001789 Composite food
Ad-hoc grp Dry preparations for soups (to be
reconstituted)
Subgroup of the FoodEx1 group A.01.001856
Ready-to-eat soups including only dry products
to be reconstituted
A.01.001346 Animal and vegetable fats and oils
A.01.001389 Margarine and similar products
A.01.001390 Margarine, normal fat
A.01.001391 Margarine, low fat
A.01.001393 Fat emulsions
Ad-hoc grp Special Fats Group not corresponding to a speciﬁc FoodEx1
group, because it includes special industrial
products
Ad-hoc grp Vegetable fats and oils Group resulting from merging A.01.001362
Vegetable fat with A.01.001367 Vegetable oil
A.01.001378 Peanut oil
Ad-hoc grp Coconut oil/fat Group resulting from merging A.01.001364
Coconut fat and A.01.001369 Coconut oil
A.01.001370 Maize oil
A.01.001375 Olive oil
A.01.001376 Palm kernel oil
Ad-hoc grp Palm oil/fat Group resulting from merging A.01.001366 Palm
fat and A.01.001377 Palm oil
A.01.001380 Rape seed oil
A.01.001383 Soya bean oil
A.01.001384 Sunﬂower seed oil
A.01.001386 Walnut oil
Ad-hoc grp Cereal-based products and similar
A.01.000184 Breakfast cereals All the subgroups are represented excluded mixed
breakfast cereals and grits
A.01.000185 Cereal ﬂakes
A.01.000210 Muesli
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Code(a) Food group Name(b) Note
A.01.000220 Cereal bars
A.01.000225 Popped cereals
A.01.000246 Porridge
A.01.000252 Fine bakery wares
A.01.000302 Cookies
Ad-hoc grp Fatty cake products Ad-hoc part of A.01.000253 Pastries and cakes
Ad-hoc grp Hot surface cooked pastries Ad-hoc part of A.01.000253 Pastries and cakes
Ad-hoc grp Puff pastry Ad-hoc part of A.01.000253 Pastries and cakes
Ad-hoc grp Shortcrusts Ad-hoc part of A.01.000253 Pastries and cakes
Ad-hoc grp Yeast leavened pastries Ad-hoc part of A.01.000253 Pastries and cakes
A.01.000098 Bread and rolls
A.01.000099 Wheat bread and rolls
A.01.000118 Rye bread and rolls
A.01.000129 Mixed wheat and rye bread and rolls
A.01.000141 Multigrain bread
A.01.000144 Unleavened bread, crispbread, rusk
Ad-hoc grp Fried, baked or roast meat or ﬁsh
products
Ad-hoc group for meat and ﬁsh baked or fried or
cooked at high temperature with fat
Ad-hoc grp Fried or roast meat Ad-hoc group including A.01.000728 Livestock
meat, A.01.000736 Poultry, A.01.000744 Game
mammals, A.01.000751 Game birds, A.01.000760
Mixed meat, A.01.000766 Edible offal, farmed
animals and A.01.000791 Edible offal, game
animals – when they are roast or fried or cooked
at high temperature with fat
Ad-hoc grp Fried or baked ﬁsh Subgroup of the FoodEx1 group A.01.000877 Fish
when it is baked or fried or cooked at high
temperature with fat
A.01.001716 Infant formulae (powder)
A.01.001717 Infant formula, milk-based, powder
Ad-hoc grp Smoked meat or ﬁsh products
Ad-hoc grp Smoked ﬁsh Subgroup of the FoodEx1 group A.01.000877
Fish when it is smoked
Ad-hoc grp Smoked meat products Subgroup of the FoodEx1 group A.01.000795
Preserved meat or A.01.000811 Sausages when
the products are smoked
Ad-hoc grp Snacks and potato products
Ad-hoc grp Miscellaneous snack products Subgroup of the FoodEx1 group A.01.001878
Snack food not including potato crisps and
popcorns (listed under potato products and
popped cereals, respectively)
Ad-hoc grp Potato products
A.01.000477 Potato croquettes
A.01.000471 French fries
A.01.001879 Potato crisps
Ad-hoc grp Oven baked and pan fried potato
products (including home made
products like pan-fried potato pieces
or Roesti)
Group collecting A.01.000475 Potato fried and
A.01.000476 Potato baked
(a): FoodEx1 code in the case that the food group corresponds to a FoodEx1 food group, ‘ad-hoc’ in the case of groups created
for the purpose of this report.
(b): The names are provided in indented form to show the hierarchical relationships.
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Table B.3: FoodEx1 food codes and corresponding food groups used in dietary exposure assessment
of 3- and 2-MCPD and glycidol
FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.000099 Wheat bread and rolls Wheat bread and
rolls
No additional calculation Bread and bread
rolls
A.01.000118 Rye bread and rolls Rye bread and rolls No additional calculation Bread and bread
rolls
A.01.000129 Mixed wheat and rye
bread and rolls
Mixed wheat and
rye bread and rolls
No additional calculation Bread and bread
rolls
A.01.000140 Multigrain bread and
rolls
Multigrain bread
and rolls
No additional calculation Bread and bread
rolls
A.01.000144 Unleavened bread,
crisp bread and rusk
Unleavened bread,
crispbread, rusk
No additional calculation Bread and bread
rolls
A.01.000154 Other bread Bread and bread
rolls
No additional calculation Bread and bread
rolls
A.01.000164 Bread products Bread and bread
rolls
No additional calculation Bread and bread
rolls
A.01.000225 Popped cereals Popped cereals No additional calculation Breakfast cereals
A.01.000255 Buns Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.000256 Cake from batter Fatty cake products No additional calculation Pastries and cakes
A.01.000257 Cheese cream cake Fatty cake products No additional calculation Pastries and cakes
A.01.000258 Cheese cream sponge
cake
Fatty cake products No additional calculation Pastries and cakes
A.01.000259 Chocolate cake Fatty cake products No additional calculation Pastries and cakes
A.01.000260 Chocolate cake with
fruits
Fatty cake products No additional calculation Pastries and cakes
A.01.000261 Cream cake Fatty cake products No additional calculation Pastries and cakes
A.01.000262 Cream cheese cake Fatty cake products No additional calculation Pastries and cakes
A.01.000263 Cream custard cake Fatty cake products No additional calculation Pastries and cakes
A.01.000264 Cream custard sponge
cake
Fatty cake products No additional calculation Pastries and cakes
A.01.000265 Croissant Puff pastry No additional calculation Pastries and cakes
A.01.000266 Croissant, ﬁlled with
chocolate
Puff pastry No additional calculation Pastries and cakes
A.01.000267 Croissant, ﬁlled with
cream
Puff pastry No additional calculation Pastries and cakes
A.01.000268 Croissant, ﬁlled with
jam
Puff pastry No additional calculation Pastries and cakes
A.01.000270 Doughnuts Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.000272 Flan Shortcrusts No additional calculation Pastries and cakes
A.01.000273 Fruit cake Shortcrusts No additional calculation Pastries and cakes
A.01.000274 Fruit pie Shortcrusts No additional calculation Pastries and cakes
A.01.000275 Cheese pie Shortcrusts No additional calculation Pastries and cakes
A.01.000276 Fruit tart Shortcrusts No additional calculation Pastries and cakes
A.01.000277 Gingerbread Fatty cake products No additional calculation Pastries and cakes
A.01.000279 Kringles Puff pastry No additional calculation Pastries and cakes
A.01.000280 Nut cream cake Fatty cake products No additional calculation Pastries and cakes
A.01.000281 Pancakes Hot surface cooked
pastries
No additional calculation Pastries and cakes
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.000284 Rhubarb ﬂan Shortcrusts No additional calculation Pastries and cakes
A.01.000285 Scone Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.000286 Sponge dough Fatty cake products No additional calculation Pastries and cakes
A.01.000287 Sponge cake Fatty cake products No additional calculation Pastries and cakes
A.01.000288 Sponge cake roll Fatty cake products No additional calculation Pastries and cakes
A.01.000289 Mufﬁns Fatty cake products No additional calculation Pastries and cakes
A.01.000290 Wafﬂes Hot surface cooked
pastries
No additional calculation Pastries and cakes
A.01.000291 Apple strudel Puff pastry No additional calculation Pastries and cakes
A.01.000292 Cream-cheese strudel Puff pastry No additional calculation Pastries and cakes
A.01.000293 Cheese pastry goods
from puff pastry
Puff pastry No additional calculation Pastries and cakes
A.01.000294 Croissant from puff
pastry
Puff pastry No additional calculation Pastries and cakes
A.01.000295 Brioche Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.000297 Lebkuchen Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.000298 Dumpling Fatty cake products No additional calculation Pastries and cakes
A.01.000299 Cake marbled, with
chocolate
Fatty cake products No additional calculation Pastries and cakes
A.01.000300 Marzipan pie Shortcrusts No additional calculation Pastries and cakes
A.01.000301 Baklava Puff pastry No additional calculation Pastries and cakes
A.01.000302 Biscuits (cookies) Cookies No additional calculation Cookies
A.01.000471 French fries French fries No additional calculation Fried or baked
potato
products
A.01.000475 Potato fried Oven-baked potato
products (include
also homemade
products like pan-
fried potato pieces
or Roesti)
No additional calculation Fried or baked
potato
products
A.01.000476 Potato baked Oven-baked potato
products (include
also homemade
products like pan-
fried potato pieces
or Roesti)
No additional calculation Fried or baked
potato
products
A.01.000477 Potato croquettes Potato croquettes No additional calculation Fried or baked
potato
products
A.01.000728 Livestock meat Fried or roast meat No additional calculation Fried or roast meat
A.01.000736 Poultry Fried or roast meat No additional calculation Fried or roast meat
A.01.000744 Game mammals Fried or roast meat No additional calculation Fried or roast meat
A.01.000751 Game birds Fried or roast meat No additional calculation Fried or roast meat
A.01.000760 Mixed meat Fried or roast meat No additional calculation Fried or roast meat
A.01.000766 Edible offal, farmed
animals
Fried or roast meat No additional calculation Fried or roast meat
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.000791 Edible offal, game
animals
Fried or roast meat No additional calculation Fried or roast meat
A.01.000795 Preserved meat Smoked meat
products
No additional calculation Smoked meat
products
A.01.000878 Herring (Clupea) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000879 Sprat (Sprattus
sprattus)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000880 Sardine and pilchard
(Sardina)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000881 Anchovy (Engraulis) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000882 Shad (Alosa) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000883 Salmon and trout
(Salmo spp.)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000884 Char (Salvelinus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000885 Smelt (Osmerus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000886 Whiteﬁsh (Coregonus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000887 Perch (Perca) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000888 Bass (Marone) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000889 Surgeonﬁsh
(Acanthurus)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000890 Mackeral (Scomber) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000891 Tuna (Thunnus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000892 Sea catﬁsh and
wolfﬁsh (Anarhichas)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000893 Grey mullet (Mugil) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000894 Cod and whiting
(Gadus spp.)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000895 Hake (Merluccius) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000896 Flounder (Platichthys
ﬂesus)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000897 Halibut (Hippoglossus
spp.)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000898 Plaice (Pleuronectes) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000899 Sole (Limanda; Solea) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000900 Roach (Rutilus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000901 Carp (Cyprinus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000902 Barbel (Barbus) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000903 Bream (Charax) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000904 Eels (Apodes) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000905 Zeomorphi
(Zeomorphi)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000906 Lophiiformes
(Pediculati)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000907 Selachoidei
(Pleurotremata)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000908 Rays (Hypotremata) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000909 Acipenseriformes
(sturgeons)
(Chondrostei)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.002100 Bonito (Sarda sarda) Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.002101 Bullet tuna (Auxis
spp.)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.002102 Sardinops (Sardinops
sagax)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.002103 Swordﬁsh (Xiphiidae
spp.)
Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000911 Fish balls Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000912 Fishcakes Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000913 Fish ﬁngers Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.000919 Crustaceans Fried or baked ﬁsh (a) Fried or baked ﬁsh
A.01.001295 Chocolate (Cocoa)
products
Chocolate spreads
and similar (22%
palm oil)
Occurrence values used
as calculated, but only in
the spreads reported
under this code
Chocolate spreads
and
similar
A.01.001299 Chocolate, cream Chocolate spreads
and similar (22%
palm oil)
Occurrence values used
as calculated
Chocolate spreads
and
similar
A.01.001364 Coconut fat Coconut oil/fat No additional calculation Vegetable fats and
oils
A.01.001366 Palm fat Palm oil/fat No additional calculation Vegetable fats and
oils
A.01.001368 Almond oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001369 Coconut oil Coconut oil/fat No additional calculation Vegetable fats and
oils
A.01.001370 Corn oil Maize oil No additional calculation Vegetable fats and
oils
A.01.001371 Cottonseed oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001372 Grape seed oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001373 Linseed oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001374 Oil, frying, blend (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001375 Olive oil Olive oil No additional calculation Vegetable fats and
oils
A.01.001376 Palm kernel oil Palm kernel oil No additional calculation Vegetable fats and
oils
A.01.001377 Palm oil Palm oil/fat No additional calculation Vegetable fats and
oils
A.01.001378 Peanut oil Peanut oil No additional calculation Vegetable fats and
oils
A.01.001379 Pumpkinseed oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.001380 Rapeseed oil Rapeseed oil No additional calculation Vegetable fats and
oils
A.01.001381 Safﬂower oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001382 Sesame oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001383 Soybean oil Soya bean oil No additional calculation Vegetable fats and
oils
A.01.001384 Sunﬂower oil Sunﬂower seed oil No additional calculation Vegetable fats and
oils
A.01.001385 Thistle oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001386 Walnut oil Walnut oil Occurrence value used as
it is
Vegetable fats and
oils
A.01.001387 Wheat germ oil (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001388 Fats of mixed origin (b) Occurrence values used
without additional
calculation
Vegetable fats and
oils
A.01.001390 Margarine, normal fat Margarine, normal
fat
No additional calculation Margarine and
similar
A.01.001391 Margarine, low fat Margarine, low fat No additional calculation Margarine and
similar
A.01.001392 Margarine with other
ingredients
Fat emulsions No additional calculation Margarine and
similar
A.01.001393 Fat emulsions Fat emulsions No additional calculation Margarine and
similar
A.01.001625 Herb and spice
mixtures
Herb and spice
mixtures
No additional calculation Herb and spice
mixtures
A.01.001640 Stock cubes (bouillon
cube)
Stock cubes
(bouillon cube)
No additional calculation Stock cubes
(bouillon
cube)
A.01.001641 Gravy thickener Other seasoning
products
No additional calculation Other seasoning
products
A.01.001642 Gravy browning Other seasoning
products
No additional calculation Other seasoning
products
A.01.001643 Gravy instant granules Other seasoning
products
No additional calculation Other seasoning
products
A.01.001644 Vegetable extracts Other seasoning
products
No additional calculation Other seasoning
products
A.01.001645 Meat extract Other seasoning
products
No additional calculation Other seasoning
products
A.01.001646 Malt extract Other seasoning
products
No additional calculation Other seasoning
products
A.01.001647 Yeast extract Other seasoning
products
No additional calculation Other seasoning
products
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.001666 Salad dressing, > 50%
oil
(b) Model combining
occurrence in dressing
with 50% occurrence
value estimated based
on the available
occurrence in oils
(excluding olive oil
and palm/coconut fats)
Dressing
A.01.001667 Salad dressing,
25–50% oil
(b) Model combining
occurrence in dressing
with 35% occurrence
value estimated based
on the available
occurrence in oils
(excluding olive oil
and palm/coconut fats)
Dressing
A.01.001668 Salad dressing, < 25%
oil
(b) Model combining
occurrence in dressing
with 20% occurrence
value estimated based on
the available occurrence
in oils (excluding olive oil
and palm/coconut fats)
Dressing
A.01.001669 Mayonnaise, > 50% oil (b) Model combining
occurrence in dressing
with 75% occurrence
value estimated based on
the available occurrence
in oils (excluding olive oil
and palm/coconut fats)
Mayonnaise
A.01.001670 Mayonnaise, 25–50%
oil
(b) Model combining
occurrence in dressing
with 30% occurrence
value estimated based on
the available occurrence
in oils (excluding olive oil
and palm/coconut fats)
Mayonnaise
A.01.001671 Mayonnaise, < 25 %
oil
(b) Model combining
occurrence in dressing
with 20% occurrence
value estimated based on
the available occurrence
in oils (excluding olive oil
and palm/coconut fats)
Mayonnaise
A.01.001685 White sauce
(Bechamel sauce,
Cheese sauce)
Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001686 Brown sauce (Gravy,
Lyonnais sauce)
Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001687 Cream sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001688 Butter sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
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FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.001689 Emulsion sauce
(Hollandaise sauce)
(b) Model combining
occurrence in savoury
sauces with 25%
occurrence value
estimated based on the
available occurrence in
oils (excluding olive oil
and palm/coconut fats)
Savoury sauces,
oil-based
A.01.001690 Oil-based sauce (b) Model combining
occurrence in savoury
sauces with 25%
occurrence value
estimated based on the
available occurrence in
oils (excluding olive oil
and palm/coconut fats)
Savoury sauces,
oil-based
A.01.001691 Alcoholic sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001692 Meat sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001693 Fish sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001694 Vegetable sauce Savoury sauces No additional calculation Savoury sauces,
non-oil-based
A.01.001716 Infant formulae,
powder
Infant formula,
milk-based, powder
No additional calculation Infant and follow-
on formulae
A.01.002000 Infant formulae, liquid Infant formula,
milk-based, powder
Dividing by a factor of 7.7
(4.5 g of powder in
30 mL)
Infant and follow-
on formulae
A.01.001722 Follow-on formulae,
powder
Follow-on formula,
milk-based, powder
No additional calculation Infant and follow-
on formulae
A.01.002010 Follow-on formulae,
liquid
Follow-on formula,
milk-based, powder
Dividing by a factor of 7.7
(4.5 g of powder in
30 mL)
Infant and follow-
on formulae
A.01.001731 Biscuits, rusks and
cookies for children
Cookies No additional calculation Cookies
A.01.001757 Protein and amino
acids supplements
Protein and amino
acids supplements
No additional calculation Protein and amino
acids supplements
A.01.001791 Sandwich and
sandwich-like meal
Bread and bread
rolls
No additional calculation Bread and bread
rolls
A.01.001800 Pizza and pizza-like
pies
Bread and bread
rolls
No additional calculation Bread and bread
rolls
A.01.001830 Meat burger Fried or roasted
meat
No additional calculation Fried or roasted
meat
A.01.001831 Meat balls Fried or roasted
meat
No additional calculation Fried or roasted
meat
A.01.001856 Ready-to-eat soups Dry preparations
for soups (to be
reconstituted)
Dividing by a factor of 12
(18 grams of dry product
in 200ml water)
Ready to eat soups
A.01.001879 Potato crisps Potato crisps No additional calculation Fried or baked
potato
products
www.efsa.europa.eu/efsajournal 120 EFSA Journal 2016;14(5):4426
MCPD and glycidyl esters in food
FoodEx1
code
Food group used
for exposure
Occurrence values
used Calculation applied
Aggregated
groups
for presenting
contribution to
exposure
A.01.001880 Corn chips Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001881 Tortilla chips Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001882 Corn curls Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001883 Popcorn Popped cereals No additional calculation Breakfast cereals
A.01.001884 Pretzels Yeast leavened
pastries
No additional calculation Pastries and cakes
A.01.001885 Fish-based snacks Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001886 Seafood chips Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001887 Cheese puffs Miscellaneous snack
products
No additional calculation Miscellaneous snack
products
A.01.001660 Soy sauce Soy sauce No additional calculation Soy sauce
A.01.001656 Barbecue sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001657 Tabasco sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001658 Horseradish sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001659 Mint sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001661 Curry sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001662 Salsa Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001663 Tartar sauce Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001664 Mixed condiment Other condiment
sauces
No additional calculation Other condiment
sauces
A.01.001757 Protein and amino
acids supplements
Protein and amino
acids supplements
No additional calculation Protein and amino
acids supplements
A.01.000185 Cereal ﬂakes Cereal ﬂakes No additional calculation Breakfast cereals
A.01.000210 Muesli Muesli No additional calculation Breakfast cereals
A.01.000220 Cereal bars Cereal bars No additional calculation Breakfast cereals
A.01.000233 Mixed breakfast
cereals
Muesli No additional calculation Breakfast cereals
A.01.000246 Porridge Porridge No additional calculation Porridge
A.01.000811 Sausages Smoked meat
products
No additional calculation Smoked meat
products
(a): In ﬁsh and ﬁsh products, the FoodEx code does not record the treatment, therefore the occurrence value for fried ﬁsh was
applied, because the occurrence levels in fried ﬁsh are either higher (more conservative choice) or similar to those in smoked
ﬁsh. It is here assumed that ﬁsh are either fried or smoked. No occurrence data are available for potential combination of
the two treatments.
(b): Occurrence estimated based on the available occurrence in oils (excluding olive oil and palm/coconut fats) and the 2011 oil
consumption in the EU (27 Members States aggregated).
www.efsa.europa.eu/efsajournal 121 EFSA Journal 2016;14(5):4426
MCPD and glycidyl esters in food
T
ab
le
B
.4
:
O
cc
ur
re
nc
e
va
lu
es
us
ed
fo
r
th
e
Fo
od
Ex
1
fo
od
gr
ou
ps
us
ed
fo
r
th
e
ex
po
su
re
as
se
ss
m
en
t
of
3-
M
CP
D
,2
-M
CP
D
an
d
gl
yc
id
ol
,f
ol
lo
w
in
g
th
e
ap
pr
oa
ch
de
sc
rib
ed
in
Ta
bl
e
B.
3
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
00
09
9
W
he
at
br
ea
d
an
d
ro
lls
24
31
37
10
15
19
11
12
12
A.
01
.0
00
11
8
Ry
e
br
ea
d
an
d
ro
lls
1.
91
8.
45
14
0
4.
64
9.
29
0.
08
0.
35
0.
63
A.
01
.0
00
12
9
M
ix
ed
w
he
at
an
d
ry
e
br
ea
d
an
d
ro
lls
5.
2
11
17
1.
45
6.
06
10
0.
55
0.
79
1.
04
A.
01
.0
00
14
0
M
ul
tig
ra
in
br
ea
d
an
d
ro
lls
13
19
25
2.
66
7.
25
11
3.
83
4.
07
4.
31
A.
01
.0
00
14
4
U
nl
ea
ve
ne
d
br
ea
d,
cr
is
p
br
ea
d
an
d
ru
sk
95
10
1
10
8
44
49
54
27
28
28
A.
01
.0
00
15
4
O
th
er
br
ea
d
23
29
36
9.
81
14
19
7.
77
8.
03
8.
3
A.
01
.0
00
16
4
Br
ea
d
pr
od
uc
ts
23
29
36
9.
81
14
19
7.
77
8.
03
8.
3
A.
01
.0
00
22
5
Po
pp
ed
ce
re
al
s
23
29
35
12
17
22
14
15
16
A.
01
.0
00
25
5
Bu
ns
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
00
25
6
Ca
ke
fr
om
ba
tt
er
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
25
7
Ch
ee
se
-c
re
am
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
25
8
Ch
ee
se
-c
re
am
sp
on
ge
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
25
9
Ch
oc
ol
at
e
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
0
Ch
oc
ol
at
e
ca
ke
w
ith
fr
ui
ts
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
1
Cr
ea
m
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
2
Cr
ea
m
-c
he
es
e
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
3
Cr
ea
m
-c
us
ta
rd
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
4
Cr
ea
m
-c
us
ta
rd
sp
on
ge
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
26
5
Cr
oi
ss
an
t
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
26
6
Cr
oi
ss
an
t,
ﬁl
le
d
w
ith
ch
oc
ol
at
e
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
26
7
Cr
oi
ss
an
t,
ﬁl
le
d
w
ith
cr
ea
m
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
26
8
Cr
oi
ss
an
t,
ﬁl
le
d
w
ith
ja
m
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
27
0
D
ou
gh
nu
ts
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
00
27
2
Fl
an
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
27
3
Fr
ui
t
ca
ke
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
27
4
Fr
ui
t
pi
e
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
27
5
Ch
ee
se
pi
e
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
2
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
00
27
6
Fr
ui
t
ta
rt
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
27
7
G
in
ge
rb
re
ad
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
27
9
Kr
in
gl
es
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
28
0
N
ut
cr
ea
m
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
28
1
Pa
nc
ak
es
24
2
24
7
25
3
11
8
12
3
12
8
13
6
13
7
13
8
A.
01
.0
00
28
4
R
hu
ba
rb
ﬂa
n
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
28
5
Sc
on
e
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
00
28
6
Sp
on
ge
do
ug
h
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
28
7
Sp
on
ge
ca
ke
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
28
8
Sp
on
ge
ca
ke
ro
ll
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
28
9
M
uf
ﬁn
s
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
29
0
W
af
ﬂe
s
24
2
24
7
25
3
11
8
12
3
12
8
13
6
13
7
13
8
A.
01
.0
00
29
1
Ap
pl
e
st
ru
de
l
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
29
2
Cr
ea
m
-c
he
es
e
st
ru
de
l
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
29
3
Ch
ee
se
pa
st
ry
go
od
s
fr
om
pu
ff
pa
st
ry
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
29
4
Cr
oi
ss
an
t
fr
om
pu
ff
pa
st
ry
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
29
5
Br
io
ch
e
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
00
29
7
Le
bk
uc
he
n
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
00
29
8
D
um
pl
in
g
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
29
9
Ca
ke
m
ar
bl
ed
,
w
ith
ch
oc
ol
at
e
13
2
13
8
14
5
66
71
75
10
2
10
2
10
3
A.
01
.0
00
30
0
M
ar
zi
pa
n
pi
e
14
8
15
4
16
0
75
79
84
14
8
14
9
14
9
A.
01
.0
00
30
1
Ba
kl
av
a
10
0
10
6
11
2
42
47
53
19
21
23
A.
01
.0
00
30
2
Bi
sc
ui
ts
(c
oo
ki
es
)
19
4
20
0
20
6
98
10
3
10
7
13
4
13
4
13
5
A.
01
.0
00
47
1
Fr
en
ch
fr
ie
s
51
57
63
19
23
28
40
41
41
A.
01
.0
00
47
5
Po
ta
to
fr
ie
d
33
40
47
23
28
32
6.
36
6.
38
6.
4
A.
01
.0
00
47
6
Po
ta
to
ba
ke
d
33
40
47
23
28
32
6.
36
6.
38
6.
4
A.
01
.0
00
47
7
Po
ta
to
cr
oq
ue
tt
es
23
30
37
12
17
21
4.
8
5
5.
21
A.
01
.0
00
72
8
Li
ve
st
oc
k
m
ea
t
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
73
6
Po
ul
tr
y
17
23
29
2.
97
8.
38
13
42
43
44
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
3
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
00
74
4
G
am
e
m
am
m
al
s
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
75
1
G
am
e
bi
rd
s
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
76
0
M
ix
ed
m
ea
t
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
76
6
Ed
ib
le
of
fa
l,
fa
rm
ed
an
im
al
s
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
79
1
Ed
ib
le
of
fa
l,
ga
m
e
an
im
al
s
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
00
79
5
Pr
es
er
ve
d
m
ea
t
17
24
30
0.
21
6.
24
12
24
27
30
A.
01
.0
00
87
8
H
er
rin
g
(C
lu
pe
a)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
87
9
Sp
ra
t
(S
pr
at
tu
s
sp
ra
tt
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
0
Sa
rd
in
e
an
d
pi
lc
ha
rd
(S
ar
di
na
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
1
An
ch
ov
y
(E
ng
ra
ul
is
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
2
Sh
ad
(A
lo
sa
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
3
Sa
lm
on
an
d
tr
ou
t
(S
al
m
o
sp
p.
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
4
Ch
ar
(S
al
ve
lin
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
5
Sm
el
t
(O
sm
er
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
6
W
hi
te
ﬁs
h
(C
or
eg
on
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
7
Pe
rc
h
(P
er
ca
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
8
Ba
ss
(M
ar
on
e)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
88
9
Su
rg
eo
nﬁ
sh
(A
ca
nt
hu
ru
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
0
M
ac
ke
ra
l(
Sc
om
be
r)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
1
Tu
na
(T
hu
nn
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
2
Se
a
ca
tﬁ
sh
an
d
w
ol
fﬁ
sh
(A
na
rh
ic
ha
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
3
G
re
y
m
ul
le
t
(M
ug
il)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
4
Co
d
an
d
w
hi
tin
g
(G
ad
us
sp
p.
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
5
H
ak
e
(M
er
lu
cc
iu
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
6
Fl
ou
nd
er
(P
la
tic
ht
hy
s
ﬂ
es
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
7
H
al
ib
ut
(H
ip
po
gl
os
su
s
sp
p.
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
8
Pl
ai
ce
(P
le
ur
on
ec
te
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
89
9
So
le
(L
im
an
da
;
So
le
a)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
0
R
oa
ch
(R
ut
ilu
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
1
Ca
rp
(C
yp
rin
us
)
42
42
43
13
14
15
30
30
30
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
4
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
00
90
2
Ba
be
l(
Ba
rb
us
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
3
Br
ea
m
(C
ha
ra
x)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
4
Ee
ls
(A
po
de
s)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
5
Ze
om
or
ph
i(
Ze
om
or
ph
i)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
6
Lo
ph
iif
or
m
es
(P
ed
ic
ul
at
i)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
7
Se
la
ch
oi
de
i(
Pl
eu
ro
tr
em
at
a)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
8
R
ay
s
(H
yp
ot
re
m
at
a)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
90
9
Ac
ip
en
se
rif
or
m
es
(s
tu
rg
eo
ns
)
(C
ho
nd
ro
st
ei
)
42
42
43
13
14
15
30
30
30
A.
01
.0
02
10
0
Bo
ni
to
(S
ar
da
sa
rd
a)
42
42
43
13
14
15
30
30
30
A.
01
.0
02
10
1
Bu
lle
t
tu
na
(A
ux
is
sp
p.
)
42
42
43
13
14
15
30
30
30
A.
01
.0
02
10
2
Sa
rd
in
op
s
(S
ar
di
no
ps
sa
ga
x)
42
42
43
13
14
15
30
30
30
A.
01
.0
02
10
3
Sw
or
dﬁ
sh
(X
ip
hi
id
ae
sp
p.
)
42
42
43
13
14
15
30
30
30
A.
01
.0
00
91
1
Fi
sh
ba
lls
42
42
43
13
14
15
30
30
30
A.
01
.0
00
91
2
Fi
sh
ca
ke
s
42
42
43
13
14
15
30
30
30
A.
01
.0
00
91
3
Fi
sh
ﬁn
ge
rs
42
42
43
13
14
15
30
30
30
A.
01
.0
00
91
9
Cr
us
ta
ce
an
s
42
42
43
13
14
15
30
30
30
A.
01
.0
01
29
5
Ch
oc
ol
at
e
(C
oc
oa
)
pr
od
uc
ts
64
1
64
1
64
1
34
4
34
4
34
5
87
0
87
0
87
0
A.
01
.0
01
29
9
Ch
oc
ol
at
e,
cr
ea
m
64
1
64
1
64
1
34
4
34
4
34
5
87
0
87
0
87
0
A.
01
.0
01
36
4
Co
co
nu
t
fa
t
60
8
60
8
60
8
14
3
16
9
19
4
47
2
47
6
47
9
A.
01
.0
01
36
6
Pa
lm
fa
t
2,
91
2
2,
91
2
2,
91
2
1,
56
3
1,
56
5
1,
56
6
3,
95
4
3,
95
5
3,
95
5
A.
01
.0
01
36
8
Al
m
on
d
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
36
9
Co
co
nu
t
oi
l
60
8
60
8
60
8
14
3
16
9
19
4
47
2
47
6
47
9
A.
01
.0
01
37
0
Co
rn
oi
l
50
2
50
3
50
5
23
3
23
3
23
3
64
7
65
0
65
4
A.
01
.0
01
37
1
Co
tt
on
se
ed
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
37
2
G
ra
pe
se
ed
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
37
3
Li
ns
ee
d
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
37
4
O
il,
fr
yi
ng
,
bl
en
d
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
37
5
O
liv
e
oi
l
48
48
49
85
86
88
0
15
31
A.
01
.0
01
37
6
Pa
lm
ke
rn
el
oi
l
62
4
62
4
62
4
24
9
27
0
29
1
41
5
42
1
42
8
A.
01
.0
01
37
7
Pa
lm
oi
l
2,
91
2
2,
91
2
2,
91
2
1,
56
3
1,
56
5
1,
56
6
3,
95
4
3,
95
5
3,
95
5
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
5
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
01
37
8
Pe
an
ut
oi
l
22
9
22
9
22
9
90
10
2
11
5
13
3
14
8
16
2
A.
01
.0
01
37
9
Pu
m
pk
in
se
ed
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
38
0
R
ap
es
ee
d
oi
l
22
4
23
2
23
9
78
10
9
14
0
14
4
16
6
18
8
A.
01
.0
01
38
1
Sa
fﬂ
ow
er
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
38
2
Se
sa
m
e
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
38
3
So
yb
ea
n
oi
l
39
2
39
4
39
6
15
9
16
7
17
5
15
7
17
1
18
6
A.
01
.0
01
38
4
Su
nﬂ
ow
er
oi
l
51
7
52
1
52
4
20
7
21
8
22
9
25
9
26
9
27
9
A.
01
.0
01
38
5
Th
is
tle
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
38
6
W
al
nu
t
oi
l
23
6
23
6
23
6
12
7
12
7
12
7
24
7
24
7
24
7
A.
01
.0
01
38
7
W
he
at
ge
rm
oi
l
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
38
8
Fa
ts
of
m
ix
ed
or
ig
in
38
2.
07
38
7.
12
39
1.
40
14
9.
77
16
7.
53
18
5.
31
20
8.
20
22
3.
24
23
8.
47
A.
01
.0
01
39
0
M
ar
ga
rin
e,
no
rm
al
fa
t
66
7
66
8
66
9
22
4
23
6
24
8
58
0
58
2
58
4
A.
01
.0
01
39
1
M
ar
ga
rin
e,
lo
w
fa
t
21
5
21
8
22
0
10
1
10
4
10
7
20
4
20
9
21
3
A.
01
.0
01
39
2
M
ar
ga
rin
e
w
ith
ot
he
r
in
gr
ed
ie
nt
s
18
1
18
1
18
1
77
80
84
11
4
11
4
11
4
A.
01
.0
01
39
3
Fa
t
em
ul
si
on
s
18
1
18
1
18
1
77
80
84
11
4
11
4
11
4
A.
01
.0
01
62
5
H
er
b
an
d
sp
ic
e
m
ix
tu
re
s
19
23
27
0
0
0
0
0
0
A.
01
.0
01
64
0
St
oc
k
cu
be
s
(b
ou
ill
on
cu
be
)
8.
49
10
13
0
0
0
0
0
0
A.
01
.0
01
64
1
G
ra
vy
th
ic
ke
ne
r
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
2
G
ra
vy
br
ow
ni
ng
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
3
G
ra
vy
in
st
an
t
gr
an
ul
es
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
4
Ve
ge
ta
bl
e
ex
tr
ac
ts
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
5
M
ea
t
ex
tr
ac
t
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
6
M
al
t
ex
tr
ac
t
11
14
17
0
0
0
0
0
0
A.
01
.0
01
64
7
Ye
as
t
ex
tr
ac
t
11
14
17
0
0
0
0
0
0
A.
01
.0
01
66
6
Sa
la
d
dr
es
si
ng
,
>
50
%
oi
l
19
8.
04
20
2.
31
20
5.
70
74
.8
8
83
.7
7
92
.6
6
10
4.
10
11
1.
62
11
9.
23
A.
01
.0
01
66
7
Sa
la
d
dr
es
si
ng
,
25
–5
0%
oi
l
14
0.
72
14
4.
24
14
6.
99
52
.4
2
58
.6
4
64
.8
6
72
.8
7
78
.1
3
83
.4
6
A.
01
.0
01
66
8
Sa
la
d
dr
es
si
ng
,
<
25
%
oi
l
83
.4
1
86
.1
7
88
.2
8
29
.9
5
33
.5
1
37
.0
6
41
.6
4
44
.6
5
47
.6
9
A.
01
.0
01
66
9
M
ay
on
na
is
e,
>
50
%
oi
l
29
3.
55
29
9.
09
30
3.
55
11
2.
33
12
5.
65
13
8.
98
15
6.
15
16
7.
43
17
8.
85
A.
01
.0
01
67
0
M
ay
on
na
is
e,
25
–5
0%
oi
l
12
1.
62
12
4.
89
12
7.
42
44
.9
3
50
.2
6
55
.5
9
62
.4
6
66
.9
7
71
.5
4
A.
01
.0
01
67
1
M
ay
on
na
is
e,
<
25
%
oi
l
83
.4
1
86
.1
7
88
.2
8
29
.9
5
33
.5
1
37
.0
6
41
.6
4
44
.6
5
47
.6
9
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
6
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
01
68
5
W
hi
te
sa
uc
e
(B
ec
ha
m
el
sa
uc
e,
Ch
ee
se
sa
uc
e)
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
68
6
Br
ow
n
sa
uc
e
(G
ra
vy
,
Ly
on
na
is
sa
uc
e)
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
68
7
Cr
ea
m
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
68
8
Bu
tt
er
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
68
9
Em
ul
si
on
sa
uc
e
(H
ol
la
nd
ai
se
sa
uc
e)
96
.7
8
10
2.
13
10
7.
29
37
.4
4
41
.8
8
46
.3
3
52
.0
5
55
.8
1
59
.6
2
A.
01
.0
01
69
0
O
il-
ba
se
d
sa
uc
e
(P
es
to
,
Ai
ol
is
au
ce
)
96
.7
8
10
2.
13
10
7.
29
37
.4
4
41
.8
8
46
.3
3
52
.0
5
55
.8
1
59
.6
2
A.
01
.0
01
69
1
Al
co
ho
lic
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
69
2
M
ea
t
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
69
3
Fi
sh
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
69
4
Ve
ge
ta
bl
e
sa
uc
e
1.
26
5.
35
9.
44
0
0
0
0
0
0
A.
01
.0
01
71
6
In
fa
nt
fo
rm
ul
ae
,
po
w
de
r
10
8
10
8
10
9
31
44
58
80
87
94
A.
01
.0
02
00
0
In
fa
nt
fo
rm
ul
ae
,
liq
ui
d
14
.0
3
14
.0
3
14
.1
6
4.
03
5.
71
7.
53
10
.3
9
11
.3
0
12
.2
1
A.
01
.0
01
72
2
Fo
llo
w
-o
n
fo
rm
ul
ae
,
po
w
de
r
10
8
10
8
10
9
31
44
58
80
87
94
A.
01
.0
02
01
0
Fo
llo
w
-o
n
fo
rm
ul
ae
,
liq
ui
d
14
.0
3
14
.0
3
14
.1
6
4.
03
5.
71
7.
53
10
.3
9
11
.3
0
12
.2
1
A.
01
.0
01
73
1
Bi
sc
ui
ts
,
ru
sk
s
an
d
co
ok
ie
s
fo
r
ch
ild
re
n
19
4
20
0
20
6
98
10
3
10
7
13
4
13
4
13
5
A.
01
.0
01
75
7
Pr
ot
ei
n
an
d
am
in
o
ac
id
s
su
pp
le
m
en
ts
22
25
28
0
0
0
0
0
0
A.
01
.0
01
79
1
Sa
nd
w
ic
h
an
d
sa
nd
w
ic
h-
lik
e
m
ea
l
23
29
36
9.
81
14
19
7.
77
8.
03
8.
3
A.
01
.0
01
80
0
Pi
zz
a
an
d
pi
zz
a-
lik
e
pi
es
23
29
36
9.
81
14
19
7.
77
8.
03
8.
3
A.
01
.0
01
83
0
M
ea
t
bu
rg
er
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
01
83
1
M
ea
t
ba
lls
17
23
29
2.
97
8.
38
13
42
43
44
A.
01
.0
01
85
6
R
ea
dy
-t
o-
ea
t
so
up
s
0.
73
0.
83
1
0
0
0
0
0
0
A.
01
.0
01
87
9
Po
ta
to
cr
is
ps
21
0
21
6
22
3
13
1
13
5
14
0
11
0
11
0
11
0
A.
01
.0
01
88
0
Co
rn
ch
ip
s
11
2
11
9
12
6
62
67
71
12
15
17
A.
01
.0
01
88
1
To
rt
ill
a
ch
ip
s
11
2
11
9
12
6
62
67
71
12
15
17
A.
01
.0
01
88
2
Co
rn
cu
rls
11
2
11
9
12
6
62
67
71
12
15
17
A.
01
.0
01
88
3
Po
pc
or
n
23
29
35
12
17
22
14
15
16
A.
01
.0
01
88
4
Pr
et
ze
ls
12
7
13
3
13
8
60
65
70
81
81
82
A.
01
.0
01
88
5
Fi
sh
-b
as
ed
sn
ac
ks
11
2
11
9
12
6
62
67
71
12
15
17
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
7
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
Fo
o
d
E
x
1
co
d
e
Fo
o
d
g
ro
u
p
u
se
d
fo
r
ex
p
o
su
re
3
-M
C
P
D
(l
g
/k
g
)
2
-M
C
P
D
(l
g
/k
g
)
G
ly
ci
d
o
l
(l
g
/k
g
)
LB
M
B
U
B
LB
M
B
U
B
LB
M
B
U
B
A.
01
.0
01
88
6
Se
af
oo
d
ch
ip
s
11
2
11
9
12
6
62
67
71
12
15
17
A.
01
.0
01
88
7
Ch
ee
se
pu
ff
s
11
2
11
9
12
6
62
67
71
12
15
17
A.
01
.0
01
66
0
So
y
sa
uc
e
1.
1
4.
47
7.
85
0
0
0
0
0
0
A.
01
.0
01
65
6
Ba
rb
ec
ue
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
65
7
Ta
ba
sc
o
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
65
8
H
or
se
ra
di
sh
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
65
9
M
in
t
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
66
1
Cu
rr
y
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
66
2
Sa
ls
a
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
66
3
Ta
rt
ar
sa
uc
e
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
66
4
M
ix
ed
co
nd
im
en
t
4.
23
8.
75
13
0
0
0
0
0
0
A.
01
.0
01
75
7
Pr
ot
ei
n
an
d
am
in
o
ac
id
s
su
pp
le
m
en
ts
22
25
28
0
0
0
0
0
0
A.
01
.0
00
18
5
Ce
re
al
ﬂa
ke
s
6.
09
12
19
3.
77
8.
71
13
5.
45
6.
29
7.
14
A.
01
.0
00
21
0
M
ue
sl
i
88
95
10
2
46
50
55
83
84
85
A.
01
.0
00
22
0
Ce
re
al
ba
rs
14
21
29
7.
3
12
16
11
12
12
A.
01
.0
00
23
3
M
ix
ed
br
ea
kf
as
t
ce
re
al
s
88
95
10
2
46
50
55
83
84
85
A.
01
.0
00
24
6
Po
rr
id
ge
0.
6
8.
8
17
0
5.
94
11
0
2.
98
5.
97
A.
01
.0
00
81
1
Sa
us
ag
es
17
24
30
0.
21
6.
24
12
24
27
30
3-
M
CP
D
:
3-
m
on
oc
hl
or
op
ro
pa
ne
-1
,2
-d
io
l;
2-
M
CP
D
:
2-
m
on
oc
hl
or
op
ro
pa
ne
-1
,3
-d
io
l;
LB
:
lo
w
er
bo
un
d;
M
B:
m
id
dl
e
bo
un
d;
U
B:
up
pe
r
bo
un
d.
w
w
w
.e
fs
a.
eu
ro
p
a.
eu
/e
fs
aj
o
u
rn
al
12
8
EF
SA
Jo
u
rn
al
20
16
;1
4(
5)
:4
42
6
M
CP
D
an
d
gl
yc
id
yl
es
te
rs
in
fo
o
d
Table B.5: Contribution of Food groups to MB mean exposure to 3-MCPD by population groups
(represented as number of surveys where the % contribution of the speciﬁc food
group falls into one of the predeﬁned ranges of % contribution)
Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Infants Bread and bread rolls 2 1 3
Breakfast cereals 3 2
Cookies 1 1 1 2 1
Fried or baked potato
products
3 1
Fried or baked ﬁsh 3 3
Fried or roasted meat 6
Herb and spice
mixtures
3
Infant and follow-on
formulae
4 2
Margarine and similar 3 1 1
Mayonnaise 4
Miscellaneous snack
products
3
Other condiment
sauces
3
Other seasoning
products
4
Pastries and cakes 1 2 1
Porridge 1 1
Ready-to-eat soups 6
Savoury sauces,
non-oil-based
2
Savoury sauces,
oil-based
1
Smoked meat
products
3 3
Soy sauce 4
Stock cubes (bouillon
cube)
3
Vegetable fats and oils 1 1 2 1 1
Toddlers Bread and bread rolls 1 1 8
Breakfast cereals 3 6 1
Chocolate spreads and
similar
1 1 1
Cookies 3 4 1 1 1
Dressing 2 1
Fried or baked potato
products
2 3 3 2
Fried or baked ﬁsh 1 7 2
Fried or roasted meat 5 4 1
Herb and spice
mixtures
6
Infant and follow-on
formulae
5 2 1 1
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Margarine and similar 2 1 1 3 1
Mayonnaise 8
Miscellaneous snack
products
6 1
Other condiment
sauces
5
Other seasoning
products
7
Pastries and cakes 1 2 2 3 1
Porridge 4
Protein and amino
acids supplements
1
Ready-to-eat soups 9
Savoury sauces,
non-oil-based
6
Savoury sauces,
oil-based
5
Smoked meat
products
9 1
Soy sauce 7
Stock cubes (bouillon
cube)
7
Vegetable fats and oils 1 2 1 3 1 2
Other
children
Bread and bread rolls 1 4 13
Breakfast cereals 7 11
Chocolate spreads and
similar
1 2 2 1
Cookies 1 2 4 5 4 2
Dressing 4 3
Fried or baked potato
products
1 7 5 4 1
Fried or baked ﬁsh 4 11 3
Fried or roasted meat 5 11 2
Herb and spice
mixtures
10
Margarine and similar 3 3 3 4 2 1 1
Mayonnaise 12 4
Miscellaneous snack
products
12 1
Other condiment
sauces
11
Other seasoning
products
9
Pastries and cakes 1 6 4 5 1
Porridge 7
Protein and amino
acids supplements
2
Ready-to-eat soups 15
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Savoury sauces,
non-oil-based
13
Savoury sauces,
oil-based
9
Smoked meat
products
1 13 4
Soy sauce 13
Stock cubes (bouillon
cube)
12
Vegetable fats and oils 3 4 3 4 2 1
Adolescents Bread and bread rolls 1 2 13 1
Breakfast cereals 5 12
Chocolate spreads and
similar
1 1 2 1
Cookies 1 3 4 7 2
Dressing 6 1
Fried or baked potato
products
3 9 3 1 1
Fried or baked ﬁsh 4 9 4
Fried or roasted meat 2 9 6
Herb and spice
mixtures
9
Margarine and similar 2 3 4 3 2 2
Mayonnaise 7 8 1
Miscellaneous snack
products
11 1
Other condiment
sauces
11
Other seasoning
products
7
Pastries and cakes 1 7 4 4
Porridge 5
Protein and amino
acids supplements
1
Ready-to-eat soups 15
Savoury sauces,
non-oil-based
13
Savoury sauces,
oil-based
9
Smoked meat
products
11 6
Soy sauce 13
Stock cubes (bouillon
cube)
11
Vegetable fats and oils 2 3 5 5 1
Adults Bread and bread rolls 1 14 2
Breakfast cereals 6 11
Chocolate spreads and
similar
5 3
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Cookies 5 6 6
Dressing 5 2
Fried or baked potato
products
2 7 4 4
Fried or baked ﬁsh 1 12 2 2
Fried or roasted meat 11 6
Herb and spice
mixtures
11
Margarine and similar 2 3 2 6 2 1 1
Mayonnaise 7 7 1
Miscellaneous snack
products
14
Other condiment
sauces
14
Other seasoning
products
7
Pastries and cakes 1 1 1 5 5 2 1
Porridge 8 2
Protein and amino
acids supplements
5
Ready-to-eat soups 16
Savoury sauces,
non-oil-based
13
Savoury sauces,
oil-based
10 1
Smoked meat
products
11 6
Soy sauce 17
Stock cubes (bouillon
cube)
14
Vegetable fats and oils 1 3 4 6 2
Elderly Bread and bread rolls 1 12 1
Breakfast cereals 6 8
Chocolate spreads and
similar
5
Cookies 7 5 2
Dressing 6 1
Fried or baked potato
products
2 8 2 1
Fried or baked ﬁsh 2 8 3 1
Fried or roasted meat 13 1
Herb and spice
mixtures
11
Margarine and similar 1 1 2 4 2 2 2
Mayonnaise 10 2
Miscellaneous snack
products
7
Other condiment
sauces
11
MCPD and glycidyl esters in food
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Other seasoning
products
8
Pastries and cakes 1 1 1 3 4 2 1
Porridge 7 3
Protein and amino
acids supplements
2
Ready-to-eat soups 13
Savoury sauces,
non-oil-based
10
Savoury sauces,
oil-based
10
Smoked meat
products
13 1
Soy sauce 11
Stock cubes (bouillon
cube)
8
Vegetable fats and oils 5 1 6 2
Very elderly Bread and bread rolls 1 10 1
Breakfast cereals 6 6
Chocolate spreads and
similar
1
Cookies 4 5 3
Dressing 2 2
Fried or baked potato
products
2 8 1
Fried or baked ﬁsh 2 6 4
Fried or roasted meat 1 10 1
Herb and spice
mixtures
6
Margarine and similar 1 1 3 4 2
Mayonnaise 8 1
Miscellaneous snack
products
2
Other condiment
sauces
8
Other seasoning
products
5
Pastries and cakes 2 1 3 2 1 2
Porridge 5 1
Protein and amino
acids supplements
1
Ready-to-eat soups 11
Savoury sauces,
non-oil-based
8
Savoury sauces,
oil-based
7 1
Smoked meat
products
11 1
Soy sauce 9
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Table B.6: Contribution of food groups to MB mean exposure to 2-MCPD by population groups. The
contribution is represented as number of surveys where the % contribution of the
speciﬁc food group falls into one of the pre-deﬁned ranges of % contribution
Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Infants Bread and bread rolls 2 1 3
Breakfast cereals 1 4
Cookies 1 1 3 1
Fried or baked potato
products
3 1
Fried or baked ﬁsh 3 3
Fried or roasted meat 6
Infant and follow-on
formulae
5 1
Margarine and similar 3 1 1
Mayonnaise 4
Miscellaneous snack
products
2 1
Pastries and cakes 1 2 1
Porridge 1 1
Savoury sauces,
oil-based
1
Smoked meat products 6
Vegetable fats and oils 1 2 2 1
Toddlers Bread and bread rolls 1 1 7 1
Breakfast cereals 3 5 2
Chocolate spreads and
similar
1 1 1
Cookies 2 1 4 1 2
Dressing 2 1
Fried or baked potato
products
2 3 3 2
Fried or baked ﬁsh 3 5 2
Fried or roasted meat 6 4
Infant and follow-on
formulae
6 1 1 1
Margarine and similar 2 2 3 1
Mayonnaise 8
Miscellaneous snack
products
5 2
Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Stock cubes (bouillon
cube)
6
Vegetable fats and oils 4 1 5 2
3-MCPD: 3-monochloropropane-1,2-diol; MB: middle bound.
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Pastries and cakes 1 2 2 3 1
Porridge 4
Savoury sauces,
oil-based
5
Smoked meat products 1 9
Vegetable fats and oils 1 2 2 3 2
Other
children
Bread and bread rolls 1 4 13
Breakfast cereals 6 8 4
Chocolate spreads and
similar
1 1 3 1
Cookies 1 2 4 5 4 2
Dressing 5 2
Fried or baked potato
products
1 3 8 5 1
Fried or baked ﬁsh 5 13
Fried or roasted meat 9 9
Margarine and similar 3 4 5 1 2 1 1
Mayonnaise 12 4
Miscellaneous snack
products
12 1
Pastries and cakes 1 5 5 4 2
Porridge 7
Savoury sauces,
oil-based
9
Smoked meat products 1 17
Vegetable fats and oils 3 3 3 2 5 1
Adolescents Bread and bread rolls 1 1 14 1
Breakfast cereals 4 12 1
Chocolate spreads and
similar
1 3 1
Cookies 1 3 4 7 1 1
Dressing 6 1
Fried or baked potato
products
2 9 3 2 1
Fried or baked ﬁsh 4 13
Fried or roasted meat 5 12
Margarine and similar 2 5 3 3 1 1 1
Mayonnaise 8 7 1
Miscellaneous snack
products
10 2
Pastries and cakes 1 7 3 5
Porridge 5
Savoury sauces,
oil-based
9
Smoked meat products 17
Vegetable fats and oils 2 3 3 3 4 1
Adults Bread and bread rolls 15 2
Breakfast cereals 5 12
MCPD and glycidyl esters in food
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Chocolate spreads and
similar
4 4
Cookies 3 7 7
Dressing 5 2
Fried or baked potato
products
2 5 5 5
Fried or baked ﬁsh 4 10 3
Fried or roasted meat 16 1
Margarine and similar 2 3 6 3 2 1
Mayonnaise 7 7 1
Miscellaneous snack
products
14
Pastries and cakes 1 1 1 5 3 4 1
Porridge 8 2
Savoury sauces,
oil-based
10 1
Smoked meat products 17
Vegetable fats and oils 1 3 1 6 2 1 2
Elderly Bread and bread rolls 12 2
Breakfast cereals 5 9
Chocolate spreads and
similar
5
Cookies 6 5 3
Dressing 6 1
Fried or baked potato
products
2 5 5 1
Fried or baked ﬁsh 2 10 2
Fried or roasted meat 3 11
Margarine and similar 2 2 4 3 2 1
Mayonnaise 10 2
Miscellaneous snack
products
7
Pastries and cakes 1 1 1 1 6 1 2
Porridge 6 3 1
Savoury sauces,
oil-based
10
Smoked meat products 14
Vegetable fats and oils 5 6 1 2
Very elderly Bread and bread rolls 1 9 1 1
Breakfast cereals 5 7
Chocolate spreads and
similar
1
Cookies 4 4 4
Dressing 3 1
Fried or baked potato
products
2 7 2
Fried or baked ﬁsh 2 9 1
Fried or roasted meat 3 9
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Number of dietary surveys
Population
group
Food groups
With % contribution to the MB mean chronic dietary exposure in
the ranges:
< 1% 1–5% 5–10% 10–20% 20–30% 30–40% 40–60% > 60%
Margarine and similar 1 1 6 1 1 1
Mayonnaise 8 1
Miscellaneous snack
products
2
Pastries and cakes 1 1 1 1 4 3
Porridge 3 3
Savoury sauces,
oil-based
7 1
Smoked meat products 12
Vegetable fats and oils 4 5 1 2
2-MCPD: 2-monochloropropane-1,3-diol; MB: middle bound.
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Table B.8: Margins of exposure (MOEs) calculated for glycidol exposure; the table presents the
MoEs for median, minimum and maximum exposure across dietary surveys for both,
average and P95 of exposure
MoE based on exposure estimates (median (min–max)) across dietary surveys(a)
LB MB UB
Mean exposure
Infants 14,600 (34,000–14,600) 14,600 (25,500–12,800) 14,600 (25,500–12,800)
Toddlers 17,000 (25,500–11,300) 17,000 (25,500–11,300) 17,000 (20,400–11,300)
Other children 20,400 (34,000–11,300) 17,000 (34,000–11,300) 17,000 (34,000–10,200)
Adolescents 34,000 (51,000–20,400) 34,000 (51,000–20,400) 34,000 (51,000–20,400)
Adults 51,000 (102,000–34,000) 51,000 (51,000–34,000) 51,000 (51,000–34,000)
Elderly 51,000 (102,000–34,000) 51,000 (102,000–34,000) 34,000 (102,000–340,00)
Very elderly 51,000 (102,000–34,000) 51,000 (102,000–34,000) 34,000 (102,000–34,000)
P95 of exposure
Infants 7,800 (8,500–4,900) 7,800 (8,500–4,900) 6,800 (7,800–4,600)
Toddlers 9,300 (10,200–5,100) 9,300 (10,200–5,100) 8,500 (10,200–4,900)
Other children 9,300 (12,800–6,000) 9,300 (12,800–6,000) 9,300 (12,800–6,000)
Adolescents 17,000 (25,500–9,300) 17,000 (25,500–9,300) 14,600 (25,500–9,300)
Adults 20,400 (34,000–17,000) 20,400 (34,000–17,000) 20,400 (34,000–14,600)
Elderly 20,400 (51,000–17,000) 20,400 (51,000–17,000) 20,400 (34,000–17,000)
Very elderly 20,400 (51,000–14,600) 20,400 (51,000–14,600) 20,400 (51,000–12,800)
bw: body weight; LB: lower-bound; MB: middle bound; UB: upper-bound.
(a): The values corresponding to LB, MB and UB occurrence are shown.
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Appendix C – Benchmark dose modelling of data from Sunahara et al.
(1993)
BMD modelling of the results of the 2-year drinking water study of Sunahara et al. (1993).
The dose–response analysis was performed on the results of the long-term toxicity study performed
by Sunahara et al. (1993). In this study, Fisher 344 rats (50 animals/sex per treatment group) were
exposed to 3-monochloropropane-1,2-diol (3-MCPD) at nominal concentrations of 0, 20, 50 or 100 mg/L
in drinking water (see Section 3.4.2.3). Average daily doses of 0, 1.1, 5.2 or 28 mg/kg body weight
(bw) per day, and 0, 1.4, 7.0 or 35 mg/kg bw per day were calculated for male and female rats,
respectively, by the study authors. A background concentration of 2.7 mg/L 3-MCPD was detected in
drinking water used in the study. The EFSA Panel on Contaminants in the Food Chain (CONTAM Panel)
calculated the intake in controls as 0.11 mg/kg bw in males and 0.14 mg/kg bw in females, and used
these corrected values for the dose-response analysis.
The relevant results of the study were initially screened by visual analysis for the presence of
monotonic dose–response trends; the presence of a dose–response trend in the subset of results
selected in the screening phase was subsequently conﬁrmed by applying the Cochran–Armitage trend
test (Haseman, 1984). The results with p < 0.05 in the aforementioned trend test were selected for
benchmark dose (BMD) analysis, which was performed by means of the software BMDS v2.6.0.86 (US
EPA). The following effects were subjected to the BMD analysis:
• Tubular hyperplasia (both sexes)
• Nephropathy (both sexes)
For the aforementioned effects, all models for dichotomous (quantal) data were selected for the
analysis at the default benchmark response (BMR) of 10% (95% conﬁdence level) advised by the EFSA
guidance on the use of BMD (EFSA, 2009a). The models allowing for restrictions (Gamma, Log
Logistic, Logprobit, Multistage and Weibull) were run both with and without the selected default
restrictions. BMDL10 were calculated separately for male and female rats. Acceptability of a model was
assessed using the log-likelihood value associated with the ﬁtted model (when tested vs the full
model). In accordance with the Scientiﬁc Opinion of the EFSA (EFSA, 2009a) a goodness-of-ﬁt was
judged as sufﬁcient if the ﬁt showed a p-value not smaller than 0.05 (i.e. p ≥ 0.05), using the
likelihood ratio test. The lowest BMDL10 calculated for each effect are reported in Table B.1.
Table C.1: Summary table of the lowest BMD and BMDL10 calculated for different effects observed
in the Sunahara et al. (1993) study
Effect
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Model Calculation details
Tubular hyperplasia (male) 1.2 0.22 Gamma (unrestricted) B1
Tubular hyperplasia (female) 0.83 0.29 Gamma (unrestricted) B2
Nephropathy (male) 0.33 0.10 Loglogistic (restricted) B3
Nephropathy (female) 1.1 0.30 Loglogistic (unrestricted) B4
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight.
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Table C.2: Male kidney hyperplasia
Incidence data
Dose (mg/kg bw per day) N Effect
0.11 50 3
1.1 50 6
5.2 50 15
28.3 50 34
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 120.43 1 < 0.001 NA
Gamma No 91.62 3 0.79 Yes 1.2 0.22
Logistic NA 94.54 2 0.052 Yes 6.4 5.2
LogLogistic No 91.58 3 0.97 Yes 1.6 0.42
LogProbit No 91.60 3 0.85 Yes 1.8 0.58
Multistage No 91.58 3 0.93 Yes 1.7 1.0
Multistage-
Cancer
NA 92.11 2 0.59 Yes 2.6 1.9
Probit NA 94.32 2 0.064 Yes 6.0 5.0
Weibull No 92.11 2 0.59 Yes 2.6 1.9
Quantal-Linear NA 92.11 2 0.59 Yes 2.6 1.9
Gamma Yes 92.11 2 0.59 Yes 2.6 1.9
LogLogistic Yes 91.58 3 0.97 Yes 1.6 1.1
LogProbit Yes 93.59 2 0.13 No 4.6 3.4
Weibull Yes 92.11 2 0.59 Yes 2.6 1.9
Multistage Yes 92.11 2 0.59 Yes 2.6 1.9
Full NA 91.58 4 NA NA
bw: body weight; BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table C.3: Female kidney hyperplasia
Incidence data
Dose (mg/kg bw per day) N Effect
0.14 50 2
1.4 50 4
7.0 50 20
35.3 50 31
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 119.52 1 < 0.001 NA
Gamma No 90.92 2 0.17 Yes 0.83 0.29
Logistic NA 97.97 2 < 0.001 No 8.5 6.9
LogLogistic No 90.34 3 0.13 Yes 1.2 0.41
LogProbit No 90.19 3 0.16 Yes 1.6 0.47
Multistage No 89.64 3 0.34 Yes 1.5 1.0
Multistage-
Cancer
NA 93.01 2 0.022 No 3.2 2.5
Probit NA 97.61 2 < 0.001 No 7.9 6.5
Weibull No 93.01 2 0.022 No 3.2 2.5
Quantal-Linear NA 93.01 2 0.022 No 3.2 2.5
Gamma Yes 93.01 2 0.022 No 3.2 2.5
LogLogistic Yes 90.67 2 0.23 Yes 1.9 1.3
LogProbit Yes 95.80 2 0.014 No 5.3 3.9
Weibull Yes 93.01 2 0.022 No 3.2 2.5
Multistage Yes 93.01 2 0.022 No 3.2 2.5
Full NA 89.19 4 NA NA
bw: body weight; BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table C.4: Male nephropathy
Incidence data
Dose (mg/kg bw per day) N Effect
0.11 50 36
1.1 50 40
5.2 50 45
28.3 50 49
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 84.54 1 < 0.001 NA
Gamma No NC NA NC NA NC NC
Logistic NA 76.71 2 0.41 Yes 1.2 0.67
LogLogistic No 75.84 3 0.85 Yes 0.34 < 0.001(a)
LogProbit No 75.83 3 0.93 Yes 0.34 < 0.001(a)
Multistage No 75.88 3 0.73 Yes 0.47 0.24
Multistage-
Cancer
NA 76.54 2 0.49 Yes 0.98 0.54
Probit NA 76.95 2 0.32 Yes 1.5 0.94
Weibull No NC NA NC NA NC NC
Quantal-Linear NA 76.54 2 0.49 Yes 0.98 0.54
Gamma Yes NC NA NC NA NC NC
LogLogistic Yes 75.84 3 0.85 Yes 0.33 0.10
LogProbit Yes 76.38 2 0.57 Yes 1.4 0.68
Weibull Yes NC NA NC NA NC NC
Multistage Yes 76.54 2 0.49 Yes 0.98 0.54
Full NA 75.82 4 NA NA
bw: body weight; BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); NA: not applicable; NC: not
calculated
(a): Ratio BMD/BMDL higher than one order of magnitude.
Plot (model resulting in the lowest BMDL10)
 0.6
 0.7
 0.8
 0.9
 1
 0  5  10  15  20  25
Fr
ac
tio
n 
A
ffe
ct
ed
dose
Log-Logistic Model, with BMR of 10% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the BMDL
10:58 09/10 2015
BMDL BMD
Log-Logistic
www.efsa.europa.eu/efsajournal 146 EFSA Journal 2016;14(5):4426
MCPD and glycidyl esters in food
Table C.5: Female nephropathy
Incidence data
Dose (mg/kg bw per day) N Effect
0.14 50 24
1.4 50 23
7.0 50 42
35.3 50 48
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 124.61 1 < 0.001 NA
Gamma No NC NA NC NA NC NC
Logistic NA 103.69 2 0.015 No 1.7 1.2
LogLogistic No 100.39 3 0.18 Yes 1.1 0.30
LogProbit No 100.62 3 0.13 Yes 1.1 0.30
Multistage No 100.60 3 0.14 Yes 0.58 0.37
Multistage-
Cancer
NA 102.32 2 0.059 Yes 1.1 0.73
Probit NA 104.52 2 0.0066 No 2.1 1.6
Weibull No 102.32 2 0.059 Yes 1.1 0.73
Quantal-Linear NA 102.32 2 0.059 Yes 1.1 0.73
Gamma Yes 102.32 2 0.059 Yes 1.1 0.73
LogLogistic Yes 100.39 3 0.18 Yes 1.1 0.30
LogProbit Yes 100.86 2 0.25 Yes 1.5 1.0
Weibull Yes 102.32 2 0.060 Yes 1.1 0.73
Multistage Yes 102.32 2 0.060 Yes 1.1 0.73
Full NA 99.50 4 NA NA
bw: body weight; BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); NA: not applicable; NC: not
calculated.
Plot (model resulting in the lowest BMDL10)
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Appendix D – Benchmark dose modelling of data from Cho et al. (2008)
BMD modelling of the results of the 2-year drinking water study of Cho et al. (2008).
The dose–response analysis was performed on the results of the long-term toxicity study performed
by Cho et al. (2008). In this study, Sprague-Dawley (SD) rats (50 animals/sex per treatment group)
were exposed to 3-monochloropropane-1,2-diol (3-MCPD) at nominal concentrations of 0, 25, 100 or
400 mg/L in drinking water (see Section 3.4.2.3). Average daily doses of 0, 2.0, 8.3 or 29.5 mg/kg
body weight (bw) per day, and 0, 2.7, 10.3 or 37.0 mg/kg bw per day were calculated for male and
female rats, respectively. The relevant results of the study were initially screened by visual analysis for
the presence of monotonic dose–response trends; the presence of a dose–response trend in the
subset of results selected in the screening phase was subsequently conﬁrmed by applying the
Cochran–Armitage trend test (Haseman, 1984). The results with p < 0.05 in the aforementioned trend
test were selected for benchmark dose (BMD) analysis, performed by means of the software BMDS
v2.6.0.86 (US EPA). The following effects were subjected to the BMD analysis:
• Tubular hyperplasia (both sexes)
• Nephropathy (both sexes)
• Tubular adenoma or carcinoma (both sexes)
• Testicular atrophy
For all the aforementioned effects, all models for dichotomous (quantal) data were selected for the
analysis at the default benchmark response (BMR) of 10% (95% conﬁdence level) advised by the EFSA
guidance on the use of benchmark dose (EFSA, 2009a). The models allowing for restrictions (Gamma,
Log Logistic, Logprobit and Weibull) were run both with and without the selected default restrictions.
BMDL10 were calculated separately for male and female rats. The existence of a monotonic trend was
conﬁrmed comparing the log likelihood of the null model versus the full model (p ≤ 0.05, using the
likelihood ratio test). In accordance with the Scientiﬁc Opinion of the EFSA (EFSA, 2009a) a goodness-
of-ﬁt was judged as sufﬁcient if the ﬁt showed a p-value not smaller than 0.05 (i.e. p ≥ 0.05), using
the likelihood ratio test. The lowest BMDL10 calculated for each effect are reported in Table D.1.
Table D.1: Summary table of the lowest BMD and BMDL10 calculated for different effects observed
in the Cho et al. (2008) study
Effect
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Model
Calculation
details
Tubular hyperplasia (male) 0.54 0.077 Gamma (unrestricted) A1
Tubular hyperplasia (female) 27 14 Quantal-linear A2
Nephropathy (male) 0.64 0.37 Loglogistic (restricted) A3
Nephropathy (female) 3.0 1.1 Gamma (unrestricted) A4
Testes atrophy 3.5 2.5 Quantal-linear A5
Tubular adenoma or carcinoma
(combined) (male)
25 15 Quantal-linear A6
Tubular adenoma or carcinoma
(combined) (female)
24 15 Logprobit (unrestricted) A7
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight.
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Table D.2: Male kidney hyperplasia
Incidence data
Dose (mg/kg bw per day) N Effect
0 50 1
2 50 11
8.3 50 21
29.5 50 36
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 128.86 3 < 0.001 NA
Gamma No 94.91 2 0.92 Yes 0.54 0.077
Logistic NA 102.47 3 0.0005 No 5.6 4.6
LogLogistic No 95.07 3 0.57 Yes 0.85 0.23
LogProbit No 95.10 3 0.54 Yes 0.93 0.28
Multistage No 95.53 3 0.27 Yes 1.3 0.91
Multistage-
Cancer
NA 97.44 2 0.079 Yes 2.1 1.7
Probit NA 102.18 2 0.0007 No 5.4 4.5
Weibull No 94.94 3 0.81 Yes 0.64 0.14
Quantal-Linear NA 97.44 2 0.079 Yes 2.1 1.7
Gamma Yes 97.44 2 0.079 Yes 2.1 1.7
LogLogistic Yes 95.36 2 0.64 Yes 1.2 0.87
LogProbit Yes 100.33 2 0.004 No 4.0 3.0
Weibull Yes 97.44 2 0.079 Yes 2.1 1.7
Multistage Yes 97.44 2 0.079 Yes 2.1 1.7
Full NA 94.91 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table D.3: Female kidney hyperplasia
Incidence data
Dose (mg/kg bw per day) N Effect
0 50 1
2.7 50 0
10.3 50 1
37.0 50 10
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 45.39 1 < 0.001 NA
Gamma No 35.53 3 0.23 Yes 27 18
Logistic NA 35.66 2 0.44 Yes 29 24
LogLogistic No 35.54 3 0.23 Yes 28 18
LogProbit No 35.53 3 0.24 Yes 26 17
Multistage No 35.41 3 0.28 Yes 27 20
Multistage-
Cancer
NA 35.61 2 0.45 Yes 28 19
Probit NA 35.71 2 0.41 Yes 28 22
Weibull No 35.54 3 0.23 Yes 23 19
Quantal-Linear NA 37.13 2 0.10 Yes 27 14
Gamma Yes 35.53 3 0.23 Yes 28 18
LogLogistic Yes 35.54 3 0.23 Yes 28 18
LogProbit Yes 35.53 3 0.24 Yes 26 18
Weibull Yes 35.54 3 0.23 Yes 28 19
Multistage Yes 35.61 2 0.45 Yes 26 19
Full NA 34.82 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table D.4: Male nephropathy
Incidence data
Dose (mg/kg bw per day) N Effect
0 50 15
2 50 27
8.3 50 39
29.5 50 41
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 133.75 1 < 0.001 NA
Gamma No 115.92 3 0.16 YES 0.0076 < 0.0001(a)
Logistic NA 121.86 2 0.002 NO 3.0 2.3
LogLogistic No 115.53 3 0.28 YES 0.13 0.001(a)
LogProbit No 115.57 3 0.26 YES 0.15 0.0013(a)
Multistage No 115.06 3 0.64 YES 0.58 0.40
Multistage-
Cancer
NA 120.23 2 0.0050 NO 1.9 1.3
Probit NA 122.12 2 0.0008 NO 3.3 2.6
Weibull No 115.75 3 0.21 YES 0.035 < 0.0001(a)
Quantal-Linear NA 120.30 2 0.0050 NO 1.9 1.3
Gamma Yes 120.30 2 0.0050 NO 1.9 1.3
LogLogistic Yes 116.68 2 0.18 YES 0.64 0.37
LogProbit Yes 121.26 2 0.0018 NO 3.1 2.0
Weibull Yes 120.30 2 0.0050 NO 1.9 1.3
Multistage Yes 120.30 2 0.0050 NO 1.9 1.3
Full NA 115.00 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
(a): Ratio BMD/BMDL higher than one order of magnitude.
Plot (model resulting in the lowest BMDL10)
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Table D.5: Female nephropathy
Incidence data
Dose(mg/kg bw per day) N Effect
0 50 6
2.7 50 8
10.3 50 23
37.0 50 42
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 134.19 1 < 0.001 NA
Gamma No 97.14 3 0.42 YES 3.0 1.1
Logistic NA 99.11 2 0.10 YES 5.4 4.4
LogLogistic No 96.87 3 0.74 YES 3.6 1.8
LogProbit No 96.83 3 0.86 YES 3.7 1.9
Multistage No 97.26 3 0.34 YES 2.5 1.5
Multistage-
Cancer
NA 97.26 3 0.34 YES 2.5 1.8
Probit NA 99.04 2 0.11 YES 5.3 4.4
Weibull No 97.18 3 0.39 YES 2.8 1.2
Quantal-Linear NA 97.29 2 0.62 YES 2.3 1.8
Gamma Yes 97.14 3 0.42 YES 3.0 1.8
LogLogistic Yes 96.87 3 0.74 YES 3.6 1.8
LogProbit Yes 96.85 2 0.97 YES 4.0 3.1
Weibull Yes 97.18 3 0.39 YES 2.8 1.8
Multistage Yes 97.26 3 0.34 YES 2.5 1.8
Full NA 96.81 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table D.6: Testicular atrophy
Incidence data
Dose(mg/kg bw per day) N Effect
0 50 6
2 50 16
8.3 50 13
29.5 50 34
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 128.86 1 < 0.001 NA
Gamma No 112.53 3 0.017 NO 2.0 0.14
Logistic NA 112.32 2 0.072 YES 6.2 5.0
LogLogistic No 112.64 3 0.015 NO 9.7 0.41
LogProbit No 113.40 3 0.0063 NO 2.2 0.22
Multistage No 112.35 3 0.021 NO 5.8 2.1
Multistage-
Cancer
NA 112.35 3 0.021 NO 5.8 2.6
Probit NA 112.31 2 0.072 YES 6.0 4.9
Weibull No 112.57 3 0.016 NO 7.2 0.24
Quantal-Linear NA 112.59 2 0.055 YES 3.5 2.5
Gamma Yes 112.65 3 0.015 NO 9.3 2.5
LogLogistic Yes 112.64 3 0.015 NO 9.7 1.7
LogProbit Yes 112.69 3 0.014 NO 10 5.2
Weibull Yes 112.57 3 0.016 NO 7.2 2.5
Multistage Yes 112.35 3 0.021 NO 5.8 2.6
Full NA 109.69 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table D.7: Male tubule adenoma or carcinoma (combined)
Incidence data
Dose(mg/kg bw per day) N Effect
0 50 0
2 50 0
8.3 50 1
29.5 50 7
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 33.59 1 < 0.001 NA
Gamma No 25.23 2 0.92 YES 24 16
Logistic NA 25.73 2 0.56 YES 27 22
LogLogistic No 25.23 2 0.92 YES 24 16
LogProbit No 25.19 2 0.97 YES 23 15
Multistage No 25.27 2 0.89 YES 24 17
Multistage-
Cancer
NA 25.27 2 0.89 YES 24 17
Probit NA 25.64 2 0.61 YES 26 21
Weibull No 25.24 2 0.92 YES 24 16
Quantal-Linear NA 25.88 1 0.69 YES 25 15
Gamma Yes 25.23 2 0.93 YES 24 16
LogLogistic Yes 25.23 2 0.92 YES 24 16
LogProbit Yes 25.34 1 0.94 YES 23 17
Weibull Yes 25.24 2 0.92 YES 24 16
Multistage Yes 25.27 2 0.89 YES 24 17
Full NA 25.15 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Table D.8: Female tubule adenoma or carcinoma (combined)
Incidence data
Dose(mg/kg bw per day) N Effect
0 50 0
2 50 0
8.3 50 1
29.5 50 7
BMD analysis results
Model Restriction
Log-
likelihood
Number of
parameters
p Accepted
BMD10
mg/kg
per day
BMDL10
mg/kg
per day
Null NA 45.39 1 < 0.001 NA
Gamma No 37.71 3 0.19 YES 26 16
Logistic NA 37.87 2 0.37 YES 30 24
LogLogistic No 37.72 3 0.19 YES 26 16
LogProbit No 37.65 3 0.21 YES 24 15
Multistage No 37.78 3 0.18 YES 27 16
Multistage-
Cancer
NA 37.78 3 0.18 YES 27 16
Probit NA 37.84 2 0.38 YES 28 23
Weibull No 37.73 3 0.19 YES 26 16
Quantal-Linear NA 38.34 2 0.23 YES 24 15
Gamma Yes 37.71 3 0.19 YES 26 16
LogLogistic Yes 37.72 3 0.19 YES 26 16
LogProbit Yes 37.78 2 0.40 YES 26 18
Weibull Yes 37.73 3 0.19 YES 26 16
Multistage Yes 37.78 3 0.18 YES 27 16
Full NA 36.87 4 NA NA
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; NA: not applicable.
Plot (model resulting in the lowest BMDL10)
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Appendix E – BMDL10 and BMD10 (mg/kg bw per day) calculated for
different non carcinogenic toxicological endpoints (adapted from Barocelli
et al., 2011)
3-MCPD mg/kg bw per
day
3-MCPD dipalmitate
mg/kg bw per day
BMD10 ratios
mg/kg or
moles/KgBMDL10 BMD10 BMDL10 BMD10
Kidney female 3.6 7.9
Kidney male 2.5 5.6 17.4 41.1 7.3 or 1.4
Testis 6.0 8.4 44.3 64.4 7.7 or 1.4
Proteinuria male 2.7 6.4 18.7 47.2 7.4 or 1.4
RBC 5% loss male 3.5 7.2 24.8 53.5 7.4 or 1.4
RBC 5% loss female 2.6 4.5 90.4 187.0 41.6 or 7.8
Mortality female 2.3 7.4 < 157 < 157 < 21 or < 4.0
Mean  SD
Excluding kidney/female
and mortality for MCPD palmitate)
6.58  1.39
(5.19–7.97)
78.6  61.2
(17.5–139.8)
BMD: benchmark dose; BMDL: benchmark dose (lower conﬁdence limit); bw: body weight; 3-MCPD: 3-monochloropropane-1,
2-diol; SD: standard deviation.
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Appendix F – Derivation of T25 levels for glycidol
As reported in EFSA (2005), the T25 is a simpliﬁed method to estimate the carcinogenic potency of
a given substance in the absence of dose–response data allowing for the application of the benchmark
dose (BMD) approach.
T25 is deﬁned as ‘the chronic dose rate in mg/kg bw per day, which will give 25% of the animal
tumours at a speciﬁc tissue site, after speciﬁc correction for the spontaneous incidence within the
standard life time of that species’. The T25 approach was applied to the NTP studies on glycidol (NTP,
1990) in rats and mice.
The derivation of T25 levels was carried out using the methodology described by Dybing et al. (1997).
In particular, both for mice and rats, T25 levels were calculated for the tumour incidences reported
at different tissues in separate sexes. T25 were calculated for all tested doses, although it is indicated
by Dybing et al. (1997) that the lowest tumour incidence data showing a signiﬁcant response are
generally used.
Tumour incidences (reported in percentages) observed in the treated groups were corrected for the
spontaneous incidences observed in controls, by applying the equation:
CI ¼ 100 ðOI SIÞ=ð100 SIÞ
where: CI is the tumour incidence corrected for the spontaneous incidence; OI is the tumour incidence
observed in the treatment group; andSI is the spontaneous incidence observed in the control
group.The T25 was calculated by applying the following equation:
T25 ¼ 25 D=CI
where CI is the corrected incidence (or the observed incidence in case there is no spontaneous tumour
incidence observed) and D is the related dose at which the incidence is reported.
No additional corrections were included in the calculation (e.g. to correct for speciﬁc treatment
regimes).
For each species and sex, the lowest T25 levels were considered.
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Table F.1: Calculation of T25 for tumours reported in male rats
Dose
(mg/kg bw
per day)
Incidence (per number of
animals)
Observed Incidence
(%)
Corrected
Incidence
T25 (mg/kg bw
per day)
0 37.5 75 0 37.5 75 37.5 75 37.5 75
Peritoneal
mesothelioma
3 (49) 34 (50) 39 (47) 6.12 68.00 82.98 65.91 81.87 14.22 22.90
Mammary
gland
ﬁbroadenoma/
carcinoma
3 (45) 8 (39) 7 (17) 6.67 20.51 41.18 14.84 36.97 63.19 50.71
Brain
glioma
0 (46) 5 (50) 6 (30) 0.00 10.00 20.00 10.00 20.00 93.75 93.75
Oral mucosa
papilloma/
carcinoma
1 (46) 2 (50) 6 (32) 2.17 4.00 18.75 1.87 16.94 502.23 110.66
Intestine
aden polyp
or adenocarc
0 (47) 1 (50) 4 (37) 0.00 2.00 10.81 2.00 10.81 468.75 173.44
Skin
sebaceous
gland tumours
0 (45) 5 (41) 4 (18) 0.00 12.20 22.22 12.20 22.22 76.88 84.38
Zymbal gland
carcinoma
1 (49) 3 (50) 6 (48) 2.04 6.00 12.50 4.04 10.68 231.96 175.61
Thyroid
follicular
cell adenoma/
carcinoma
1 (46) 4 (42) 6 (19) 2.17 9.52 31.58 7.51 30.06 124.78 62.38
Table F.2: Calculation of T25 for tumours reported in female rats
Dose
(mg/kg bw
per day)
Incidence (per number of
animals)
Observed Incidence
(%)
Corrected
Incidence
T25 (mg/kg
bw per day)
0 37.5 75 0 37.5 75 37.5 75 37.5 75
Mammary
gland
ﬁbroadenoma/
carcinoma
14 (49) 32 (46) 29 (44) 28.57 69.57 65.91 57.39 52.27 16.34 35.87
Brain
glioma
0 (49) 4 (46) 4 (46) 0.00 8.70 8.70 8.70 8.70 107.81 215.63
Oral mucosa
papilloma/
carcinoma
0 (47) 4 (38) 11 (30) 0.00 10.53 36.67 10.53 36.67 89.06 51.14
Clitoral gland
adenoma/
carcinoma
5 (49) 9 (47) 12 (45) 10.20 19.15 26.67 9.96 18.33 94.11 102.27
Thyroid
follicular
cell adenoma/
carcinoma
0 (49) 1 (38) 3 (35) 0.00 2.63 8.57 2.63 8.57 356.25 218.75
Hematopoietic
system
leukaemia
13 (49) 14 (44) 20 (41) 26.53 31.82 48.78 7.20 30.28 130.26 61.91
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Table F.4: Calculation of T25 for tumours reported in female mice
Dose (mg/kg
bw per day)
Incidence (per number of
animals)
Incidence (%)
Incidence over
background
T25 (mg/kg bw
Per day)
0 25 50 0 25 50 25 50 25 50
Harderian gland
adenoma
4 46 11 43 17 43 8.70 25.58 39.53 18.49 33.78 33.79 37.01
Mammary gland
adenoma,
adenocarc
2 50 6 50 15 50 4.00 12.00 30.00 8.33 27.08 75.00 46.15
Uterus carcinoma
or adenocarc
0 50 3 50 3 50 0.00 6.00 6.00 6.00 6.00 104.17 208.33
Subcutaneous
tissue sarcoma or
ﬁbrosarcoma
0 50 3 50 9 50 0.00 6.00 18.00 6.00 18.00 104.17 69.44
Skin squamous
cell papilloma or
carcinoma
0 50 0 50 2 50 0.00 0.00 4.00 0.00 4.00 NA 312.50
Table F.3: Calculation of T25 for tumours reported in male mice
Dose
(mg/kg bw
per day)
Incidence (per number of
animals)
Observed Incidence
(%)
Corrected
Incidence
T25 (mg/kg bw
per day)
0 25 50 0 25 50 25 50 25 50
Harderian
gland
adenoma
8 (46) 12 (41) 22 44 17.39 29.27 50.00 14.38 39.47 43.47 31.67
Forestomach
squamous
cell
papilloma or
carcinoma
1 (50) 2 (50) 10 50 2.00 4.00 20.00 2.04 18.37 306.25 68.06
Skin
squamous
cell
papilloma or
carcinoma
0 (50) 0 (50) 4 50 0.00 0.00 8.00 0.00 8.00 NA 156.25
Liver
adenoma or
carcinoma
24 (50) 31 (50) 35 50 48.00 62.00 70.00 26.92 42.31 23.21 29.55
Lung
alveolar/
bronchiolar
adenoma or
carcinoma
13 (50) 11 (50) 21 50 26.00 22.00 42.00 5.41 21.62 NA 57.81
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